WO2014204723A1 - Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions - Google Patents

Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions Download PDF

Info

Publication number
WO2014204723A1
WO2014204723A1 PCT/US2014/041790 US2014041790W WO2014204723A1 WO 2014204723 A1 WO2014204723 A1 WO 2014204723A1 US 2014041790 W US2014041790 W US 2014041790W WO 2014204723 A1 WO2014204723 A1 WO 2014204723A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
crispr
cells
target
cas9
Prior art date
Application number
PCT/US2014/041790
Other languages
French (fr)
Other versions
WO2014204723A9 (en
Inventor
Feng Zhang
Benjamin Levine EBERT
Dirk HECKL
Original Assignee
The Broad Institute Inc.
Massachusetts Institute Of Technology
The Brigham Women's Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Broad Institute Inc., Massachusetts Institute Of Technology, The Brigham Women's Hospital, Inc. filed Critical The Broad Institute Inc.
Priority to EP14738672.6A priority Critical patent/EP3011035B1/en
Publication of WO2014204723A1 publication Critical patent/WO2014204723A1/en
Priority to US14/971,459 priority patent/US20160168594A1/en
Publication of WO2014204723A9 publication Critical patent/WO2014204723A9/en
Priority to US16/003,085 priority patent/US20190106710A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present invention generally relates to the delivery, engineering, optimization and therapeutic applications of systems, methods, compositions and vectors used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.
  • sequence targeting such as genome perturbation or gene-editing
  • CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
  • the CRISPR-Cas system does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target.
  • Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases.
  • An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide.
  • the guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
  • the invention provides methods for using one or more elements of a CRISPR system.
  • the CRISPR complex of the inve tion provides an effective means for modifying a target polynucleotide.
  • the CRISPR complex of the invention has a wide variety of utilities including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types in various tissues and organs.
  • modifying e.g., deleting, inserting, translocating, inactivating, activating
  • a target polynucleotide in a multiplicity of cell types in various tissues and organs.
  • the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene or genome editing, gene therapy, generation of cell and animal model systems, drug discovery, drug screening, disease diagnosis, and prognosis.
  • aspects of the invention relate to the CRISPR-Cas system having the utility of engineering primary cells that recapitulate the genetic complexity of human disease. This complexity arises from the interaction of multiple genetic lesions, which is particularly true in the case of proliferative disorders like cancer,
  • the invention comprehends a method of inducing a proliferative condition in a an organism comprising: isolating a first population of cells from the organism, transducing the first population of cells with a non -naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I.
  • a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRjNlA) polynucleotide sequence wherein the polynucleotide sequence comprises (a.) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism, (b) a tracr mate sequence, and (c) a tracr sequence, and II a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences ( LSs), wherein (a), (b) and (c) are arranged in a 5' to 3 ' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1 ) the
  • the invention may be a cancer, particularly a myeloid malignancy.
  • the first population of cells may be a population of stern cells, particular ⁇ ' a population of hematopoietic stem and progenitor cells.
  • the vector system is a lentiviral vector system.
  • the first regulatory element may be a Pol III promoters such as a U6 promoter and the second regulatory element may be an EFS promoter.
  • the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences.
  • the target sequences may be associated with tumor suppressor genes.
  • the organism is a mouse.
  • the invention also comprehends a method of interrogating function of one or more genes in a proliferative condition in an organism comprising: inducing the proliferative condition by a method comprising isolating a first population of cells from the organism, transducing the first population of cells with a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I.
  • a first regulatory element operably linked to a CRISPR-Cas system chiRNA polynucleotide sequence wherein the polynucleotide sequence comprises (a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism, (b) a tracr mate sequence, and (c) a tracr sequence, and 11.
  • a second regulator ⁇ ' element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme comprising at least one or more NLSs, wherein (a), (b) and (c) are arranged in a 5 ' to 3 ' orientation, wherein components I and 11 are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hvbridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme alters the genome of the first population of cells to obtain a second population of cells, transplanting the second population of cells into the organism thereby inducing the proliferative condition; and determining changes in expression of the one or more genes in the proliferative condition thereby interrog
  • the first population of ceils may be a population of stem cells, particulary a population of hematopoietic stem and progenitor cells.
  • the vector system is a lentiviral vector system.
  • the first regulator ⁇ ' element may be a Pol ill promoter such as a IJ6 or a H I promoter and the second regulatory element may be an EPS promoter.
  • the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences. The invention also comprehends that the target sequences may be associated with tumor suppressor genes.
  • the organism is a mouse.
  • the genes that are useful for this invention are any of the genes that are recurrently mutated in cancer.
  • Embodiments herein are relevant for any gene(s) with ioss- of-function mutation(s) in cancer. This is sometimes referred to as a tumor suppressor, but probably more accurate to refer to gene(s) with loss-of-function mutation(s).
  • Loss-of- function mutation(s) result in the gene product having less or no function.
  • the allele has a complete loss of function (null allele) it is often called an amorphic mutation. Phenotypes associated with such mutations are most often recessive.
  • 90.1 instant invention also can be used to introduce specific mutations, e.g., cut or nick, insertion, deletion, substitution.
  • the list of genes with, loss-of-function mutation is large - in the hundreds. Indeed, the Bioinformatics and Systems Medicine Laboratory of Vanderbilt University Medical Center has a website, the TS GENE TUMOR. SUPPRESSOR GENE DATABASE, http://bioinfb.mc.vanderbiit.edu/TSGene/index.html, that includes 716 human genes (637 coding and 79 non-coding genes), 628 mouse genes, and 567 rat genes. The invention is applicable to each of those genes.
  • the invention is applicable to any gene for which loss of function mutation(s) leads to neoplasm or tumor growth or cancer; and the skilled person well appreciates loss of function mutation(s) in cancer (as well as gain of function mutations in cancer and the invention can be analogously applicable to such mutations).
  • tumor suppressor is herein used as understood in the art, namely to include loss of function mutation(s) in or involved in or that leads to or contributes to or is a factor in neoplasm or tumor growth or cancer, including tumor formation and/or spread and/or Hyperplasia (altered cell divides in an uncontrolled manner leading to an excess of cells in that region of the tissue) and/or Dysplasia (additional genetic changes in the hyperplastic cells lead to increasingly abnormal growth; cells and the the tissue no longer look normal; cells and the tissue may- become disorganized) and/or Carcinoma in situ (additional changes make the cells and tissues appear even more abnormal cells are spread over a larger area and the region of the tissue involved primarily contains altered cells; cells often 'regress' or become
  • the invention provides a non-naturally occurring or engineered composition for generating an in vivo, in vitro or ex vivo proliferative condition comprising multiple genetic lesions in a population of cells comprising a viral vector such as a lentiviral vector system comprising one or more lentiviral vectors comprising I. a Pol III promoter operably linked to a CRISPR-Cas system c iRNA polynucleotide sequence, wherein the polynucleotide sequence comprises (a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism, (b) a tracr mate sequence, and (c) a tracr sequence, and II.
  • a EES promoter operably linked to an enzyme- coding sequence encoding a CRISPR enzyme comprising at least one or more NLSs, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, and wherein the C TSPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence.
  • the first population of cells may be a population of stem cells, particulary a population of hematopoietic stem and progenitor cells.17.
  • the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences.
  • the invention also comprehends that the target sequences may be associated with tumor suppressor genes.
  • aspects of the invention relate to Cas9 enzymes having improved target specificity in a CRISPR-Cas9 system having guide RNAs having optimal activity, smaller in length than wild-type Cas9 enzymes and nucleic acid molecules coding therefor, and chimeric Cas9 enzymes, as well as methods of improving the target specificity of a Cas9 enzyme or of designing a CRISPR-Cas9 system comprising designing or preparing guide RNAs having optimal activity and/or selecting or preparing a Cas9 enzyme having a smaller size or length than wild-type Cas9 whereby packaging a nucleic acid coding therefor into a delivery vector is advanced as there is less coding therefor in the deliver ⁇ ' vector than for wild-type Cas9, and/or generating chimeric Cas9 enzymes.
  • a Cas9 enzyme may comprise one or more mutations and may be used as a generic DNA binding protein with or without fusion to a functional domain.
  • the mutations may be artificially introduced mutations or gain- or loss-of-function mutations.
  • the mutations may include but are not limited to mutations in one of the catalytic domains (D10 and H84Q). Further mutations have been characterized and may be used in one or more compositions of the invention.
  • the mutated Cas9 enzyme may be fused to a protein domain, e.g., such as a transcriptional activation domain.
  • the transcriptional activation domain may be VP64.
  • the 90.1 repressor domain may be KRAB or SID4X.
  • Other aspects of the invention relate to the mutated Cas 9 enzyme being fused to domains which include but are not limited to a transcriptional activator, repressor, a reeombinase, a transposase, a. histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducibie/controllable domain or a chemically inducible/controllable domain.
  • the Cas enzyme has at least one or more mutations in a catalytic domain.
  • the Cas enzyme is a.
  • the invention provides for methods to generate mutant tracrRNA and direct repeat sequences or mutant chimeric guide sequences that allow for enhancing performance of these RNAs in cells. Aspects of the invention also provide for selection of said sequences.
  • aspects of the invention also provide for methods of simplifying the cloning and delivery of components of the CRISPR complex.
  • a suitable promoter such as a Pol III promoter, e.g., a HI or a U6 promoter
  • a DNA oligo is amplified with a DNA oligo and positioned contiguous to and upstream of a sequence encoding the guide RNA.
  • the resulting PGR product can then be trans fected into cells to drive expression of the guide RNA.
  • aspects of the invention also relate to the guide RNA being transcribed in vitro or ordered from a synthesis company and directly transfected.
  • the invention provides for methods to improve activity by using a more active polymerase.
  • a T7 promoter may be inserted contiguous to and upstream of a sequence encoding a guide RNA.
  • the expression of guide RNAs under the control of the T7 promoter is driven by the expression of the T7 polymerase in the cell.
  • the cell is a eukaryotic cell.
  • the eukaryotic cell is a human cell.
  • the human cell is a patient specific cell
  • the invention provides for methods of reducing the toxicity of Cas enzymes.
  • the Cas enzyme is any Cas9 as described herein, for instance any naturally -occurring bacterial Cas9 as well as any chimaeras, mutants, omoiogs or orthologs.
  • the Cas enzyme is a nickase.
  • the Cas9 is delivered into the cell in the form of mRNA. This allows for the transient expression of the enzyme thereby reducing toxicity.
  • the Cas 9 is delivered into the cell in the nucleotide construct that encodes and expresses the Cas 9 enzyme.
  • the invention also provides for methods of expressing Cas9 under the control of an inducible promoter the constructs used therein.
  • the invention provides for methods of improving the in vivo applications of the CRISPR-Cas system.
  • the Cas enzyme is wiidtype Cas9 or any of the modified versions described herein, including any naturally- occurring bacterial Cas9 as well as any chimaeras, mutants, homologs or orthologs.
  • the Cas enzyme is a nickase.
  • An advantageous aspect of the invention provides for the selection of Cas9 homologs that are easily packaged into viral vectors for delivery.
  • Cas9 orthologs typically share the general organization of 3-4 RuvC domains and a HNH domain. The 5' most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand. All notations are in reference to the guide sequence.
  • the catalytic residue in the 5' RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S, pyogenes type II CRISPR locus, S. thermophiius CRISPR locus 1, S. thermophiius CRISPR locus 3, and Franeiscilla novicida type II CRISPR locus), and the conserved Asp residue is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non-complementary-strand nicking enzyme.
  • the CRISPR enzyme is a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme.
  • This type II CRISPR enzyme may be any Cas enzyme.
  • a Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system.
  • the Cas9 enzyme is from, or is derived from, spCas9 or saCas9.
  • derived Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wiidtype enzyme, but that it has been mutated (modified) in some way as described herein
  • Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent.
  • residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes (annotated alternatively as SpCas9 or spCas9).
  • this invention includes many more Cas9s from other species of microbes, such as SpCas9 derived from S. pyogenes, SaCas9 derived from S. aureus, StlCas9 derived from S. thermophiius and so forth. Further examples are provided herein.
  • codon optimized sequence in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, e.g., see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species other than human, or for codon optimization for specific organs such as the brain, is known.
  • the invention provides for methods of enhancing the function of Cas9 by generating chimeric Cas9 proteins. These methods may comprise fusing N -terminal fragments of one Cas9 homolog with C-terminal fragments of another Cas9 homolog. These methods also allo for the selection of new properties displayed by the chimeric proteins.
  • the modification may occur ex vivo or in vitro, for instance in a cell culture and in some instances not in vivo, in other embodiments, it may occur in vivo.
  • the invention provides a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest comprising:
  • A) - 1 a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:
  • a polynucleotide sequence encoding a CRTSPR enzyme comprising at least one or more nuclear localization sequences
  • the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRTSPR complex to the target sequence
  • the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybrid! zableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA,
  • polynucleotides comprising: (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and
  • the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence
  • the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizabieto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA.
  • any or all of the polynucleotide sequence encoding a CRISPR enzyme, guide sequence, tracr mate sequence or tracr sequence may be RNA, DNA or a combination of RNA and DNA.
  • the polynucleotides comprising the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence are RNA.
  • the polynucleotides comprising the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence are DNA.
  • the polynucleotides are a mixture of DNA and RNA, wherein some of the polynucleotides comprising the sequence encoding one or more of the CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence are DNA and some of the polynucleotides are RNA.
  • the polynucleotide comprising the sequence encoding the CRISPR enzyme is a DNA and the guide sequence, tracr mate sequence or tracr sequence are RNA.
  • the one or more polynucleotides comprising the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence may be delivered via nanoparticles, exosomes, microvesciles, or a gene-gun.
  • the RNA sequence includes the feature.
  • the DNA sequence is or can be transcribed into the RNA that comprises the feature at issue.
  • the feature is a protein, such as the CRISPR enzyme
  • the DNA or RNA sequence referred to is, or can be, translated (and in the case of DNA transcribed first).
  • RNA encoding the CRISP enzyme is provided to a ceil, it is understood that the RNA is capable of being translated by the cell into which it is delivered.
  • the invention provides method of modifying an organism, e.g., mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest comprising delivering a non-naturally occurring or engineered composition comprising a viral or plasmid vector system comprising one or more viral or plasmid vectors operably encoding a composition for expression thereof, wherein the composition comprises: (A) a non- naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising 1.
  • chiR A CRISPR-Cas system chimeric RNA
  • a second regulatory element operably linked to an enzyme-coding sequence encoding a CRJSPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS), wherein (a), (b) and (c) are arranged in a 5' to 3 ' orientation, wherein components 1 and 11 are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRJSPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybrid!
  • a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulator element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III.
  • a third regulatory element operably linked to a tracr sequence wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence -specific binding of a.
  • CRJSPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence.
  • the vector comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence.
  • the vector comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence.
  • 90.1 system comprises a viral vector system, e.g., an AAV vector or AA ⁇ /T vector system or a lentivirus-deri ved vector system.
  • the Cas enzyme is a niekase.
  • the vector is a viral vector, such as a lenti- or bacuio- or preferably adeno-viral/adeno-associated viral vectors, but other means of deliver)' are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided.
  • a viral vector such as a lenti- or bacuio- or preferably adeno-viral/adeno-associated viral vectors, but other means of deliver
  • the viral or plasmid vectors may be delivered via nanoparticles, exosomes, microvesciles, or a gene-gun.
  • Applicants mean the alteration of the target sequence, which may include the epigenetic manipulation of a target sequence.
  • This epigenetic manipulation may be of the chromatin state of a target sequence, such as by modification of the methylaiion state of the target sequence (i.e. addition or removal of methylaiion or methylaiion patterns or CpG islands), hi stone modification, increasing or reducing accessibility to the target sequence, or by promoting or reducing 3D folding.
  • the invention provides a method of treating or inhibiting a condition caused by a defect in a target sequence in a genomic locus of interest in an organism (e.g., mammal or human) or a non-human organism (e.g., mammal, such as a mouse) in need thereof comprising modifying the organism or a non-human organism by manipulation of the target sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non-naturally occurring or engineered composition comprising an adenoviral, an AAV or lentiviral vector system comprising one or more vectors comprising operably encoding a.
  • a non-naturally occurring or engineered composition comprising an adenoviral, an AAV or lentiviral vector system comprising one or more vectors comprising operably encoding a.
  • composition for expression thereof wherein the target sequence is manipulated by the composition when expressed, wherein the composition comprises: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a. tracr mate sequence, and (c) a tracr sequence, and II.
  • chiRNA CRISPR-Cas system chimeric RNA
  • a second regulatory element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS) wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (!
  • a non-naturaliy occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic ceil, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III.
  • the vector system comprises a viral vector system, e.g., an AAV vector or AAV vector system or a lenti virus-derived vector system.
  • the Cas enzyme is a nickase.
  • Some methods of the invention can include inducing expression.
  • the organism or subject is a eukaryote (including mammal including human) or a non-human eukaryote or a non-human animal or a non-human mammal.
  • the organism or subject is a plant.
  • the organism or subject is a mammal or a non-human mammal.
  • the organism or subject is algae.
  • the viral vector is an AAV.
  • the CRISPR CRISPR
  • the 90.1 enzyme is a Cas9, In some methods of the invention the CRISPR enzyme copmprises one or more mutations in one of the catalytic domains. In some methods of the invention the CRISPR enzyme is a Cas9 nickase. In some methods of the invention the expression of the guide sequence is under the control of the T7 promoter that is driven by the expression of T7 polymerase. In some methods of the inven tion the expression of the guide sequence is under the control of a U6 promoter.
  • Applicants mean the alteration of the target sequence, which may include the epigenetic manipulation of a target sequence.
  • This epigenetic manipulation may be of the chromatin state of a target sequence, such as by modification of the methylation state of the target sequence (i.e. addition or removal of methylation or methylation patterns or CpG islands), histone modification, increasing or reducing accessibility to the target sequence, or by promoting or reducing 3D folding.
  • the invention provides methods and compositions related to generating models to study proliferative disorders.
  • These models maybe encompassed in non-human organisms, e.g. mouse, rat, primates etc.
  • proliferative disorders or cancers include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermis, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small ceil lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g.
  • exocrine pancreatic carcinoma stomach, cervix, thyroid, prostate, gastrointestinal system, e.g. gastrointestinal stromal tumours, or skin, for example squamous ceil carcinoma; a hematopoieitic tumour of lymphoid lineage, for example leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma (such as diffuse large B cell lymphoma), T-cell lymphoma, Tiodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkitt's lymphoma; a hematopoieitic tumour of lymphoid lineage, for example leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma (such as diffuse large B cell lymphoma), T-cell lymphoma, Tiodgkin's lymph
  • 90.1 hematopoietic tumour of myeloid lineage including, but not limited to acute myeloid leukaemia, chronic myeloid leukaemias, myelogenous leukaemias, and Imatinib sensitive and refractory chronic myelogenous leukaemias, myelodyspiastic syndrome, Bortezomib sensitive and refractory multiple myeloma, myeloproliferative disease or promyelocyte leukaemia; thyroid follicular cancer; a tumour of mesenchymal origin, for example fibrosarcoma or rhabdomyosarcoma; a tumour of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma (a High grade glioma) or schwannoma; melanoma (e.g.
  • tumour of mesenchymal origin is Ewing's sarcoma.
  • carcinomas for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermis, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, gall bladder, ovary, pancreas e.g. exocrine pancreatic carcinoma, stomach, thyroid, prostate, gastrointestinal system, e.g.
  • gastrointestinal stromal tumours or skin, for example squamous cell carcinoma
  • a hematopoietic tumour of lymphoid lineage for example leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma (such as diffuse large B cell lymphoma), T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkitt's lymphoma
  • a hematopoietic tumour of myeloid lineage including acute myeloid leukaemia, chronic myeloid leukaemias, myelogenous leukaemias, and Imatinib sensitive and refractor)' chronic myelogenous leukaemias, myelodyspiastic syndrome, Bortezomib sensitive and refractor ⁇ ' multiple myeloma, myeloproliferative disease or promye
  • tumours selected from metastatic breast cancer which is HER2 positive; adenocarcinoma of the prostate; metastatic melanoma; non-small ceil carcinoma of the lung (NSCLC ); small ceil carcinoma of the lung (SCLC); high grade gliomas; gastrointestinal stromal tumors (GIST); colorectal cancer; glioblastoma; melanoma; metastatic thyroid cancer; prostate cancer; and rectal cancer.
  • a particular subgroup consists of colorectal cancer; glioblastoma; melanoma; metastatic thyroid cancer; prostate cancer; and rectal cancer,
  • One group of cancers includes human breast cancers (e.g. primary breast tumours, node-negative breast cancer, invasive duct adenocarcinomas of the breast, non- endometrioid breast cancers); and mantle cell lymphomas.
  • human breast cancers e.g. primary breast tumours, node-negative breast cancer, invasive duct adenocarcinomas of the breast, non- endometrioid breast cancers
  • other cancers are colorectal and endometrial cancers.
  • Another sub-set of cancers includes hematopoietic tumours of both lymphoid and myeloid lineage, for example acute lymphoblastic leukemia, chronic lymphocytic leukaemia (Both T and B cell), acute myeloid leukaemia, chronic myeloid leukaemia, mantle cell lymphoma and B-ceil lymphoma (such as diffuse large B cell lymphoma) and optionally further includes chronic myelogenous leukaemia and multiple myeloma.
  • acute lymphoblastic leukemia chronic lymphocytic leukaemia (Both T and B cell)
  • acute myeloid leukaemia chronic myeloid leukaemia
  • chronic myeloid leukaemia chronic myeloid leukaemia
  • mantle cell lymphoma such as diffuse large B cell lymphoma
  • B-ceil lymphoma such as diffuse large B cell lymphoma
  • a sub-set of cancers consists of ErbB2 -positive breast, prostate, lung, and gastric cancer; chronic myeloid leukemia; androgen receptor dependent prostate cancer; Flt3 -dependent acute myeloid leukaemia; melanoma associated with Braf mutation; multiple myeloma; velcade refractory multiple myeloma; and gastrointestinal stromal tumours (GIST).
  • Another sub-set of cancers consists of hormone refractory prostate cancer, metastatic melanoma, HER2 positive breast cancer, mutant EGFR positive non-small cell lung carcinoma and Gleevec resistant gastrointestinal stromal tumours.
  • a further sub-set of cancers consists of hormone refractory prostate cancer, metastatic melanoma, HER2 positive breast cancer, mutant EGFR positive non-small cell lung carcinoma, Small Cell Lung Carcinoma and gastrointestinal stromal tumours.
  • the invention provides a method of treating or inhibiting a condition caused by a defect in a target sequence in a genomic locus of interest in an organism or a non-human organism in need thereof comprising modifying the organism or a non-human organism by manipulation of the target sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non-naturaliy occurring or engineered composition comprising an AAV or a lenti viral vector system comprising one or more AAV or lenti viral vectors comprising operably encoding a composition for expression thereof, wherein the target sequence is manipulated by the composition when expressed, wherein the composition comprises: (A) a non-naturaliy occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system
  • chiR A 90.1 chimeric RNA (chiR A) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a. tracr sequence, and 11.
  • a firs t regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme, and III.
  • the vector system comprises a viral vector system, e.g., an AAV vector or AAV vector system or a lenti virus-derived vector system.
  • the Cas enzyme is a nickase.
  • Some methods of the invention can include inducing expression.
  • the organism or subject is a eukaryote or a non-human eukaryote or a non-human animal
  • the organism or subject is a plant.
  • the organism or subject is a mammal or a non- human mammal.
  • the organism or subject is algae.
  • the viral vector is an AAV or a lenti viral vector.
  • the CRISPR enzyme is a Cas9. In some methods of the
  • the expression of the guide sequence is under the control of the T7 promoter is driven by the expression of T ' 7 polymerase.
  • the invention in some embodiments comprehends a method of delivering a CRTSPR enzyme comprising delivering to a cell mRNA encoding the CRISPR enzyme.
  • the CRISPR enzyme is a Cas9.
  • the invention in some embodiments comprehends a method of preparing the AAV or lentivims vector of the invention comprising transfecting one or more plasmid(s) containing or consisting essentially of nucleic acid molecule(s) coding for the AAV or lentivirus into AAV- or lentivirus-infetable cells, and supplying AAV rep and/or cap obligatory for replication and packaging of the AAV or supplying the essential proteins that may be needed for packaging, replication and transduction of a lentivims (e.g. gag, pol, rev).
  • a lentivims e.g. gag, pol, rev
  • the AAV rep ami/or cap obligator)' for replication and packaging of the AAV are supplied by transfecting the cells with helper plasmid(s) or helper virus(es).
  • the helper vims is a poxvirus, adenovirus, herpesvirus or baculovirus.
  • the poxvirus is a vaccinia vims.
  • the cells are mammalian cells. And in some embodiments the cells are insect ceils and the helper vims is bacuiovirus.
  • pathogens are often host-specific.
  • Fusarium oxysporum f. sp. tycopersici causes tomato wilt but attacks only tomato
  • Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants.
  • there can be non-host resistance e.g., the host and pathogen are incompatible.
  • Horizontal Resistance e.g., partial resistance against ail races of a pathogen, typically controlled by many genes
  • Vertical Resistance e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes.
  • plants and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance.
  • the sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents.
  • plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in
  • the viral vector is a tobacco mosaic vims vector or an Agrobacterium Ti or Ri plasmid.
  • the invention further comprehends a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in medicine.
  • the invention comprehends a composition according to the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in a method according to the invention.
  • the invention provides for the use of a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in ex vivo gene or genome editing.
  • the invention comprehends use of a.
  • composition of the invention or a CRISPR enzyme thereof in the manufacture of a medicament for ex vivo gene or genome editing or for use in a method according of the invention.
  • the CRISPR enzyme comprises one or more mutations in one of the catalytic domains.
  • the CRISPR enzyme is a nickase.
  • the invention comprehends in some embodiments a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme), wherein the target sequence is flanked at its 3' end by 5 '-motif termed a proto-spacer adjacent motif (PAM), especially where the Cas9 is (or is derived from) S. pyogenes or S. aureus Cas9.
  • PAM proto-spacer adjacent motif
  • a suitable PAM is 5 -NRG or 5 NNGRR (where N is any Nucleotide) for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively, as mentioned below.
  • SpCas9 or SaCas9 are those from or derived from S. pyogenes or S. aureus Cas9.
  • Apects of the invention comprehend improving the specificity of a CRISPR enzyme, e.g. Cas9, mediated gene targeting and reducing the likelihood of off-target modification by the CRISPR enzyme, e.g. Cas9.
  • the invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a. second target sequence on opposite strands of a DNA duplex in a genomic locus of interest in a cell comprising delivering a non-naturally occurring or engineered composition comprising :
  • a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence wherein the first polynucleotide sequence comprises:
  • a second CRISPR-Cas system chiRNA polynucleotide sequence wherein the second polynucleotide sequence comprises:
  • a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences and comprising one or more mutations wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein when transcribed, the first and the second tracr mate sequence hybridize to the first and second tracr sequence respectively and the first and the second guide sequence directs sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRISPR complex comprises the CRISPR enzyme complexed with (1 ) the first guide sequence that is hybridizabieto the first target sequence, and (2) the first tracr mate sequence that is hybridized to the first tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridizabieto the second target sequence, and (2) the second tracr mate sequence that is hybridized to the second tracr sequence, wherein the polynucleo
  • the first nick and the second nick in the DNA is offset relative to each other by at least one base pair of the duplex. In one aspect, the first nick and the second nick are offset relative to each other so that the resulting DNA break as a 3' overhang. In one aspct, the first nick and the second nick are offset relative to each other so that the resulting DNA break has a 5 ' overhang. In one aspect, the first nick and the second nick are positioned relative to each other such that the overhang is at least 1 nt, at least 10 nt, at least 15 nt, at least 26 nt, at least 30 nt, at least 50 nt or more that at least
  • any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence is/are RNA
  • the polynucleotides comprising the sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence is/are RNA and are delivered via nanoparticles, exosomes, microvesciles, or a gene -gun.
  • the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity.
  • the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9.
  • the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of DIOA, E762A, H840A, N854A, N863A and D986A.
  • the CRISPR enzyme has the DIOA mutation.
  • the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the opposite strand near the second target sequence results in a 5' overhang.
  • the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs.
  • the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs,
  • the invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a second target sequence on opposite strands of a. DNA duplex in a genomic locus of interest in a ceil, the method comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising
  • ITT a third regulatory element operably linked to an enzyme -coding sequence encoding a CRTSPR enzyme
  • components I, II, III and IV are located on the same or different vectors of the system
  • the tracr mate sequence hybridizes to the tracr sequence and the first and the second guide sequence directs sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively
  • the first CRTSPR complex comprises the CRISPR enzyme complexed with (I) the first guide sequence that is hybridizableto the first target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence
  • the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridizableto the second target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence
  • the polynucleotide sequence encoding a CRISPR enzyme is DNA or R A
  • the first guide sequence directs cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the opposite strand of the DNA duplex near the second target sequence inducing an offset double
  • any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence is/are RNA.
  • the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity.
  • the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9.
  • the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of DIOA, E762A, H84QA, N854A, N863A and D986A.
  • the CRISPR enzyme has the DIOA mutation.
  • one or more of the viral vectors are delivered via nanoparticles, exosomes, microvesicles, or a gene-gun. ⁇ 57]
  • the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the opposite strand near the second target sequence results in a 5' overhang.
  • the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.
  • the invention in some embodiments comprehends a method of modifying a genomic locus of interest by minimizing off-target modifications by introducing into a cell, said cell containing and expressing a double stranded DNA molecule encoding the gene product, an engineered, non-naiurally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations in a catalytic domain and two guide RNAs that target a first strand and a second strand of the DNA molecule respectively, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.
  • the Cas protein nicldng each of the first strand and the second strand of the DNA molecule encoding the gene product results in a 5' overhang.
  • the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs.
  • the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.
  • Embodiments of the invention also comprehend the guide RNAs comprising a guide sequence fused to a tracr mate sequence and a tracr sequence.
  • the Cas protein is codon optimized for expression in a eukaryotic cell, wherein it may be a mammalian cell or a human cell or a specific tissue -type cell
  • the Cas protein is a. type II CRISPR-Cas protein, e.g. a Cas 9 protein.
  • the Cas protein is a Cas9 protein, e.g. SpCas9.
  • the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A.
  • the Cas protein has the D10A mutation, in many aspects of the invention, the Cas protein is a nickase.
  • aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the fragment comprising the DNA sequence between the two nick sites to be lost and the remaining two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased.
  • the gene product is a protein
  • the gene product is a microRNA.
  • the regulator ⁇ ' region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
  • the invention also comprehends an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations and two guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product in a cell, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA duplex molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.
  • the guide RNAs may comprise a guide sequence fused to a tracr mate sequence and a tracr sequence.
  • the Cas protein is a type II CRISPR-Cas protein.
  • the Cas protein is codon optimized for expression in a eukaryotic cell, wherein it may be a mammalian cell or a human cell or a cell of a specific tissue type.
  • the Cas protein is a type II CRISPR-Cas protein, e.g. a Cas 9 protein.
  • the Cas protein is a Cas9 protein, e.g. SpCas9.
  • the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A.
  • the Cas protein has the D10A mutation.
  • the Cas protein is a nickase.
  • aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased or decreased.
  • the gene product is a protein, in an embodiment of the
  • the gene product is a microRNA.
  • the regulator ⁇ ' region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
  • the invention also comprehends an engineered, non-naturally occurring vector system comprising one or more vectors comprising:
  • components (a) and b) are located on same or different vectors of the system, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.
  • the guide RNAs may comprise a guide sequence fused to a tracr mate sequence and a tracr sequence.
  • the Cas protein is a type II CRISPR-Cas protein.
  • the Cas protein is codon optimized for expression in a eukaryotic ceil, wherein it may be a mammalian cell or a human cell.
  • the Cas protein is a type II CRTSPR-Cas protein, e.g. a Cas 9 protein.
  • the Cas protein is a Cas9 protein, e.g. SpCas9.
  • the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, 854A, N863A and D986A, In a highly preferred embodiment the Cas protein has the D10A mutation.
  • aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5 ' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased.
  • the gene product is a protein.
  • the gene product is a microRNA.
  • the regulatory region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
  • the vectors of the system are viral vectors.
  • the vectors of the system are delivered via nanoparticies, exosomes, microvesicles, or a gene-gun.
  • the invention provides a method of modifying a target polynucleotide in a eukaryotic cell.
  • the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
  • said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence.
  • the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.
  • said vectors are delivered to the eukaryotic cell in an organism.
  • said modifying takes place in said eukaryotic cell in a cell culture.
  • the method further comprises isolating said eukaryotic cell from an organism prior to said modifying.
  • the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said organism.
  • the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell.
  • the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
  • the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.
  • the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene.
  • a disease gene is any gene associated an increase in the risk of having or developing a disease.
  • the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene.
  • said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.
  • the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cell (s), the method comprising: introducing one or more vectors into t e prokaryotic ceil (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and an editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the celi(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRISPR complex comprises the CRISPR.
  • the CRJSPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more prokaryotic cell(s) in which one or more mutations have been introduced to be selected.
  • the CRJSPR enzyme is Cas9.
  • the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system.
  • the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell.
  • the method comprises allowing a CRJSPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRJSPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
  • this invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell.
  • the method comprises increasing or decreasing expression of a target polynucleotide by using a CRISPR complex that binds to the polynucleotide.
  • one or more vectors comprising a tracr sequence, a guide sequence linked to the tracr mate sequence, a sequence encoding a CRISPR enzyme is delivered to a cell.
  • the one or more vectors comprises a regulator ⁇ ' element operably linked to an enzyme- coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; and a regulator)' element operably linked to a tracr mate sequence and one or more insertion sites for inserting a guide sequence upstream of the tracr mate sequence.
  • the guide sequence directs sequence -specific binding of a CRISPR complex to a target sequence in a ceil.
  • the CRISPR complex comprises a CRISPR enzyme complexed with (1 ) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence.
  • the vector system comprises a viral vector system, e.g., an AAV vector or AAV vector system or a lend vims -derived vector system.
  • a target polynucleotide can be inactivated to effect the modification of the expression in a cell
  • the target polynucleotide upon the binding of a CRISPR complex to a target sequence in a cell, the target polynucleotide is inactivated such that the sequence is not transcribed, the coded protein is not produced, or the sequence does not function as the wild-type sequence does.
  • 90.1 sequence may be inactivated such that the protein or microRNA or pre-microR A transcript is not produced.
  • the CR1SPR enzyme comprises one or more mutations D10A, E762A, H840A, N854A, 863A or D986A and/or the one or more mutations is in a RuvCl or HNH domain of the CRTSPR enzyme or is a mutation as otherwise as discussed herein.
  • the CR1SPR enzyme has one or more mutations in a catalytic domain, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRTSPR complex to the target sequence, and wherein the enzyme further comprises a functional domain.
  • the mutated Cas9 enzyme may be fused to a protein domain, e.g., such as a transcriptional activation domain.
  • a transcriptional activation domain is VP64.
  • a transcription repression domains is KRAB.
  • a transcription repression domain is SID, or concatemers of SID (i.e. SID4X).
  • an epigenetic modifying enzyme is provided.
  • an activation domain is provided, which may be the P65 activation domain.
  • the CRISPR enzyme is a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme.
  • This type II CRISPR enzyme may be any Cas enzyme.
  • a Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system.
  • the Cas9 enzyme is from, or is derived from, spCas9 or saCas9.
  • derived Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein.
  • Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent.
  • residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes.
  • this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCa9, St.ICas9 and so forth,
  • codon optimization for a host species other than human or for codon optimization for specific organs or tissues such as the brain, is known.
  • delivery is in the form of a vector which may be a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-assoeiated viral vectors, but other means of deliver ⁇ ' are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided,
  • a vector may mean not only a viral or yeast system (for instance, where the nucleic acids of interest may be operably linked to and under the control (in terms of expression, such as to ultimately provide a processed RNA) a promoter), but also direct deliver ⁇ ' of nucleic acids into a host cell.
  • the vector may be a viral vector and this is advantageously an AAV
  • viral vectors as herein discussed can be employed.
  • baculoviruses may be used for expression in insect cells. These insect cells may, in turn be useful for producing large quantities of further vectors, such as AAV vectors adapted for delivery of the present invention.
  • a method of delivering the present CRISPR enzyme comprising delivering to a cell mRNA encoding the CRTSPR enzyme.
  • the CRISPR enzyme is truncated, comprised of less than one thousand amino acids or less than four thousand amino acids, is a nuclease or nickase, is codon-optimized comprises one or more mutations, and/or comprises a chimeric CRISPR enzyme, or the other options as herein discussed.
  • AAV viral vectors or lentiviral vectors are preferred.
  • the target sequence is flanked or followed, at its 3 ' end, by a PAM suitable for the CRISPR enzyme, typically a Cas and in particular a Cas9.
  • a suitable PAM is 5'-NRG or 5VN GRR for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively.
  • SpCas9 or SaCas9 are those from or derived from S. pyogenes or S. aureus Cas9.
  • 90.1 disclose a disclaimer of any previously described product, process of making the product, or method of using the product.
  • FIG. 1 shows a schematic model of the CRISPR system.
  • the Cas9 nuclease from Streptococcus pyogenes (yellow) is targeted to genomic DNA by a synthetic guide RN (sgRNA) consisting of a 20-nt guide sequence (blue) and a scaffold (red).
  • the guide sequence base-pairs with the DNA target (blue), directly upstream of a. requisite 5' -NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double -stranded break (DSB) -3 bp upstream of the PAM (red triangle),
  • Figure 2A-F shows an exemplary CRISPR system, a possible mechanism of action, an example adaptation for expression in eukaryotic cells, and results of tests assessing nuclear localization and CRISPR activity.
  • Figure 3A-D shows results of an evaluation of SpCas9 specificity for an example target.
  • Figure 4A-G sho an exemplar vector system and results for its use in directing homologous recombination in eukaryotic cells.
  • Figure 5 provides a table of protospacer sequences and summarizes modification efficiency results for protospacer targets designed based on exemplary S. pyogenes and S. thermophilus CRISPR systems with corresponding PAMs against loci in
  • Figure 6A-C shows a. comparison of different tracrRNA transcripts for Cas9- mediated gene targeting.
  • Figure 7 shows a schematic of a surveyor nuclease assay for detection of double strand break-induced micro-insertions and -deletions.
  • Figure 8A-B shows exemplary bicistronic expression vectors for expression of CRISPR system elements in eukaryotic cells.
  • Figure 9A-C shows histograms of distances between adjacent S. pyogenes SF370 locus 1 PAM ( GG) ( Figure 9A) and S. thermophilus LMD9 locus 2 PAM (NNAGAAW) ( Figure 9B) in the human genome; and distances for each PAM by chromosome (Chr) ( Figure 9C).
  • Figure 10A-D shows an exemplary CRISPR system, an example adaptation for expression in eukaryotic cells, and results of tests assessing CRISPR activity.
  • Figure 11A-C shows exemplary manipulations of a CRISPR system for targeting of genomic loci in mammalian cells.
  • Figure 12A-B shows the results of a Northern blot analysis of crRN processing in mammalian cells.
  • Figure 13A-B shows an exemplary selection of protospacers in the human PVALB and mouse Th loci.
  • Figure 14 shows example protospacer and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX 1 locus.
  • Figure 15 provides a table of sequences for primers and probes used for Surveyor, RFLP, genomic sequencing, and Northern blot assays,
  • Figure 16A-C shows exemplary manipulation of a CRISPR system with chimeric RNAs and results of SURVEYOR assays for system activity in eukaryotic cells.
  • Figure 17A-B shows a graphical representation of the results of SURVEYOR assays for CRISPR system activity in eukaryotic ceils.
  • Figure 18 shows an exemplary visualization of some S. pyogenes Cas9 target sites in the human genome using the UCSC genome browser.
  • Figure 19A-D shows a circular depiction of the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (-1100 amino acids),
  • Figure 20A-F shows the linear depic tion of the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (-1100 amino acids).
  • Figure 21A-D shows genome editing via homologous recombination
  • (a) Schematic of SpCas9 nickase, with D10A mutation in the RuvC I catalytic domain (b) Schematic representing homologous recombination (HR) at the human EMXl focus using either sense or antisense single stranded oligonucleotides as repair templates. Red arrow above indicates sgRNA cleavage site; PGR primers for genotyping (Tables J and K) are indicated as arrows in right panel, (c) Sequence of region modified by HR.
  • Figure 22 -B shows single vector designs for SpCas9.
  • Figure 23 shows a graph representing the length distribution of Cas9 oithoiogs.
  • Figure 24A-M shows sequences where the mutation points are located within the SpCas9 gene.
  • Figure 25A-B shows the Conditional Cas9, Rosa26 targeting vector map and (B) shows the Constitutive Cas9, Rosa26 targeting vector map.
  • Figure 26 shows a schematic of the important elements in the Constitutive and Conditional Cas9 constructs
  • Figure 27 shows delivery and in vivo mouse brain Cas9 expression data
  • Figure 28A-C shows RNA delivery of Cas9 and chimeric RNA into cells
  • A Delivery of a GFP reporter as either DNA or mRNA into Neuro-2A cells.
  • B Deliver ⁇ ' of Cas9 and chimeric RNA against the Icam2 gene as RNA results in cutting for one of two spacers tested.
  • C Delivery of Cas9 and chimeric RNA against the F7 gene as RNA results in cutting for one of two spacers tested.
  • Figure 29 shows how DNA double-strand break (DSB) repair promotes gene editing.
  • NHEJ error-prone non-homologous end joining
  • the ends of a DSB are processed by endogenous DNA repair machineries and rejoined together, which can result in random insertion/deletion (indel) mutations at the site of junction.
  • Indel random insertion/deletion
  • a repair template in the form of a plasm id or single-stranded oligodeoxynucleotides can be supplied to leverage the homology-directed repair (HDR) pathway, which allows high fidelity and precise editing.
  • Figure 30A-C shows anticipated results for HDR in HEK and HUES9 cells,
  • Either a targeting plasmid or an ssODN (sense or antisense) with homology arms can be used to edit the sequence at a target genomic locus cleaved by Cas9 (red triangle).
  • a targeting plasmid or an ssODN (sense or antisense) with homology arms can be used to edit the sequence at a target genomic locus cleaved by Cas9 (red triangle).
  • Applicants introduced a Hindlll site (red bar) into the target locus, which was PGR -amplified with primers that anneal outside of the region of homology.
  • ssOD s oriented in either the sense or the antisense (s or a) direction relative to the locus of interest, can be used in combination with Cas9 to achieve efficient HDR- mediated editing at the target locus.
  • ssODNs Example of the effect of ssODNs on HDR in the EMXl locus is shown using both wild-type Cas9 and Cas9 nickase (D10A).
  • Each ssODN contains homology arms of 90 bp flanking a 12-bp insertion of two restriction sites.
  • Figure 31A-C shows the repair strategy for Cystic Fibrosis delta F508 mutation.
  • Figure 32A-B (a) shows a schematic of the GAA repeat expansion in FXN intron 1 and (b) shows a schematic of the strategy adopted to excise the GAA expansion region using the CRTSPR/Cas system.
  • Figure 33 shows a screen for efficient SpCas9 mediated targeting of Tetl -3 and Dnmtl , 3a and 3b gene loci.
  • Surveyor assay on DNA from transfected N2A cells demonstrates efficient DNA cleavage by using different gRNAs.
  • Figure 34 shows a strategy of multiplex genome targeting using a 2 -vector system in an AAV 1/2 delivery system, Tetl -3 and Dnmtl, 3a and 3b gRNA under the control of the ⁇ 6 promoter.
  • GFP-KASH under the control of the human synapsin promoter.
  • Restriction sides shows simple gRNA replacement strategy by subcloning.
  • HA- tagged SpCas9 flanked by two nuclear localization signals (NLS) is shown. Both vectors are delivered into the brain by AAV 1/2 virus in a 1 : 1 ratio.
  • Figure 35 shows verification of multiplex DNMT targeting vector #1 functionality using Surveyor assay. N2A cells were co-transfected with the DNMT targeting vector #1 (+) and the SpCas9 encoding vector for testing SpCas9 mediated
  • Figure 36 shows verification of multiplex DNMT targeting vector #2 functionality using Surveyor assay.
  • N2A cells were co-transfected with the DNMT targeting vector #1 (+) and the SpCas9 encoding vector for testing SpCas9 mediated cleavage of DNMTs genes family loci.
  • gRNA only ( ⁇ ) is negative control. Cells were harvested for DNA purification and downstream processing 48 h after transfection.
  • Figure 37 shows schematic overview of short promoters and short poly.A versions used for HA-SpCas9 expression in vivo. Sizes of the encoding region from L-ITR to R-ITR are shown on the right.
  • Figure 38 shows schematic overview of short promoters and short polyA versions used for HA-SaCas9 expression in vivo. Sizes of the encoding region from L-ITR to R-ITR are shown on the right.
  • Figure 39 shows expression of SpCas9 and SaCas9 in N2A ceils. Representative Western blot of HA -tagged SpCas9 and SaCas9 versions under the control of different short promoters and with or short polyA (spA) sequences. Tubulin is loading control. mCherry (mCh) is a. transfection control Cells were harvested and further processed for Western blotting 48 h after transfection.
  • Figure 40 shows screen for efficient SaCas9 mediated targeting of Tet.3 gene locus.
  • Surveyor assay on DNA from transfected N2A cells demonstrates efficient DNA cleavage by using different gRNAs with NNGGGT sequence.
  • GFP transfected cells and cells expressing only SaCas9 are controls.
  • Figure 41 shows expression of HA-SaCas9 in the mouse brain. Animals were injected into dentate gyri with vims driving expression of HA-SaCas9 under the control of human Synapsin promoter. Animals were sacrificed 2 weeks after surgery. HA tag was detected using rabbit monoclonal antibody C29F4 (Cell Signaling). Cell nuclei stained in blue with DAPI stain,
  • Figure 42 shows expression of SpCas9 and SaCas9 in cortical primary neurons in culture 7 days after transduction. Representative Western blot of HA-tagged SpCas9 and SaCas9 versions under the control of different promoters and with bgli or short polyA (spA) sequences. Tubulin is loading control.
  • spA short polyA
  • Figure 43 shows LIVE/DEAD stain of primary cortical neurons 7 days after transduction with AAVl particles carrying SpCas9 with different promoters and multiplex gRNAs constructs (example shown on the last panel for DNMTs), Neurons after AAV
  • Figure 44 shows LIVE/DEAD stain of primary cortical neurons 7 days after transduction with AAV1 particles carrying SaCas9 with different promoters. Red nuclei indicate permeabilized, dead cells (second line of panels). Live ceils are marked in green color (third line of panels).
  • Figure 45 shows comparison of morphology of neurons after transduction with AAV1 virus carrying SpCas9 and gRNA multiplexes for TETs and DNMTs genes loci. Neurons without transduction are shown as a control.
  • Figure 46 shows verification of multiplex DNMT targeting vector #1 functionality using Surveyor assay in primary cortical neurons. Cells were co-transduced with the DNMT targeting vector #1 and the SpCas9 viruses with different promoters for testing SpCas9 mediated cleavage of DNMTs genes family loci.
  • Figure 47 shows in vivo efficiency of SpCas9 cleavage in the brain.
  • Mice were injected with AAV 1/2 virus carrying gRNA multiplex targeting DNMT family genes loci together with SpCas9 viruses under control of 2 different promoters: mouse Mecp2 and rat Maplb.
  • Figure 48 shows purification of GFP-KASH labeled cell nuclei from hippocampal neurons.
  • the outer nuclear membrane (ONM) of the ceil nuclear membrane is tagged with a fusion of GFP and the ASH protein transmembrane domain. Strong GFP expression in the brain after one week of stereotactic surgery and AAV1 /2 injection. Density gradient centrifugation step to purify cell nuclei from intact brain. Purified nuclei are shown. Chromatin stain by Vybrant ⁇ DyeCycleTM Ruby Stain is shown in red, GFP labeled nuclei are green. Representative FACS profile of GFPF and GFP- cell nuclei (Magenta: Vybrant® DyeCycleTM Ruby Stain, Green: GFP).
  • Figure 49 shows efficiency of SpCas9 cleavage in the mouse brain.
  • Mice were injected with AAV 1/2 virus carrying gRNA multiplex targeting TET family genes loci together with SpCas9 viruses under control of 2 different promoters: mouse Mecp2 and rat Maplb.
  • Figure 50 shows GFP-KASH expression irs cortical neurons in culture. Neurons were transduced with AAVl virus carrying gRNA multiplex constructs targeting TET genes loci. The strongest signal localize around cells nuclei due to KASH domain localization.
  • Figure 51 shows (top) a list of spacing (as indicated by the pattern of arrangement for two PAM sequences) between pairs of guide RNAs. Only guide RNA pairs satisfying patterns 1, 2, 3, 4 exhibited indels when used with SpCas9(D10A) nickase. (bottom) Gel images showing that combination of SpCas9(D10A) with pairs of guide RNA satisfying patterns 1, 2, 3, 4 led to the formation of indels in the target site.
  • Figure 52 shows a. list of U6 reverse primer sequences used to generate U6- guide RNA expression casssettes. Each primer needs to be paired with the U6 forward primer "gcactgagggcctatttcccatgattc" (SEQ ID NO: ) to generate amplicons containing
  • Figure 53 shows a Genomic sequence map from the human Emxl locus showing the locations of the 24 patterns listed in Fig. 51.
  • Figure 54 shows on (right) a gel image indicating the formation of indels at the target site when variable 5' overhangs are present after cleavage by the Cas9 nickase targeted by different pairs of guide RNAs.
  • a table indicating the lane numbers of the gel on the right and various parameters including identifying the guide RNA pairs used and the length of the 5' overhang present following cleavage by the Cas9 nickase,
  • Figure 55 shows a Genomic sequence map from the human Emxl locus showing the locations of the different pairs of guide RNAs that result in the gel patterns of Fig, 54 (right) and which are further described in Example 35,
  • Figure 56A-E shows stable modification of hematopoietic stem ceils by a lentiviral CRISPR-Cas delivery system
  • A Depiction of a lentiviral vector for bi-cistronic expression of the sgRNA from a U6 promoter (U6) and Cas9 from a short EFla promoter (EFS) with a fluorescent protein marker (eGFP) from a picorna vims derived 2A auto- cleavage site (P2A),
  • eGFP fluorescent protein marker
  • RFP657 lentiviral vector that allows incorporation of target sites into the coding sequence of a fluorescent protein
  • a Purornycin resistance gene PAC
  • IRS internal ribosomal entry site
  • Figure 57A-D shows multiplex gene targeting induces clonal development in vivo
  • C Peripheral blood CRISPR Cas-eGFP vector expression (x-axis) and expression of a pool of vectors expressing RFP657 (y-axis) over time starting 4 weeks post-transplant. Clonal populations were detected by the pattern of eGFP/RFP657 expression.
  • Figure 58A-G shows myeloid malignancy modeling with multiplex genome editing
  • CRISPR/Cas vectors and for myeloid (Grl +/CD1 Ib-F). Detected mutations are shown in the right panel (displayed in red box). Sequence alignments are shown in Fig. 67.
  • F) Lineage distribution in peripheral blood from secondary mice 8 weeks post-transplant (n 5).
  • FIG 59A-C shows a modular CRISPR/Cas lentiviral vector system for genome engineering
  • U6 U6 promoter
  • SFFV Spleen Focus Forming Virus
  • eGFP or tagRFP fluorescent protein marker
  • PAC Purmomycin acetyl transferase
  • BSD Blasticidin deaminase
  • Figure 60 shows that Lentiviral CRISPR-Cas mediates highly efficient genome editing at endogenous loci Surveyor Assay on targeted region of Tet2 target site 3(TS3) (left, marked red in Fig. 56C) and Run l target site 1 (TS1) (right , marked red in Fig. 56C) one week post-transduction of murine BaF3 cells with a lentiviral CRISPR-Cas vector.
  • CRISPR/Cas expressing cells were purified by FACS. The percentage of cleaved PGR product is noted below.
  • FIG. 6IA-C shows CRISPR/Cas mediated knock out of Runxl in Flt3-ITD heterozygous HSCs induces a competitive advantage
  • A) Flow cytometric assessment of CRISPR/Cas transduced ceils in the peripheral blood of mice over a period of 19 weeks after transplantation (control sgRNA left;
  • Runxl sgRNA right B) Gating scheme of HSPC populations in mice transduced with CRISPR/Cas lentiviral vectors.
  • MPP MuStipotent progenitors (LSK CD 150- CD48+);
  • ST-HSC
  • Figure 62A-B shows stable genome modification in long-term repopulating HSCs in-vivo by Next Generation Sequencing. Mutational analysis of peripheral blood samples at 5 weeks post-transplant and 19 weeks post-transplant. A) Samples were analyzed to detect all unique mutations from each mouse at 5 weeks and at 19 weeks for mutations at the Runxl target site. Mutations detected at both time points and only at 5 weeks are shown. B) Mutations found at 19 weeks but not at 5 weeks are shown.
  • Figure 63A-B shows flow cytometry based clonality analysis of C57B1/6 mice shows expansion of CRISPR/Cas engineered populations over time Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgRNAonly vector expression (RFP657) for control sgRNA (A) and pooled sgRNAs (B) in C57BI/6 wild-type mice.
  • eGFP CRISPR/Cas vector expression
  • RFP657 sgRNAonly vector expression
  • Figure 64 shows sequence alignment of targeted gene loci in a putatively clonal CRISPR/Cas modified population with dim Cas9-eGFP expression shows gene editing Alignment of sequences obtained for targeted genes from imsorted peripheral blood of a mouse that presented with expanding RFP657 positive and eGFP-dim/negative population. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence.
  • Upper panel shows lineages distribution in GFP+ / RFP657+ populations in mice with pooled targeting CRISPR/Cas vectors compared to CRISPR/Cas non-targeting controls.
  • Lower panel shows lineages distribution in GFP-dim/neg / RFP657+ populations in mice with pooled targeting CRISPR/Cas vectors compared to CRISPR Cas non-targeting controls.
  • Statistical differences were using t-test (two-sided, unpaired). Welch correction was performed if statistical significant variance was detected.
  • Figure 66A-B shows Sequence alignments of genes mutated in putatively clonal hematopoietic CRISPR/Cas modified populations identified after multiplex CRISPR/Cas genome engineering
  • Figure 67 shows sequence alignments of DnmiSa, Ezh2, Smc3, and Nfl mutations in AML cells. Alignment of sequences obtained for targeted genes from sorted leukemic cells shown in Fig. 58A. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence.
  • Figure 68A-B shows lentivims CRJSPR-Cas induced AML engrafts secondary recipients
  • Figure 69A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a C57B1/6 with Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 mutation
  • eGFP CRISPR/Cas vector expression
  • RFP657 sgRNA-only vector expression
  • Figure 70A-B shows flow cytometry based clonaliiy analysis of FU3-ITD heterozygous mice shows expansion of CRISPR/Cas engineered populations over time.
  • the Runxl targeting sgRNA was provided with the Cas9.
  • B) The Tet2 sgRNA was provided with the Cas9. Each row shows vector expression at the given time point from an individual mouse.
  • Figure 71A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a Flt.3-ITD heterozygous mouse with Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 mutation A) Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and
  • 90.1 sgRNA-only vector expression for pooled sg NAs in a leukemic mouse that presented with mild leukocytosis (I 5.4xlO A 6/ml) and splenomegaly (326mg).
  • Myeloid cell marker expression (lower panel) was assessed both in GFP-dim ceils (left) and GFP- pos cells (right).
  • Figure 72A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a Flt3-ITD heterozygous mouse with Rural, Nfl, and Ezh2 mutation
  • A) Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgRNA-only vector expression (RFP657) for pooled sgRNAs in a leukemic mouse with leukocytosis (40.4x10 A 6/ml) and splenomegaly (533mg). Expression of myeloid cell markers (right).
  • C) Mutation analysis on targeted genomic regions showed mutations in rural, Nfl, and Ezh2.
  • Figure 73A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a Flt3-ITD heterozygous mouse with Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 mutation
  • eGFP CRISPR/Cas vector expression
  • RFP657 sgRNA-only vector expression
  • Figure 74A-B shows Lentivirai delivered CRISPR-Cas mediates transformation of human leukemia cells.
  • Figure 75A-E shows stable modification of hematopoietic stem cells by a lentivirai sgRN A:Cas9 delivery system, including: A) Depiction of a lentivirai vector for
  • a non- targeting sgR A:Cas9 vector does not affect reporter fluorescence. Quantification by plotting the MFI of the reporter in targeting (blue) vs non-targeting (red) sgRNA transduced cells (black box, left plot).
  • F Stable expression of the sgR A:Cas9 vector after 19 weeks in hematopoietic stem and progenitor cells. Overlay of eGFP expression in sgRNA:Cas9 transduced cells (blue) and non- transduced cells (red) of the respective cell population.
  • MPP Multipoteni progenitors
  • ST- HSC s ort-term FISCs
  • LT-HSC long-term HSCs
  • LT-HSC CD34- most quiescent long- term-HSCs
  • Figure 76A-D shows multiplex gene targeting induces clonal development in vivo:
  • C Peripheral blood sgRNA:Cas-eGFP vector expression (x-axis) and expression of a pool of vectors expressing RFP657 (y-axis) over time starting 4 weeks post- transplant. Clonal populations were detected by the pattern of eGFP/RFP657 expression. Two clones were isolated (red gates indicate clones) and genomic regions of
  • Figure 77A-G shows myeloid malignancy modeling with multiplex genome editing, including: A) Flow cytometric analysis of a diseased C57B1/6 mouse for expression of the introduced Cas9: sgRNA vectors and for myeloid (Grl+/CDl lb+). Detected mutations are shown in the right panel (displayed in red box). Sequence alignments are shown in Figure 86. B) Peripheral blood smear (left; May- Gmenwald/Giemsa (MGG); lOOOx) and BM (right; Hematoxylin-Eosin(HE), l OOOx) showing granulocytic cells and blasts.
  • E) Lineage distribution in peripheral blood from secondary mice 8 weeks post- transplant (n 5).
  • Figure 78A-C shows a modular CRISPR/Cas lentiviral vector system for genome engineering, including: A) Schematic depiction of a lentiviral vector for bi- cistronic expression of the sgRNA from a U6 promoter (U6) and expression of Cas9 from a short EFla promoter (EES) or Spleen Focus Forming Virus (SFFV) promoter with a fluorescent protein marker (eGFP or tagRFP) or drug selectable marker (Purmomycm acetyl transferase (PAC) or Blasticidin deaminase (BSD)) from a picorna virus derived 2A auto-cleavage site (P2A).
  • U6 U6 promoter
  • SFFV Spleen Focus Forming Virus
  • Figure 7 A-C shows sgR A:Cas9 mediated knock out of Runxl in Flt3-1TD heterozygous HSCs induces a competitive advantage including: A) Flow cytometric assessment of sgRNA: Cas9 transduced cells in the peripheral blood of mice over 19 weeks (control sgRNA left; Runxl sgRNA right). B) Gating scheme of HSPC populations in
  • mice transduced with sgR A:Cas9 lenti viral vectors.
  • C Summarized sgRNA:Cas9 vector expression in different HSPC populations at 19 weeks post transplantation for control sgRNA (left) or Runxl sgRNA (right). Significant differences are indicated where applicable (t-test, two sided, unpaired; Welch corrected for comparisons with signicantly different variances).
  • MPP - Multipotent progenitors LSK CD150- CD48+
  • ST-HSC - short-term HSCs LSK CD 150- CD48-
  • LT-HSC - long-term HSCs LSK CD150+ CD48-
  • LT-HSC CD34- most quiescent long-term-HSCs (LSK CD 150+ CD48- CD34- ) ⁇
  • Figure 80 shows sgRNA:Cas9 expression does not alter lineage maturation in the BM. Flow cytometry based quantification of mature hematopoietic lineages within the GFP negative and GFP positive population in the BM of mice expressing Cas9 (GFP+) and a control sgRNA shows no significant differences (t-test, two sided, unpaired) in the maturation potential of Cas9 expressing ceils.
  • Figure 81A-B shows that next Generation Sequencing shows stable genome modification in long-term repopulating HSCs in-vivo Mutational analysis of peripheral blood samples at 5 weeks post-transplant and 19 weeks post-transplant, including: A) Samples were analyzed to detect all unique mutations from each mouse at 5 weeks and at 19 weeks for mutations at the Runxl target site. Mutations detected at both time points and only at 5 weeks are shown. B) Mutations found at 19 weeks but not at 5 weeks are shown.
  • Figure 82 - shows flow cytometry based clonality analysis of C57B3/6 mice shows expansion of sgRNA:Cas9 engineered populations over time Flow cytometric assessment of sgRNA: Cas9 vector expression (eGFP) and sgRNA only vector expression (RFP657) for control sgRNA (A) and pooled sgRNAs (B) in C57B1/6 wild-type mice. Each row shows vector expression at the given time point from an individual mouse.
  • eGFP Cas9 vector expression
  • RFP657 sgRNA only vector expression
  • Figure 83 - shows sequence alignment of targeted gene loci in a putatively clonal sgRNA :Cas9 modified population with dim Cas9 - eGFP expression and shows gene editing Alignment of sequences obtained for targeted genes from sorted cell populations shown in Figure 76. Ratio of bacterial clones with presented adjacent sequence out of the total clones sequenced for the respective gene shown behind each sequence A) Genes found mutated in the clone shown in Figure 76C. B) Genes found mutated for the clone shown in Figure 76D. PAM underlined
  • Figure 84 - shows myeloid lineage skewing induced by multiplex CRISPR/Cas in eGFP-higb and eGFP-dim sgRNA :Cas9 expressing populations.
  • sgRNA-Pool targeting sgRNA-Pool
  • sgRNA-ctrl nontargeting control
  • Lower Panel shows lineage distribution in the GFP-dim/neg / RFP657+ population of mice with the targeting sgRNA-Pool (sgRNA-Pool) compared to the non-targeting control (sgRNA-ctrl). Statistical differences are indicated (t-test, two sided, unpaired; Welch corrected for comparisons with significantly different variances).
  • Figure 85A-B shows sequence alignments of genes mutated in putatively clonal hematopoietic sgRNA:Cas9 modified populations identified after multiplex sgRNA:Cas9 genome engineering
  • Figure 86 shows sequence alignments of Dnmt3a, Ezh2, Smc3, and Nil mutations in AML cells Alignment of sequences obtained for targeted genes from sorted leukemic cells shown in Figure 77A. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence. PAM underlined (due to deletion size not possible for Dnmt3a).
  • Figure 87 shows leukemia induced by sgRNA:Ca 9 genome editing shows enhanced replating capacity Serial replating capacity of normal BM compared to the leukemic BM ceils from the leukemia presented in Figure 77.
  • Figure 88A-E shows primary sgRNA:Cas9 induced leukemia engrafts in secondary mice and re-initiates disease.
  • C WBC counts of the same secondary mice at 3 and 8 weeks post transplant.
  • D Survival of the secondary mice.
  • E Low magnification (200x, HE) BM histology of a leukemic secondary mouse (left) and high magnification peripheral blood smear (MGG, l OOOx) of a leukemic secondary mouse (right).
  • Figure 89A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a C57B1/6 with Tet2, Dnmt3a, Runxl , NfL and Ezh2 mutation.
  • eGFP sgRNA:Cas9 vector expression
  • RFP657 sg NA-only vector expression
  • myeloid lineage marker expression right
  • Figure 90 shows survival of mice transplanted with pooled sgRNAs targeting tumor supressor genes. Survival of C57B3/6 mice with the targeting sgRNA -pool and Cas9 or non-targeting sgRNA and Cas9, and Flt3--iT D heterozygous mice transplanted targeting sgRNA-Pool .
  • Figure 91A-B shows flow cytometry based clonality analysis of Fit 3 - ITD heterozygous mice shows expansion of sgRNA:Cas9 engineered populations over time.
  • eGFP sgRNA:Cas9 vector expression
  • RFP657 sgRNAonly vector expression
  • Figure 92 shows summarized blood counts and spleen weights from leukemic Mice. Summarized WBC (left), RBC (middle), and spleen weight of leukemic mice presented in the study. Each mouse is presented in all three plots by one colour. A legend where data has been presented is given below. Range of control mice for each value is given as grey boxes. Control spleen weights are from Flt3-ITD control mice presented in Figure 75E/F and Figure 77.
  • Figure 93A-C shows characterization of a Cas9:sgRNA induced myeloid leukemia in a Flt3-TTD heterozygous mouseA
  • eGFP sgRNA:Cas9 vector expression
  • RFP657 sgRNA-only vector expression
  • Myeloid marker expression was assessed both in GFP-dim cells (left) and GFP-pos ceils (right).
  • Figure 94A-C shows characterization of a sgRNA:Cas9 induced myeloid leukemia in a Fit3-ITD heterozygous mouse
  • eGFP sgRNA:Cas9 vector expression
  • RFP657 sgRNA-onfy vector expression
  • myeloid lineage marker expression right
  • Figure 95A-C shows characterization of a sgR A:Cas9 induced myeloid leukemia in a FU3-ITD heterozygous mouse with
  • A) Flow cytometric assessment of sgRNA:Cas9 vector expression (eGFP), sgRNA-only vector expression (RFP657) (left) and myeloid lineage marker expression (right) in a leukemic mouse in a leukemic mouse with leukocytosis (78.1 A 6/ml) and splenomegaly (1036mg) and myeloid marker expression. Expression of myeloid markers (right).
  • RNA-Guided CRISP R Cas9 for Enhanced Genome Editing Specificity.
  • Jiang et al. used the clustered, regularly interspaced, short palindromic repeats (CRISPR)-assoeiated Cas9 endonuclease complexed with dual -RNAs to introduce precise mutations in the genomes of Streptococcus pneumoniae and Escherichia coil
  • CRISPR clustered, regularly interspaced, short palindromic repeats
  • the study reported reprogramming dual- RNA:Cas9 specificity by changing the sequence of short CR1SPR RNA (crRNA) to make single- and multinucleotide changes carried on editing templates.
  • the Cas9 nuclease from the microbial CRISPR-Cas system is targeted to specific genomic loci by a 20 nt guide sequence, which can tolerate certain mismatches to the DNA target and thereby promote undesired off -target mutagenesis.
  • Ran et al. described an approach that combined a. Cas9 nickase mutant with paired guide RNAs to introduce targeted double-strand breaks. Because individual nicks in the genome are repaired with high fidelity, simultaneous nicking via appropriately offset guide RNAs is required for double-stranded breaks and extends the number of specifically recognized bases for target cleavage.
  • Nishimasu ei al. reported the crystal stmcture of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA at 2.5 A° resolution.
  • the structure revealed a bilobed architecture composed of target recognition and nuclease lobes, accommodating the sgRNA:DNA heteroduplex in a positively charged groove at their interface.
  • the recognition lobe is essential for binding sgR A and UNA
  • the nuclease lobe contains the HNH and RuvC nuclease domains, which are properly positioned for cleavage of the complementary and non -complementary strands of the target DNA, respectively.
  • the nuclease lobe also contains a carboxyl-terminal domain responsible for the interaction with the protospacer adjacent motif (PAM).
  • PAM protospacer adjacent motif
  • Hsu 2014 is a review article that discusses generally CRISPR-Cas9 history from yogurt to genome editing, including genetic screening of cells, that is in the information, data and findings of the applications in the lineage of this specification filed prior to June 5, 2014.
  • the general teachings of Hsu 2014 do not involve the specific models, animals of the instant specification.
  • the invention relates to the engineering and optimization of systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to the CRISPR-Cas system and components thereof.
  • the Cas enzyme is Cas9.
  • the Cas enzyme is a nickase.
  • An advantage of the present methods is that the CRISPK system avoids off- target binding and its resulting side effects. This is achieved using systems arranged to have a high degree of sequence specificity for the target DNA.
  • Cas9 optimization may be used to enhance function or to develop new functions, one can generate chimeric Cas9 proteins. Examples that the Applicants have generated are provided in Example 6. Chimeric Cas9 proteins can be made by combining fragments from different Cas9 omologs. For example, two example chimeric Cas9 proteins from the Cas9s described herein. For example, Applicants fused the N-term of StlCas9 (fragment from this protein is in bold) with C-term of SpCas9.
  • chimeric Cas9s include any or all of: reduced toxicity; improved expression in eukaryotic cells; enhanced specificity; reduced molecular weight of protein, make protein smaller by combining the smallest domains from different Cas9 homologs; and/or altering the PAM sequence requirement.
  • the chimeric Cas enzyme is a nickase.
  • the Cas9 may be used as a generic DNA binding protein.
  • Apficants used Cas9 as a generic DNA binding protein by mutating the two catalytic domains (D10 and H840) responsible for cleaving both strands of the DNA target.
  • the transcriptional activation domain VP64
  • Other transcriptional activation domains are known.
  • transcriptional activation is possible.
  • gene repression in this case of the beta-catenin gene
  • Cas9 repressor DNA-binding domain
  • Transgenic animals are also provided.
  • Preferred examples include animals comprising Cas9, in terms of polynucleotides encoding Cas9 or the protein itself. Mice, rats and rabbits are preferred.
  • To generate transgenic mice with the constructs as exemplified herein one may inject pure, linear DNA into the pronucleus of a zygote from a pseudo pregnant female, e.g. a CB56 female. Founders may then be identified, genotyped, and backcrossed to CB57 mice. The constructs may then be cloned and optionally verified, for instance by Sanger sequencing. Knock outs are envisaged where for instance
  • Knock-in Cas9 mouse was generated and this is exemplified. To generate Cas9 knock in mice one may target the same constitutive and conditional constructs to the osa26 locus, as described herein (Figs. 25A-B and 26).
  • transgenic animals are also provided, as are transgenic plants, especially crops and algae.
  • the transgenic may be useful in applications outside of providing a disease model. These may include food of feed production through expression of, for instance, higher protein, carbohydrate, nutrient or vitamins levels than would normally be seen in the wildtype.
  • transgenic plants, especially pulses and tubers, and animals, especially mammals such as livestock (cows, sheep, goats and pigs), but also poultry and edible insects, are preferred.
  • Transgenic algae or other plants such as rape may be particularly useful in the production of vegetable oils or biofuels such as alcohols (especially methanol and ethanol), for instance. These may be engineered to express or overexpress high levels of oil or alcohols for use in the oil or biofuel industries.
  • alcohols especially methanol and ethanol
  • AAV is advantageous over other viral vectors for a couple of reasons:
  • AAV has a packaging limit of 4.5 or 4.75 Kb. This means that Cas9 as well as a promoter and transcription terminator have to be all fit into the same viral vector. Constmcts larger than 4.5 or 4.75 Kb will lead to significantly reduced vims production, SpCas9 is quite large, the gene itself is over 4.1 Kb, which makes it difficult for packing into AA ⁇ /T . Therefore embodiments of the invention include utilizing homologs of Cas9 that are shorter. For example:
  • Promoter-gRNA(N)-terminator up to size limi t of vector
  • Double virus vector Double virus vector
  • Vector 1 containing one expression cassette for driving the expression of Cas9 Promoter-Cas9 coding nucleic acid molecule-terminator
  • Vector 2 containing one more expression cassettes for driving the expression of one or more guideRNAs
  • an additional vector is used to deliver a homology-direet repair template.
  • Promoters used to drive Cas9 coding nucleic acid molecule expression can include:
  • AAV 1TR can serve as a promoter: this is advantageous for eliminating the need for an additional promoter element (which can take up space in the vector).
  • the additional space freed up can be used to drive the expression of additional elements (gRNA, etc.).
  • ITR activity is relatively weaker, so can be used to reduce toxicity due to over expression of Cas9;
  • promoters CMV, CAG, CBh, PGK, SV40, Ferritin heavy or light chains, etc.;
  • For brain expression can use promoters: Synapsinl for all neurons, CaMKIIalpha for excitatory neurons, GAD67 or GAD65 or VGAT for GABAergic neurons, etc.;
  • For liver expression can use Albumin promoter;
  • For lung expression can use SP-B;
  • ICAM ICAM
  • hematopoietic cells can use IFNbeta or CD45 ;
  • Promoter used to drive guide RNA can include:
  • Pol III promoters such as U6 or HI
  • the AAV can be AAVl, AAV2, AAV5 or any combination thereof.
  • AAV8 is useful for delivery to the liver. The above promoters and vectors are preferred individually.
  • RNA delivery is also a useful method of in vivo delivery.
  • Fig. 27 shows deliver ⁇ ' and in vivo mouse brain Cas9 expression data. It is possible to deliver Cas9 and gRNA (and, for instance, HR repair template) into cells using liposomes or nanoparticles.
  • delivery of the CRISPR enzyme, such as a Cas9 and'Or deliver ⁇ ' of the RNAs of the invention may be in RNA form and via microvesicles, liposomes or nanoparticles.
  • Cas9 mRNA and gRNA can be packaged into liposomal particles for deliver ⁇ ' in vivo.
  • Liposomal transfeetion reagents such as Invivofectamine from Life Technologies and other reagents on the market can effectively deliver RNA molecules into the liver, [00202]
  • Enhancing NHEJ or HR efficiency is also helpful for delivery. It is preferred that NHEJ efficiency is enhanced by co-expressing end-processing enzymes such as Trex2 (Dumitrache et al. Genetics, 2011 August: 188(4): 787-797). It is preferred that HR efficiency is increased by transiently inhibiting NHEJ machineries such as u70 and K.u86. HR efficiency can also be increased by co-expressing prokaryotic or eukaryotic homologous recombination enzymes such as RceBCD, RecA.
  • the CRISPR enzyme for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can be delivered using adeno associated virus (AAV), lentivims, adenovirus or other viral vector types, or combinations thereof.
  • Cas9 and one or more guide RNAs can be packaged into one or more viral vectors.
  • the viral vector is delivered to the tissue of interest by, for example, an intramuscular injection, while other times the viral delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery may be either via a single dose, or multiple doses.
  • the actual dosage to be delivered herein may vary greatly depending upon a variety of factors, such as the vector chose, the target cell, organism, or tissue, the general condition of the organism or subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transform.ation/modifi.cat,ion sought, etc.
  • Such a dosage may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically-acceptable earner (e.g., phosphate-buffered saline), a pharmaceutically-acceptable excipient, an adjuvant to enhance antigenicity, an immunostimulatory compound or molecule, and/or other compounds known in the art.
  • a carrier water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.
  • a pharmaceutically-acceptable earner e.g., phosphate-buffered saline
  • a pharmaceutically-acceptable excipient e.g., an
  • the adjuvant herein may contain a suspension of minerals (alum, aluminum hydroxide, aluminum phosphate) on which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in oil (MF-59, Freund's incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity (inhibits degradation of antigen and/or
  • Adjuvants also include immunostimulatory molecules, such as cytokines, costimulatory molecules, and for example, immunostimulatory DNA or R A molecules, such as CpG oligonucleotides.
  • immunostimulatory molecules such as cytokines, costimulatory molecules, and for example, immunostimulatory DNA or R A molecules, such as CpG oligonucleotides.
  • the dosage may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benz shareholders shareholders, etc.
  • auxiliary substances such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present herein.
  • one or more other conventional pharmaceutical ingredients such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially if the dosage form is a reconstitutabie form.
  • Suitable exemplary ingredients include mierocrystalline cellulose, carboxymethylcelhilose sodium, poiysorbate 80, phenyiethyl alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gal late, the parabens, ethyl vanil lin, glycerin, phenol, parachioropbenol, gelatin, albumin and a combination thereof.
  • a thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991) which is incorporated by reference herein.
  • the delivery is via a recombinant viral vector delivery system derived from an adenovirus or a leniivirus, which may be at a single booster dose containing at least 1 x 10 s particles (also referred to as particle units, pu) of adenoviral or lentiviral vector.
  • the dose preferably is at least about 1 x 10 6 particles (for example, about 1 x 10°- 1 x 10 i particles), more preferably at least about 1 x 10 ' ' particles, more preferably at least about 1 x 10 5 particles (e.g., about 1 x 10*- 1 x 10 ! ! particles or about 1 x 10 8 -!
  • x 10 12 particles and most preferably at least about ! x 10° particles (e.g., about 1 * x 10 9 -1 x 10 f particles or about 1 x 10 x 10 U particles), or even at least about 1 x 10 ! 0 particles (e.g., about 1 x lG i0 -l x I0 l 2 particles) of the adenoviral or lentiviral vector.
  • the dose comprises no more than about I x 10 14 particles, preferably no more than about 1 x 10" particles, even more preferably no more than about 1 x 10 ' 2 particles, even more preferably no more than about 1 x 10 1 1 particles, and most preferably no more than about 1 x 10 10 particles (e.g., no more than about I x 10 9 articles).
  • the dose may contain a single dose of adenoviral vector with, for example, about 1 x 10 6 particle units (pu), about 2 x 10° pu, about 4 x 10 6 pu, about 1 x
  • the delivery is via a recombinant viral vector deliver ⁇ ' system derived from an AAV or a lenti virus.
  • a therapeutically effective dosage for in vivo delivery of the AAV or lentiviras to a human is believed to be in the range of from about 20 to about 50 ml of saline solution containing from about 1 x 10 3lJ to about 1 x 10 10 functional AAV/ml or lentivirus/ml solution. The dosage may be adjusted to balance the therapeutic benefit against any side effects.
  • the AAV dose is generally in the range of concentrations of from about 1 x 10 5 to 1 x 10 50 genomes AAV, from about 1 x 10 s to 1 x 10 20 genomes AAV, from about 1 x 10 i0 to about 1 x I0 ! 6 genomes, or about 1 x 10 11 to about 1 x I0 i6 genomes AAV.
  • a human dosage may be about 1 x 10 i 3 genomes AAV.
  • concentrations may be delivered in from about 0.001 ml to about 100 ml, about 0.05 to about 50 ml, or about 10 to about 25 ml of a carrier solution.
  • Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. See, for example, U.S. Patent No. 8,404,658 B2 to Hajjar, et al., granted on March 26, 2013, at col. 27, lines 45-60.
  • the deliver ⁇ ' is via a plasmid.
  • the dosage should be a sufficient amount of plasmid to elicit a response.
  • suitable quantities of plasmid DNA in plasmid compositions can be from about 0.1 to about 2 mg, or from about I fig to about 10 .g.
  • the doses herein are based on an average 70 kg individual.
  • the frequency of administration is within the ambit of the medical or veterinar ⁇ ' practitioner (e.g., physician, veterinarian), or scientist skilled in the art.
  • Cas9 and one or more guide RNA can be delivered using a vector delivery system derived from an adeno associated virus (AAV), lentiviras, adenovirus or other
  • 90.1 plasmid or viral vector types using formulations and doses from, for example, US Patents Nos. 8,454,972 (formulations, doses for adenovirus), 8,404,658 (formulations, doses for AAV) and 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivirus, AAV and adenovirus.
  • the route of administration, formulation and dose can be as in US Patent No. 8,454,972 and as in clinical trials involving AAV.
  • the route of administration, ionnulation and dose can be as in US Patent No. 8,404,658 and as in clinical trials involving adenovirus.
  • the route of administration, formulation and dose can be as in US Patent No 5,846,946 and as in clinical studies involving plasmids.
  • Doses may be based on or extrapolated to an average 70 kg individual, and can be adjusted for patients, organisms or subjects, mammals of different weight and species. Frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), depending on usual factors including the age, sex, general health, other conditions of the patient or subject and the particular condition or symptoms being addressed,
  • the viral vectors can be injected into the tissue of interest.
  • the expression of Cas9 can be driven by a cell-type specific promoter.
  • liver-specific expression might use the Albumin promoter and neuron-specific expression might use the Synapsin T promoter,
  • RNA. delivery The CRISPR enzyme, for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can also be deiivered in the form of RNA.
  • Cas9 rriRNA can be generated using in vitro transcription.
  • Cas9 mRNA can be synthesized using a PCR cassette containing the following elements: T7_promoter-kozak sequence (GCCACC)-Cas9-3 ' UTR from beta globin-polyA tail (a string of 120 or more adenines).
  • the cassette can be used for transcription by T7 polymerase.
  • Guide RNAs can also be transcribed using in vitro transcription from a cassette containing T7_promoter- GG-guide RNA sequence.
  • the CRISPR enzyme and/or guide RNA can be modified using pseudo-U or 5 -Methyl -C.
  • CRISPR enzyme mRNA and guide RNA may be delivered simultaneously using nanoparticles or lipid envelopes.
  • PBAE poly(P-amino ester)
  • the pH-responsive PBAE component was chosen to promote endosome disruption, while the lipid surface layer was selected to minimize toxicity of the polycation core. Such are, therefore, preferred for delivering RNA of the present invention.
  • CRISPR enzyme mRNA and guide RNA might also be delivered separately.
  • CRISPR enzyme mRNA can be delivered prior to the guide RNA to give time for CRISPR enzyme to be expressed.
  • CRISPR enzyme mRNA might be administered 1 -12 hours (preferably around 2-6 hours) prior to the administration of guide RNA.
  • CRISPR. enzyme mRNA and guide RNA can be administered together.
  • a second booster dose of guide RNA can be administered 1 - 12 hours (preferably around 2-6 hours) after the initial administration of CRISPR enzyme mRNA + guide RNA.
  • CRISPR enzyme mRN and/or guide RNA might be useful to achieve the most efficient levels of genome modification.
  • CRISPR enzyme mRNA and guide RN delivered Optimal concentrations of CRISPR enzyme mRNA and guide RNA can be determined by testing different concentrations in a cellular or animal model and using deep sequencing the analyze the extent of modification at potential off-target genomic loci. For example, for the guide sequence targeting 5 ' -GAGTCCGAGC AGAAGAAGAA -3 ' (SEQ ID NO: ) in the EM 1 gene of the human genome, deep sequencing can be used to assess the level of modification at the following two off-target loci, 1 : 5'-
  • CRISPR enzyme nickase mRNA for example S. pyogenes Cas9 with the D10A mutation
  • CRISPR enzyme nickase mRNA can be delivered with a pair of guide RNAs targeting a site of interest.
  • the two guide RNAs need to be spaced as follows. Guide sequences in red (single underline) and blue (double underline) respectively (these examples are based on the PAM requirement for Streptococcus pyogenes Cas9.
  • the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs or 1 -34 base pairs.
  • the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the opposite strand near the second target sequence results in a blunt cut or a 3 ' overhang.
  • the 3 ' overhang is at most 150, 100 or 25 base pairs or at least 15, 10 or 1 base pairs. In preferred embodiments the 3' overhang is 1 - 100 basepairs.
  • aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased.
  • the gene product is a protein.
  • the gene product is a rnieroRNA.
  • the regulatory region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
  • Additional delivery options for the brain include encapsulation of CRISPR enzyme and guide RNA in the form of either DNA or RNA into liposomes and conjugating to molecular Trojan horses for trans-blood brain barrier (BBB) delivery.
  • BBB trans-blood brain barrier
  • Molecular Trojan horses have been shown to be effective for deliver ⁇ ' of B-gal expression vectors into the brain of non-human primates.
  • the same approach can be used to delivery vectors containing CRISPR enzyme and guide RNA.
  • Xia CF and Boado RJ, Pardridge WM Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm. 2009 May-Jun;6(3):747-51.
  • siRNA short interfering RNA
  • mAb monoclonal antibody
  • avidin-biotin a receptor-specific monoclonal antibody
  • the authors also report that because the bond between the targeting mAb and the siRNA is stable with avidin-biotin technology, and RNAi effects at distant sites such as brain are observed in vivo following an intravenous administration of the targeted siRNA.
  • 90.1 describe how expression plasmids encoding reporters such as luciferase were encapsulated in the interior of an "artificial vims" comprised of an 85 nm pegylated immunoliposome, which was targeted to the rhesus monkey brain in vivo with a monoclonal antibody (MAb) to the human insulin receptor (HTR).
  • MAb monoclonal antibody
  • HTR human insulin receptor
  • the HIRMAb enables the liposome carrying the exogenous gene to undergo transcytosis across the blood-brain barrier and endocytosis across the neuronal plasma, membrane following intravenous injection.
  • the level of luciferase gene expression in the brain was 50-fold higher in the rhesus monkey as compared to the rat.
  • RNA Ribonucleicies
  • nanoparticies Clio, 8., Goldberg, fvl., Son, S., Xu, Q., Yang, F., Mel Y., Bogatyrev, S., Langer, R. and Anderson, D., Lipid-like nanoparticies for small interfering RNA delivery to endothelial cells, Advanced Functional Materials, 19: 31 12-31 18, 2010
  • exosomes Schroeder, A., Levins, C, Coitez, C, Langer, ft, and Anderson, D., Lipid-based nanotherapeutics for si RNA delivery-, Journal of Internal Medicine, 267: 9-21, 2010, PMID: 20059641).
  • exozomes have been shown to be particularly useful in delivery siRNA, a system with some parallels to the CRISPR system.
  • El-Andaloussi S, et al. (“Exosome-mediated delivery of siRNA in vitro and in vivo.” Nat Protoc. 2012 Dec;7(12):21 12-26. doi: 10.1038/nprot.2012.131. Epub 2012 Nov 15.) describe how exosomes are promising tools for drug delivery across different biological barriers and can be harnessed for delivery of siRNA in vitro and in vivo.
  • Their approach is to generate targeted exosomes through transiection of an expression vector, comprising an exosomal protein fused with a peptide ligand. The exosomes are then purify and characterized from transfected cell supernatant, then siRNA is loaded into the exosomes.
  • Targeted deletion of genes is preferred. Examples are exemplified in Example 1 8. Preferred are, therefore, genes involved in cholesterol biosynthesis, fatty acid biosynthesis, and other metabolic disorders, genes encoding mis-folded proteins involved in amyloid and other diseases, oncogenes leading to cellular transformation, latent viral genes, and genes leading to dominant-negative disorders, amongst other disorders. As exemplified here, Applicants prefer gene deliver ⁇ ' of a CRTSPR-Cas system to the liver, brain, ocular, epithelial, hematopoetic, or another tissue of a organism, subject or a patient
  • Therapeutic applications of the CRISPR-Cas system include Glaucoma, Amyloidosis, and Huntington's disease. These are exemplified in Example 20 and the features described therein are preferred alone or in combination.
  • CRISPR-Cas guide RNAs that target the vast majority of the HIV- 1 genome while taking into account HTV-1 strain variants for maximal coverage and effectiveness.
  • host immune cells could be a) isolated, transduced with CRISPR-Cas, selected, and re-introduced in to the host or b) transduced in vivo by systemic deliver)' of the CRISPR-Cas system.
  • the first approach allows for generation of a resistant immune population whereas the second is more likely to target latent viral reservoirs within the host. This is discussed in more detail in the Examples section.
  • the present invention generates a gene knockout cell library. Each cell may have a single gene knocked out. This Is exemplified in Example 23.
  • This library is useful for the screening of gene function in cellular processes as well as diseases.
  • To make this ceil library one may integrate Cas9 driven by an inducible promoter (e.g. doxycycline inducible promoter) into the ES cell.
  • an inducible promoter e.g. doxycycline inducible promoter
  • To make the ES cell library one may simply mix ES cells with a library of genes encoding guide RNAs targeting each gene in the human genome.
  • the immunoge icity of protein drugs can be ascribed to a few immunodominant helper T lymphocyte (HTL) epitopes. Reducing the MHC binding affinity of these HTL epitopes contained within these proteins can generate drugs with lower immunogenicitv (Tangri S, et al. ("Rationally engineered therapeutic proteins with reduced immunogenicitv” J Immunol, 2005 Mar 15; 174(6):3187-96,)
  • the immunogenicitv of the CRISPR enzyme in particular may be reduced following the approach first set out in Tangri et al with respect to erythropoietin and subsequently developed. Accordingly, directed evolution or rational design may be used to reduce the immunogenicitv of the CRISPR enzyme (for instance a Cas9) in the host species (human or other species).
  • Example 28 Applicants used 3 guideR As of interest and were able to visualize efficient DNA cleavage in vivo occurring only in a small subset of cells. Essentially, Applicants have shown targeted in vivo cleavage. In particular, this provides proof of concept that specific targeting in higher organisms such as mammals can also be achieved. It also highlights multiplex aspect in that multiple guide sequences (i.e. separate targets) can be used sim ltaneously (in the sense of co-delivery). In other words, Applicants used a multiple approach, with several different sequences targeted at the same time, but independently.
  • Example 34 A suitable example of a protocol for producing AAV, a preferred vector of the invention is provided in Example 34.
  • Nucleotide repeat disorders are preferred conditions to be treated. These are also exemplified herein.
  • a method of gene therapy for the treatment of an organism or a subject having a mutation in the CFTR gene comprises administering a therapeutically effective amount of a CRISPR-Cas gene therapy particle, optionally via a biocompatible pharmaceutical carrier, to the cells of an organism or a subject.
  • the target UNA comprises the mutation deltaF508.
  • the mutation is repaired to the wildtype.
  • the mutation is a deletion of the three nucleotides that comprise the codon for phenylalanine (F) at position 508, Accordingly, repair in this instance requires reintroduction of the missing codon into the mutant.
  • an adenovirus/AAV vector system is introduced into the host cell, cells or patient.
  • the system comprises a Cas9 (or Cas9 nickase) and the guide RNA along with a adenovirus/AAV vector system comprising the homology repair template containing the F508 residue.
  • This may be introduced into the organism or subject via one of the methods of delivery discussed earlier.
  • the CRISPR-Cas system may be guided by the CFTRdelta 508 chimeric guide RNA. It targets a specific site of the CFTR genomic locus to be nicked or cleaved.
  • the repair template is inserted into the cleavage site via homologous recombination correcting the deletion that results in cystic fibrosis or causes cystic fibrosis related symptoms.
  • This strategy to direct delivery and provide systemic introduction of CRISPR systems with appropriate guide RNAs can be employed to target genetic mutations to edit or otherwise manipulate genes that cause metabolic, liver, kidney and protein diseases and disorders such as those in Table B.
  • Example 22 demonstrates gene transfer or gene delivery of a CRISPR-Cas system in airways of an organism, a subject or a patient in need thereof, suffering from cystic fibrosis or from cystic fibrosis (CF) related symptoms, using adeno-associated virus (AAV) particles.
  • AAV adeno-associated virus
  • CF cystic fibrosis
  • AAV adeno-associated virus
  • CF cystic fibrosis
  • suitable patients may include: Human, non-primate human, canine, feline, bovine, equine and other domestic animals.
  • Applicants utilized a CRISPR-Cas system comprising a Cas9 enzyme to target deltaF508 or other CFTR-inducing mutations.
  • the treated subjects in this instance receive pharmaceutically effective amount of aerosolized AAV vector system per lung endobronchial! ⁇ ' delivered while spontaneously breathing.
  • aerosolized delivery is preferred for AAV deliver in general.
  • An adenovirus or an AAV particle may be used for delivery.
  • Suitable gene constructs, each operably linked to one or more regulator ⁇ ' sequences, may be cloned into the delivery vector.
  • the following constructs are provided as examples: Cbh or EFla promoter for Cas9, U6 or HI promoter for chimeric guide RNA),:
  • a preferred arrangement is to use a CFTRdelta508 targeting chimeric guide, a repair template for deltaF508 mutation and a.
  • Cas9s are those with nuclease or nickase activity
  • NLS(s) nuclear localization signal or sequence(s)
  • Applicants analyzed the human CFTR genomic locus and identified the Cas9 target site.
  • the PAM may contain a NGG or a NNAGAAW motif.
  • the present method comprises manipulation of a target sequence in a genomic locus of interest comprising
  • composition comprising a viral vector system comprising one or more viral vectors operably encoding a composition for expression thereof, wherein the composition comprises:
  • composition comprising a vector system comprising one or more vectors comprising
  • a second regulator ⁇ ' element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3 ' orientation,
  • components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and
  • the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence.
  • preferred target DNA sequences comprise the CFTRdeIta508 mutation.
  • a preferred PAM is described above.
  • a preferred CRISPR enzyme is any Cas (described herein, but particularly that described in Example 22).
  • Alternatives to CF include any genetic disorder and examples of these are well known.
  • Another preferred method or use of the invention is for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease.
  • a "guide sequence” may be distinct from “guide RNA",
  • a guide sequence may refer to an approx. 20bp sequence, within the guide RNA, that specifies the target site.
  • the Cas9 is (or is derived from) the SpCas9.
  • preferred mutations are at any or all or positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 or corresponding positions in other Cas9s (which may be ascertained for instance by standard sequence comparison tools.
  • any or all of the following mutations are preferred in SpCas9: DI0A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged.
  • the same (or conservative substitutions of these mutations) at corresponding positions in other Cas9s are also preferred.
  • residues corresponding to SpCas9 D10 and H840 are also preferred. These are advantageous as they provide nicka.se activity.
  • the invention uses nucleic acids to bind target DNA sequences. This is advantageous as nucleic acids are much easier and cheaper to produce and the specificity can be varied according to the length of the stretch where homology is sought. Complex 3-D positioning of multiple fingers, for example is not required,
  • polynucleotide refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown.
  • polynucleotides coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomai RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro- RNA (udiRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers.
  • loci locus
  • loci defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomai RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro- RNA (likeRNA), ribozymes, cDNA, recombinant polynucleot
  • a polynucleotide may comprise one or more modified nucleotides, such
  • nucleotide 90.1 as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer.
  • the sequence of nucleotides may be interrupted by non-nueleotide components.
  • a polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component,
  • wild type is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
  • nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.
  • Complementarity refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non-traditional types.
  • a percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary).
  • Perfectly complementary means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.
  • Substantially complementary refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 1 8, 19, 20, 21 , 22, 23, 24, 25, .30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.
  • stringent conditions for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors, in general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part X, Second Chapter “Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N,Y.
  • complementary or partially complementary sequences are also envisaged. These are preferably capable of hybridising to the reference sequence under highly stringent conditions.
  • relatively low- stringency hybridization conditions are selected: about 20 to 25° C. lower than the thermal melting point (T m ).
  • T m is the temperature at which 50% of specific target sequence hybridizes to a perfectly complementary probe in solution at a defined ionic strength and pH.
  • highly stringent washing conditions are selected to be about 5 to 15° C. lower than the T m .
  • moderately-stringent washing conditions are selected to be about 15 to 30° C. lower than the T m .
  • Highly permissive (very low stringency) washing conditions may be as low as 50° C, below the T m , allowing a high level of mis-matching between hybridized sequences.
  • Other physical and chemical parameters in the hybridization and wash stages can also be altered to affect the outcome of a detectable hybridization signal from a specific level of homology between target and probe sequences.
  • Preferred highly s tringent conditions comprise incubation in 50% formamide, 5> ⁇ SSC, and 1% SDS at 42° C, or incubation in 5xSSC and 1% SDS at 65° C, with wash in 0.2xSSC and 0.1% SDS at 65° C.
  • Hybridization refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues.
  • the hydrogen bonding may occur by Watson Crick base pairing, Hoogstem binding, or in any other sequence specific manner.
  • the complex may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self-hybridizing strand, or any combination of these.
  • a hybridization reaction may constitute a step in a more extensive process, such as the initiation of PGR, or the cleavage of a polynucleotide by an enzyme.
  • a sequence capable of hybridizing with a given sequence is referred to as the "complement" of the given sequence.
  • genomic locus or “locus” (plural loci) is the specific location of a gene or DNA sequence on a chromosome.
  • locus refers to stretches of DNA or RNA that encode a polypeptide or an RNA chain that has functional role to play
  • genes include regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences.
  • a gene includes, but Is not necessarily limited to, promoter sequences, terminators, translational regulator ⁇ ' sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
  • expression of a genomic locus or “gene expression” is the process by which information from a gene is used in the synthesis of a functional gene product.
  • the products of gene expression are often proteins, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is functional RNA.
  • the process of gene expression is used by ail known life - eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea) and viruses to generate functional products to survive.
  • expression of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context.
  • expression also refers to the process by which a polynucleotide is transcribed from a D A template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins.
  • Transcripts and encoded polypeptides may be collectively referred to as "gene product.” If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
  • polypeptide refers to polymers of amino acids of any length.
  • the polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids.
  • the tenns also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component.
  • amino acid includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
  • domain refers to a part of a protein sequence that may exist and function independently of the rest of the protein chain.
  • sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences.
  • the capping region of the dTALEs described herein have sequences that are at least 95% identical or share identity to the capping region amino acid sequences provided herein.
  • Sequence homologies may be generated by any of a number of computer programs known in the art, for example BLAST or FASTA, etc.
  • a suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et al,, 1984, Nucleic Acids Research 12:387).
  • Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid - Chapter 18), FASTA (Atsclml et al., 1 990, I Mol. Biol, 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al, 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.
  • Percentage (%) sequence homology may be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an "un gapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
  • BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program.
  • a new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2): 247-50; FEMS Microbiol Lett. 1999 177(1 ): 1 87-8 and the website of the National Center for Biotechnology information at the website of the National Institutes for Health).
  • the final % homology may be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pair- wise comparison based on chemical similarity or evolutionary distance.
  • a scaled similarity score matrix is generally used that assigns scores to each pair- wise comparison based on chemical similarity or evolutionary distance.
  • An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs, GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table, if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
  • percentage homologies may be calculated using the multiple alignment feature in DNASIS 1M (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244), Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result,
  • sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance.
  • Deliberate amino acid substitutions may be made on the basis of similarity in amino acid properties (such as polarity, charge, solubility, hydrophobic ity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups.
  • Amino acids may be grouped together based on the properties of their side chains alone. However, it is more useful to include mutation data, as well. The sets of amino acids thus derived are likely to be conserved for stractural reasons.
  • polypeptide which may comprise homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue or nucleotide, with an alternative residue or nucleotide) that may occur i.e., like-for-like substitution in the case of amino acids such as basic for basic, acidic for acidic, polar for polar, etc.
  • Non-homologous substitution may also occur i.e., from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norieucine ornithine (hereinafter referred to as Q), pyriylalanine, ihienylalanine, naphthylalanine and phenylgiycine.
  • Z ornithine
  • B diaminobutyric acid ornithine
  • Q norieucine ornithine
  • pyriylalanine ihienylalanine
  • naphthylalanine naphthylalanine
  • phenylgiycine phenylgiycine
  • Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or ⁇ - alanine residues.
  • alkyl groups such as methyl, ethyl or propyl groups
  • amino acid spacers such as glycine or ⁇ - alanine residues.
  • a further form of variation which involves the presence of one or more amino acid residues in peptoid form, may be well understood by those skilled in the art.
  • the peptoid form is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue's nitrogen atom rather than the a-carbon.
  • the invention provides for vectors that are used in the engineering and optimization of CRISPR-Cas systems.
  • a "vector” is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment. Generally, a vector is capable of replication when associated with the proper control elements. In general, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • Vectors include, but are not limited to, nucleic acid molecules that are single- stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques.
  • viral vector wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g.
  • Viral vectors also include polynucleotides carried by a. virus for transfection into a host ceil.
  • Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • Other vectors e.g., non- episomal mammalian vectors are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors.”
  • Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed.
  • "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host ceil).
  • aspects of the invention relate to bicistronic vectors for chimeric RNA and Cas9.
  • Bicistronic expression vectors for chimeric RNA and Cas9 are preferred.
  • Cas9 is preferably driven by the CBh promoter.
  • the chimeric RNA may preferably be driven by a Pol III promoter such as a HI or a U6 promoter. Ideally the two are combined.
  • the chimeric guide RNA typically consists of a 20bp guide sequence (Ns) and this may be joined to the tracr sequence (mnning from the first "U” of the lower strand to the end of the transcript).
  • the tracr sequence may be tnincaied at various positions as indicated.
  • the guide and tracr sequences are separated by the tracr-mate sequence, which may be GUUUUAGAGCUA. This may be followed by the loop sequence GAAA as shown. Both of these are preferred examples.
  • Applicants have demonstrated Cas9-mediated indels at the human EMX1 and PVALB loci by SURVEYOR assays.
  • ChiRNAs are indicated by their "+n" designation, and crRNA refers to a hybrid RNA where guide and tracr sequences are expressed as separate transcripts. Throughout this application, chimeric RNA may also be called single guide, or synthetic guide RNA (sgRNA).
  • the loop is preferably GAAA, but it is not limited to this sequence or indeed to being only 4bp in length. Indeed, preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences.
  • the sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG.
  • regulatory element is intended to include promoters, enhancers, internal ribosornal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poiy-U sequences).
  • promoters e.g. promoters, enhancers, internal ribosornal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poiy-U sequences).
  • IRES internal ribosornal entry sites
  • tissue-specific regulator ⁇ ' sequences A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal -dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific.
  • a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol I promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof.
  • pol III promoters include, but are not limited to, U6 and HI promoters.
  • pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41 :521-530 ( 1985)], the SV40 promoter, the dihydrofolate reductase promoter, the ⁇ -actin promoter, the phosphogiycerol kinase (PGK) promoter, and the EFl promoter.
  • RSV Rous sarcoma virus
  • CMV cytomegalovirus
  • PGK phosphogiycerol kinase
  • enhancer elements such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Moi. Cell, Biol., Vol. 8(1 ), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit ⁇ -globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc.
  • a vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRTSPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
  • nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRTSPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.).
  • CRTSPR clustered regularly interspersed short palindromic repeats
  • Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells.
  • CRISPR transcripts e.g. nucleic acid transcripts, proteins, or enzymes
  • CRISPR transcripts can be expressed in bacterial ceils such as Escherichia coii, insect cells (using baculovirus expression vectors), yeast ceils, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990).
  • the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
  • Vectors may be introduced and propagated in a prokaryote or prokaryotic cell.
  • a prokaryote is used to amplify copies of a vector to be introduced
  • a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins.
  • Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein.
  • Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification.
  • a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein.
  • Such enzymes, and their cognate recognition sequences include Factor Xa, thrombin and enterokinase.
  • Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988, Gene 67: 31-40), pMAL (Mew England Biolabs, Beverly, Mass.) and pRlT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
  • GST glutathione S-transferase
  • Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301 -315) and pET l i d (Studier et al, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
  • a vector is a yeast expression vector.
  • yeast Saccharornyces cerivisae examples include pYepSec l (Baldari, et al,, 1987. EMBO J. 6: 229-234), pMFa ( uijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).
  • a vector drives protein expression in insect cells using baculovirus expression vectors.
  • Baculovirus vectors available for expression of proteins in cultured insect cells include the pAc series (Smith, et al., 1983. Mol. Cell, Biol. 3 : 2156-21 65) and the pVL series (Lucklow and Summers, 1989, Virology 170: 31-39).
  • a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector.
  • mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195).
  • the expression vector's control functions are typically provided by one or more regulatory elements.
  • commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art.
  • the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid).
  • tissue-specific regulatory elements are known in the art.
  • suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al, 1987. Genes Dev. 1 : 268-277), lymphoid-specific promoters (Caiame and Eaton, 1988. Adv. Immunol 43 : 235-275), in particular promoters of T ceil receptors (Winoto and Baltimore, 1989. EMBO J.
  • a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CR1SPR system.
  • CRISPRs Clustered Regularly Interspaced Short Palindromic Repeats
  • SPIDRs Sacer Interspersed Direct Repeats
  • the CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in E. coli (Ishino et al, J. Bacterial, 169:5429-5433 [1987]; and Nakata et al, J.
  • the CRISPR loci typically differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al, OMICS J. Meg. Biol, 6:23-33 [2002]; and Mojica et al, Mol Microbiol, 36:244-246 [2000]).
  • SRSRs short regularly spaced repeats
  • the repeats are short elements that occur in clusters that are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al, [2000], supra).
  • the repeat sequences are highly conserved between strains, the number of interspersed repeats and the sequences of the spacer regions typically differ from strain to strain (van Embden et al, J.
  • CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al, Mol Microbiol, 43: 1 565-1575 [2002]; and Mojica et al, [2005]) including, but not limited to Aeropyrum, Pyrobacuiurn, Sulfolobus, Archaeogiobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophiius, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobmm, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitro
  • CRISPR system refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated (“Cas”) genes, including sequences encoding a Cas gene, a tracr (trans -activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer” in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus.
  • a tracr trans -activating CRISPR
  • tracr-mate sequence encompassing a "direct repeat” and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system
  • guide sequence also referred to as a "spacer” in the context of an endogenous CRISPR
  • one or more elements of a CRISPR system is derived from a type I, type IL or type III CRISPR system.
  • one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes.
  • a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system).
  • target sequence refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a. target sequence and a. guide sequence promotes the formation of a CRJSPR complex.
  • a target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides.
  • a target sequence is located in the nucleus or cytoplasm of a cell .
  • direct repeats may be identified in silico by searching for repetitive motifs that fulfill any or all of the following criteria:
  • 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.
  • candidate tracrRNA may be subsequently predicted by sequences that fulfill any or all of the following criteria:
  • 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.
  • chimeric synthetic guide RNAs may incorporate at least 12 bp of duplex structure between the direct repeat and tracrRNA.
  • the CRJSPR system is a type II CRISPR system and the Cas enzyme is Cas9, which catalyzes DNA cleavage.
  • the Cas enzyme is Cas9, which catalyzes DNA cleavage.
  • Enzymatic action by Cas9 derived from Streptococcus pyogenes or any closely related Cas9 generates double stranded breaks at target site sequences which hybridize to 20 nucleotides of the guide sequence and that have a protospacer- adjacent motif (PAM) sequence (examples include NGG/NRG or a PAM that can be determined as described herein) following the 20 nucleotides of the target sequence.
  • PAM protospacer- adjacent motif
  • CRISPR activity through Cas9 for site-specific DNA recognition and cleavage is defined by the guide sequence, the tracr sequence that hybridizes in pari, to the guide sequence and the PAM sequence. More aspects of the CRISPR system are described in Karginov and Hannon, The CRISPR system: small RNA- guided defence in bacteria and archaea, Mole Cell 2010, January 15; 37( 1): 7.
  • the type II CRISPR locus from Streptococcus pyogenes SF370 which contains a cluster of four genes Cas9, Cas l, Cas2, and Csnl, as well as two non -coding RJS!A elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non -repetitive sequences (spacers, about 30bp each).
  • DSB targeted DNA double-strand break
  • tracrRNA hybridizes to the direct repeats of pre-crRNA, which is then processed into mature crRNAs containing individual spacer sequences.
  • the mature crRNA:traerRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA.
  • Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer (Fig. 2A).
  • Fig. 2B demonstrates the nuclear localization of the codon optimized Cas9.
  • the RNA polymerase Ill- based U6 promoter was selected to drive the expression of tracrRNA (Fig. 2C).
  • a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr- mate sequences"; Fig. 2C).
  • the initial spacer was designed to target a 33-base-pair (bp) target site (30-bp protospacer plus a 3 -bp CRISPR motif (PAM) sequence satisfying the NGG recognition motif of Cas9) in the human EMX1 locus (Fig. 2C), a key gene in the development of the cerebral cortex.
  • bp 33-base-pair
  • PAM 3 -bp CRISPR motif
  • CRISPR complex comprising a guide sequence hybridized to a target sequence
  • the tracr sequence which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g.
  • one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites.
  • a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors.
  • two or more of the elements expressed from the same or different regulatory elements may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector.
  • CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream" of) or 3' with respect to ("downstream" of) a second element.
  • the coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction.
  • a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or ail in a single intron).
  • the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
  • a vector comprises one or more insertion sites, such as a restriction endomiclease recognition sequence (also referred to as a "cloning site").
  • one or more insertion sites e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites
  • a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that, following
  • a. vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site.
  • the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these.
  • a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell.
  • a single vector may comprise about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences.
  • about or more than about I, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-containing vectors may be provided, and optionally delivered to a cell [00296]
  • a vector comprises a. regulatory element operably linked to an enzyme-coding sequence encoding a. CRISPR enzyme, such as a. Cas protein.
  • Non- limiting examples of Cas proteins include Casl , Cas IB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), Cas 10, Csyl , Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, CsO, Csf4, homologues thereof, or modified versions thereof.
  • the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9.
  • the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
  • a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a. target polynucleotide containing a target sequence.
  • an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand).
  • mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A.
  • two or more catalytic domains of Cas 9 may be mutated to produce a mutated Cas9 substantially lacking all UN cleavage activity.
  • a D10A mutation Is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity.
  • CRISPR enzyme is considered to substantially lack ail DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1 %, 0.1 %, 0.01 %, or lower with respect to its non-mutated form.
  • a Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes t at share homology to the biggest nuclease with multiple nuclease domains from the type 11 CRISPR system.
  • the Cas9 enzyme is from, or is derived from, spCas9 or saCas9.
  • Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein.
  • Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent.
  • residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes.
  • this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCa9, StlCas9 and so forth,
  • codon optimized sequence in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that. other examples are possible and codon optimization for a host speeIes . oiher than human, or for codon optimization for specific organs such as the brain, is known.
  • an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells.
  • the eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human mammal or primate.
  • processes for modifying the germ line genetic identity of human beings and/or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes may be excluded,
  • codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about I, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that axe more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence.
  • codon bias differs in codon usage between organisms
  • mRNA messenger RNA
  • tJRNA transfer RN
  • Codon usage tables are readily available, for example, at the "Codon Usage Database” available at www.kazusa. orjp/codon/ (visited Jul. 9, 2002), and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000"Nucl.
  • codon optimizing a particular sequence for expression in a particular host ceil are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available.
  • one or more codons e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons
  • one or more codons in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
  • a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about I, 2, 3, 4, 5,
  • the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the ammo-terminus, about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy - terminus, or a combination of these (e.g. one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus).
  • NLS NLS at the amino-terminus and one or more NLS at the carboxy terminus.
  • each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies.
  • the CRISPR enzyme comprises at most 6 NLSs.
  • an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus.
  • NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV (SEQ ID NO: ); the NLS from nucleoplasmin (e.g. the nucleoplasmin bipartite NLS with the sequence
  • KRPAATKKAGQAKKKK (SEQ ID NO: ); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: ) or RQRRNELKRSP (SEQ ID NO: ); the hRNPAl M9 NLS having the sequence
  • NQSSNFGPMKGGNFGGRSSGPYGGGGQYFA PRNQGGY SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID NO: ); the sequence RMRIZFKNK
  • POPKKKPL (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: ).
  • the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a. detectable amount in the nucleus of a eukaryotic cell.
  • strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors.
  • Detection of accumulation in the nucleus may be performed by any suitable technique.
  • a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with, a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI).
  • Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for D A cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR. enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a. CRISPR enzyme lacking the one or more NLSs.
  • an assay for the effect of CRISPR complex formation e.g. assay for D A cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR. enzyme activity
  • CRISPR enzyme lacking the one or more NLSs.
  • a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence.
  • the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more.
  • Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith- Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows- Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign ( ovocraft Technologies; available at www.novocraft.com), ELAND (Iilumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
  • any suitable algorithm for aligning sequences include the Smith- Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows- Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign ( ovocraft Technologies; available at www.novocraft.com), ELAND (Iilumina, San Diego, CA),
  • a guide sequence is about or more than about 5, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay.
  • the components of a CRISPR system sufficient to form a CRISPR complex may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein.
  • cleavage of a target polynucleotide sequence may be
  • 90.1 evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions.
  • Other assays are possible, and will occur to those skilled in the art.
  • a guide sequence may be selected to target any target sequence.
  • the target sequence is a sequence within a genome of a cell.
  • Exemplary target sequences include those that are unique in the target genome.
  • a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXGG (SEQ ID NO: ) where
  • NNNNNNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) (SEQ ID NO: ) has a single occurrence in the genome.
  • a unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGG where NNNTNNNNNNXGG (N is A, G,
  • T or C; and X can be anything) (SEQ ID NO: ) has a single occurrence in the genome.
  • a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXXAGAAW
  • a unique target sequence in a genome may include an S. thermophilus CRISPR I Cas9 target site of the form MMMMMMMMMNN NNN NNN XXAGAAW (SEQ ID NO: ) where NNWNWNWNW NXXAG A A W (N is A, G, T, or C; X can be anything; and W is A or T) (SEQ ID NO: ) has a single occurrence in the genome.
  • a unique target sequence in a genome may include an S. thermophilus CRISPR I Cas9 target site of the form MMMMMMMMMNN NNN NNN XXAGAAW (SEQ ID NO: ) where NNWNWNWNW NXXAG A A W (N is A, G, T, or C; X can be anything; and W is
  • a or T) (SEQ ID NO: ) has a single occurrence in the genome.
  • S pyogenes
  • a unique target sequence in a genome may include a Cas9 target site of the form
  • a unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form
  • N is A, G, T, or C; and X can be anything
  • SEQ ID NO: has a single occurrence in the genome.
  • M may be A, G, T, or C, and need not be considered in identifying a sequence as unique.
  • a guide sequence is selected to reduce the degree secondary structure within the guide sequence. In some embodiments, about or less than
  • Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133 - 148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A.R. Gruber et al , 2008, Cell 106(1): 23-24; and PA Can- and GM Church, 2009, Nature Biotechnology 27(12): 1 151-62).
  • a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CR1SPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence.
  • degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences.
  • Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary stmctures, such as self-complementarity within either the tracr sequence or tracr mate sequence.
  • the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher.
  • the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length.
  • the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin.
  • the transcript or transcribed polynucleotide sequence has at least two or more hairpins.
  • the transcript has two, three, four or five hairpins.
  • the transcript has at most five hairpins.
  • the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence
  • the portion of the sequence 3 ' of the loop corresponds to the tracr sequence
  • single polynucleotides comprising a guide sequence, a tracr mate sequence
  • 90.1 and a tracr sequence are as follows (listed 5' to 3 '), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1) a ggcttcatgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (SEQ ID NO: );
  • sequences (1) to (3) are used in combination with Cas9 from S. thermophilus CRISPRl.
  • sequences (4) to (6) are used in combination with Cas9 from S. pyogenes.
  • the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence.
  • a recombination template is also provided.
  • recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide.
  • a recombination template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a pari of a CRISPR complex.
  • a template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length.
  • the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence.
  • a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1, 5, 10, 15, 20, or more nucleotides).
  • the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.
  • the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme).
  • a CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains.
  • epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags.
  • reporter genes include, but are not limited to, glutathione- S -transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-giucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofiuorescent proteins including blue fluorescent protein (BFP).
  • GST glutathione- S -transferase
  • HRP horseradish peroxidase
  • CAT chloramphenicol acetyltransferase
  • beta-galactosidase beta-galactosidase
  • beta-giucuronidase beta-galactosidase
  • luciferase green fluorescent protein
  • GFP green fluorescent protein
  • HcRed HcRed
  • DsRed cyan fluorescent protein
  • a CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind D A molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP 16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US201 10059502, incorporated herein by reference. In some embodiments, a tagged CRISPR enzyme is used to identify the location of a target sequence.
  • MBP maltose binding protein
  • DBD Lex A DNA binding domain
  • HSV herpes simplex virus
  • a CRISPR enzyme may form a component of an inducible system.
  • the inducible nature of the system would allow for spatioiemporal control of gene editing or gene expression using a form of energy.
  • the form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy.
  • inducible system examples include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytoehrome, LOV domains, or cryptochrome).
  • the CRISPR enzyme may be a part of a Light Inducible Transcriptional Effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner.
  • the components of a light may include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain.
  • LITE Light Inducible Transcriptional Effector
  • the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell.
  • the invention further provides cells produced by such methods, and animals comprising or produced from such cells.
  • a CRISPR enzyme in combination with (and optionally complexed with) a guide sequence is delivered to a cell.
  • Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture, or in a host organism.
  • Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell
  • Methods of non-viral delivery of nucleic acids include lipofection, microinjection, hiolistics, virosomes, liposomes, immunoliposom.es, polycation or lipidmucieic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA.
  • Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., TransfectamTM and LipofectinTM).
  • Cationic and neutral lipids that are suitable for efficient receptor- recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
  • RNA or DNA viral based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus.
  • Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo).
  • Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues,
  • Lenti viral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis -acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis- acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression.
  • Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immune deficiency virus (S1V), human immuno deficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al, I Virol 66:2731-2739 (1992); Johann et al, J. Virol 66: 1635-1640 (1992); Sommnerfelt et al, Virol 176:58-59 (1990); Wilson et al, I Virol. 63 :2374-2378 (1989); Miller et al, J. Virol. 65:2220-2224 (1991); PCT/US94/05700).
  • MiLV murine leukemia virus
  • GaLV gibbon ape leukemia virus
  • S1V Simian Immune deficiency virus
  • HAV human immuno deficiency virus
  • adenoviral based systems may be used.
  • Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer
  • This vector can be produced in large quantities in a relatively simple system.
  • Adeno-associated vims may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al, Virology 160:38-47 (1987): U.S. Pat. No. 4,797,368: WO 93/24641; otin, Human Gene Therapy 5:793-801 ( 1994); Muzyczka, J. Clin. Invest. 94: 1351 ( 1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat, No.
  • Packaging cells are typically used to form virus particles that are capable of infecting a host cell.
  • ceils include 293 cells, which package adenovirus, and ⁇ 2 cells or PA317 ceils, which package retrovirus.
  • Viral vectors used in gene therapy are usually generated by producer a cell line that packages a nucleic acid vector into a viral particle.
  • the vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polyniicleotideis ) to be expressed.
  • the missing viral functions are typically supplied in trans by the packaging ceil line.
  • AAV vectors used in gene therapy typically only possess TTR sequences from the AAV genome which are required for packaging and integration into the host genome.
  • Viral DMA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences.
  • the cell line may also infected with adenovirus as a helper.
  • the helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid.
  • the helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
  • AAV is considered an ideal candidate for use as a transducing vector.
  • Such AAV transducing vectors can comprise sufficient cis-acting functions to replicate in the presence of adenovirus or herpesvirus or poxvirus (e.g., vaccinia vims) helper functions provided in trans.
  • Recombinant AAV rAAV
  • rAAV Recombinant AAV
  • the AAV cap and/or rep genes are deleted from the viral genome and replaced with a DNA segment of choice.
  • Current AA V vectors may accommodate up to 4300 bases of inserted DNA.
  • rAAV 90.1 0 ⁇ 32 ⁇
  • the invention provides rAA V and methods for preparing rAAV.
  • plasmid(s) containing or consisting essentially of the desired viral construct are transfected into AAV-infected ceils.
  • a second or additional helper plasmid is cotransfected into these cells to provide the AAV rep and'Or cap genes which are obligator ⁇ ' for replication and packaging of the recombinant viral construct Under these conditions, the rep and/or cap proteins of AAV act in trans to stimulate replication and packaging of the rAAV construct.
  • Two to Three days after transfection rAAV is harvested.
  • rAAV is harvested from the cells along with adenovirus. The contaminating adenovirus is then inactivated by heat treatment. In the instant invention, rAAV is advantageously harvested not from the cells themselves, but from cell supernatant.
  • rAAV can be prepared by a method that comprises or consists essentially of: infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, and helper vims (e.g., adenovirus, herpesvirus, poxvirus such as vaccinia virus) wherein the rAAV lacks functioning cap and/or rep (and the helper vims (e.g., adenovirus, herpesvirus, poxvirus such as vaccinia vims) provides the cap and/or rev function that the rAAV lacks); or infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, wherein the recombinant lacks functioning cap and'Or rep, and transfecting said cells with a plasmid supplying cap and/or rep function that the rAAV lacks; or infecting susceptible cells with a rAAV containing helper vims (e.g., adenovirus, herpesvirus
  • the rAAV can be from an AAV as herein described, and advantageously can be an rAAV I , r.AAV2, AAV5 or rAAV having hybrid or capsid which may comprise AAV 1, AAV2, AAV5 or any combination thereof.
  • the invention provides rAAV that contains or consists essentially of an exogenous nucleic acid molecule encoding a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system, e.g., a plurality of cassettes comprising or consisting a first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a CRISPR-associated (Cas) protein (putative nuclease or helicase proteins), e.g., Cas9 and a terminator, and a two, or more, advantageously up to the packaging size limit of the vector, e.g., in total (including the first cassette) five, cassettes comprising or consisting essentially of a promoter, nucleic acid molecule encoding guide RNA (gRNA) and a terminator (e.g., each cassette schematically represented as Promoter-gRNAl- terminator, Promoter-gRNA2-terminator ...
  • CRISPR Clustered Regularly
  • Promoter-gRNA(N)-terminator (where N is a number that can be inserted that is at an upper limit of the packaging size limit of the vector), or two or more individual rAAVs, each containing one or more than one cassette of a CRISPR system, e.g., a first rAAV containing the first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding Cas, e.g., Cas9 and a terminator, and a second rAAV containing a plurality, four, cassettes comprising or
  • RNA 90.1 consisting essentially of a promoter, nucleic acid molecule encoding guide RNA (gRNA) and a terminator (e.g., each cassette schematically represented as Promoter-gRN A 1 - terminator, Promoter-gRNA2-terminator ... Promo ter-gRNA(N ⁇ -temiina or (where N is a number that can be inserted that is at an upper limit of the packaging size limit of the vector).
  • gRNA nucleic acid molecules in the herein discussion concerning AAV or rAAV are advantageously DNA
  • the promoter is in some embodiments advantageously human Synapsin I promoter (hSyn).
  • Lentiviruses are complex retroviruses that have the ability to infect and express their genes in both mitotic and post-mitotic cells.
  • the most commonly known lentivirus is the human immunodeficiency virus (HIV), which uses the envelope glycoproteins of other viruses to target a broad range of cell types.
  • HIV human immunodeficiency virus
  • lentivirai transfer plasmid pCasESlO
  • packaging plasmids 5 ⁇ g of pMD2.G (VSV-g pseudoiype), and 7.5ug of psPAX2 (gag/pol/rev/tat).
  • Transfection was done in 4mL OptiMEM with a cationic lipid delivery agent (50uL Lipofectamine 2000 and lOOul Plus reagent). After 6 hours, the media was changed to antibiotic-tree DMEM with 10% fetal bovine serum.
  • Preparation of lentivirai vectors of the invention is further described in Example 36.
  • Lentivirus may be purified as follows. Viral supernatants were harvested after 48 hours. Supernatants were first cleared of debris and filtered through a. 0.45um low- protein binding (PVDF) filter. They were then spun in a uitracentrifuge for 2 hours at 24,000 rpm. Viral pellets were resuspended in 50ui of DMEM overnight at 4C. They were then aliquotted and immediately frozen at -80C.
  • PVDF low- protein binding
  • minimal non-primate lentivirai vectors based on the equine infectious anemia virus are also contemplated, especially for ocular gene therapy (see, e.g., Balagaan, J Gene Med 2006; 8: 275 - 285, Published online 21 November 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: l().1002/jgm.845).
  • RetinoStai® an equine infectious anemia virus-based lentivirai gene therapy vector that expresses angiostatic proteins endostain and angiostatin that is delivered via a subretinal injection for the treatment of the web form of
  • 90.1 age-related macular degeneration is also contemplated (see, e.g., Bi ley et al., HUMAN GENE THERAPY 23:980-991 (September 2012)) may be modified for the CRISPR-Cas system of the present invention.
  • self-inactivating lentiviral vectors with an siRNA targeting a common exon shared by HTV tat/rev, a nucleolar-locaiizing TAR decoy, and an anti--CCR5-specific hammerhead ribozyme may be adapted to the CRISPR-Cas system of the present invention.
  • a minimum of 2,5 x 106 CD34+ cells per kilogram patient weight may be collected and prestimulated for 16 to 20 hours in X-VTVO 1 medium (Lonza) containing 2mM.L- giutamine, stem cell factor (100 ng ml), Fit -3 ligand (Flt-3L) (100 ng ml), and thrombopoietin ( 10 ng/ml) (CellGenix) at a density of 2 x 106 cells/ml.
  • X-VTVO 1 medium LiM.L- giutamine
  • stem cell factor 100 ng ml
  • Fit -3 ligand Flt-3L
  • thrombopoietin 10 ng/ml
  • Prestimulated cells may be transduced with lentiviral at a multiplicity of infection of 5 for 16 to 24 hours in 75-cm2 tissue culture flasks coated with fibronectin (25 mg/cm2) (RetroNectin,Takara Bio Inc.).
  • Lentiviral vectors have been disclosed as in the treatment for Parkinson's Disease, see, e.g., US Patent Publication No. 20120295960 and US Patent Nos. 7303910 and 7351585. Lentiviral vectors have also been disclosed for the treatment of ocular diseases, see e.g., US Patent Publication Nos. 20060281 180, 20090007284, US201 10! 17189; US20090017543; US2007005496L US20100317109. Lentiviral vectors have also been disclosed for delivery to the train, see, e.g., US Patent Publication Nos. US20110293571; US20110293571, US20040013648, US20070025970, US200901 11 106 and US Patent No. US7259015.
  • a host cell is transiently or non-trans iently transfected with one or more vectors described herein.
  • a cell is transfected as it naturally occurs in an organism.
  • a cell that is transfected is taken from an organism.
  • the cell is derived from cells taken from a an organism, such as a cell line. A wide variety of ceil lines for tissue culture are known in the art.
  • cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, 1 lei . a -S3.
  • a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences.
  • a cell transiently transfected with the components of a CRISPR system as described herein (such as by transient transiection of one or more vectors, or transiection with RNA), and modified through the activity of a CRISPR complex, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence.
  • cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells are used in assessing one or more test compounds,
  • one or more vectors described herein are used to produce a non-human transgenic animal.
  • the transgenic animal is a. mammal, such as a mouse, rat, or rabbit.
  • Methods for producing transgenic animals are known in the art, and generally begin with a method of cell transiection, such as described herein.
  • the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro.
  • the method comprises sampling a cell or population of cells from a human
  • the cell or cells may even be re-introduced into the non-human animal.
  • the cells are stem cells.
  • the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme compiexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
  • the invention provides a. method of modifying expression of a polynucleotide in a eukaryotic cell.
  • the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme compiexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
  • Similar considerations and conditions apply as above for methods of modifying a target poiynucieotide. In fact, these sampling, culturing and re-introduction options apply across the aspects of the present invention.
  • the CRISPR complex may comprise a CRISPR enzyme compiexed with a guide sequence hybridized lo a target sequence, wherein said guide sequence may be linked to a tracr mate sequence which in turn may hybridize to a tracr sequence. Similar considerations and conditions apply as above for methods of modifying a target polynucleotide.
  • kits containing any one or more of the elements disclosed in the above methods and compositions. Elements may be provided individually or in combinations, and may be provided in any suitable container, such as a. vial, a bottle, or a tube. In some embodiments, the kit includes instructions in one or more languages, for example in more than one language.
  • a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein.
  • Reagents may be provided in any suitable container.
  • a kit may provide one or more reaction or storage buffers.
  • Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g. in
  • a buffer can be any buffer, , including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof.
  • the buffer is alkaline.
  • the buffer has a pH from about 7 to about 10.
  • the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element.
  • the kit comprises a homologous recombination template polyn uc3 eoti de.
  • the invention provides methods for using one or more elements of a. CRISPR system.
  • the CRISPR complex of the invention provides an effective means for modifying a target polynucleotide.
  • the CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types.
  • modifying e.g., deleting, inserting, translocating, inactivating, activating
  • the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis.
  • An exemplar)' CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide.
  • the guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
  • this invention provides a method of cleaving a target polynucleotide.
  • the method comprises modifying a target polynucleotide using a CRISPR complex that binds to the target polynucleotide and effect cleavage of said target polynucleotide.
  • the CRISPR complex of the invention when introduced into a cell, creates a break (e.g., a single or a double strand break) in the genome sequence.
  • the method can be used to cleave a disease gene in a ceil.
  • the break created by the CRISPR complex can be repaired by a repair processes such as the error prone non-homologous end joining (NHE.T) pathway or the high fidelity homology-directed repair (HDR) (Fig. 29).
  • NHE.T error prone non-homologous end joining
  • HDR high fidelity homology-directed repair
  • an exogenous polynucleotide template can be introduced into the genome sequence.
  • the HDR process is used modify genome sequence.
  • an exogenous polynucleotide template comprising a sequence to be integrated flanked by an upstream sequence and a downstream sequence is introduced into a cell.
  • the upstream and downstream sequences share sequence similarity with either side of the site of integration in the chromosome.
  • a donor polynucleotide can be DNA, e.g., a DNA plasmid, a bacterial artificial chromosome (BAG), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a. PGR fragment, a naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poioxamer.
  • DNA e.g., a DNA plasmid, a bacterial artificial chromosome (BAG), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a. PGR fragment, a naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poioxamer.
  • the exogenous polynucleotide template comprises a sequence to be integrated (e.g., a. mutated gene).
  • the sequence for integration may be a. sequence endogenous or exogenous to the cell.
  • Examples of a sequence to be integrated include polynucleotides encoding a protein or a non-coding RNA (e.g., a microRNA).
  • the sequence for integration may be operably linked to an appropriate control sequence or sequences.
  • the sequence to be integrated may provide a. regulatory function.
  • the upstream and downstream sequences in the exogenous polynucleotide template are selected to promote recombination between the chromosomal sequence of interest and the donor polynucleotide.
  • the upstream sequence is a nucleic acid sequence that shares sequence similarity with the genome sequence upstream of the targeted site for integration.
  • the downstream sequence is a nucleic acid sequence that shares sequence similarity with the chromosomal sequence downstream of the targeted site of integration.
  • the upstream and downstream sequences in the exogenous polynucleotide template can have 75%, 80%, 85%, 90%, 95%, or 100% sequence identity with the targeted genome sequence.
  • the upstream and downstream sequences in the exogenous polynucleotide template have about 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the targeted genome sequence. In some methods, the upstream and downstream sequences in the exogenous polynucleotide template have about 99% or 100% sequence identity with the targeted genome sequence.
  • An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp.
  • the exemplary upstream or downstream sequence have about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000 bp.
  • the exogenous polynucleotide template may further comprise a marker.
  • a marker may make it easy to screen for targeted integrations. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers.
  • the exogenous polynucleotide template of the invention can be constructed using
  • a double stranded break is introduced into the genome sequence by the CRISPR complex, the break is repaired via homologous recombination an exogenous polynucleotide template such that the template is integrated into the genome.
  • the presence of a double-stranded break facilitates integration of the template
  • this invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell
  • the method comprises increasing or decreasing expression of a target polynucleotide by using a CRISPR complex that binds to the polynucleotide.
  • a target polynucleotide can be inactivated to effect the modification of the expression in a cell. For example, upon the binding of a CRISPR complex to a target sequence in a cell, the target polynucleotide is inactivated such that the sequence is not transcribed, the coded protein is not produced, or the sequence does not function as the wild-type sequence does. For example, a protein or microRNA coding sequence may be inactivated such that the protein or microRNA or pre-microRNA transcript is not produced.
  • control sequence refers to any nucleic acid sequence that effects the transcription, translation, or accessibility of a nucleic acid sequence.
  • control sequence include, a promoter, a transcription terminator, and an enhancer are control sequences.
  • the inactivated target sequence may include a deletion mutation (i.e., deletion of one or more nucleotides), an insertion mutation (i.e., insertion of one or more nucleotides), or a nonsense mutation (i.e., substitution of a single nucleotide for another nucleotide such that a stop codon is introduced).
  • a deletion mutation i.e., deletion of one or more nucleotides
  • an insertion mutation i.e., insertion of one or more nucleotides
  • a nonsense mutation i.e., substitution of a single nucleotide for another nucleotide such that a stop codon is introduced.
  • a method of the invention may be used to create a plant, an animal or cell that may be used as a disease model.
  • disease refers to a disease, disorder, or indication in a subject.
  • a method of the invention may be used to create an animal or cell that comprises a modification in one or more nucleic acid sequences associated with a disease, or a plant, animal or cell in which the expression of one or more
  • nucleic acid sequences associated with a disease are altered.
  • Such a nucleic acid sequence may encode a disease associated protein sequence or may be a disease associated control sequence.
  • a plant, subject, patient, organism or cell can be a non-human subject, patient, organism or cell.
  • the invention provides a plant, animal or cell, produced by the present methods, or a progeny thereof.
  • the progeny may be a clone of the produced plant or animal, or may result from sexual reproduction by crossing with other individuals of the same species to introgress further desirable traits into their offspring.
  • the cell may be in vivo or ex vivo in the cases of multicellular organisms, particularly animals or plants.
  • a ceil line may be established if appropriate culturing conditions are met and preferably if the cell is suitably adapted for this purpose (for instance a stem cell).
  • Bacterial cell lines produced by the invention are also envisaged. Hence, cell lines are also envisaged.
  • the disease model can be used to study the effects of mutations on the animal or cell and development and/or progression of the disease using measures commonly used in the study of the disease.
  • a disease model is useful for studying the effect of a pharmaceutically active compound on the disease.
  • the disease model can be used to assess the efficacy of a potential gene therapy strategy. That is, a disease-associated gene or polynucleotide can be modified such that the disease development and/or progression is inhibited or reduced.
  • the method comprises modifying a disease-associated gene or polynucleotide such that an altered protein is produced and, as a result, the animal or cell has an altered response.
  • a genetically modified animal may be compared with an animal predisposed to development of the disease such that the effect of the gene therapy event may be assessed.
  • t is invention provides a method of developing a biologically active agent that modulates a cell signaling event associated with a disease gene.
  • the method comprises contacting a. test compound with a cell comprising one or more vectors that drive expression of one or more of a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and detecting a change in a readout that is indicative of a reduction or an augmentation of a ceil signaling event associated with, e.g., a mutation in a disease gene contained in the cell.
  • a cell model or animal model can be constructed in combination with the method of the invention for screening a cellular function change.
  • Such a model may be
  • a cellular function model may be used to study the effect of a modified genome sequence on intracellular signaling or extracellular signaling.
  • a cellular function model may be used to study the effects of a modified genome sequence on sensor ⁇ ' perception.
  • one or more genome sequences associated with a signaling biochemical pathway in the model are modified.
  • An altered expression of one or more genome sequences associated with a signaling biochemical pathway can be determined by assaying for a difference in the mRNA levels of the corresponding genes between the test model cell and a control cell, when they are contacted with a candidate agent.
  • the differential expression of the sequences associated with a signaling biochemical pathway is determined by detecting a difference in the level of the encoded polypeptide or gene product.
  • nucleic acid contained in a sample is first extracted according to standard methods in the art.
  • mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook et al. (1989), or extracted by nucleic-acid-binding resins following the accompanying instructions provided by the manufacturers.
  • the mRNA contained in the extracted nucleic acid sample is then detected by amplification procedures or conventional hybridization assays (e.g. Northern blot analysis) according to methods widely known in the art or based on the methods exemplified herein.
  • amplification means any method employing a. primer and a polymerase capable of replicating a target sequence with reasonable fidelity.
  • Amplification may be carried out by natural or recombinant DNA polymerases such as TaqGoldTM, 17 DNA polymerase, Kienow fragment of E.coii DNA polymerase, and reverse transcriptase.
  • a preferred amplification method is PGR.
  • the isolated RNA can be subjected to a reverse transcription assay that is coupled with a quantitative
  • RT-PCR 90.1 polymerase chairs reaction
  • Detection of the gene expression level can be conducted in real time in an amplification assay.
  • the amplified products can be directly visualized with fluorescent DNA-binding agents including but not limited to DNA intercalators and DNA groove binders.
  • DNA-binding dye suitable for this application include SYBR green, SYBR blue, DAP1, propidium iodine, Hoesie, SYBR gold, ethidium bromide, acridines, proflavine, acridine orange, acriflavine, fiuorcoumanin, ellipticine, daunomycin, chloroquine, distamycin D, ehromomyein, homidium, mithramycin, ruthenium polypyridyls, anthramycin, and the like.
  • probe-based quantitative amplification relies on the sequence - specific detection of a desired amplified product, it utilizes fluorescent, target-specific probes (e.g., TaqMan® probes) resulting in increased specificity and sensitivity.
  • target-specific probes e.g., TaqMan® probes
  • probes are allowed to form stable complexes with the sequences associated with a signaling biochemical pathway contained within the biological sample derived from the test subject in a hybridization reaction.
  • antisense used as the probe nucleic acid
  • the target polynucleotides provided in the sample are chosen to be complementary to sequences of the antisense nucleic acids.
  • the target polynucleotide is selected to be complementary to sequences of the sense nucleic acid.
  • Hybridization can be performed under conditions of various stringency. Suitable hybridization conditions for the practice of the present invention are such that the recognition interaction between the probe and sequences associated with a signaling
  • 90.1 biochemical pathway is both sufficiently specific and sufficiently stable.
  • Conditions that increase the stringency of a hybridization reaction are widely known and published in the art. See, for example, (Sambrook, et ai, (1989); Nonradioactive In Situ Hybridization Application Manual, Boehringer Mannheim, second edition).
  • the hybridization assay can be formed using probes immobilized on any solid support, including but are not limited to nitrocellulose, glass, silicon, and a variety of gene arrays.
  • a preferred hybridization assay is conducted on high-density gene chips as described in U.S. Patent No. 5,445,934.
  • the nucleotide probes are conjugated to a detectable label.
  • Detectable labels suitable for use in the present invention include any composition detectable by photochemical, biochemical, spectroscopic, immunochemical, electrical, optical or chemical means.
  • a wide variety of appropriate detectable labels are known in the art, which include fluorescent or chemiluminescent labels, radioactive isotope labels, enzymatic or other ligands.
  • a fluorescent label or an enzyme tag such as digoxigenin, ⁇ -galactosidase, urease, alkaline phosphatase or peroxidase, avidin/biotin complex.
  • the detection methods used to detect or quantify the hybridization intensity will typically depend upon the label selected above.
  • radiolabels may be detected using photographic film or a phosphoimager.
  • Fluorescent markers may be detected and quantified using a pbotodetector to detect emitted fight.
  • Enzymatic labels are typically detected by providing the enzyme with a substrate and measuring the reaction product produced by the action of the enzyme on the substrate; and finally colorimetric labels are detected by simply visualizing the colored label.
  • An agent-induced change in expression of sequences associated with a signaling biochemical pathway can also be determined by examining the corresponding gene products. Determining the protein level typically involves a) contacting the protein contained in a biological sample with an agent that specifically bind to a protein associated with a signaling biochemical pathway; and (b) identifying any agenfcprotein complex so formed.
  • the agent that specifically binds a protein associated with a signaling biochemical pathway is an antibody, preferably a monoclonal antibody.
  • the reaction is performed by contacting the agent with a sample of the proteins associated with a signaling biochemical pathway derived from the test samples under conditions that will allow a complex to form between the agent and the proteins associated
  • the agents are supplied with a detectable label and unreacted agents may be removed from the complex; the amount of remaining label thereby indicating the amount of complex fonned.
  • the label does not interfere with the binding reaction.
  • an indirect detection procedure may use an agent that contains a label introduced either chemically or enzymatically. A desirable label generally does not interfere with binding or the stability of the resulting agentpolypeptide complex.
  • the label is typically designed to be accessible to an antibody for an effective binding and hence generating a detectable signal.
  • a wide variety of labels suitable for detecting protein levels are known in the art. Non-limiting examples include radioisotopes, enzymes, colloidal metals, fluorescent compounds, bioluminescent compounds, and chemiluminescent compounds.
  • agentpolypeptide complexes formed during the binding reaction can be quantified by standard quantitative assays. As illustrated above, the formation of agentpolypeptide complex can be measured directly by the amount of label remained at the site of binding.
  • the protein associated with a signaling biochemical pathway is tested for its ability to compete with a labeled analog for binding sites on the specific agent. In this competitive assay, the amount of label captured is inversely proportional to the amount of protein sequences associated with a signaling biochemical pathway present in a test sample.
  • Antibodies that specifically recognize or bind to proteins associated with a signaling biochemical pathway are preferable for conducting the aforementioned protein analyses.
  • antibodies that recognize a. specific type of post-translational modifications e.g., signaling biochemical pathway inducible modifications can be used.
  • Post-translational modifications include but are not limited to glycosyiation, lipidation, acerylation, and phosphorylation. These antibodies may be purchased from commercial
  • anti-phosphotyrosme antibodies that specifically recognize tyrosme-phosphorylated proteins are available from a number of vendors including Invitrogen and Perkin Elmer.
  • Anti-phosphotyrosine antibodies are particularly useful in detecting proteins that are differentially phosphorylated on their tyrosine residues in response to an ER stress.
  • proteins include but are not limited to eukaryotic translation initiation factor 2 alpha (eIF-2a).
  • eIF-2a eukaryotic translation initiation factor 2 alpha
  • these antibodies can be generated using conventional polyclonal or monoclonal antibody technologies by immunizing a host animal or an antibody-producing cell with a target protein that exhibits the desired post-translational modification.
  • An altered expression of a gene associated with a signaling biochemical pathway can also be determined by examining a. change in activity of the gene product relative to a control cell.
  • the assay for an agent-induced change in the activity of a protein associated with a signaling biochemical pathway will dependent on the biological activity and/or the signal transduction pathway that is under investigation. For example, where the protein is a kinase, a change in its ability to phosphorylate the downstream substrate(s) can be determined by a variety of assays known in the art.
  • Representative assays include but are not limited to immunoblotting and immunopreeipitation with antibodies such as anti-phosphotyrosine antibodies that recognize phosphorylated proteins, in addition, kinase activity can be detected by high throughput chemiluminescent assays such as AlphaScreenTM (available from Perkin Elmer) and eTagTM assay (Chan-Hui, et al. (2003) Clinical Immunology 1 11 : 162- 174).
  • AlphaScreenTM available from Perkin Elmer
  • eTagTM assay Cho-Hui, et al. (2003) Clinical Immunology 1 11 : 162- 174.
  • the protein associated with a signaling biochemical pathway is part of a signaling cascade leading to a fluctuation of intracellular pH condition
  • pFT sensitive molecules such as fluorescent pH dyes can be used as the reporter molecules.
  • the protein associated with a signaling biochemical pathway is an ion channel
  • fluctuations in membrane potential and'Or intracellular ion concentration can be monitored.
  • a number of commercial kits and high-throughput devices are particularly- suited for a rapid and robust screening for modulators of ion channels. Representative
  • a suitable vector can be introduced to a cell or an embryo via one or more methods known in the art, including without limitation, microinjection, electroporation, sonoporation, biohsties, calcium phosphate-mediated transfectkm, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary agent -enhanced uptake of nucleic acids, and delivery via liposomes, immunoliposomes, virosomes, or artificial virions.
  • the vector is introduced into an embryo by microinjection.
  • the vector or vectors may be microinjected into the nucleus or the cytoplasm of the embryo. In some methods, the vector or vectors may be introduced into a cell by nucleofection.
  • the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic ceil
  • the target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA).
  • target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide.
  • target polynucleotides include a disease associated gene or polynucleotide.
  • a "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control.
  • a disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease.
  • the transcribed or translated products may be kno wn or unknown, and may be at a normal or abnormal level.
  • the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell.
  • the target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA).
  • a gene product e.g., a protein
  • a non-coding sequence e.g., a regulatory polynucleotide or a junk DNA
  • the target polynucleotide of a CRISPR complex may include a number of disease-associated genes and polynucleotides as well as signaling biochemical pathway- associated genes and polynucleotides as listed in US provisional patent applications 61/736,527 and 61/748,427 having Broad reference BI-2011/008/WSGR Docket No. 44063-701.101 and BI-2011/008/WSGR Docket No. 44063-701.102 respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively, the contents of all of which are herein incorporated by reference in their entirety.
  • target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway- associated gene or polynucleotide.
  • target polynucleotides include a disease associated gene or polynucleotide.
  • a "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease -affected tissues compared with tissues or cells of a non disease control.
  • a disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease.
  • the transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.
  • Such genes, proteins and pathways may be the target polynucleotide of a CRISPR complex.
  • CF CF, MRP7; Glycogen storage diseases (SLC2A2, GLUT2, G6PC, G6PT, G6PT1, GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS2, PYGL, PFKM); Hepatic adenoma, 142330 (TCF1, HNFIA, MODY3), Hepatic failure, early onset, and neurologic disorder (SCQD1, SCOl), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer and carcinomas (CTNNB1, PDGFRL, PDGRL, PRLTS, ⁇ 1, ⁇ , CTNNBl, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5; Medullary cystic kidney disease (UMOD, HNFJ, FJHN, MCKD2, ADMCKD2); Phenylketonuria (PAH, PKU1, QDPR, DHPR, P
  • DMD Muscular / Skeletal Becker muscular dystrophy
  • DMD Muscular / Skeletal Becker muscular dystrophy
  • LMNA Emery-Dreifuss muscular dystrophy
  • VEGF-a VEGF-b, neuronal diseases and VEGF-c
  • AMieimer disease APP, AAA, CVAP, ADl, APOE, AD2, disorders PSEN2, AD4, STM2, APBB2, FE65L1, NOS3, PLAU, URK, ACE,
  • Autism Mecp2, BZRAP1, MDGA2, SemaSA, Neurexin 1, GLOl, MECP2, RTT, PPMX, MRX16, MRX
  • HIT Hauntington's Dx
  • SBMA/SMAX!/AR Kennedy's Dx
  • FX /X25 Friedrich's Ataxia
  • ATX3 Machado- Joseph's Dx
  • VLDLR VLDLR
  • Occular diseases and Age-related macular degeneration Abcr, CcS2, Cc2, cp (ceruloplasmin), disorders Timp3, cathepsinD, Vldlr, Ccr2); Cataract (CRYAA, CRYA1, CRYBB2,
  • IGF-l Signaling IGF1; PRKCZ; ELKl; MAPKl; PTPNll; NEDD4; AKT2;
  • PIK3CA PIK3CA
  • PRKCl PRKCl
  • PTK2 PTK2
  • FOS PIK3CB
  • P1K3C3 MAPK8;
  • IGF1R insulin receptor
  • IRS1 MAPK3
  • IGFBP7 IGFBP7
  • KRAS PIK3C2A
  • PDPK1 MAP2K1; IGFBP2; SFN; JUN; CYR61; AKT3;
  • NRF2 -mediated PRKCE EP300; SOD2; PRKCZ; MAPKl; SQSTM1;
  • PRKD1 PRK3; KRAS; PRKCD; GSTPl; MAPK9; FTL;
  • MAP2K2 AKT1; PTK3R1; MAP2K1; PPIB; JUN; KEAP1;
  • GSK3B ATF4; PRKCA; EIF2AK3; F1SP90AA1
  • Hepatic Fibrosis/Hepatic EDM IGF1; KDR; FLT1; SMAD2; FGFR1; MET; PGF;
  • IGF1R IGF1R
  • IL6R RELA
  • TLR4 PDGFRB
  • TNF RELB
  • IL8 IL8
  • PDGFRA NFKB1; TGFBR1; SMAD4; VEGFA; BAX;
  • IL1R1 IL1R1; CCL2; HGF; MMPl; STAT I; TL6; CTGF; MMP9
  • PPARGC1A PDGFRB
  • TNF PDGFRB
  • INSR RAF1
  • IKBKG IKBKG
  • MAP2K1 ; NFKB1 ; JUN; ILIRI; HSP90AA1
  • PRKD1 MAPK3; MAPK10; KRAS; MAPKl 3; PRKCD;
  • MAPK9 MAPK9; PIK3C2A; BTK; MAPKl 4; TNF; RAF1; FYN;
  • PIK3CA Receptor Signaling PIK3CA; CREB1; GNAQ; NFKB2; CAMK2A; PIK3CB;
  • PIK3C3 MAPK3; KRAS; RELA; SRC; PIK3C2A; RAF1 ;
  • PDPKl PDPKl
  • STAT3 MAP2K1; NFKB1; BRAF; ATF4; AKT3;
  • Inositol Phosphate PRKCE Inositol Phosphate PRKCE; IRAKI; PRKAA2; E1F2AK2; PTEN; GRK6;
  • MAPKl Metabolism MAPKl; PLKl; AKT2; PIK3CA; CDK8; PIK3CB; P1K3C3;
  • MAP2K1 MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK
  • E1F2AK2 ELKl; ABL2; MAPKl; PIK3CA; FOS; PIK3CB;
  • PIK3C3 PIK3C3
  • MAPK8 CAV1; ABL1; MAPK3; KRAS; SRC;
  • PIK3C2A PIK3C2A
  • PDGFRB PDGFRB
  • RAF1 MAP2K2
  • JAK1 JAK2
  • JAK2 JAK2
  • PIK3R1 PIK3R1
  • PDGFRA PDGFRA
  • STAT3 SPHKl
  • MAP2K1 MYC
  • Trpal Pome: Cg ; Crf; Pka; Era; Nr2b; TRPM5; Prkaca;
  • Prkacb Prkarla: Prkar2a
  • Wnt2b Wnt3a; Wnt4; WntSa; Wnt6; Wnt7b; WntSb;
  • Embodiments of the invention also relate to methods and compositions related to knocking out genes, amplifying genes and repairing particular mutations associated with DNA repeat instability and neurological disorders (Robert D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 201 1 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeat instability: role of RNA » DNA hybrids. Mclvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct;7(5):551-8). The CRISPR-Cas system may be harnessed to correct these defects of genomic instability.
  • a further aspect of the invention relates to utilizing the CRISPR-Cas system for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease.
  • Lafora disease is an autosomal recessive condition which is characterized by progressive myoclonus epilepsy which may start as epileptic seizures in adolescence. A few cases of the disease may be caused by mutations in genes yet to be identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and eventually death. There is currently no therapy that has proven effective against disease progression.
  • the CRISPR-Cas system may be used to correct ocular defects that arise from several genetic mutations further described in Genetic Diseases of the Eye, Second Edition, edited by Elias L Traboulsi, Oxford University Press, 2012.
  • the genetic brain diseases may include but are not limited to Adrenoleukodystrophy, Agenesis of the Corpus Caliosum, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barfh Syndrome, Batten Disease, CADASIL,
  • the condition may be neoplasia.
  • the genes to be targeted are any of those listed in Table A (in this case PTEN and so forth).
  • the condition may be Age-related Macular Degeneration.
  • the condition may be a Schizophrenic Disorder.
  • the condition may be a Trinucleotide Repeat Disorder.
  • the condition may be Fragile X Syndrome.
  • the condition may be a Secretase Related Disorder.
  • the condition may be a Prion ⁇ related disorder.
  • the condition may be ALS, In some embodiments, the condition may be a drug addiction. In some embodiments, the condition may be Autism, In some embodiments, the condition may be Alzheimer's Disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson's Disease.
  • proteins associated with Parkinson's disease include but are not limited to a-symiclein, DJ-1 , LRRK2, PINKl , Parkin, UCHL1, Synphilin-1 , and NURR1.
  • Examples of addiction-related proteins may include ABAT for example.
  • inflammation-related proteins may include the monocyte chemoattractant protein-! (MCP! ) encoded by the Ccr2 gene, the C-C chemokine receptor type 5 (CCR.5) encoded by the Cer5 gene, the IgG receptor ⁇ (FCGR2b, also termed CD32) encoded by the Fegr2b gene, or the Fc epsilon Rig (FCERlg) protein encoded by the Fcerl g gene, for example.
  • MCP! monocyte chemoattractant protein-!
  • CCR.5 C-C chemokine receptor type 5
  • FCGR2b also termed CD32
  • FCERlg Fc epsilon Rig
  • cardiovascular diseases associated proteins may include IL1B (interleukin 1, beta), XDH (xanthine dehydrogenase), TP53 (tumor protein p53), PTGIS (prostaglandin 12 (prostacyclin) synthase), MB (myoglobin), IL4 (interleukin 4), ANGPT1 (angiopoietin 1), ABCG8 (AT -binding cassette, sub-family G (WHITE), member 8), or CTSK (cathepsin K), for example.
  • IL1B interleukin 1, beta
  • XDH xanthine dehydrogenase
  • TP53 tumor protein p53
  • PTGIS prostaglandin 12 (prostacyclin) synthase)
  • MB myoglobin
  • IL4 interleukin 4
  • ANGPT1 angiopoietin 1
  • ABCG8 AT -binding cassette, sub-family G (WHITE), member 8
  • CTSK
  • Examples of Alzheimer's disease associated proteins may include the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin- like modifier activating enzyme 1 (UBA1 ) encoded by the UBA1 gene, or the NEDD8-
  • VLDLR very low density lipoprotein receptor protein
  • UBA1 ubiquitin-like modifier activating enzyme 1
  • proteins associated Autism Spectmm Disorder may include the benzodiazapine receptor (peripheral) associated protein 1 (BZRAPl) encoded by the BZRAPl gene, the AF4/FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also termed MFR2), the fragile X mental retardation autosomal homolog 1 protein (FXR1) encoded by the FXR1 gene, or the fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene, for example.
  • BZRAPl benzodiazapine receptor (peripheral) associated protein 1
  • AFF2 AF4/FMR2 family member 2 protein
  • FXR1 fragile X mental retardation autosomal homolog 1 protein
  • FXR2 fragile X mental retardation autosomal homolog 2 protein
  • proteins associated Macular Degeneration may include the ATP- binding cassette, sub-family A (ABC1) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoproiein E protein (APOE) encoded by the APOE gene, or the chemoldne (C-C motif) Ligand 2 protein (CCL2) encoded by the CCL2 gene, for example.
  • ABC1 sub-family A
  • APOE apolipoproiein E protein
  • CCL2 chemoldne
  • proteins associated Schizophrenia may include NRGl, ErbB4, CPLXL TPH1, TPH2, NRXN L GSK3A, BDNF, DISC I, GSK3B, and combinations thereof.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to enable genome engineering in an organism to recapitulate the genetic complexity of disease or a condition and further interrogate gene function.

Description

ONCOGENIC MODELS BASED ON DELIVERY AND USE OE THE CRISPR- CAS SYSTEMS, VECTORS AND COMPOSITIONS
RELATED APPLICATIONS AND INCO ORATION BY REFERENCE ΘΘ01] Priority is claimed to US provisional patent applications 61/915,397, filed on December 12, 2013, and 61/836, 123, filed June 17, 2013, both of which are incorporated herein by reference,
[0002] The foregoing application(s), and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appin cited documents, and all documents cited or referenced herein ("herein cited documents"), and all documents cited or referenced in herein cited documents, together with any instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
FIELD OF THE INVENTION
[0003] The present invention generally relates to the delivery, engineering, optimization and therapeutic applications of systems, methods, compositions and vectors used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and components thereof.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0004] This invention was made with government support under the NIH Pioneer Award (1DP1MH100706) and NIH (P01 CA108631) grant awarded by the National Institutes of Health. The government has certain rights in the invention.
BACKGROUND OF THE INVENTION
[0005] Recent advances in genome sequencing techniques and analysis methods have significantly accelerated the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. Precise genome targeting technologies are needed to enable systematic reverse engineering of causal genetic variations by allowing selective perturbation of individual genetic elements, as well as to advance synthetic biology, biotechnological, and medical applications. Although genome-editing techniques such as designer zinc fingers, transcription activator-like effectors (TALEs), or homing meganucleases are available for producing targeted genome perturbations, there remains a need for new genome engineering technologies that are affordable, easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome.
SUMMARY OF THE INVENTION
[0006] The CRISPR-Cas system does not require the generation of customized proteins to target specific sequences but rather a single Cas enzyme can be programmed by a short RNA molecule to recognize a specific DNA target. Adding the CRISPR-Cas system to the repertoire of genome sequencing techniques and analysis methods may significantly simplify the methodology and accelerate the ability to catalog and map genetic factors associated with a diverse range of biological functions and diseases. To utilize the CRISPR-Cas system effectively for genome editing without deleterious effects, it is critical to understand aspects of engineering, optimization and tissue/organ specific delivery of these genome engineering tools, which are aspects of the claimed invention.
[0007] There exists a pressing need for alternative and robust systems and techniques for sequence targeting with a wide array of applications. Aspects of this invention address this need and provides related advantages. An exemplary CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
[0008] In one aspect, the invention provides methods for using one or more elements of a CRISPR system. The CRISPR complex of the inve tion provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utilities including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types in various tissues and organs. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene or genome editing, gene therapy, generation of cell and animal model systems, drug discovery, drug screening, disease diagnosis, and prognosis.
[0009] Aspects of the invention relate to the CRISPR-Cas system having the utility of engineering primary cells that recapitulate the genetic complexity of human disease. This complexity arises from the interaction of multiple genetic lesions, which is particularly true in the case of proliferative disorders like cancer,
2
90.1 ΘΘ10] The invention comprehends a method of inducing a proliferative condition in a an organism comprising: isolating a first population of cells from the organism, transducing the first population of cells with a non -naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRjNlA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a.) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism, (b) a tracr mate sequence, and (c) a tracr sequence, and II a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences ( LSs), wherein (a), (b) and (c) are arranged in a 5' to 3 ' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1 ) the guide sequence that is liybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme alters the genome of the first population of cells to obtain a second population of cells, and transplanting the second population of cells into the organism thereby inducing the proliferative condition. In an embodiment of the invention may be a cancer, particularly a myeloid malignancy. In another embodiment of the invention the first population of cells may be a population of stern cells, particular}' a population of hematopoietic stem and progenitor cells. In a preferred embodiment the vector system is a lentiviral vector system. In further embodiments of the invention the first regulatory element may be a Pol III promoters such as a U6 promoter and the second regulatory element may be an EFS promoter. In a further aspect of the invention the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences. The invention also comprehends that the target sequences may be associated with tumor suppressor genes. In one embodiment, the organism is a mouse.
[ΘΘ11] The invention also comprehends a method of interrogating function of one or more genes in a proliferative condition in an organism comprising: inducing the proliferative condition by a method comprising isolating a first population of cells from the organism, transducing the first population of cells with a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chiRNA polynucleotide sequence, wherein the polynucleotide sequence comprises (a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism, (b) a tracr mate sequence, and (c) a tracr sequence, and 11. a second regulator}' element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme comprising at least one or more NLSs, wherein (a), (b) and (c) are arranged in a 5 ' to 3 ' orientation, wherein components I and 11 are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hvbridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the CRISPR enzyme alters the genome of the first population of cells to obtain a second population of cells, transplanting the second population of cells into the organism thereby inducing the proliferative condition; and determining changes in expression of the one or more genes in the proliferative condition thereby interrogating the function of one or more genes. In an embodiment of the invention may be a cancer, particularly a myeloid malignancy. In another embodiment of the invention the first population of ceils may be a population of stem cells, particulary a population of hematopoietic stem and progenitor cells. In a preferred embodiment the vector system is a lentiviral vector system. In further embodiments of the invention the first regulator}' element may be a Pol ill promoter such as a IJ6 or a H I promoter and the second regulatory element may be an EPS promoter. In a further aspect of the invention the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences. The invention also comprehends that the target sequences may be associated with tumor suppressor genes. In one embodiment, the organism is a mouse.
[ΘΘ12] The genes that are useful for this invention are any of the genes that are recurrently mutated in cancer. Embodiments herein are relevant for any gene(s) with ioss- of-function mutation(s) in cancer. This is sometimes referred to as a tumor suppressor, but probably more accurate to refer to gene(s) with loss-of-function mutation(s). Loss-of- function mutation(s) result in the gene product having less or no function. When the allele has a complete loss of function (null allele) it is often called an amorphic mutation. Phenotypes associated with such mutations are most often recessive. (Exceptions are when the organism is haploid, or when the reduced dosage of a normal gene product is not enough for a normal phenotype (this is called haplomsufficiency).) The CRISPR-Cas9 system of the instant invention and the utilization of the system in the practice of the
4
90.1 instant invention also can be used to introduce specific mutations, e.g., cut or nick, insertion, deletion, substitution. The list of genes with, loss-of-function mutation is large - in the hundreds. Indeed, the Bioinformatics and Systems Medicine Laboratory of Vanderbilt University Medical Center has a website, the TS GENE TUMOR. SUPPRESSOR GENE DATABASE, http://bioinfb.mc.vanderbiit.edu/TSGene/index.html, that includes 716 human genes (637 coding and 79 non-coding genes), 628 mouse genes, and 567 rat genes. The invention is applicable to each of those genes. The invention is applicable to any gene for which loss of function mutation(s) leads to neoplasm or tumor growth or cancer; and the skilled person well appreciates loss of function mutation(s) in cancer (as well as gain of function mutations in cancer and the invention can be analogously applicable to such mutations). See Komarova Journal of Statistical Physics, July 2007, Volume 128, Issue 1-2, pp 413-446, "Loss- and Gain-of-Function Mutations in Cancer: Mass-action, Spatial and Hierarchical Models." The term "tumor suppressor" is herein used as understood in the art, namely to include loss of function mutation(s) in or involved in or that leads to or contributes to or is a factor in neoplasm or tumor growth or cancer, including tumor formation and/or spread and/or Hyperplasia (altered cell divides in an uncontrolled manner leading to an excess of cells in that region of the tissue) and/or Dysplasia (additional genetic changes in the hyperplastic cells lead to increasingly abnormal growth; cells and the the tissue no longer look normal; cells and the tissue may- become disorganized) and/or Carcinoma in situ (additional changes make the cells and tissues appear even more abnormal cells are spread over a larger area and the region of the tissue involved primarily contains altered cells; cells often 'regress' or become more primitive in their capabilities, e.g., a liver cell that no longer makes liver-specific proteins; cells may be de-differentiated or anaplastic and/or 'benign tumor(s)' and/or Cancer (including Malignant tumor(s)).
[0013] The invention provides a non-naturally occurring or engineered composition for generating an in vivo, in vitro or ex vivo proliferative condition comprising multiple genetic lesions in a population of cells comprising a viral vector such as a lentiviral vector system comprising one or more lentiviral vectors comprising I. a Pol III promoter operably linked to a CRISPR-Cas system c iRNA polynucleotide sequence, wherein the polynucleotide sequence comprises (a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism, (b) a tracr mate sequence, and (c) a tracr sequence, and II. a EES promoter operably linked to an enzyme- coding sequence encoding a CRISPR enzyme comprising at least one or more NLSs, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, and wherein the C TSPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In an embodiment of the invention may be a cancer, particularly a myeloid malignancy. In another embodiment of the invention the first population of cells may be a population of stem cells, particulary a population of hematopoietic stem and progenitor cells.17. The composition of claim 12, wherein the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences. In a further aspect of the invention the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences. The invention also comprehends that the target sequences may be associated with tumor suppressor genes.
[0014] Aspects of the invention relate to Cas9 enzymes having improved target specificity in a CRISPR-Cas9 system having guide RNAs having optimal activity, smaller in length than wild-type Cas9 enzymes and nucleic acid molecules coding therefor, and chimeric Cas9 enzymes, as well as methods of improving the target specificity of a Cas9 enzyme or of designing a CRISPR-Cas9 system comprising designing or preparing guide RNAs having optimal activity and/or selecting or preparing a Cas9 enzyme having a smaller size or length than wild-type Cas9 whereby packaging a nucleic acid coding therefor into a delivery vector is advanced as there is less coding therefor in the deliver}' vector than for wild-type Cas9, and/or generating chimeric Cas9 enzymes.
[0015] Also provided are uses of the present sequences, vectors, enzymes or systems, in medicine. Also pro vided are uses of the same in gene or genome editing.
[0016] In an additional aspect of the invention, a Cas9 enzyme may comprise one or more mutations and may be used as a generic DNA binding protein with or without fusion to a functional domain. The mutations may be artificially introduced mutations or gain- or loss-of-function mutations. The mutations may include but are not limited to mutations in one of the catalytic domains (D10 and H84Q). Further mutations have been characterized and may be used in one or more compositions of the invention. In one aspect of the invention, the mutated Cas9 enzyme may be fused to a protein domain, e.g., such as a transcriptional activation domain. In one aspect of the invention, the transcriptional activation domain may be VP64. In other aspects of the invention, the transcriptional
6
90.1 repressor domain may be KRAB or SID4X. Other aspects of the invention relate to the mutated Cas 9 enzyme being fused to domains which include but are not limited to a transcriptional activator, repressor, a reeombinase, a transposase, a. histone remodeler, a DNA methyltransferase, a cryptochrome, a light inducibie/controllable domain or a chemically inducible/controllable domain. In one aspect, the Cas enzyme has at least one or more mutations in a catalytic domain. In one aspect, the Cas enzyme is a. nickase, [0017] In a further embodiment, the invention provides for methods to generate mutant tracrRNA and direct repeat sequences or mutant chimeric guide sequences that allow for enhancing performance of these RNAs in cells. Aspects of the invention also provide for selection of said sequences.
[ΘΘ18] Aspects of the invention also provide for methods of simplifying the cloning and delivery of components of the CRISPR complex. In the preferred embodiment of the invention, a suitable promoter, such as a Pol III promoter, e.g., a HI or a U6 promoter, is amplified with a DNA oligo and positioned contiguous to and upstream of a sequence encoding the guide RNA. The resulting PGR product can then be trans fected into cells to drive expression of the guide RNA. Aspects of the invention also relate to the guide RNA being transcribed in vitro or ordered from a synthesis company and directly transfected.
[0019] In one aspect, the invention provides for methods to improve activity by using a more active polymerase. In one aspect, a T7 promoter may be inserted contiguous to and upstream of a sequence encoding a guide RNA. In a preferred embodiment, the expression of guide RNAs under the control of the T7 promoter is driven by the expression of the T7 polymerase in the cell. In an advantageous embodiment, the cell is a eukaryotic cell. In a preferred embodiment the eukaryotic cell is a human cell. In a more preferred embodiment the human cell is a patient specific cell
[0020] In one aspect, the invention provides for methods of reducing the toxicity of Cas enzymes. In certain aspects, the Cas enzyme is any Cas9 as described herein, for instance any naturally -occurring bacterial Cas9 as well as any chimaeras, mutants, omoiogs or orthologs. In one aspect, the Cas enzyme is a nickase. In a preferred embodiment, the Cas9 is delivered into the cell in the form of mRNA. This allows for the transient expression of the enzyme thereby reducing toxicity. In another embodiment, the Cas 9 is delivered into the cell in the nucleotide construct that encodes and expresses the Cas 9 enzyme. In another preferred embodiment, the invention also provides for methods of expressing Cas9 under the control of an inducible promoter the constructs used therein.
90.1 ΘΘ21] In another aspect, the invention provides for methods of improving the in vivo applications of the CRISPR-Cas system. In the preferred embodiment, the Cas enzyme is wiidtype Cas9 or any of the modified versions described herein, including any naturally- occurring bacterial Cas9 as well as any chimaeras, mutants, homologs or orthologs. In one aspect, the Cas enzyme is a nickase. An advantageous aspect of the invention provides for the selection of Cas9 homologs that are easily packaged into viral vectors for delivery. Cas9 orthologs typically share the general organization of 3-4 RuvC domains and a HNH domain. The 5' most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand. All notations are in reference to the guide sequence.
[0022] The catalytic residue in the 5' RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S, pyogenes type II CRISPR locus, S. thermophiius CRISPR locus 1, S. thermophiius CRISPR locus 3, and Franeiscilla novicida type II CRISPR locus), and the conserved Asp residue is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non-complementary-strand nicking enzyme.
[0023] In some embodiments, the CRISPR enzyme is a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme may be any Cas enzyme. A Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, spCas9 or saCas9. By derived. Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wiidtype enzyme, but that it has been mutated (modified) in some way as described herein
[0024] It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes (annotated alternatively as SpCas9 or spCas9). However, it will be appreciated that this invention includes many more Cas9s from other species of microbes, such as SpCas9 derived from S. pyogenes, SaCas9 derived from S. aureus, StlCas9 derived from S. thermophiius and so forth. Further examples are provided herein.
[0025] An example of a codo optimized sequence, in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, e.g., see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species other than human, or for codon optimization for specific organs such as the brain, is known.
[0026] In further embodiments, the invention provides for methods of enhancing the function of Cas9 by generating chimeric Cas9 proteins. These methods may comprise fusing N -terminal fragments of one Cas9 homolog with C-terminal fragments of another Cas9 homolog. These methods also allo for the selection of new properties displayed by the chimeric proteins.
[ΘΘ27] It will be appreciated that in the present methods, where the organism is an animal or a plant, the modification may occur ex vivo or in vitro, for instance in a cell culture and in some instances not in vivo, in other embodiments, it may occur in vivo.
[0028] In one aspect, the invention provides a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest comprising:
delivering a non-naturaily occurring or engineered composition comprising :
A) - 1, a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:
(a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
II. a polynucleotide sequence encoding a CRTSPR enzyme comprising at least one or more nuclear localization sequences,
wherein (a), (b) and (c) are arranged in a 5' to 3' orientation,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRTSPR complex to the target sequence, and
wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybrid! zableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA,
or
(B) I. polynucleotides comprising: (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and
(b) at least one or more tracr mate sequences,
II. a polynucleotide sequence encoding a CRISPR enzyme, and
III. a polynucleotide sequence comprising a tracr sequence,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and
wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizabieto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, and the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA.
[0029] Any or all of the polynucleotide sequence encoding a CRISPR enzyme, guide sequence, tracr mate sequence or tracr sequence, may be RNA, DNA or a combination of RNA and DNA. In one aspect, the polynucleotides comprising the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence are RNA. In one aspect, the polynucleotides comprising the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence are DNA. In one aspect, the polynucleotides are a mixture of DNA and RNA, wherein some of the polynucleotides comprising the sequence encoding one or more of the CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence are DNA and some of the polynucleotides are RNA. In one aspect, the polynucleotide comprising the sequence encoding the CRISPR enzyme is a DNA and the guide sequence, tracr mate sequence or tracr sequence are RNA. The one or more polynucleotides comprising the sequence encoding a CRISPR enzyme, the guide sequence, tracr mate sequence or tracr sequence may be delivered via nanoparticles, exosomes, microvesciles, or a gene-gun.
[0030] It will be appreciated that where reference is made to a polynucleotide, where that polynucleotide is RNA and is said to 'comprise' a feature such as a tracr mate sequence, the RNA sequence includes the feature. Where the polynucleotide is DNA and is said to comprise a feature such as a tracr mate sequence, the DNA sequence is or can be transcribed into the RNA that comprises the feature at issue. Where the feature is a protein, such as the CRISPR enzyme, the DNA or RNA sequence referred to is, or can be, translated (and in the case of DNA transcribed first). Furthermore, in cases where an
10
90.1 RNA encoding the CRISP enzyme is provided to a ceil, it is understood that the RNA is capable of being translated by the cell into which it is delivered.
[0031] Accordingly, in certain embodiments the invention provides method of modifying an organism, e.g., mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest comprising delivering a non-naturally occurring or engineered composition comprising a viral or plasmid vector system comprising one or more viral or plasmid vectors operably encoding a composition for expression thereof, wherein the composition comprises: (A) a non- naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising 1. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiR A) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a tracr sequence, and 11. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRJSPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS), wherein (a), (b) and (c) are arranged in a 5' to 3 ' orientation, wherein components 1 and 11 are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRJSPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybrid! zabieto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or (B) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulator element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence -specific binding of a. CRJSPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In one embodiment, the vector
11
90.1 system comprises a viral vector system, e.g., an AAV vector or AA\/T vector system or a lentivirus-deri ved vector system. In one aspect, the Cas enzyme is a niekase.
[0032] Preferably, the vector is a viral vector, such as a lenti- or bacuio- or preferably adeno-viral/adeno-associated viral vectors, but other means of deliver)' are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided. In some embodiments, one or more of the viral or plasmid vectors may be delivered via nanoparticles, exosomes, microvesciles, or a gene-gun.
[0033] By manipulation of a target sequence, Applicants mean the alteration of the target sequence, which may include the epigenetic manipulation of a target sequence. This epigenetic manipulation may be of the chromatin state of a target sequence, such as by modification of the methylaiion state of the target sequence (i.e. addition or removal of methylaiion or methylaiion patterns or CpG islands), hi stone modification, increasing or reducing accessibility to the target sequence, or by promoting or reducing 3D folding.
[0034] It will be appreciated that where reference is made to a method of modifying an organism or mammal including human or a non-human mammal or organism by manipulation of a target sequence in a genomic locus of interest, this may apply to the organism (or mammal) as a whole or just a. single cell or population of cells from that organism (if the organism is multicellular). In the case of humans, for instance, Applicants envisage, inter alia, a single cell or a population of cells and these may preferably be modified ex vivo and then re-introduced. In this case, a biopsy or other tissue or biological fluid sample may be necessary. Stem cells are also particularly preferred in this regard. But, of course, in vivo embodiments are also envisaged.
[0035] In certain embodiments the invention provides a method of treating or inhibiting a condition caused by a defect in a target sequence in a genomic locus of interest in an organism (e.g., mammal or human) or a non-human organism (e.g., mammal, such as a mouse) in need thereof comprising modifying the organism or a non-human organism by manipulation of the target sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non-naturally occurring or engineered composition comprising an adenoviral, an AAV or lentiviral vector system comprising one or more vectors comprising operably encoding a. composition for expression thereof, wherein the target sequence is manipulated by the composition when expressed, wherein the composition comprises: (A) a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a. tracr mate sequence, and (c) a tracr sequence, and II. a second regulatory element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS) wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (! ) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or (B) a non-naturaliy occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic ceil, and (b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and HI are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In one embodiment, the vector system comprises a viral vector system, e.g., an AAV vector or AAV vector system or a lenti virus-derived vector system. In one embodiment, the Cas enzyme is a nickase.
[0036] Some methods of the invention can include inducing expression. In some methods of the invention the organism or subject is a eukaryote (including mammal including human) or a non-human eukaryote or a non-human animal or a non-human mammal. In some methods of the invention the organism or subject is a plant. In some methods of the invention the organism or subject is a mammal or a non-human mammal. In some methods of the invention the organism or subject is algae. In some methods of the invention the viral vector is an AAV. In some methods of the invention the CRISPR
13
90.1 enzyme is a Cas9, In some methods of the invention the CRISPR enzyme copmprises one or more mutations in one of the catalytic domains. In some methods of the invention the CRISPR enzyme is a Cas9 nickase. In some methods of the invention the expression of the guide sequence is under the control of the T7 promoter that is driven by the expression of T7 polymerase. In some methods of the inven tion the expression of the guide sequence is under the control of a U6 promoter.
[0037] By manipulation of a target sequence, Applicants mean the alteration of the target sequence, which may include the epigenetic manipulation of a target sequence. This epigenetic manipulation may be of the chromatin state of a target sequence, such as by modification of the methylation state of the target sequence (i.e. addition or removal of methylation or methylation patterns or CpG islands), histone modification, increasing or reducing accessibility to the target sequence, or by promoting or reducing 3D folding.
[0038] It will be appreciated that where reference is made to a method of modifying an organism or a non-human organism by manipulation of a target sequence in a genomic locus of interest, this may apply to the organism as a whole or just a single cell or population of cells from that organism (if the organism is multicellular). In the case of humans, for instance, Applicants envisage, inter alia, a. single ceil or a population of ceils and these may preferably be modified ex vivo and then re-introduced. In this case, a biopsy or other tissue or biological fluid sample may be necessary. Stem cells are also particularly preferred in this regard. But, of course, in vivo embodiments are also envisaged.
[ΘΘ39] In preferred embodiments, the invention provides methods and compositions related to generating models to study proliferative disorders. These models maybe encompassed in non-human organisms, e.g. mouse, rat, primates etc. Examples of such proliferative disorders or cancers include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermis, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small ceil lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g. exocrine pancreatic carcinoma, stomach, cervix, thyroid, prostate, gastrointestinal system, e.g. gastrointestinal stromal tumours, or skin, for example squamous ceil carcinoma; a hematopoieitic tumour of lymphoid lineage, for example leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma (such as diffuse large B cell lymphoma), T-cell lymphoma, Tiodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkitt's lymphoma; a
14
90.1 hematopoietic tumour of myeloid lineage, including, but not limited to acute myeloid leukaemia, chronic myeloid leukaemias, myelogenous leukaemias, and Imatinib sensitive and refractory chronic myelogenous leukaemias, myelodyspiastic syndrome, Bortezomib sensitive and refractory multiple myeloma, myeloproliferative disease or promyelocyte leukaemia; thyroid follicular cancer; a tumour of mesenchymal origin, for example fibrosarcoma or rhabdomyosarcoma; a tumour of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma (a High grade glioma) or schwannoma; melanoma (e.g. malignant or metastatic melanoma); seminoma; teratocarcinoma; osteosarcoma; keratoacanthoma; thyroid follicular cancer; or Kaposi's sarcoma. A further example of a tumour of mesenchymal origin is Ewing's sarcoma.
[0040] One sub-group of cancers includes a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermis, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, gall bladder, ovary, pancreas e.g. exocrine pancreatic carcinoma, stomach, thyroid, prostate, gastrointestinal system, e.g. gastrointestinal stromal tumours, or skin, for example squamous cell carcinoma; a hematopoietic tumour of lymphoid lineage, for example leukaemia, acute lymphocytic leukaemia, chronic lymphocytic leukaemia, B-cell lymphoma (such as diffuse large B cell lymphoma), T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkitt's lymphoma; a hematopoietic tumour of myeloid lineage, including acute myeloid leukaemia, chronic myeloid leukaemias, myelogenous leukaemias, and Imatinib sensitive and refractor)' chronic myelogenous leukaemias, myelodyspiastic syndrome, Bortezomib sensitive and refractor}' multiple myeloma, myeloproliferative disease or promyelocyte leukaemia; thyroid follicular cancer; a tumour of mesenchymal origin, for example fibrosarcoma or rhabdomyosarcoma; a tumour of the central or peripheral nervous system, for example astrocytoma, glioma (a High grade glioma); melanoma (e.g. malignant or metastatic meianoma); osteosarcoma; or thyroid follicular cancer. A further example of a tumour of mesenchymal origin is Ewing's sarcoma, ΘΘ41] One group of cancers consists of solid tumours selected from metastatic breast cancer which is HER2 positive; adenocarcinoma of the prostate; metastatic melanoma; non-small ceil carcinoma of the lung (NSCLC ); small ceil carcinoma of the lung (SCLC); high grade gliomas; gastrointestinal stromal tumors (GIST); colorectal cancer; glioblastoma; melanoma; metastatic thyroid cancer; prostate cancer; and rectal cancer.
15
90.1 ΘΘ42] Within this group of cancers, a particular subgroup consists of colorectal cancer; glioblastoma; melanoma; metastatic thyroid cancer; prostate cancer; and rectal cancer,
[0043] One group of cancers includes human breast cancers (e.g. primary breast tumours, node-negative breast cancer, invasive duct adenocarcinomas of the breast, non- endometrioid breast cancers); and mantle cell lymphomas. In addition, other cancers are colorectal and endometrial cancers. Another sub-set of cancers includes hematopoietic tumours of both lymphoid and myeloid lineage, for example acute lymphoblastic leukemia, chronic lymphocytic leukaemia (Both T and B cell), acute myeloid leukaemia, chronic myeloid leukaemia, mantle cell lymphoma and B-ceil lymphoma (such as diffuse large B cell lymphoma) and optionally further includes chronic myelogenous leukaemia and multiple myeloma. A sub-set of cancers consists of ErbB2 -positive breast, prostate, lung, and gastric cancer; chronic myeloid leukemia; androgen receptor dependent prostate cancer; Flt3 -dependent acute myeloid leukaemia; melanoma associated with Braf mutation; multiple myeloma; velcade refractory multiple myeloma; and gastrointestinal stromal tumours (GIST).
[0044] Another sub-set of cancers consists of hormone refractory prostate cancer, metastatic melanoma, HER2 positive breast cancer, mutant EGFR positive non-small cell lung carcinoma and Gleevec resistant gastrointestinal stromal tumours. A further sub-set of cancers consists of hormone refractory prostate cancer, metastatic melanoma, HER2 positive breast cancer, mutant EGFR positive non-small cell lung carcinoma, Small Cell Lung Carcinoma and gastrointestinal stromal tumours.
[0045] In certain embodiments the invention provides a method of treating or inhibiting a condition caused by a defect in a target sequence in a genomic locus of interest in an organism or a non-human organism in need thereof comprising modifying the organism or a non-human organism by manipulation of the target sequence and wherein the condition is susceptible to treatment or inhibition by manipulation of the target sequence comprising providing treatment comprising: delivering a non-naturaliy occurring or engineered composition comprising an AAV or a lenti viral vector system comprising one or more AAV or lenti viral vectors comprising operably encoding a composition for expression thereof, wherein the target sequence is manipulated by the composition when expressed, wherein the composition comprises: (A) a non-naturaliy occurring or engineered composition comprising a vector system comprising one or more vectors comprising I. a first regulatory element operably linked to a CRISPR-Cas system
16
90.1 chimeric RNA (chiR A) polynucleotide sequence, wherein the polynucleotide sequence comprises (a) a guide sequence capable of hybridizing to a target sequence in a eukaryotic cell, (b) a tracr mate sequence, and (c) a. tracr sequence, and 11. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (or optionally at least one or more nuclear localization sequences as some embodiments can involve no NLS) wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein components 1 and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with ( 1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, or (B) a non-naturaliy occurring or engineered composition comprising a vector system comprising one or more vectors comprising 1. a firs t regulatory element operably linked to (a) a guide sequence capable of hybridizing to a target sequence in a prokaryotic cell, and b) at least one or more tracr mate sequences, II. a second regulatory element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme, and III. a third regulatory element operably linked to a tracr sequence, wherein components I, II and III are located on the same or differen t vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In one embodiment, the vector system comprises a viral vector system, e.g., an AAV vector or AAV vector system or a lenti virus-derived vector system. In one aspect, the Cas enzyme is a nickase.
[0046] Some methods of the invention can include inducing expression. In some methods of the invention the organism or subject is a eukaryote or a non-human eukaryote or a non-human animal In some methods of the invention the organism or subject is a plant. In some methods of the invention the organism or subject is a mammal or a non- human mammal. In some methods of the invention the organism or subject is algae. In some methods of the invention the viral vector is an AAV or a lenti viral vector. In some methods of the invention the CRISPR enzyme is a Cas9. In some methods of the
17
90.1 invention the expression of the guide sequence is under the control of the T7 promoter is driven by the expression of T'7 polymerase.
[0047] The invention in some embodiments comprehends a method of delivering a CRTSPR enzyme comprising delivering to a cell mRNA encoding the CRISPR enzyme. In some of these methods the CRISPR enzyme is a Cas9.
[0048] The invention in some embodiments comprehends a method of preparing the AAV or lentivims vector of the invention comprising transfecting one or more plasmid(s) containing or consisting essentially of nucleic acid molecule(s) coding for the AAV or lentivirus into AAV- or lentivirus-infetable cells, and supplying AAV rep and/or cap obligatory for replication and packaging of the AAV or supplying the essential proteins that may be needed for packaging, replication and transduction of a lentivims (e.g. gag, pol, rev). In some embodiments the AAV rep ami/or cap obligator)' for replication and packaging of the AAV are supplied by transfecting the cells with helper plasmid(s) or helper virus(es). In some embodiments the helper vims is a poxvirus, adenovirus, herpesvirus or baculovirus. In some embodiments the poxvirus is a vaccinia vims. In some embodiments the cells are mammalian cells. And in some embodiments the cells are insect ceils and the helper vims is bacuiovirus.
[0049] In plants, pathogens are often host-specific. For example, Fusarium oxysporum f. sp. tycopersici causes tomato wilt but attacks only tomato, and F. oxysporum f. dianthn Puccima graminis f. sp. tritici attacks only wheat. Plants have existing and induced defenses to resist most pathogens. Mutations and recombination events across plant generations lead to genetic variability that gives rise to susceptibility, especially as pathogens reproduce with more frequency than plants. In plants there can be non-host resistance, e.g., the host and pathogen are incompatible. There can also be Horizontal Resistance, e.g., partial resistance against ail races of a pathogen, typically controlled by many genes and Vertical Resistance, e.g., complete resistance to some races of a pathogen but not to other races, typically controlled by a few genes. In a Gene-for-Gene level, plants and pathogens evolve together, and the genetic changes in one balance changes in other. Accordingly, using Natural Variability, breeders combine most useful genes for Yield, Quality, Uniformity, Hardiness, Resistance. The sources of resistance genes include native or foreign Varieties, Heirloom Varieties, Wild Plant Relatives, and Induced Mutations, e.g., treating plant material with mutagenic agents. Using the present invention, plant breeders are provided with a new tool to induce mutations. Accordingly, one skilled in the art can analyze the genome of sources of resistance genes, and in
18
90.1 Varieties having desired characteristics or traits employ the present invention to induce the rise of resistance genes, with more precision than previous mutagenic agents and hence accelerate and improve plant breeding programs. In some methods of the invention the viral vector is a tobacco mosaic vims vector or an Agrobacterium Ti or Ri plasmid.
[0050] The invention further comprehends a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in medicine. In some embodiments the invention comprehends a composition according to the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) for use in a method according to the invention. In some embodiments the invention provides for the use of a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in ex vivo gene or genome editing. In certain embodiments the invention comprehends use of a. composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme) in the manufacture of a medicament for ex vivo gene or genome editing or for use in a method according of the invention. In some methods of the invention the CRISPR enzyme comprises one or more mutations in one of the catalytic domains. In some methods of the invention the CRISPR enzyme is a nickase. The invention comprehends in some embodiments a composition of the invention or a CRISPR enzyme thereof (including or alternatively mRNA encoding the CRISPR enzyme), wherein the target sequence is flanked at its 3' end by 5 '-motif termed a proto-spacer adjacent motif (PAM), especially where the Cas9 is (or is derived from) S. pyogenes or S. aureus Cas9. For example, a suitable PAM is 5 -NRG or 5 NNGRR (where N is any Nucleotide) for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively, as mentioned below.
[0051] It will be appreciated that SpCas9 or SaCas9 are those from or derived from S. pyogenes or S. aureus Cas9.
[0052] Apects of the invention comprehend improving the specificity of a CRISPR enzyme, e.g. Cas9, mediated gene targeting and reducing the likelihood of off-target modification by the CRISPR enzyme, e.g. Cas9. The invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a. second target sequence on opposite strands of a DNA duplex in a genomic locus of interest in a cell comprising delivering a non-naturally occurring or engineered composition comprising :
19
90.1 I. a first CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the first polynucleotide sequence comprises:
(a) a first guide sequence capable of hybridizing to the first target sequence,
(b) a firs t tracr mate sequence, and
(c) a first tracr sequence,
II. a second CRISPR-Cas system chiRNA polynucleotide sequence, wherein the second polynucleotide sequence comprises:
(a) a second guide sequence capable of hybridizing to the second target sequence,
(b) a second tracr mate sequence, and
(c) a second tracr sequence, and
III. a polynucleotide sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences and comprising one or more mutations, wherein (a), (b) and (c) are arranged in a 5' to 3' orientation, wherein when transcribed, the first and the second tracr mate sequence hybridize to the first and second tracr sequence respectively and the first and the second guide sequence directs sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRISPR complex comprises the CRISPR enzyme complexed with (1 ) the first guide sequence that is hybridizabieto the first target sequence, and (2) the first tracr mate sequence that is hybridized to the first tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridizabieto the second target sequence, and (2) the second tracr mate sequence that is hybridized to the second tracr sequence, wherein the polynucleotide sequence encoding a CRISPR enzyme is DNA or RNA, and wherein the first guide sequence directs cleava ge of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the opposite strand near the second target sequence, thereby inducing an offset double strand break in the DNA duplex, thereby modifying the organism or the non-human organism by minimizing off- target modifications. In one aspect, the first nick and the second nick in the DNA is offset relative to each other by at least one base pair of the duplex. In one aspect, the first nick and the second nick are offset relative to each other so that the resulting DNA break as a 3' overhang. In one aspct, the first nick and the second nick are offset relative to each other so that the resulting DNA break has a 5 ' overhang. In one aspect, the first nick and the second nick are positioned relative to each other such that the overhang is at least 1 nt, at least 10 nt, at least 15 nt, at least 26 nt, at least 30 nt, at least 50 nt or more that at least
20
90.1 50 nt. Additional aspects of the invention comprising the resulting offset double nicked DNA strand can be appreciated by one skilled in the art, and exemplar}' uses of the double nick system are provided herein.
[0053] In some methods of the invention any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA, In further embodiments of the invention the polynucleotides comprising the sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA and are delivered via nanoparticles, exosomes, microvesciles, or a gene -gun. In certain embodiments of the invention, the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity. In preferred embodiments of the invention the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9. In an aspect of the invention the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of DIOA, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the CRISPR enzyme has the DIOA mutation.
[0054] In preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the opposite strand near the second target sequence results in a 5' overhang. In embodiments of the invention the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs,
[0055] The invention in some embodiments comprehends a method of modifying an organism or a non-human organism by minimizing off-target modifications by manipulation of a first and a second target sequence on opposite strands of a. DNA duplex in a genomic locus of interest in a ceil, the method comprising delivering a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising
I. a first regulatory element operably linked to
(a) a first guide sequence capable of hybridizing to the first target sequence, and
(b) at least one or more tracr mate sequences,
II. a second regulatory element operably linked to
21
90.1 (a) a second guide sequence capable of hybridizing to the second target sequence, and
(b) at least one or more tracr mate sequences,
ITT. a third regulatory element operably linked to an enzyme -coding sequence encoding a CRTSPR enzyme, and
IV. a. fourth regulatory element operably linked to a tracr sequence,
wherein components I, II, III and IV are located on the same or different vectors of the system,
when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the first and the second guide sequence directs sequence-specific binding of a first and a second CRISPR complex to the first and second target sequences respectively, wherein the first CRTSPR complex comprises the CRISPR enzyme complexed with (I) the first guide sequence that is hybridizableto the first target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the second CRISPR complex comprises the CRISPR enzyme complexed with (1) the second guide sequence that is hybridizableto the second target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein the polynucleotide sequence encoding a CRISPR enzyme is DNA or R A, and wherein the first guide sequence directs cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directs cleavage of the opposite strand of the DNA duplex near the second target sequence inducing an offset double strand break, thereby modifying the organism or the non-human organism by minimizing off-target modifications.
[ΘΘ56] In some methods of the invention any or all of the polynucleotide sequence encoding the CRISPR enzyme, the first and the second guide sequence, the first and the second tracr mate sequence or the first and the second tracr sequence, is/are RNA. In further embodiments of the invention the first and second tracr mate sequence share 100% identity and/or the first and second tracr sequence share 100% identity. In preferred embodiments of the invention the CRISPR enzyme is a Cas9 enzyme, e.g. SpCas9. In an aspect of the invention the CRISPR enzyme comprises one or more mutations in a catalytic domain, wherein the one or more mutations are selected from the group consisting of DIOA, E762A, H84QA, N854A, N863A and D986A. In a highly preferred embodiment the CRISPR enzyme has the DIOA mutation. In a further embodiment of the invention, one or more of the viral vectors are delivered via nanoparticles, exosomes, microvesicles, or a gene-gun. ΘΘ57] In preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the opposite strand near the second target sequence results in a 5' overhang. In embodiments of the invention the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.
ΘΘ58] The invention in some embodiments comprehends a method of modifying a genomic locus of interest by minimizing off-target modifications by introducing into a cell, said cell containing and expressing a double stranded DNA molecule encoding the gene product, an engineered, non-naiurally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations in a catalytic domain and two guide RNAs that target a first strand and a second strand of the DNA molecule respectively, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.
[0059] In preferred methods of the invention the Cas protein nicldng each of the first strand and the second strand of the DNA molecule encoding the gene product results in a 5' overhang. In embodiments of the invention the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs.
[0060] Embodiments of the invention also comprehend the guide RNAs comprising a guide sequence fused to a tracr mate sequence and a tracr sequence. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic cell, wherein it may be a mammalian cell or a human cell or a specific tissue -type cell In further embodiments of the invention the Cas protein is a. type II CRISPR-Cas protein, e.g. a Cas 9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the Cas protein has the D10A mutation, in many aspects of the invention, the Cas protein is a nickase.
23
90.1 [0061] Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the fragment comprising the DNA sequence between the two nick sites to be lost and the remaining two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased. In an embodiment of the invention, the gene product is a protein, in an embodiment of the invention, the gene product is a microRNA. In one embodiment, the regulator}' region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
[0062] The invention also comprehends an engineered, non-naturally occurring CRISPR-Cas system comprising a Cas protein having one or more mutations and two guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product in a cell, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA duplex molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.
[0063] In aspects of the invention the guide RNAs may comprise a guide sequence fused to a tracr mate sequence and a tracr sequence. In an embodiment of the invention the Cas protein is a type II CRISPR-Cas protein. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic cell, wherein it may be a mammalian cell or a human cell or a cell of a specific tissue type. In further embodiments of the invention the Cas protein is a type II CRISPR-Cas protein, e.g. a Cas 9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, N854A, N863A and D986A. In a highly preferred embodiment the Cas protein has the D10A mutation. In many embodiments of the invention, the Cas protein is a nickase.
[ΘΘ64] Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased or decreased. In an embodiment of the invention, the gene product is a protein, in an embodiment of the
24
90.1 invention, the gene product is a microRNA. In one embodiment, the regulator}' region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
[0065] The invention also comprehends an engineered, non-naturally occurring vector system comprising one or more vectors comprising:
a) a first regulator}' element operably linked to each of two CRISPR-Cas system guide RNAs that target a first strand and a second strand respectively of a double stranded DNA molecule encoding a gene product,
b) a second regulator}' element operably linked to a Cas protein,
wherein components (a) and b) are located on same or different vectors of the system, whereby the guide RNAs target the DNA molecule encoding the gene product and the Cas protein nicks each of the first strand and the second strand of the DNA molecule encoding the gene product, whereby expression of the gene product is altered; and, wherein the Cas protein and the two guide RNAs do not naturally occur together.
[0066] In aspects of the invention the guide RNAs may comprise a guide sequence fused to a tracr mate sequence and a tracr sequence. In an embodiment of the invention the Cas protein is a type II CRISPR-Cas protein. In an aspect of the invention the Cas protein is codon optimized for expression in a eukaryotic ceil, wherein it may be a mammalian cell or a human cell In further embodiments of the invention the Cas protein is a type II CRTSPR-Cas protein, e.g. a Cas 9 protein. In a highly preferred embodiment the Cas protein is a Cas9 protein, e.g. SpCas9. In aspects of the invention the Cas protein has one or more mutations selected from the group consisting of D10A, E762A, H840A, 854A, N863A and D986A, In a highly preferred embodiment the Cas protein has the D10A mutation.
[0067] Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5 ' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased. In an embodiment of the invention, the gene product is a protein. In an embodiment of the invention, the gene product is a microRNA. In one embodiment, the regulatory region of a gene is targeted, thereby modifying the expression of the corresponding gene product. In preferred embodiments of the invention the vectors of the system are viral vectors. In a further embodiment, the vectors of the system are delivered via nanoparticies, exosomes, microvesicles, or a gene-gun.
25
90.1 0Θ68] In one aspect, the invention provides a method of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expressed from a gene comprising the target sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cell, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence. In some embodiments, said vectors are delivered to the eukaryotic cell in an organism. In some embodiments, said modifying takes place in said eukaryotic cell in a cell culture. In some embodiments, the method further comprises isolating said eukaryotic cell from an organism prior to said modifying. In some embodiments, the method further comprises returning said eukaryotic cell and/or cells derived therefrom to said organism.
[0069] In one aspect, the invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. In some embodiments, the method further comprises delivering one or more vectors to said eukaryotic cells, wherein the one or more vectors drive expression of one or more of: the CRISPR enzyme, the guide sequence linked to the tracr mate sequence, and the tracr sequence.
26
90.1 ΘΘ70] In one aspect, the invention provides a method of generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, a disease gene is any gene associated an increase in the risk of having or developing a disease. In some embodiments, the method comprises (a) introducing one or more vectors into a eukaryotic cell, wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and (b) allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said disease gene, wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, thereby generating a model eukaryotic cell comprising a mutated disease gene. In some embodiments, said cleavage comprises cleaving one or two strands at the location of the target sequence by said CRISPR enzyme. In some embodiments, said cleavage results in decreased transcription of a target gene. In some embodiments, the method further comprises repairing said cleaved target polynucleotide by homologous recombination with an exogenous template polynucleotide, wherein said repair results in a mutation comprising an insertion, deletion, or substitution of one or more nucleotides of said target polynucleotide. In some embodiments, said mutation results in one or more amino acid changes in a protein expression from a gene comprising the target sequence.
[0071] In one aspect the invention provides for a method of selecting one or more prokaryotic cell(s) by introducing one or more mutations in a gene in the one or more prokaryotic cell (s), the method comprising: introducing one or more vectors into t e prokaryotic ceil (s), wherein the one or more vectors drive expression of one or more of: a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, a tracr sequence, and an editing template; wherein the editing template comprises the one or more mutations that abolish CRISPR enzyme cleavage; allowing homologous recombination of the editing template with the target polynucleotide in the celi(s) to be selected; allowing a CRISPR complex to bind to a target polynucleotide to effect cleavage of the target polynucleotide within said gene, wherein the CRISPR complex comprises the CRISPR. enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence within the target polynucleotide, and (2) the tracr mate sequence that is hybridized to the tracr sequence, wherein binding of the CRISPR complex to the target polynucleotide induces cell death, thereby allowing one or more prokaryotic cell(s) in which one or more mutations have been introduced to be selected. In a preferred embodiment, the CRJSPR enzyme is Cas9. In another aspect of the invention the cell to be selected may be a eukaryotic cell. Aspects of the invention allow for selection of specific cells without requiring a selection marker or a two-step process that may include a counter-selection system.
[0072] In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRJSPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRJSPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
[0073] In other embodiments, this invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell. The method comprises increasing or decreasing expression of a target polynucleotide by using a CRISPR complex that binds to the polynucleotide.
[0074] Where desired, to effect the modification of the expression in a cell, one or more vectors comprising a tracr sequence, a guide sequence linked to the tracr mate sequence, a sequence encoding a CRISPR enzyme is delivered to a cell. In some methods, the one or more vectors comprises a regulator}' element operably linked to an enzyme- coding sequence encoding said CRISPR enzyme comprising a nuclear localization sequence; and a regulator)' element operably linked to a tracr mate sequence and one or more insertion sites for inserting a guide sequence upstream of the tracr mate sequence. When expressed, the guide sequence directs sequence -specific binding of a CRISPR complex to a target sequence in a ceil. Typically, the CRISPR complex comprises a CRISPR enzyme complexed with (1 ) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In one embodiment, the vector system comprises a viral vector system, e.g., an AAV vector or AAV vector system or a lend vims -derived vector system.
[0075] In some methods, a target polynucleotide can be inactivated to effect the modification of the expression in a cell For example, upon the binding of a CRISPR complex to a target sequence in a cell, the target polynucleotide is inactivated such that the sequence is not transcribed, the coded protein is not produced, or the sequence does not function as the wild-type sequence does. For example, a protein or microRNA coding
28
90.1 sequence may be inactivated such that the protein or microRNA or pre-microR A transcript is not produced.
[0076] In certain embodiments, the CR1SPR enzyme comprises one or more mutations D10A, E762A, H840A, N854A, 863A or D986A and/or the one or more mutations is in a RuvCl or HNH domain of the CRTSPR enzyme or is a mutation as otherwise as discussed herein. In some embodiments, the CR1SPR enzyme has one or more mutations in a catalytic domain, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRTSPR complex to the target sequence, and wherein the enzyme further comprises a functional domain. In some embodiments, , the mutated Cas9 enzyme may be fused to a protein domain, e.g., such as a transcriptional activation domain. In one aspect, a transcriptional activation domain is VP64. In some embodiments, a transcription repression domains is KRAB. In some embodiments, a transcription repression domain is SID, or concatemers of SID (i.e. SID4X). In some embodiments, an epigenetic modifying enzyme is provided. In some embodiments, an activation domain is provided, which may be the P65 activation domain.
[0077] In some embodiments, the CRISPR enzyme is a type I or III CRISPR enzyme, preferably a type II CRISPR enzyme. This type II CRISPR enzyme may be any Cas enzyme. A Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes that share homology to the biggest nuclease with multiple nuclease domains from the type II CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, spCas9 or saCas9. By derived. Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein.
[0078] It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes. However, it will be appreciated that this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCa9, St.ICas9 and so forth,
[0079] An example of a codon optimized sequence, in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that
29
90.1 other examples are possible and codon optimization for a host species other than human, or for codon optimization for specific organs or tissues such as the brain, is known.
[0080] Preferably, delivery is in the form of a vector which may be a viral vector, such as a lenti- or baculo- or preferably adeno-viral/adeno-assoeiated viral vectors, but other means of deliver}' are known (such as yeast systems, microvesicles, gene guns/means of attaching vectors to gold nanoparticles) and are provided, A vector may mean not only a viral or yeast system (for instance, where the nucleic acids of interest may be operably linked to and under the control (in terms of expression, such as to ultimately provide a processed RNA) a promoter), but also direct deliver}' of nucleic acids into a host cell. While in herein methods the vector may be a viral vector and this is advantageously an AAV, other viral vectors as herein discussed can be employed. For example, baculoviruses may be used for expression in insect cells. These insect cells may, in turn be useful for producing large quantities of further vectors, such as AAV vectors adapted for delivery of the present invention. Also envisaged is a method of delivering the present CRISPR enzyme comprising delivering to a cell mRNA encoding the CRTSPR enzyme. It will be appreciated that the CRISPR enzyme is truncated, comprised of less than one thousand amino acids or less than four thousand amino acids, is a nuclease or nickase, is codon-optimized comprises one or more mutations, and/or comprises a chimeric CRISPR enzyme, or the other options as herein discussed. AAV viral vectors or lentiviral vectors are preferred.
[0081] In certain embodiments, the target sequence is flanked or followed, at its 3 ' end, by a PAM suitable for the CRISPR enzyme, typically a Cas and in particular a Cas9.
[0082] For example, a suitable PAM is 5'-NRG or 5VN GRR for SpCas9 or SaCas9 enzymes (or derived enzymes), respectively.
[0083] It will be appreciated that SpCas9 or SaCas9 are those from or derived from S. pyogenes or S. aureus Cas9.
[0084] Accordingly, it is an object of the invention to not encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.8.C. § 1 12, first paragraph) or the EPO (Article 83 of the EPC), such that Applicants reserve the right and hereby
30
90.1 disclose a disclaimer of any previously described product, process of making the product, or method of using the product.
[0085] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U.S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of and "consists essentially of have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
[0086] These and other embodiments are disclosed or are obvious from and encompassed by, the following Detailed Description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0087] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
[0088] Figure I shows a schematic model of the CRISPR system. The Cas9 nuclease from Streptococcus pyogenes (yellow) is targeted to genomic DNA by a synthetic guide RN (sgRNA) consisting of a 20-nt guide sequence (blue) and a scaffold (red). The guide sequence base-pairs with the DNA target (blue), directly upstream of a. requisite 5' -NGG protospacer adjacent motif (PAM; magenta), and Cas9 mediates a double -stranded break (DSB) -3 bp upstream of the PAM (red triangle),
[ΘΘ89] Figure 2A-F shows an exemplary CRISPR system, a possible mechanism of action, an example adaptation for expression in eukaryotic cells, and results of tests assessing nuclear localization and CRISPR activity.
[0090] Figure 3A-D shows results of an evaluation of SpCas9 specificity for an example target.
[0091] Figure 4A-G sho an exemplar vector system and results for its use in directing homologous recombination in eukaryotic cells.
[0092] Figure 5 provides a table of protospacer sequences and summarizes modification efficiency results for protospacer targets designed based on exemplary S. pyogenes and S. thermophilus CRISPR systems with corresponding PAMs against loci in
31
90.1 human and mouse genomes. Cells were transfected with Cas9 and either pre- erRNA/tracrRNA or chimeric RNA, and analyzed 72 hours after transfection. Percent indels are calculated based on Surveyor assay results from indicated ceil lines (N=3 for all protospacer targets, errors are S.E.M., N.D. indicates not detectable using the Surveyor assay, and N.T. indicates not tested in this study).
[0093] Figure 6A-C shows a. comparison of different tracrRNA transcripts for Cas9- mediated gene targeting.
[0094] Figure 7 shows a schematic of a surveyor nuclease assay for detection of double strand break-induced micro-insertions and -deletions.
[0095] Figure 8A-B shows exemplary bicistronic expression vectors for expression of CRISPR system elements in eukaryotic cells.
[0096] Figure 9A-C shows histograms of distances between adjacent S. pyogenes SF370 locus 1 PAM ( GG) (Figure 9A) and S. thermophilus LMD9 locus 2 PAM (NNAGAAW) (Figure 9B) in the human genome; and distances for each PAM by chromosome (Chr) (Figure 9C).
[0097] Figure 10A-D shows an exemplary CRISPR system, an example adaptation for expression in eukaryotic cells, and results of tests assessing CRISPR activity.
[0098] Figure 11A-C shows exemplary manipulations of a CRISPR system for targeting of genomic loci in mammalian cells.
[0099] Figure 12A-B shows the results of a Northern blot analysis of crRN processing in mammalian cells.
[00100] Figure 13A-B shows an exemplary selection of protospacers in the human PVALB and mouse Th loci.
[00101] Figure 14 shows example protospacer and corresponding PAM sequence targets of the S. thermophilus CRISPR system in the human EMX 1 locus.
[00102] Figure 15 provides a table of sequences for primers and probes used for Surveyor, RFLP, genomic sequencing, and Northern blot assays,
[00103] Figure 16A-C shows exemplary manipulation of a CRISPR system with chimeric RNAs and results of SURVEYOR assays for system activity in eukaryotic cells.
[00104] Figure 17A-B shows a graphical representation of the results of SURVEYOR assays for CRISPR system activity in eukaryotic ceils.
[00105] Figure 18 shows an exemplary visualization of some S. pyogenes Cas9 target sites in the human genome using the UCSC genome browser.
32
90.1 [00106] Figure 19A-D shows a circular depiction of the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (-1100 amino acids),
[00107] Figure 20A-F shows the linear depic tion of the phylogenetic analysis revealing five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (-1100 amino acids).
[00108] Figure 21A-D shows genome editing via homologous recombination, (a) Schematic of SpCas9 nickase, with D10A mutation in the RuvC I catalytic domain, (b) Schematic representing homologous recombination (HR) at the human EMXl focus using either sense or antisense single stranded oligonucleotides as repair templates. Red arrow above indicates sgRNA cleavage site; PGR primers for genotyping (Tables J and K) are indicated as arrows in right panel, (c) Sequence of region modified by HR. d, SURVEYOR assay for wildtype (wt) and nickase (D10A) SpCas9-mediated indels at the EMXl target 1 locus (n=3). Arrows indicate positions of expected fragment sizes.
[00109] Figure 22 -B shows single vector designs for SpCas9.
[00110] Figure 23 shows a graph representing the length distribution of Cas9 oithoiogs.
[00111] Figure 24A-M shows sequences where the mutation points are located within the SpCas9 gene.
[00112] Figure 25A-B (A) shows the Conditional Cas9, Rosa26 targeting vector map and (B) shows the Constitutive Cas9, Rosa26 targeting vector map.
[001 3] Figure 26 shows a schematic of the important elements in the Constitutive and Conditional Cas9 constructs,
[00114] Figure 27 shows delivery and in vivo mouse brain Cas9 expression data,
[00115] Figure 28A-C shows RNA delivery of Cas9 and chimeric RNA into cells (A) Delivery of a GFP reporter as either DNA or mRNA into Neuro-2A cells. (B) Deliver}' of Cas9 and chimeric RNA against the Icam2 gene as RNA results in cutting for one of two spacers tested. (C) Delivery of Cas9 and chimeric RNA against the F7 gene as RNA results in cutting for one of two spacers tested.
[00116] Figure 29 shows how DNA double-strand break (DSB) repair promotes gene editing. In the error-prone non-homologous end joining (NHEJ) pathway, the ends of a DSB are processed by endogenous DNA repair machineries and rejoined together, which can result in random insertion/deletion (indel) mutations at the site of junction. Tndel mutations occurring within the coding region of a gene can result in frame-shift and a
33
90.1 premature stop codon, leading to gene knockout. Alternatively, a repair template in the form of a plasm id or single-stranded oligodeoxynucleotides (ssODN) can be supplied to leverage the homology-directed repair (HDR) pathway, which allows high fidelity and precise editing.
[00117] Figure 30A-C shows anticipated results for HDR in HEK and HUES9 cells, (a) Either a targeting plasmid or an ssODN (sense or antisense) with homology arms can be used to edit the sequence at a target genomic locus cleaved by Cas9 (red triangle). To assay the efficiency of HDR, Applicants introduced a Hindlll site (red bar) into the target locus, which was PGR -amplified with primers that anneal outside of the region of homology. Digestion of the PGR product with Hindlll reveals the occurrence of HDR events, (b) ssOD s, oriented in either the sense or the antisense (s or a) direction relative to the locus of interest, can be used in combination with Cas9 to achieve efficient HDR- mediated editing at the target locus. A minimal homology region of 40 bp, and preferably 90 bp, is recommended on either side of the modification (red bar), (c) Example of the effect of ssODNs on HDR in the EMXl locus is shown using both wild-type Cas9 and Cas9 nickase (D10A). Each ssODN contains homology arms of 90 bp flanking a 12-bp insertion of two restriction sites.
|00118] Figure 31A-C shows the repair strategy for Cystic Fibrosis delta F508 mutation.
[00119] Figure 32A-B (a) shows a schematic of the GAA repeat expansion in FXN intron 1 and (b) shows a schematic of the strategy adopted to excise the GAA expansion region using the CRTSPR/Cas system.
[00120] Figure 33 shows a screen for efficient SpCas9 mediated targeting of Tetl -3 and Dnmtl , 3a and 3b gene loci. Surveyor assay on DNA from transfected N2A cells demonstrates efficient DNA cleavage by using different gRNAs.
[00121] Figure 34 shows a strategy of multiplex genome targeting using a 2 -vector system in an AAV 1/2 delivery system, Tetl -3 and Dnmtl, 3a and 3b gRNA under the control of the Ό6 promoter. GFP-KASH under the control of the human synapsin promoter. Restriction sides shows simple gRNA replacement strategy by subcloning. HA- tagged SpCas9 flanked by two nuclear localization signals (NLS) is shown. Both vectors are delivered into the brain by AAV 1/2 virus in a 1 : 1 ratio.
[00122] Figure 35 shows verification of multiplex DNMT targeting vector #1 functionality using Surveyor assay. N2A cells were co-transfected with the DNMT targeting vector #1 (+) and the SpCas9 encoding vector for testing SpCas9 mediated
34
90.1 cleavage of D MTs genes family loci, gRNA only (-) is negative control. Cells were harvested for DNA purification and downstream processing 48 h after transfection.
[00123] Figure 36 shows verification of multiplex DNMT targeting vector #2 functionality using Surveyor assay. N2A cells were co-transfected with the DNMT targeting vector #1 (+) and the SpCas9 encoding vector for testing SpCas9 mediated cleavage of DNMTs genes family loci. gRNA only (■) is negative control. Cells were harvested for DNA purification and downstream processing 48 h after transfection.
[0Θ124] Figure 37 shows schematic overview of short promoters and short poly.A versions used for HA-SpCas9 expression in vivo. Sizes of the encoding region from L-ITR to R-ITR are shown on the right.
|00125] Figure 38 shows schematic overview of short promoters and short polyA versions used for HA-SaCas9 expression in vivo. Sizes of the encoding region from L-ITR to R-ITR are shown on the right.
[00126] Figure 39 shows expression of SpCas9 and SaCas9 in N2A ceils. Representative Western blot of HA -tagged SpCas9 and SaCas9 versions under the control of different short promoters and with or short polyA (spA) sequences. Tubulin is loading control. mCherry (mCh) is a. transfection control Cells were harvested and further processed for Western blotting 48 h after transfection.
[00127] Figure 40 shows screen for efficient SaCas9 mediated targeting of Tet.3 gene locus. Surveyor assay on DNA from transfected N2A cells demonstrates efficient DNA cleavage by using different gRNAs with NNGGGT sequence. GFP transfected cells and cells expressing only SaCas9 are controls.
[0Θ128] Figure 41 shows expression of HA-SaCas9 in the mouse brain. Animals were injected into dentate gyri with vims driving expression of HA-SaCas9 under the control of human Synapsin promoter. Animals were sacrificed 2 weeks after surgery. HA tag was detected using rabbit monoclonal antibody C29F4 (Cell Signaling). Cell nuclei stained in blue with DAPI stain,
[00129] Figure 42 shows expression of SpCas9 and SaCas9 in cortical primary neurons in culture 7 days after transduction. Representative Western blot of HA-tagged SpCas9 and SaCas9 versions under the control of different promoters and with bgli or short polyA (spA) sequences. Tubulin is loading control.
[00130] Figure 43 shows LIVE/DEAD stain of primary cortical neurons 7 days after transduction with AAVl particles carrying SpCas9 with different promoters and multiplex gRNAs constructs (example shown on the last panel for DNMTs), Neurons after AAV
35
90.1 transduction were compared with control untransduced neurons. Red nuclei indicate permeabilized, dead cells (second line of panels). Live cells are marked in green color (third line of panels).
[00131] Figure 44 shows LIVE/DEAD stain of primary cortical neurons 7 days after transduction with AAV1 particles carrying SaCas9 with different promoters. Red nuclei indicate permeabilized, dead cells (second line of panels). Live ceils are marked in green color (third line of panels).
[0Θ132] Figure 45 shows comparison of morphology of neurons after transduction with AAV1 virus carrying SpCas9 and gRNA multiplexes for TETs and DNMTs genes loci. Neurons without transduction are shown as a control.
|00133] Figure 46 shows verification of multiplex DNMT targeting vector #1 functionality using Surveyor assay in primary cortical neurons. Cells were co-transduced with the DNMT targeting vector #1 and the SpCas9 viruses with different promoters for testing SpCas9 mediated cleavage of DNMTs genes family loci.
[00134] Figure 47 shows in vivo efficiency of SpCas9 cleavage in the brain. Mice were injected with AAV 1/2 virus carrying gRNA multiplex targeting DNMT family genes loci together with SpCas9 viruses under control of 2 different promoters: mouse Mecp2 and rat Maplb. Two weeks after injection brain tissue was extracted and nuclei were prepped and sorted using FACS, based on the GFP expression driven by Synapsin promoter from gRNA multiplex construct After gDNA extraction Surveyor assay was run. + indicates GFP positive nuclei and - control, GFP-negaiive nuclei from the same animal. Numbers on the gel indicate assessed SpCas9 efficiency.
[00135] Figure 48 shows purification of GFP-KASH labeled cell nuclei from hippocampal neurons. The outer nuclear membrane (ONM) of the ceil nuclear membrane is tagged with a fusion of GFP and the ASH protein transmembrane domain. Strong GFP expression in the brain after one week of stereotactic surgery and AAV1 /2 injection. Density gradient centrifugation step to purify cell nuclei from intact brain. Purified nuclei are shown. Chromatin stain by Vybrant© DyeCycle™ Ruby Stain is shown in red, GFP labeled nuclei are green. Representative FACS profile of GFPF and GFP- cell nuclei (Magenta: Vybrant® DyeCycle™ Ruby Stain, Green: GFP).
[00136] Figure 49 shows efficiency of SpCas9 cleavage in the mouse brain. Mice were injected with AAV 1/2 virus carrying gRNA multiplex targeting TET family genes loci together with SpCas9 viruses under control of 2 different promoters: mouse Mecp2 and rat Maplb. Three weeks after injection brain tissue was extracted, nuclei were prepped and
36
90.1 sorted using FACS, based on the GFP expression driven by Synapsin promoter from gRNA multiplex construct After gDNA extraction Surveyor assay was run. + indicates GFP positive nuclei and - control, GFP-negative nuclei from the same animal. Numbers on the gel indicate assessed SpCas9 efficiency.
[00137] Figure 50 shows GFP-KASH expression irs cortical neurons in culture. Neurons were transduced with AAVl virus carrying gRNA multiplex constructs targeting TET genes loci. The strongest signal localize around cells nuclei due to KASH domain localization.
[0ΘΪ 38] Figure 51 shows (top) a list of spacing (as indicated by the pattern of arrangement for two PAM sequences) between pairs of guide RNAs. Only guide RNA pairs satisfying patterns 1, 2, 3, 4 exhibited indels when used with SpCas9(D10A) nickase. (bottom) Gel images showing that combination of SpCas9(D10A) with pairs of guide RNA satisfying patterns 1, 2, 3, 4 led to the formation of indels in the target site.
[00139] Figure 52 shows a. list of U6 reverse primer sequences used to generate U6- guide RNA expression casssettes. Each primer needs to be paired with the U6 forward primer "gcactgagggcctatttcccatgattc" (SEQ ID NO: ) to generate amplicons containing
U6 and the desired guide RNA.
[00140] Figure 53 shows a Genomic sequence map from the human Emxl locus showing the locations of the 24 patterns listed in Fig. 51.
[00141] Figure 54 shows on (right) a gel image indicating the formation of indels at the target site when variable 5' overhangs are present after cleavage by the Cas9 nickase targeted by different pairs of guide RNAs. On (left) a table indicating the lane numbers of the gel on the right and various parameters including identifying the guide RNA pairs used and the length of the 5' overhang present following cleavage by the Cas9 nickase,
[00142] Figure 55 shows a Genomic sequence map from the human Emxl locus showing the locations of the different pairs of guide RNAs that result in the gel patterns of Fig, 54 (right) and which are further described in Example 35,
[00143] Figure 56A-E shows stable modification of hematopoietic stem ceils by a lentiviral CRISPR-Cas delivery system A) Depiction of a lentiviral vector for bi-cistronic expression of the sgRNA from a U6 promoter (U6) and Cas9 from a short EFla promoter (EFS) with a fluorescent protein marker (eGFP) from a picorna vims derived 2A auto- cleavage site (P2A), A lentiviral vector that allows incorporation of target sites into the coding sequence of a fluorescent protein (RFP657) is depicted at the bottom. A Purornycin resistance gene (PAC) is expressed from an internal ribosomal entry site (IRES) B) Super-
37
90.1 transduction of a reporter cell line with an eGFP tagged CRISPR/Cas vector targeting the respective site (blue) induces loss of reporter fluorescence. A non-targeting CRISPR/Cas vector (red) does not affect reporter fluorescence. Quantification by plotting the mean fluorescent intensity (MFI) of the reporter in targeting (blue) vs non-targeting (red) sgRNA transduced cells (black box, left plot). C) Efficacy of CRISPR/Cas spacers for recurrently mutated genes in myeloid malignancy. Efficacy was assessed with the RFP657 reporter system described in A) and B). Results were normalized to non-targeting spacer. Spacers marked in red were used in following experiments. D) Peripheral blood CRISPR/Cas vector marking tracked over a period of 19 weeks. A significant increase of CRISPR/Cas expressing cells with a spacer targeting Runxl (n=4) was observed in comparison to mice expressing a non-targeting spacer (n=4). E) Stable expression of the CRISPR/Cas vector after 19 weeks in hematopoietic stem and progenitor cells. Overlay of eGFP expression in CRISPR/Cas transduced cells (blue) and non-transduced cells (red) of the respective cell population. MPP=Multipotent progenitors; ST-HSC=short-term HSCs; LT-HSC=4ong-term HSCs; LT-HSC CD34-=most quiescent long-term-HSCs.
[00144] Figure 57A-D shows multiplex gene targeting induces clonal development in vivo A) Schematic for multiplex gene targeting with two lentiviral vectors: a CRISPR/Cas- eGFP vector expressing sgRNA, Cas9 and eGFP, and a vector expressing additional sgRNAs with a RFP657 fluorescent reporter gene from a short EFla promoter. B) Multiplexed gene targeting in mice (n=5) significantly increases myelomonocytic cells (Grl+/CDl lb+), decreases B-cells (B220+), and increases white blood cell counts at 12 weeks post-transplant in comparison to mice that were transplanted with control sgRNA vector transduced cells (n=4). C) Peripheral blood CRISPR Cas-eGFP vector expression (x-axis) and expression of a pool of vectors expressing RFP657 (y-axis) over time starting 4 weeks post-transplant. Clonal populations were detected by the pattern of eGFP/RFP657 expression. Two clones were isolated (red gates indicate clones) and genomic regions of targeted genes were sequenced (displayed in red box). Mono- and bi- allelic deletions in Tet2, Dnmt3a, Nfl and Runxl were detected in one case. Detected mutations at 8 weeks are shown below. Sequences of the deletions are shown in Fig, 66A. D) Another clone was analyzed as in panel C, and was found to have mutations in Tet2, Ezh2, Nfl, and Runxl B-IL Detected mutations at 8 weeks are shown below. Sequences of the deletions are shown in Fig. 66B.
[00145] Figure 58A-G shows myeloid malignancy modeling with multiplex genome editing A) Flow cytometric analysis of a diseased C57BS/6 mouse for expression of the
38
90.1 Introduced CRISPR/Cas vectors and for myeloid (Grl +/CD1 Ib-F). Detected mutations are shown in the right panel (displayed in red box). Sequence alignments are shown in Fig. 67. B) Peripheral blood smear (left; May-Gmenwald/Giemsa (MGG); 400x) and BM (right; Hematoxylin-Eosin(HE), 400x) showing granulocytic cells and blasts. C) Western blots of Ezh2, Smc3, and activated Erkl/2 (pErk) protein levels In the leukemic BM compared to normal C57B1/6 wild-type BM. D) Serial replating capacity of normal BM compared to the leukemic BM. E) Representative flow cytometry of secondary transplant recipient mouse peripheral blood. F) Lineage distribution in peripheral blood from secondary mice 8 weeks post-transplant (n=5). G) Histopathology analysis of blood smear (MGG; 400x) from a secondary mouse shows myelo-monocytic leukocytosis and blast ceils in peripheral blood.
[00146] Figure 59A-C shows a modular CRISPR/Cas lentiviral vector system for genome engineering A) Schematic depiction of a lentiviral vector for bi-cistronic expression of the sgRNA from a U6 promoter (U6) and expression of Cas9 from a short EFI a promoter (EFS) or Spleen Focus Forming Virus (SFFV) promoter with a fluorescent protein marker (eGFP or tagRFP) or drug selectable marker (Purmomycin acetyl transferase (PAC) or Blasticidin deaminase (BSD)) from a picorna vims derived 2A auto- cleavage site (P2 A). B) Depiction of a lentiviral vector for expression of Cas9 without the sgRNA. C) Depiction of a lentiviral vector for expression of the sgRNA only with a fluorescent protein marker or selectable marker form an EFS promoter.
[00147] Figure 60 shows that Lentiviral CRISPR-Cas mediates highly efficient genome editing at endogenous loci Surveyor Assay on targeted region of Tet2 target site 3(TS3) (left, marked red in Fig. 56C) and Run l target site 1 (TS1) (right , marked red in Fig. 56C) one week post-transduction of murine BaF3 cells with a lentiviral CRISPR-Cas vector. CRISPR/Cas expressing cells were purified by FACS. The percentage of cleaved PGR product is noted below. Control sgRNA transduced ceils served as negative control [00148] Figure 6IA-C shows CRISPR/Cas mediated knock out of Runxl in Flt3-ITD heterozygous HSCs induces a competitive advantage A) Flow cytometric assessment of CRISPR/Cas transduced ceils in the peripheral blood of mice over a period of 19 weeks after transplantation (control sgRNA left;
Runxl sgRNA right). B) Gating scheme of HSPC populations in mice transduced with CRISPR/Cas lentiviral vectors. C) Summarized CRISPR Cas vector expression in different HSPC populations at 19 weeks post-transplantation for control sgRNA (left) or Runxl sgRNA (right). MPP = MuStipotent progenitors (LSK CD 150- CD48+); ST-HSC =
39
90.1 short-term HSCs (LSK CD 150- CD48-); LT-HSC - long-term HSCs (LSK CD 150+ CD48-); LT-HSC CD34- = most quiescent long-term-HSCs (LSK CD 150+ CD48- CD34- ).
[00149] Figure 62A-B shows stable genome modification in long-term repopulating HSCs in-vivo by Next Generation Sequencing. Mutational analysis of peripheral blood samples at 5 weeks post-transplant and 19 weeks post-transplant. A) Samples were analyzed to detect all unique mutations from each mouse at 5 weeks and at 19 weeks for mutations at the Runxl target site. Mutations detected at both time points and only at 5 weeks are shown. B) Mutations found at 19 weeks but not at 5 weeks are shown.
[00150] Figure 63A-B shows flow cytometry based clonality analysis of C57B1/6 mice shows expansion of CRISPR/Cas engineered populations over time Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgRNAonly vector expression (RFP657) for control sgRNA (A) and pooled sgRNAs (B) in C57BI/6 wild-type mice. Each row shows vector expression at the given time point from an individual mouse, [0Θ151 ] Figure 64 shows sequence alignment of targeted gene loci in a putatively clonal CRISPR/Cas modified population with dim Cas9-eGFP expression shows gene editing Alignment of sequences obtained for targeted genes from imsorted peripheral blood of a mouse that presented with expanding RFP657 positive and eGFP-dim/negative population. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence.
[00152] Figure 65 shows Myeloid lineage skewing induced by multiplex CRISPR/Cas in eGFP-high and eGFP-dim CRISPR Cas expressing populations Flow cytometric assessment of mature hematopoietic lineage (myeloid = CDl lb+/Grl+; B-cells = B220 (CD45R)+; T-cells = CD3e+) distribution in mice transduced with sgRNA-control or sgRNA -pool 10 weeks post-transplant. Mice are shown in Fig. 63. Upper panel shows lineages distribution in GFP+ / RFP657+ populations in mice with pooled targeting CRISPR/Cas vectors compared to CRISPR/Cas non-targeting controls. Lower panel shows lineages distribution in GFP-dim/neg / RFP657+ populations in mice with pooled targeting CRISPR/Cas vectors compared to CRISPR Cas non-targeting controls. Statistical differences were using t-test (two-sided, unpaired). Welch correction was performed if statistical significant variance was detected.
[00153] Figure 66A-B shows Sequence alignments of genes mutated in putatively clonal hematopoietic CRISPR/Cas modified populations identified after multiplex CRISPR/Cas genome engineering A) Alignment of sequences obtained for targeted genes
40
90.1 from sorted cell populations shown in Fig. 57. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence. A) Genes found to be mutated in the clone shown in Fig. 57C. B) Genes found to be mutated for the clone shown in Fig. 57D.
[00154] Figure 67 shows sequence alignments of DnmiSa, Ezh2, Smc3, and Nfl mutations in AML cells. Alignment of sequences obtained for targeted genes from sorted leukemic cells shown in Fig. 58A. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence.
[00155] Figure 68A-B shows lentivims CRJSPR-Cas induced AML engrafts secondary recipients A) Engrafiment of primary leukemic cells in secondary recipients was assessed by flow cytometry of peripheral blood for eGFP and RFP657 expressing cells at 3 and 8 weeks post transplant. B) White blood cell counts (WBC) of secondary recipients was assessed at 3 and 8 weeks post transplant.
[00156] Figure 69A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a C57B1/6 with Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 mutation A) Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgRNA-only vector expression (RFP657) for pooled sgRNAs in a leukemic mouse with leukocytosis (33.6x10A6/ml) and splenomegaly (412mg). Expression of myeloid cell markers (right). B) Peripheral blood smear (MGG; 400X) showing myelo-monocytic phenotype with low blast cell percentage. C) Mutation analysis on targeted genomic regions showed mutations in Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 (*cumulatrve number of wildtype sequences detected are given. Alignment of wildtype sequence is shown for all mutations with different length shown),
[00157] Figure 70A-B shows flow cytometry based clonaliiy analysis of FU3-ITD heterozygous mice shows expansion of CRISPR/Cas engineered populations over time. Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgK Aonly vector expression (RFP657) for pooled sgRNAs in Flt3-ITD heterozygous mice. A) The Runxl targeting sgRNA was provided with the Cas9. B) The Tet2 sgRNA was provided with the Cas9. Each row shows vector expression at the given time point from an individual mouse.
[00158] Figure 71A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a Flt.3-ITD heterozygous mouse with Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 mutation A) Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and
41
90.1 sgRNA-only vector expression (RFP657) for pooled sg NAs in a leukemic mouse that presented with mild leukocytosis (I 5.4xlOA6/ml) and splenomegaly (326mg). Myeloid cell marker expression (lower panel) was assessed both in GFP-dim ceils (left) and GFP- pos cells (right). B) Blood smear (MGG; 400X) shows a myelo-monocytic phenotype with high blast cell percentage. C) Mutation analysis on targeted genomic regions. Mutations were assessed for both flow sorted GFP-dim and GFP-pos cells. Redundant mutation on one allele in Tet2, Dnmtia, Rural, Nfl, and Ezh2 suggests subclonai architecture.
[00159] Figure 72A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a Flt3-ITD heterozygous mouse with Rural, Nfl, and Ezh2 mutation A) Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgRNA-only vector expression (RFP657) for pooled sgRNAs in a leukemic mouse with leukocytosis (40.4x10A6/ml) and splenomegaly (533mg). Expression of myeloid cell markers (right). B) Blood smear (MGG; 400X) showed myelo-monocytic phenotype with intermediate blast cell percentage. C) Mutation analysis on targeted genomic regions showed mutations in Rural, Nfl, and Ezh2.
[00160] Figure 73A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a Flt3-ITD heterozygous mouse with Tet2, Dnmt3a, Runxl, Nfl, and Ezh2 mutation A) Flow cytometric assessment of CRISPR/Cas vector expression (eGFP) and sgRNA-only vector expression (RFP657) for pooled sgRNAs in a leukemic mouse with leukocytosis (78.1 6/ml) and splenomegaly (1036mg) and myeloid cell marker expression. Expression of myeloid cell markers (right). B) Blood smear (MGG; 400X) showed myelo-monocytic phenotype with intermediate blast cell percentage. C) Mutation analysis on targeted genomic regions showed mutations in Tet2, Dnmt3a, Runxl, Nfl, and Ezh2.
[00161] Figure 74A-B shows Lentivirai delivered CRISPR-Cas mediates transformation of human leukemia cells. A) Reporter assay based efficiency testing of lentivirai delivered Cas9 and sgRNAs targeting human tumor suppressor genes and transcription factor genes recurrently mutated in leukemia. Efficacy has been assessed as shown in Figure 56. B) Cumulative ceil count over time of isogenic cell lines generated from cytokine dependent human erythroleukemia cell line TF1 after cytokine deprivation. Genes targeted are shown on the right. Transformation to growth factor independence was observed after CRISPR-Cas mediated targeting of PTEN or EZH2.
[00162] Figure 75A-E shows stable modification of hematopoietic stem cells by a lentivirai sgRN A:Cas9 delivery system, including: A) Depiction of a lentivirai vector for
42
90.1 bi-cistronic expression of the sgRNA from a U6 promoter (U6) and cas9 from a short EFla promoter (EPS) with a fluorescent protein marker (eGFP) from a picorna virus derived 2A auto-cleavage site (P2A). A ientivirai vector that allows incorporation of target sites into the coding sequence of a fluorescent protein (RFP657) is depicted at the bottom. A Puromycin resistance gene (PAC) is expressed from an internal ribosomal entry site (IRES) B) Super-transduction of a reporter cell line with an eGFP tagged sgRNA:Cas9 vector targeting the respective site (blue) induces loss of reporter fluorescence. A non- targeting sgR A:Cas9 vector (red) does not affect reporter fluorescence. Quantification by plotting the MFI of the reporter in targeting (blue) vs non-targeting (red) sgRNA transduced cells (black box, left plot). C) Efficacy of spacers for recurrently mutated genes in myeloid malignancy. Efficacy was assessed with the RFP657 reporter system described in A) and B). Results were normalized to non-targeting spacer. Spacer marked in red were used in following experiments. D) Surveyor assay based confirmation of target site cleavage at genomic loci for Tet2 and Runxl spacers indicated in panel C compared to non-targeting spacer. Percentages above are quantified cleavage efficacies. E) Peripheral blood sgRNA:Cas9 vector marking tracked over a period of 19 weeks. A significant increase of sgRNA:Cas9 expressing ceils with a spacer targeting Runxl (n=4) was observed in comparison to mice expressing a non-targeting spacer (n;;;4). F) Stable expression of the sgR A:Cas9 vector after 19 weeks in hematopoietic stem and progenitor cells. Overlay of eGFP expression in sgRNA:Cas9 transduced cells (blue) and non- transduced cells (red) of the respective cell population. MPP=Multipoteni progenitors; ST- HSC=s ort-term FISCs; LT-HSC=long-term HSCs; LT-HSC CD34-=most quiescent long- term-HSCs
[00163] Figure 76A-D shows multiplex gene targeting induces clonal development in vivo: A) Schematic for multiplex gene targeting with two Ientivirai vectors: a sgRNA:Cas9-eGFP vector expressing sgRNA, Cas9 and eGFP, and a vector expressing additional sgR As with a RFP657 fluorescent reporter gene from a short EFla promoter. B) Multiplexed gene targeting in mice (n=5) significantly increases myelomonocytic ceils (CDl lb+), decreases B-cells (B220+), and increases white blood cell counts at 12 weeks post-transplant in comparison to mice that were transplanted with control sgRNA vector transduced cells (n=4). C) Peripheral blood sgRNA:Cas-eGFP vector expression (x-axis) and expression of a pool of vectors expressing RFP657 (y-axis) over time starting 4 weeks post- transplant. Clonal populations were detected by the pattern of eGFP/RFP657 expression. Two clones were isolated (red gates indicate clones) and genomic regions of
43
90.1 targeted genes were sequenced (displayed in red box). Mono- and bi-allelie deletions in Tet2, DnmtSa, Nfl and Runxl were detected in one case. Detected mutations at 8 weeks are shown below. Sequences of the deletions are shown in Figure 85A. D) Another clone was analyzed as in panel C, and was found to have mutations in Tell, Ezh2, Nfl, and Runxl B-IL Detected mutations at 8 weeks are shown below. Sequences of the deletions are shown in Figure 85B.
[00164] Figure 77A-G shows myeloid malignancy modeling with multiplex genome editing, including: A) Flow cytometric analysis of a diseased C57B1/6 mouse for expression of the introduced Cas9: sgRNA vectors and for myeloid (Grl+/CDl lb+). Detected mutations are shown in the right panel (displayed in red box). Sequence alignments are shown in Figure 86. B) Peripheral blood smear (left; May- Gmenwald/Giemsa (MGG); lOOOx) and BM (right; Hematoxylin-Eosin(HE), l OOOx) showing granulocytic cells and blasts. C) Western blots of Ezh2, Smc3, and activated Erkl/2 (pErk) protein levels in the leukemic BM compared to normal C57B1/6 wild-type BM. D) Representative flow cytometry of secondary transplant recipient mouse peripheral blood. E) Lineage distribution in peripheral blood from secondary mice 8 weeks post- transplant (n=5). F) Histopafhology analysis of BM (MGG; 400x) from a secondary mouse that succumbed to leukemia. G) Heatmap summarizing mutations detected in all mice. Each column presents clone. Targeted genes are presented in rows. Color legend is given below. A table indicating where individual clones have been presented is given on the right.
[00165] Figure 78A-C shows a modular CRISPR/Cas lentiviral vector system for genome engineering, including: A) Schematic depiction of a lentiviral vector for bi- cistronic expression of the sgRNA from a U6 promoter (U6) and expression of Cas9 from a short EFla promoter (EES) or Spleen Focus Forming Virus (SFFV) promoter with a fluorescent protein marker (eGFP or tagRFP) or drug selectable marker (Purmomycm acetyl transferase (PAC) or Blasticidin deaminase (BSD)) from a picorna virus derived 2A auto-cleavage site (P2A). B) Depiction of a lentiviral vector for expression of Cas9 without the sgRNA. C) Depiction of a lentiviral vector for expression of the sgRNA only with a fluorescent protein marker or selectable marker form an EFS promoter.
[00166] Figure 7 A-C shows sgR A:Cas9 mediated knock out of Runxl in Flt3-1TD heterozygous HSCs induces a competitive advantage including: A) Flow cytometric assessment of sgRNA: Cas9 transduced cells in the peripheral blood of mice over 19 weeks (control sgRNA left; Runxl sgRNA right). B) Gating scheme of HSPC populations in
44
90.1 mice transduced with sgR A:Cas9 lenti viral vectors. C) Summarized sgRNA:Cas9 vector expression in different HSPC populations at 19 weeks post transplantation for control sgRNA (left) or Runxl sgRNA (right). Significant differences are indicated where applicable (t-test, two sided, unpaired; Welch corrected for comparisons with signicantly different variances). MPP - Multipotent progenitors (LSK CD150- CD48+); ST-HSC - short-term HSCs (LSK CD 150- CD48-); LT-HSC - long-term HSCs (LSK CD150+ CD48-) ; LT-HSC CD34- = most quiescent long-term-HSCs (LSK CD 150+ CD48- CD34- )·
[0Θ167] Figure 80 shows sgRNA:Cas9 expression does not alter lineage maturation in the BM. Flow cytometry based quantification of mature hematopoietic lineages within the GFP negative and GFP positive population in the BM of mice expressing Cas9 (GFP+) and a control sgRNA shows no significant differences (t-test, two sided, unpaired) in the maturation potential of Cas9 expressing ceils.
[00168] Figure 81A-B shows that next Generation Sequencing shows stable genome modification in long-term repopulating HSCs in-vivo Mutational analysis of peripheral blood samples at 5 weeks post-transplant and 19 weeks post-transplant, including: A) Samples were analyzed to detect all unique mutations from each mouse at 5 weeks and at 19 weeks for mutations at the Runxl target site. Mutations detected at both time points and only at 5 weeks are shown. B) Mutations found at 19 weeks but not at 5 weeks are shown.
[00169] Figure 82 - shows flow cytometry based clonality analysis of C57B3/6 mice shows expansion of sgRNA:Cas9 engineered populations over time Flow cytometric assessment of sgRNA: Cas9 vector expression (eGFP) and sgRNA only vector expression (RFP657) for control sgRNA (A) and pooled sgRNAs (B) in C57B1/6 wild-type mice. Each row shows vector expression at the given time point from an individual mouse.
[00170] Figure 83 - shows sequence alignment of targeted gene loci in a putatively clonal sgRNA :Cas9 modified population with dim Cas9 - eGFP expression and shows gene editing Alignment of sequences obtained for targeted genes from sorted cell populations shown in Figure 76. Ratio of bacterial clones with presented adjacent sequence out of the total clones sequenced for the respective gene shown behind each sequence A) Genes found mutated in the clone shown in Figure 76C. B) Genes found mutated for the clone shown in Figure 76D. PAM underlined
[00171] Figure 84 - shows myeloid lineage skewing induced by multiplex CRISPR/Cas in eGFP-higb and eGFP-dim sgRNA :Cas9 expressing populations. Flow
45
90.1 cytometric assessment of mature hematopoietic lineage distribution in mice transduced with sgRNA-eontrol or sgRNA-pool 10 weeks post transplant (myeloid = CDl lb+/Grl+; B-cells=B220+; T-cells=CD3+. Mice are shown in Figure 82. Upper panel shows lineage distribution in the GFP+ / RFP657+ population of mice with the targeting sgRNA-Pool (sgRNA-Pool) compared to the nontargeting control (sgRNA-ctrl). Lower Panel shows lineage distribution in the GFP-dim/neg / RFP657+ population of mice with the targeting sgRNA-Pool (sgRNA-Pool) compared to the non-targeting control (sgRNA-ctrl). Statistical differences are indicated (t-test, two sided, unpaired; Welch corrected for comparisons with significantly different variances).
[00172] Figure 85A-B shows sequence alignments of genes mutated in putatively clonal hematopoietic sgRNA:Cas9 modified populations identified after multiplex sgRNA:Cas9 genome engineering A) Alignment of sequences obtained for targeted genes from sorted cell populations shown in Figure 76. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence. A) Genes found to be mutated in the clone shown in Figure 76C. B) Genes found to be mutated for the clone shown in Figure 76D. PAM underlined.
[00173] Figure 86 shows sequence alignments of Dnmt3a, Ezh2, Smc3, and Nil mutations in AML cells Alignment of sequences obtained for targeted genes from sorted leukemic cells shown in Figure 77A. The ratio of the number of bacterial clones with each sequence over the total clones sequenced for the respective gene is shown following each sequence. PAM underlined (due to deletion size not possible for Dnmt3a).
[0Θ 74] Figure 87 shows leukemia induced by sgRNA:Ca 9 genome editing shows enhanced replating capacity Serial replating capacity of normal BM compared to the leukemic BM ceils from the leukemia presented in Figure 77.
[00175] Figure 88A-E shows primary sgRNA:Cas9 induced leukemia engrafts in secondary mice and re-initiates disease. A) Low magnification (2G0x, HE) BM histology of the leukemic mouse presented in Figure 77. B) Engraftment of primary leukemia ceils in sublethally irradiated secondary recipients as assessed by flow cytometry for eGFP and RFP657 at 3 and 8 weeks post transplant, C) WBC counts of the same secondary mice at 3 and 8 weeks post transplant. D) Survival of the secondary mice. E) Low magnification (200x, HE) BM histology of a leukemic secondary mouse (left) and high magnification peripheral blood smear (MGG, l OOOx) of a leukemic secondary mouse (right).
46
90.1 [00176] Figure 89A-C shows characterization of a CRISPR/Cas induced myeloid leukemia in a C57B1/6 with Tet2, Dnmt3a, Runxl , NfL and Ezh2 mutation. A) Flow cytometric assessment of sgRNA:Cas9 vector expression (eGFP),sg NA-only vector expression (RFP657) for pooled sgRNAs (left), and myeloid lineage marker expression (right) in a leukemic mouse transplanted with C57B1/6 donor cells that presented with leukocytosis (33.6xl0A6/mi) and splenomegaly (412mg). B) High magnification peripheral blood smear (MGG, l OOOx) of the leukemic mouse (left). Low magnification (200x, HE) BM histology (middle) and high magnification BM histology ( 10 OOx, HE) (right) of the leukemic mouse. C) Mutation analysis on targeted genomic regions showed mutations in Tet2, Dnmt3a, Runxl, NfL and Ezh2. PAM underlined (due to deletion size not possible for some Dnmt3a sequences).
[00177] Figure 90 shows survival of mice transplanted with pooled sgRNAs targeting tumor supressor genes. Survival of C57B3/6 mice with the targeting sgRNA -pool and Cas9 or non-targeting sgRNA and Cas9, and Flt3--iT D heterozygous mice transplanted targeting sgRNA-Pool .
[00178] Figure 91A-B shows flow cytometry based clonality analysis of Fit 3 - ITD heterozygous mice shows expansion of sgRNA:Cas9 engineered populations over time. Flow cytometric assessment of sgRNA:Cas9 vector expression (eGFP) and sgRNAonly vector expression (RFP657) for pooled sgRNAs in FU3-ITD heterozygous mice. A) The Runxl targeting sgRNA was provided with the Cas9. B) The Tet2 sgRNA was provided with the Cas9. Each row shows vector expression at the given time point from an individual mouse.
[00179] Figure 92 shows summarized blood counts and spleen weights from leukemic Mice. Summarized WBC (left), RBC (middle), and spleen weight of leukemic mice presented in the study. Each mouse is presented in all three plots by one colour. A legend where data has been presented is given below. Range of control mice for each value is given as grey boxes. Control spleen weights are from Flt3-ITD control mice presented in Figure 75E/F and Figure 77.
[00180] Figure 93A-C shows characterization of a Cas9:sgRNA induced myeloid leukemia in a Flt3-TTD heterozygous mouseA) Flow cytometric assessment of sgRNA:Cas9 vector expression (eGFP), sgRNA-only vector expression (RFP657) (upper panel) in a leukemic mouse that presented with mild leukocytosis (15.4xlOA6/ml) and splenomegaly (326mg). Myeloid marker expression (lower panel) was assessed both in GFP-dim cells (left) and GFP-pos ceils (right). B) Low magnification (200x, HE) BM
47
90.1 histology (left) and high magnification BM histology (lOOOx, HE) (right) of the leukemic mouse, C) Mutation analysis on targeted genomic regions. Mutations were assessed for both flow sorted GFP-dim and GFP-pos cells. Redundant mutation on one allele in Tet2, Nf! , Dnmt3a, un l, and Ezh2 suggests subclonal architecture. Figure 93 - Characterization of a Cas9:sgRNA induced myeloid leukemia in a Flt3-ITD heterozygous mouse PAM underlined.
[00181] Figure 94A-C shows characterization of a sgRNA:Cas9 induced myeloid leukemia in a Fit3-ITD heterozygous mouse A) Flow cytometric assessment of sgRNA:Cas9 vector expression (eGFP), sgRNA-onfy vector expression (RFP657) (left) and myeloid lineage marker expression (right) in a leukemic mouse in a. leukemic mouse with leukocytosis (40.4x10A6/ml) and splenomegaly (533mg). Expression of myeloid markers (right), B) High magnification peripheral blood smear (MGG, lOOOx) of the leukemic mouse (left). Low magnification (200x, HE) BM histology (middle) and high magnification BM histology IQGGx, HE) (right) of the leukemic mouse. C) Mutation analysis on targeted genomic regions showed mutations in Runxl , Nfl , and Ezh2. PAM underlined.
[00182] Figure 95A-C shows characterization of a sgR A:Cas9 induced myeloid leukemia in a FU3-ITD heterozygous mouse with A) Flow cytometric assessment of sgRNA:Cas9 vector expression (eGFP), sgRNA-only vector expression (RFP657) (left) and myeloid lineage marker expression (right) in a leukemic mouse in a leukemic mouse with leukocytosis (78.1A6/ml) and splenomegaly (1036mg) and myeloid marker expression. Expression of myeloid markers (right). B) High magnification peripheral blood smear (MGG, lOOOx) of the leukemic mouse (left). Low magnification (200x, HE) BM histology (middle) and high magnification BM histology IQQGx, HE) (right) of the leukemic mouse. C) Mutation analysis on targeted genomic regions showed mutations in Tet2, Runxl, Dnmt3a, Nfl , and Ezh2. PAM underlined.
[00183] The figures herein are for illustrative purposes only and are not necessarily drawn to scale.
DETAILED DESCRIPTION OF THE INVENTION
[00184] With respect to general information on CRISPR-Cas Systems: Reference is also made to US provisional patent applications 61/915,397, 61/758,468; 61/802, 174; 61 /806,375; 61 /814,263; 61/819,803 and 61 /828, 130, filed on December 12, 2013 and
48
90.1 January 30, 2013; March 15, 2013; March 28, 2013; April 20, 2013; May 6, 2013 and May 28, 2013 respectively, incorporated herein by reference. Reference is also made to US provisional patent applications 61/835,931, 61/835,936, 61/836,127, 61/836,101, 61/836,080, 61/835,973, and 61/836, 123, all filed June 17, 2013. Reference is further made to US provisional patent applications 61/736,527 and 61/748,427, filed on December 12, 2012 and January 2, 2013, respectively. Reference is additionally made to US provisional patent applications 61/791,409 and 61/799,800, both filed March 15, 2013. Further reference is made to US provisional patent applications 61/862,468 and 61 /862,355 filed on August 5, 2013; 61/871,301 filed on August 28, 2013; 61/960,777 filed on September 25, 2013 and 61/961, 980 filed on October 28, 2013, Each of these applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appln cited documents, together with any instructions, descriptions, product specifications, and product sheets for any products mentioned therein or in any document therein and incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. All documents (e.g., these applications and the appln cited documents) are incorporated herein by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.
[00185] Also with respect to general information on CRISPR-Cas Systems, mention is made of:
> Multiplex genome engineering using CRISPR/Cas systems. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., & Zhang, F. Science Feb 15;339(6121):8I 9-23 (2013);
RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Jiang W., Bikard D., Cox D., Zhang F, Marraffini LA. Nat Biotechnol Mar;31(3):233-9 (2013);
> One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISP JCas-Mediated Genome Engineering. Wang H., Yang H., Shivalila CS., Dawlaty MM., Cheng AW., Zhang F., Jaenisch R. Cell May 9; 153(4):9 0-8 (2013);
Optical control of mammalian endogenous transcription and epigenetic states. Konermann S, Brigham MD, Trevino AE, Hsu PD, Heidenreich M, Cong L, Plait RJ, Scott DA, Church GM, Zhang F. Nature. 2013 Aug 22;500(7463):472-6. doi: 10.1038 Naturel 2466. Epub 2013 Aug 23;
49
90.1 > Double Nicking by RNA-Guided CRISP R Cas9 for Enhanced Genome Editing Specificity. Ran, FA., Hsu, PD., Lin, CY,, Gootenberg, IS., Konermann, S., Trevino, AE., Scott, DA., Inoue, A., Matoba, S., Zhang, Y., & Zhang, F. Cell Aug 28. pii: 80092-8674(13)01015-5. (2013);
> DNA targeting specificity of RNA -guided Cas9 nucleases. Hsu, P., Scott, D., Weinstein, J., Ran, FA., Konermann, S., Agarwala, V., Li, Y., Fine, E., Wu, X., Shalem, ()., Cradick, TJ., Marraffini, LA., Bao, G., & Zhang, F. Nat Biotechnol doi: 10.10.38/nbt.2647 (2013);
> Genome engineering using the CRISPR-Cas9 system. Ran, FA., Hsu, PD., Wright, J., Agarwala, V., Scott, DA., Zhang, F. Nature Protocols ov;8(l l):2281-308.
(2013) ;
> Genome-Scale CRJSPR-Cas9 Knockout Screening in Human Cells. Shalem, O., Sanjana, NE., Hartenian, E., Shi, X., Scott, DA., Mikkelson, T., Heckl, D,, Ebert, BL., Root, DE., Doench, JG., Zhang, F. Science Dec 12. (2013 ). [Epub ahead of print];
> Crystal structure of cas9 in complex with guide RNA and target DNA. Nishimasu, H., Ran, FA., Hsu, PD., Konermann, S., Shehata, SI., Dohmae, N., Ishitani, R., Zhang, F., Nureki, O. Cell Feb 27. (2014). 156(5):935-49;
Genome-wide binding of the CRJSPR endonuclease Cas9 in mammalian cells. Wu X., Scott DA., Kriz AJ., Chiu AC, Hsu PD., Dadon DB., Cheng AW., Trevino AE., Konermann S., Chen S., Jaenisch R., Zhang F., Sharp PA. Nat Biotechnol.
(2014) Apr 20. doi: 10. i0.38/nbt.2889, and
> Development and Applications of CRISPR-Cas9 for Genome Engineering, Hsu et al, Ceil 157, 1262-1278 (June 5, 2014) (Hsu 2014),
each of which is incorporated herein by reference, and discussed briefly below:
* Cong el al. engineered type II CRISPR/Cas systems for use in eukaryotic cells based on both Streptococcus thermophilus Cas9 and also Streptoccocus pyogenes Cas9 and demonstrated that Cas9 nucleases can be directed by short RNAs to induce precise cleavage of DNA in human and mouse cells. Their study further showed that Cas9 as converted into a nicking enzyme can be used to facilitate homology- directed repair in eukaryotic cells with minimal mutagenic activity. Additionally, their study demonstrated that multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several at endogenous genomic loci sites within the mammalian genome, demonstrating easy
50
90.1 programmability and wide applicability of the RNA-guided nuclease technology. This ability to use KNA to program sequence specific DNA cleavage in cells defined a new class of genome engineering tools. These studies further showed that other CRJSPR loci are likely to be transplantable into mammalian cells and can also mediate mammalian genome cleavage. Importantly, it can be envisaged that several aspects of the CRISPR/Cas system can be further improved to increase its efficiency and versatility.
Jiang et al. used the clustered, regularly interspaced, short palindromic repeats (CRISPR)-assoeiated Cas9 endonuclease complexed with dual -RNAs to introduce precise mutations in the genomes of Streptococcus pneumoniae and Escherichia coil The approach relied on dual-RNA:Cas9-directed cleavage at the targeted genomic site to kill unmutated cells and circumvents the need for selectable markers or counter-selection systems. The study reported reprogramming dual- RNA:Cas9 specificity by changing the sequence of short CR1SPR RNA (crRNA) to make single- and multinucleotide changes carried on editing templates. The study showed that simultaneous use of two erR As enabled multiplex mutagenesis. Furthermore, when the approach was used in combination with recombineering, in S. pneumoniae, nearly 100% of cells that were recovered using the described approach contained the desired mutation, and in E. coii, 65% that were recovered contained the mutation.
onermann et al. addressed the need in the art for versatile and robust technologies that enable optical and chemical modulation of DNA-binding domains based CRISPR Cas9 enzyme and also Transcriptional Activator Like Effectors
As discussed in the present specification, the Cas9 nuclease from the microbial CRISPR-Cas system is targeted to specific genomic loci by a 20 nt guide sequence, which can tolerate certain mismatches to the DNA target and thereby promote undesired off -target mutagenesis. To address this, Ran et al. described an approach that combined a. Cas9 nickase mutant with paired guide RNAs to introduce targeted double-strand breaks. Because individual nicks in the genome are repaired with high fidelity, simultaneous nicking via appropriately offset guide RNAs is required for double-stranded breaks and extends the number of specifically recognized bases for target cleavage. The authors demonstrated that using paired nicking can reduce off-target activity by 50- to 1,500-fold in cell lines and to facilitate gene knockout in mouse zygotes without sacrificing on -target cleavage efficiency. This versatile strategy enables a wide variety of genome editing applications that require high specificity,
* Hsu et al. characterized SpCas9 targeting specificity in human ceils to inform the selection of target sites and avoid off-target effects. The study evaluated >700 guide RNA variants and SpCas9-induced irsdel mutation levels at > 100 predicted genomic off-target loci in 293T and 293FT cells. The authors that SpCas9 tolerates mismatches between guide RNA and target DNA at different positions in a sequence-dependent manner, sensitive to the number, position and distribution of mismatches. The authors further showed that SpCas9-mediated cleavage is unaffected by DNA methylation and that the dosage of SpCas9 and sgRNA can be titrated to minimize off-target modification. Additionally, to facilitate mammalian genome engineering applications, the authors reported providing a web-based software tool to guide the selection and validation of target sequences as well as off-target analyses.
■ Ran et al. described a set of tools for Cas9-mediated genome editing via nonhomologous end joining (NHEJ) or homology-directed repair (HDR.) in mammalian ceils, as well as generation of modified cell lines for downstream functional studies. To minimize off-target cleavage, the authors further described a double-nicking strategy using the Cas9 nickase mutant with paired guide R As. The protocol by the authors provided experimentally derived guidelines for the selection of target sites, evaluation of cleavage efficiency and analysis of off -target activity. The studies showed that beginning with target design, gene modifications can be achieved within as little as 1 -2 weeks, and modified clonal cell fines can be derived within 2-3 wreeks.
» Shalem et al, described a new way to interrogate gene function on a genome-wide scale. Their studies showed that delivery of a genome-scale CRJSPR-Cas9 knockout (GeCKO) library targeted 18,080 genes with 64,751 unique guide sequences enabled both negative and positive selection screening in human cells. First, the authors showed use of the GeCKO library to identify genes essential for cell viability in cancer and pluripotent stem cells. Next, in a melanoma model, the authors screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic that inhibits mutant protein kinase BRAF. Their studies showed that the highest-ranking candidates included previously validated genes NF1 and MED 12 as well as novel hits NF2, CTJL3, TADA2B, and TADA1. The authors observed a high level of consistency between independent guide RNAs targeting the same gene and a high rate of hit confirmation, and thus demonstrated the promise of genome-scale screening with Cas9.
* Nishimasu ei al. reported the crystal stmcture of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA at 2.5 A° resolution. The structure revealed a bilobed architecture composed of target recognition and nuclease lobes, accommodating the sgRNA:DNA heteroduplex in a positively charged groove at their interface. Whereas the recognition lobe is essential for binding sgR A and UNA, the nuclease lobe contains the HNH and RuvC nuclease domains, which are properly positioned for cleavage of the complementary and non -complementary strands of the target DNA, respectively. The nuclease lobe also contains a carboxyl-terminal domain responsible for the interaction with the protospacer adjacent motif (PAM). This high-resolution stmcture and accompanying functional analyses have revealed the molecular mechanism of RNA-guided DNA targeting by Cas9, thus paving the way for the rational design of new, versatile genome- editing technologies.
" Wu et al. mapped genome-wide binding sites of a catalytically inactive Cas9 (dCas9) from Streptococcus pyogenes loaded with single guide RNAs (sgRNAs ) in mouse embryonic stem cells (mESCs). The authors showed that each of the four sgRNAs tested targets dCas9 to between tens and thousands of genomic sites, frequently characterized by a 5 -nucleotide seed region in the sgRNA and an NGG protospacer adjacent motif (PAM). Chromatin inaccessibility decreases dCas9 binding to other sites with matching seed sequences; thus 70% of off-target sites are associated with genes. The authors showed that targeted sequencing of 295 dCas9 binding sites in mESCs transfected with catalytically active Cas9 identified only one site mutated above background levels. The authors proposed a two-state model for Cas9 binding and cleavage, in which a seed match triggers binding but extensive pairing with target DNA is required for cleavage.
■ Hsu 2014 is a review article that discusses generally CRISPR-Cas9 history from yogurt to genome editing, including genetic screening of cells, that is in the information, data and findings of the applications in the lineage of this specification filed prior to June 5, 2014. The general teachings of Hsu 2014 do not involve the specific models, animals of the instant specification.
53
90.1 [0Θ186] The invention relates to the engineering and optimization of systems, methods and compositions used for the control of gene expression involving sequence targeting, such as genome perturbation or gene-editing, that relate to the CRISPR-Cas system and components thereof. In advantageous embodiments, the Cas enzyme is Cas9. In one aspect, the Cas enzyme is a nickase.
[00187] An advantage of the present methods is that the CRISPK system avoids off- target binding and its resulting side effects. This is achieved using systems arranged to have a high degree of sequence specificity for the target DNA.
[00188] Cas9 optimization may be used to enhance function or to develop new functions, one can generate chimeric Cas9 proteins. Examples that the Applicants have generated are provided in Example 6. Chimeric Cas9 proteins can be made by combining fragments from different Cas9 omologs. For example, two example chimeric Cas9 proteins from the Cas9s described herein. For example, Applicants fused the N-term of StlCas9 (fragment from this protein is in bold) with C-term of SpCas9. The benefit of making chimeric Cas9s include any or all of: reduced toxicity; improved expression in eukaryotic cells; enhanced specificity; reduced molecular weight of protein, make protein smaller by combining the smallest domains from different Cas9 homologs; and/or altering the PAM sequence requirement. In one aspect, the chimeric Cas enzyme is a nickase.
[00189] The Cas9 may be used as a generic DNA binding protein. For example, and as shown in Example 7, Apficants used Cas9 as a generic DNA binding protein by mutating the two catalytic domains (D10 and H840) responsible for cleaving both strands of the DNA target. In order to upregulate gene transcription at a target locus Applicants fused the transcriptional activation domain (VP64) to Cas9. Other transcriptional activation domains are known. As shown in Example 17, transcriptional activation is possible. As also shown in Example 17, gene repression (in this case of the beta-catenin gene) is possible using a Cas9 repressor (DNA-binding domain) that binds to the target gene sequence, thus repressing its activity.
[00190] Transgenic animals are also provided. Preferred examples include animals comprising Cas9, in terms of polynucleotides encoding Cas9 or the protein itself. Mice, rats and rabbits are preferred. To generate transgenic mice with the constructs, as exemplified herein one may inject pure, linear DNA into the pronucleus of a zygote from a pseudo pregnant female, e.g. a CB56 female. Founders may then be identified, genotyped, and backcrossed to CB57 mice. The constructs may then be cloned and optionally verified, for instance by Sanger sequencing. Knock outs are envisaged where for instance
54
90.1 one or more genes are knocked out in a model. However, knockins are also envisaged (alone or in combination). An example Knock-in Cas9 mouse was generated and this is exemplified. To generate Cas9 knock in mice one may target the same constitutive and conditional constructs to the osa26 locus, as described herein (Figs. 25A-B and 26).
[00191] Utility of the conditional Cas9 mouse: Applicants have shown in 293 cells that the Cas9 conditional expression construct can be activated by co-expression with Cre. Applicants also sho thai the correctly targeted Rl mESCs can have active Cas9 when Cre is expressed. Because Cas9 is followed by the P2A peptide cleavage sequence and then EGFP Applicants identify successful expression by observing EGFP. Applicants have shown Cas9 activation in mESCs. This same concept is what makes the conditional Cas9 mouse so useful. Applicants may cross their conditional Cas9 mouse with a mouse that ubiquitously expresses Cre (ACTB-Cre line) and may arrive at a mouse that expresses Cas9 in every cell. It should only take the delivery of chimeric R A to induce genome editing in embryonic or adult mice. Interestingly, if the conditional Cas9 mouse is crossed with a mouse expressing Cre under a tissue specific promoter, there should only be Cas9 in the tissues that also express Cre. 'This approach may be used to edit the genome in only- precise tissues by delivering chimeric RNA to the same tissue.
|00192] As mentioned above, transgenic animals are also provided, as are transgenic plants, especially crops and algae. The transgenic may be useful in applications outside of providing a disease model. These may include food of feed production through expression of, for instance, higher protein, carbohydrate, nutrient or vitamins levels than would normally be seen in the wildtype. In this regard, transgenic plants, especially pulses and tubers, and animals, especially mammals such as livestock (cows, sheep, goats and pigs), but also poultry and edible insects, are preferred.
|00193] Transgenic algae or other plants such as rape may be particularly useful in the production of vegetable oils or biofuels such as alcohols (especially methanol and ethanol), for instance. These may be engineered to express or overexpress high levels of oil or alcohols for use in the oil or biofuel industries.
[0Θ194] In terms of in vivo delivery, AAV is advantageous over other viral vectors for a couple of reasons:
o Low toxicity (this may be due to the purification method not requiring ultra cenirifugation of cell particles thai can activate the immune response) o Low probability of causing insertional mutagenesis because it doesn't integrate into the host genome.
55
90.1 [00195] AAV has a packaging limit of 4.5 or 4.75 Kb. This means that Cas9 as well as a promoter and transcription terminator have to be all fit into the same viral vector. Constmcts larger than 4.5 or 4.75 Kb will lead to significantly reduced vims production, SpCas9 is quite large, the gene itself is over 4.1 Kb, which makes it difficult for packing into AA\/T. Therefore embodiments of the invention include utilizing homologs of Cas9 that are shorter. For example:
Species Cas9 Size
Corynebacter diphtheriae 3252 Eubacterium ventriosum 3321 Streptococcus pasteurianus 3390 Lactobacillus farcimmis 3378 Sphaerochaeta globus 3537 Azospirillum B510 3504 Gluconacetobacter diazotrophicus 3150 Neisseria cinerea 3246 Roseburia intestinalis 3420 Parvibaculum lavamentivorans 311 1 Staphylococcus aureus 3159 Nitratifractor saisuginis DSM 1651 1 3396 Campylobacter lari CF89-12 3009 Streptococcus thermophilus LMD-9 3396
[00196] These species are therefore, in general, preferred Cas9 species. Applicants have shown delivery and in vivo mouse brain Cas9 expression data.
[00197] Two ways to package Cas9 coding nucleic acid molecules, e.g., DNA, into viral vectors to mediate genome modification in vivo are preferred:
To achieve NHEJ-mediated gene knockout:
Single vims vector:
Vector containing two or more expression cassettes:
Promoter-Cas9 coding nucleic acid molecule -terminator
Promoter-gRN A] -terminator
Promoter-gRJS!A2-terminator
Promoter-gRNA(N)-terminator (up to size limi t of vector)
Double virus vector:
Vector 1 containing one expression cassette for driving the expression of Cas9 Promoter-Cas9 coding nucleic acid molecule-terminator
Vector 2 containing one more expression cassettes for driving the expression of one or more guideRNAs
Promoter-gRN A 1 -terminator
56
90.1 Promoter-gRNA(N)-terminator (up to size limit of vector)
To mediate homology-directed repair. In addition to the single and double vims vector approaches described above, an additional vector is used to deliver a homology-direet repair template.
[00198] Promoters used to drive Cas9 coding nucleic acid molecule expression can include:
AAV 1TR can serve as a promoter: this is advantageous for eliminating the need for an additional promoter element (which can take up space in the vector). The additional space freed up can be used to drive the expression of additional elements (gRNA, etc.). Also, ITR activity is relatively weaker, so can be used to reduce toxicity due to over expression of Cas9;
For ubiquitous expression, can use promoters: CMV, CAG, CBh, PGK, SV40, Ferritin heavy or light chains, etc.;
For brain expression, can use promoters: Synapsinl for all neurons, CaMKIIalpha for excitatory neurons, GAD67 or GAD65 or VGAT for GABAergic neurons, etc.; For liver expression, can use Albumin promoter;
For lung expression, can use SP-B;
For endothelial cells, can use ICAM;
For hematopoietic cells can use IFNbeta or CD45 ; and
For Osteoblasts can use QG-2;
[00199] Promoter used to drive guide RNA can include:
Pol III promoters such as U6 or HI;
Use of Pol II promoter and intronic cassettes to express gRNA.
[00200] As to AAV, the AAV can be AAVl, AAV2, AAV5 or any combination thereof. One can select the AAV of the AAV with regard to the cells to be targeted; e.g., one can select AAV serotypes 1 , 2, 5 or a hybrid or capsid AAVl , AAV2, AAV5 or any combination thereof for targeting brain or neuronal cells; and one can select AAV4 for targeting cardiac tissue. AAV8 is useful for delivery to the liver. The above promoters and vectors are preferred individually.
[00201 ] RNA delivery is also a useful method of in vivo delivery. Fig. 27 shows deliver}' and in vivo mouse brain Cas9 expression data. It is possible to deliver Cas9 and gRNA (and, for instance, HR repair template) into cells using liposomes or nanoparticles. Thus delivery of the CRISPR enzyme, such as a Cas9 and'Or deliver}' of the RNAs of the invention may be in RNA form and via microvesicles, liposomes or nanoparticles. For
57
90.1 example, Cas9 mRNA and gRNA can be packaged into liposomal particles for deliver}' in vivo. Liposomal transfeetion reagents such as Invivofectamine from Life Technologies and other reagents on the market can effectively deliver RNA molecules into the liver, [00202] Enhancing NHEJ or HR efficiency is also helpful for delivery. It is preferred that NHEJ efficiency is enhanced by co-expressing end-processing enzymes such as Trex2 (Dumitrache et al. Genetics, 2011 August: 188(4): 787-797). It is preferred that HR efficiency is increased by transiently inhibiting NHEJ machineries such as u70 and K.u86. HR efficiency can also be increased by co-expressing prokaryotic or eukaryotic homologous recombination enzymes such as RceBCD, RecA.
[00203] Various means of delivery are described herein, and further discussed in this section.
[00204] Viral delivery: The CRISPR enzyme, for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can be delivered using adeno associated virus (AAV), lentivims, adenovirus or other viral vector types, or combinations thereof. Cas9 and one or more guide RNAs can be packaged into one or more viral vectors. In some embodiments, the viral vector is delivered to the tissue of interest by, for example, an intramuscular injection, while other times the viral delivery is via intravenous, transdermal, intranasal, oral, mucosal, or other delivery methods. Such delivery may be either via a single dose, or multiple doses. One skilled in the art understands that the actual dosage to be delivered herein may vary greatly depending upon a variety of factors, such as the vector chose, the target cell, organism, or tissue, the general condition of the organism or subject to be treated, the degree of transformation/modification sought, the administration route, the administration mode, the type of transform.ation/modifi.cat,ion sought, etc.
[00205] Such a dosage may further contain, for example, a carrier (water, saline, ethanol, glycerol, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, etc.), a diluent, a pharmaceutically-acceptable earner (e.g., phosphate-buffered saline), a pharmaceutically-acceptable excipient, an adjuvant to enhance antigenicity, an immunostimulatory compound or molecule, and/or other compounds known in the art. The adjuvant herein may contain a suspension of minerals (alum, aluminum hydroxide, aluminum phosphate) on which antigen is adsorbed; or water-in-oil emulsion in which antigen solution is emulsified in oil (MF-59, Freund's incomplete adjuvant), sometimes with the inclusion of killed mycobacteria (Freund's complete adjuvant) to further enhance antigenicity (inhibits degradation of antigen and/or
58
90.1 causes influx of macrophages). Adjuvants also include immunostimulatory molecules, such as cytokines, costimulatory molecules, and for example, immunostimulatory DNA or R A molecules, such as CpG oligonucleotides. Such a dosage formulation is readily ascertainable by one skilled in the art. The dosage may further contain one or more pharmaceutically acceptable salts such as, for example, a mineral acid salt such as a hydrochloride, a hydrobromide, a phosphate, a sulfate, etc.; and the salts of organic acids such as acetates, propionates, malonates, benzoaies, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, gels or gelling materials, flavorings, colorants, microspheres, polymers, suspension agents, etc. may also be present herein. In addition, one or more other conventional pharmaceutical ingredients, such as preservatives, humectants, suspending agents, surfactants, antioxidants, anticaking agents, fillers, chelating agents, coating agents, chemical stabilizers, etc. may also be present, especially if the dosage form is a reconstitutabie form. Suitable exemplary ingredients include mierocrystalline cellulose, carboxymethylcelhilose sodium, poiysorbate 80, phenyiethyl alcohol, chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gal late, the parabens, ethyl vanil lin, glycerin, phenol, parachioropbenol, gelatin, albumin and a combination thereof. A thorough discussion of pharmaceutically acceptable excipients is available in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991) which is incorporated by reference herein.
[00206] In an embodiment herein the delivery is via a recombinant viral vector delivery system derived from an adenovirus or a leniivirus, which may be at a single booster dose containing at least 1 x 10s particles (also referred to as particle units, pu) of adenoviral or lentiviral vector. In an embodiment herein, the dose preferably is at least about 1 x 106 particles (for example, about 1 x 10°- 1 x 10i particles), more preferably at least about 1 x 10'' particles, more preferably at least about 1 x 105 particles (e.g., about 1 x 10*- 1 x 10! ! particles or about 1 x 108-! x 1012 particles), and most preferably at least about ! x 10° particles (e.g., about 1 * x 109-1 x 10f particles or about 1 x 10 x 10U particles), or even at least about 1 x 10! 0 particles (e.g., about 1 x lGi0-l x I0l 2 particles) of the adenoviral or lentiviral vector. Alternatively, the dose comprises no more than about I x 1014 particles, preferably no more than about 1 x 10" particles, even more preferably no more than about 1 x 10 '2 particles, even more preferably no more than about 1 x 101 1 particles, and most preferably no more than about 1 x 1010 particles (e.g., no more than about I x 109 articles). Thus, the dose may contain a single dose of adenoviral vector with, for example, about 1 x 106 particle units (pu), about 2 x 10° pu, about 4 x 106 pu, about 1 x
59
90.1 10 ' pu, about 2 x 10' pu, about 4 x 107 pu, about 1 x 10* pu, about 2 x 10* pu, about 4 x 10s pu, about 1 x 109 pu, about 2 x 109 pu, about 4 x 109 pu, about 1 x 1050 pu, about 2 x 103lJ pu, about 4 x 103lJ pu, about 1 x 10H pu, about 2 x 10H pu, about 4 x 10H pu, about 1 x 1012 pu, about 2 x 10l2 pu, or about 4 x 1012 pu of adenoviral or lentiviral vector. See, for example, trie adenoviral vectors in U.S. Patent No. 8,454,972 B2 to Nabel, et. al,, granted on June 4, 2013; incorporated by reference herein, and the dosages at col 29, lines 36-58 thereof. In an embodiment herein, the adenovirus is delivered via multiple doses. Similarly, consider U.S. Patent No. 7,250,299 to Naldini et. al. granted on July 31 , 2007 and U.S. Patent No. 7,226,780 to Arya granted on June 5, 2007 for dosage of lentiviral vectors.
|00207] In an embodiment herein, the delivery is via a recombinant viral vector deliver}' system derived from an AAV or a lenti virus. A therapeutically effective dosage for in vivo delivery of the AAV or lentiviras to a human is believed to be in the range of from about 20 to about 50 ml of saline solution containing from about 1 x 103lJ to about 1 x 1010 functional AAV/ml or lentivirus/ml solution. The dosage may be adjusted to balance the therapeutic benefit against any side effects. In an embodiment herein, the AAV dose is generally in the range of concentrations of from about 1 x 105 to 1 x 1050 genomes AAV, from about 1 x 10s to 1 x 1020 genomes AAV, from about 1 x 10i0 to about 1 x I0! 6 genomes, or about 1 x 1011 to about 1 x I0i6 genomes AAV. A human dosage may be about 1 x 10i 3 genomes AAV. Such concentrations may be delivered in from about 0.001 ml to about 100 ml, about 0.05 to about 50 ml, or about 10 to about 25 ml of a carrier solution. Other effective dosages can be readily established by one of ordinary skill in the art through routine trials establishing dose response curves. See, for example, U.S. Patent No. 8,404,658 B2 to Hajjar, et al., granted on March 26, 2013, at col. 27, lines 45-60.
[00208] In an embodiment herein the deliver}' is via a plasmid. In such plasmid compositions, the dosage should be a sufficient amount of plasmid to elicit a response. For instance, suitable quantities of plasmid DNA in plasmid compositions can be from about 0.1 to about 2 mg, or from about I fig to about 10 .g.
[0Θ209] The doses herein are based on an average 70 kg individual. The frequency of administration is within the ambit of the medical or veterinar}' practitioner (e.g., physician, veterinarian), or scientist skilled in the art.
[00210] Cas9 and one or more guide RNA can be delivered using a vector delivery system derived from an adeno associated virus (AAV), lentiviras, adenovirus or other
60
90.1 plasmid or viral vector types, using formulations and doses from, for example, US Patents Nos. 8,454,972 (formulations, doses for adenovirus), 8,404,658 (formulations, doses for AAV) and 5,846,946 (formulations, doses for DNA plasmids) and from clinical trials and publications regarding the clinical trials involving lentivirus, AAV and adenovirus. For examples, for AAV, the route of administration, formulation and dose can be as in US Patent No. 8,454,972 and as in clinical trials involving AAV. For Adenovirus, the route of administration, ionnulation and dose can be as in US Patent No. 8,404,658 and as in clinical trials involving adenovirus. For plasmid deliver)', the route of administration, formulation and dose can be as in US Patent No 5,846,946 and as in clinical studies involving plasmids. Doses may be based on or extrapolated to an average 70 kg individual, and can be adjusted for patients, organisms or subjects, mammals of different weight and species. Frequency of administration is within the ambit of the medical or veterinary practitioner (e.g., physician, veterinarian), depending on usual factors including the age, sex, general health, other conditions of the patient or subject and the particular condition or symptoms being addressed,
[0Θ2Ϊ 1 ] The viral vectors can be injected into the tissue of interest. For cell-type specific genome modification, the expression of Cas9 can be driven by a cell-type specific promoter. For example, liver-specific expression might use the Albumin promoter and neuron-specific expression might use the Synapsin T promoter,
[00212] RNA. delivery: The CRISPR enzyme, for instance a Cas9, and/or any of the present RNAs, for instance a guide RNA, can also be deiivered in the form of RNA. Cas9 rriRNA can be generated using in vitro transcription. For example, Cas9 mRNA can be synthesized using a PCR cassette containing the following elements: T7_promoter-kozak sequence (GCCACC)-Cas9-3 ' UTR from beta globin-polyA tail (a string of 120 or more adenines). The cassette can be used for transcription by T7 polymerase. Guide RNAs can also be transcribed using in vitro transcription from a cassette containing T7_promoter- GG-guide RNA sequence.
[00213] To enhance expression and reduce toxicity, the CRISPR enzyme and/or guide RNA can be modified using pseudo-U or 5 -Methyl -C.
[00214] CRISPR enzyme mRNA and guide RNA may be delivered simultaneously using nanoparticles or lipid envelopes.
[00215] For example, Su X, Fricke J, Kavanagh DG, Irvine DJ ("In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles" Mol Pharm. 2011 Jun 6;8(3):774-87. doi: 10.1021/mpl00390w. Epub 201 1 Apr 1) describes
61
90.1 biodegradable core-shell structured nanoparticles with a poly(P-amino ester) (PBAE) core enveloped by a phospholipid bilayer shelf. These were developed for in vivo mRNA delivery. The pH-responsive PBAE component was chosen to promote endosome disruption, while the lipid surface layer was selected to minimize toxicity of the polycation core. Such are, therefore, preferred for delivering RNA of the present invention.
[00216] Furthermore, Michael 8 D Kormann et al. ("Expression of therapeutic proteins after delivery of chemically modified niRNA in mice: Nature Biotechnology, Volume:29, Pages: 154-157 (201 1) Published online 09 January 2011) describes the use of lipid envelopes to deliver RNA. Use of lipid envelopes is also preferred in the present invention,
|00217] mRNA deliver methods are especially promising for liver delivery currently.
[00218] CRISPR enzyme mRNA and guide RNA might also be delivered separately. CRISPR enzyme mRNA can be delivered prior to the guide RNA to give time for CRISPR enzyme to be expressed. CRISPR enzyme mRNA might be administered 1 -12 hours (preferably around 2-6 hours) prior to the administration of guide RNA.
[0Θ219] Alternatively, CRISPR. enzyme mRNA and guide RNA can be administered together. Advantageously, a second booster dose of guide RNA can be administered 1 - 12 hours (preferably around 2-6 hours) after the initial administration of CRISPR enzyme mRNA + guide RNA.
[00220] Additional administrations of CRISPR enzyme mRN and/or guide RNA might be useful to achieve the most efficient levels of genome modification.
[0Θ22Ϊ ] For minimization of toxicity and off -target effect, it will be important to control t e concentration of CRISPR. enzyme mRNA and guide RN delivered. Optimal concentrations of CRISPR enzyme mRNA and guide RNA can be determined by testing different concentrations in a cellular or animal model and using deep sequencing the analyze the extent of modification at potential off-target genomic loci. For example, for the guide sequence targeting 5 ' -GAGTCCGAGC AGAAGAAGAA -3 ' (SEQ ID NO: ) in the EM 1 gene of the human genome, deep sequencing can be used to assess the level of modification at the following two off-target loci, 1 : 5'-
GAGTCCTAGCAGGAGAAGA A-3 '(SEQ ID NO: ) and 2: 5'-
GAGTCTAAGCAGAAGAAGAA-3 ' (SEQ ID NO: ). The concentration that gives the highest level of on-target modification while minimizing the level of off-target modification should be chosen for in vivo delivery.
62
90.1 0Θ222] Alternatively, to minimize the level of toxicity and off-target effect, CRISPR enzyme nickase mRNA (for example S. pyogenes Cas9 with the D10A mutation) can be delivered with a pair of guide RNAs targeting a site of interest. The two guide RNAs need to be spaced as follows. Guide sequences in red (single underline) and blue (double underline) respectively (these examples are based on the PAM requirement for Streptococcus pyogenes Cas9.
Figure imgf000064_0001
63
90.1
Figure imgf000065_0001
3 ' 5 '
13 5 ' 3 '
3 ' 5 '
14 5 ' 3 '
3 ' 5 '
15 5 ' 3 '
3 ' 5 '
16 5 ' 3 '
3 '' -NNNNNNN NNNNNNNNNNNNNNCCN^ 5 '
1 5 ' 3 '
3 ·' -NNNNNNN NNNNNNNNNNNNNNCCN^ 5 '
[00223] Further interrogation of the system have given Applicants evidence of the 5' overhang (see, e.g., Ran et al.. Cell 2013 Sep 12; 154(6): 1380-9 and US Provisional Patent Application Serial No. 61/871 ,301 filed August 28, 2013). Applicants have further identified parameters that relate to efficient cleavage by the Cas9 nickase mutant when combined with two guide RNAs and these parameters include but are not limited to the length of the 5' overhang, in embodiments of the invention the 5' overhang is at most 200 base pairs, preferably at most 100 base pairs, or more preferably at most 50 base pairs. In embodiments of the invention the 5' overhang is at least 26 base pairs, preferably at least 30 base pairs or more preferably 34-50 base pairs or 1 -34 base pairs. In other preferred methods of the invention the first guide sequence directing cleavage of one strand of the DNA duplex near the first target sequence and the second guide sequence directing cleavage of the opposite strand near the second target sequence results in a blunt cut or a 3 ' overhang. In embodiments of the invention the 3 ' overhang is at most 150, 100 or 25 base pairs or at least 15, 10 or 1 base pairs. In preferred embodiments the 3' overhang is 1 - 100 basepairs.
[00224] Aspects of the invention relate to the expression of the gene product being decreased or a template polynucleotide being further introduced into the DNA molecule encoding the gene product or an intervening sequence being excised precisely by allowing the two 5' overhangs to reanneal and ligate or the activity or function of the gene product being altered or the expression of the gene product being increased. In an embodiment of
65
90.1 the invention, the gene product is a protein. In an embodiment of the invention, the gene product is a rnieroRNA. In one embodiment, the regulatory region of a gene is targeted, thereby modifying the expression of the corresponding gene product.
[00225] Only sgRNA pairs creating 5' overhangs with less than 8bp overlap between the guide sequences (offset greater than about 8 bp) were able to mediate detectable indel formation. Importantly, each guide used in these assays is able to efficiently induce indeis when paired with wildtype Cas9, indicating that the relative positions of the guide pairs are the most important parameters in predicting double nicking activity,
[0Θ226] Since Cas9n and Cas9H840A nick opposite strands of DNA, substitution of Cas9n with Cas9H840A with a given sgRNA pair should result in the inversion of the overhang type. For example, a pair of sgRNAs that will generate a 5' overhang with Cas9n should in principle generate the corresponding 3 ' overhang instead. Therefore, sgRNA pairs that lead to the generation of a 3 ' overhang with Cas9n might be used with Cas9H840A to generate a 5' overhang. Applicants tested Cas9H840A with a set of sgRNA pairs designed to generate both 5' and 3 ' overhangs (offset range from -278 to +-58 bp), but, unexpectedly, were unable to observe indel formation. Further work may be needed to identify the necessary design rules for sgRNA pairing to allow double nicking by Cas9H840A.
[00227] Additional delivery options for the brain include encapsulation of CRISPR enzyme and guide RNA in the form of either DNA or RNA into liposomes and conjugating to molecular Trojan horses for trans-blood brain barrier (BBB) delivery. Molecular Trojan horses have been shown to be effective for deliver}' of B-gal expression vectors into the brain of non-human primates. The same approach can be used to delivery vectors containing CRISPR enzyme and guide RNA. For instance, Xia CF and Boado RJ, Pardridge WM ("Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology." Mol Pharm. 2009 May-Jun;6(3):747-51. doi: 10.1021/mp800194) describes how delivery of short interfering RNA (siRNA) to ceils in culture, and in vivo, is possible with combined use of a receptor-specific monoclonal antibody (mAb) and avidin-biotin technology. The authors also report that because the bond between the targeting mAb and the siRNA is stable with avidin-biotin technology, and RNAi effects at distant sites such as brain are observed in vivo following an intravenous administration of the targeted siRNA.
[00228] Zhang Y, Schiachetzki F, Pardridge WM. ("Global non-viral gene transfer to the primate brain following intravenous administration." Mol Ther. 2003 Jan;7(l): l l-8.)
66
90.1 describe how expression plasmids encoding reporters such as luciferase were encapsulated in the interior of an "artificial vims" comprised of an 85 nm pegylated immunoliposome, which was targeted to the rhesus monkey brain in vivo with a monoclonal antibody (MAb) to the human insulin receptor (HTR). The HIRMAb enables the liposome carrying the exogenous gene to undergo transcytosis across the blood-brain barrier and endocytosis across the neuronal plasma, membrane following intravenous injection. The level of luciferase gene expression in the brain was 50-fold higher in the rhesus monkey as compared to the rat. Widespread neuronal expression of the beta-gal actosidase gene in primate brain was demonstrated by both histochemistry and confocal microscopy. The authors indicate that this approach makes feasible reversible adult transgenics in 24 hours. Accordingly, the use of immunoliposome is preferred. These may be used in conjunction with antibodies to target specific tissues or cell surface proteins.
[00229] Other means of delivery or RNA are also preferred, such as via nanoparticies (Clio, 8., Goldberg, fvl., Son, S., Xu, Q., Yang, F., Mel Y., Bogatyrev, S., Langer, R. and Anderson, D., Lipid-like nanoparticies for small interfering RNA delivery to endothelial cells, Advanced Functional Materials, 19: 31 12-31 18, 2010) or exosomes (Schroeder, A., Levins, C, Coitez, C, Langer, ft, and Anderson, D., Lipid-based nanotherapeutics for si RNA delivery-, Journal of Internal Medicine, 267: 9-21, 2010, PMID: 20059641). Indeed, exozomes have been shown to be particularly useful in delivery siRNA, a system with some parallels to the CRISPR system. For instance, El-Andaloussi S, et al. ("Exosome-mediated delivery of siRNA in vitro and in vivo." Nat Protoc. 2012 Dec;7(12):21 12-26. doi: 10.1038/nprot.2012.131. Epub 2012 Nov 15.) describe how exosomes are promising tools for drug delivery across different biological barriers and can be harnessed for delivery of siRNA in vitro and in vivo. Their approach is to generate targeted exosomes through transiection of an expression vector, comprising an exosomal protein fused with a peptide ligand. The exosomes are then purify and characterized from transfected cell supernatant, then siRNA is loaded into the exosomes.
[00230] Targeted deletion of genes is preferred. Examples are exemplified in Example 1 8. Preferred are, therefore, genes involved in cholesterol biosynthesis, fatty acid biosynthesis, and other metabolic disorders, genes encoding mis-folded proteins involved in amyloid and other diseases, oncogenes leading to cellular transformation, latent viral genes, and genes leading to dominant-negative disorders, amongst other disorders. As exemplified here, Applicants prefer gene deliver}' of a CRTSPR-Cas system to the liver, brain, ocular, epithelial, hematopoetic, or another tissue of a organism, subject or a patient
67
90.1 In need thereof, suffering from metabolic disorders, amyloidosis and protein -aggregation related diseases, cellular transformation arising from genetic mutations and translocations, dominant negative effects of gene mutations, latent viral infections, and other related symptoms, using either viral or nanopartiele delivery system.
[00231] Therapeutic applications of the CRISPR-Cas system include Glaucoma, Amyloidosis, and Huntington's disease. These are exemplified in Example 20 and the features described therein are preferred alone or in combination.
[00232] As an example, chronic infection by HTV-1 may be treated or prevented. In order to accomplish this, one may generate CRISPR-Cas guide RNAs that target the vast majority of the HIV- 1 genome while taking into account HTV-1 strain variants for maximal coverage and effectiveness. One may accomplish delivery of the CRISPR-Cas system by conventional adenoviral or lentiviral-mediated infection of the host immune system. Depending on approach, host immune cells could be a) isolated, transduced with CRISPR-Cas, selected, and re-introduced in to the host or b) transduced in vivo by systemic deliver)' of the CRISPR-Cas system. The first approach allows for generation of a resistant immune population whereas the second is more likely to target latent viral reservoirs within the host. This is discussed in more detail in the Examples section.
|00233] It is also envisaged that the present invention generates a gene knockout cell library. Each cell may have a single gene knocked out. This Is exemplified in Example 23.
[00234] One may make a library of ES cells where each cell has a single gene knocked out, and the entire library of ES cells will have ever)' single gene knocked out. This library is useful for the screening of gene function in cellular processes as well as diseases. To make this ceil library, one may integrate Cas9 driven by an inducible promoter (e.g. doxycycline inducible promoter) into the ES cell. In addition, one may integrate a single guide RNA targeting a specific gene in the ES cell. To make the ES cell library, one may simply mix ES cells with a library of genes encoding guide RNAs targeting each gene in the human genome. One may first introduce a single BxB l attB site into the AAVSl locus of the human ES cell. Then one may use the BxBl integrate to facilitate the integration of individual guide RN genes into the BxB l attB site in AAVSl locus. To facilitate integration, each guide RNA gene may be contained on a plasmid that carries of a single attP site. This way BxBl will recombine the attB site in the genome with the aitP site on the guide RNA containing plasmid. To generate the cell library, one may take the library-
68
go. i of cells that have single guide RNAs integrated and induce Cas9 expression. After induction, Cas9 mediates double strand break at sites specified by the guide RNA.
[00235] Chronic administration of protein therapeutics may elicit unacceptable immune responses to the specific protein. The immunoge icity of protein drugs can be ascribed to a few immunodominant helper T lymphocyte (HTL) epitopes. Reducing the MHC binding affinity of these HTL epitopes contained within these proteins can generate drugs with lower immunogenicitv (Tangri S, et al. ("Rationally engineered therapeutic proteins with reduced immunogenicitv" J Immunol, 2005 Mar 15; 174(6):3187-96,) In the present invention, the immunogenicitv of the CRISPR enzyme in particular may be reduced following the approach first set out in Tangri et al with respect to erythropoietin and subsequently developed. Accordingly, directed evolution or rational design may be used to reduce the immunogenicitv of the CRISPR enzyme (for instance a Cas9) in the host species (human or other species).
[00236] In Example 28, Applicants used 3 guideR As of interest and were able to visualize efficient DNA cleavage in vivo occurring only in a small subset of cells. Essentially, Applicants have shown targeted in vivo cleavage. In particular, this provides proof of concept that specific targeting in higher organisms such as mammals can also be achieved. It also highlights multiplex aspect in that multiple guide sequences (i.e. separate targets) can be used sim ltaneously (in the sense of co-delivery). In other words, Applicants used a multiple approach, with several different sequences targeted at the same time, but independently.
[0Θ237] A suitable example of a protocol for producing AAV, a preferred vector of the invention is provided in Example 34.
[00238] Nucleotide repeat disorders are preferred conditions to be treated. These are also exemplified herein.
[00239] According to another aspect, a method of gene therapy for the treatment of an organism or a subject having a mutation in the CFTR gene is provided and comprises administering a therapeutically effective amount of a CRISPR-Cas gene therapy particle, optionally via a biocompatible pharmaceutical carrier, to the cells of an organism or a subject. Preferably, the target UNA comprises the mutation deltaF508. In general, it is of preferred that the mutation is repaired to the wildtype. In this case, the mutation is a deletion of the three nucleotides that comprise the codon for phenylalanine (F) at position 508, Accordingly, repair in this instance requires reintroduction of the missing codon into the mutant. 0Θ240] To implement this Gene Repair Strategy, it is preferred that an adenovirus/AAV vector system is introduced into the host cell, cells or patient. Preferably, the system comprises a Cas9 (or Cas9 nickase) and the guide RNA along with a adenovirus/AAV vector system comprising the homology repair template containing the F508 residue. This may be introduced into the organism or subject via one of the methods of delivery discussed earlier. The CRISPR-Cas system may be guided by the CFTRdelta 508 chimeric guide RNA. It targets a specific site of the CFTR genomic locus to be nicked or cleaved. After cleavage, the repair template is inserted into the cleavage site via homologous recombination correcting the deletion that results in cystic fibrosis or causes cystic fibrosis related symptoms. This strategy to direct delivery and provide systemic introduction of CRISPR systems with appropriate guide RNAs can be employed to target genetic mutations to edit or otherwise manipulate genes that cause metabolic, liver, kidney and protein diseases and disorders such as those in Table B.
[00241] For an example of CFTRdelta508 chimeric guide RNA, see Example 22 which demonstrates gene transfer or gene delivery of a CRISPR-Cas system in airways of an organism, a subject or a patient in need thereof, suffering from cystic fibrosis or from cystic fibrosis (CF) related symptoms, using adeno-associated virus (AAV) particles. In particular, they exemplify a repair strategy for Cystic Fibrosis delta F508 mutation. This type of strategy should apply across all organisms. With particular reference to CF, suitable patients may include: Human, non-primate human, canine, feline, bovine, equine and other domestic animals. In this instance, Applicants utilized a CRISPR-Cas system comprising a Cas9 enzyme to target deltaF508 or other CFTR-inducing mutations.
[0Θ242] The treated subjects in this instance receive pharmaceutically effective amount of aerosolized AAV vector system per lung endobronchial!}' delivered while spontaneously breathing. As such, aerosolized delivery is preferred for AAV deliver in general. An adenovirus or an AAV particle may be used for delivery. Suitable gene constructs, each operably linked to one or more regulator}' sequences, may be cloned into the delivery vector. In this instance, the following constructs are provided as examples: Cbh or EFla promoter for Cas9, U6 or HI promoter for chimeric guide RNA),: A preferred arrangement is to use a CFTRdelta508 targeting chimeric guide, a repair template for deltaF508 mutation and a. codon optimized Cas9 enzyme (preferred Cas9s are those with nuclease or nickase activity) with optionally one or more nuclear localization signal or sequence(s) (NLS(s)), e.g., two (2) NLSs. Constructs without NLS are also envisaged. [00243] In order to identify the Cas9 target site, Applicants analyzed the human CFTR genomic locus and identified the Cas9 target site. Preferably, in general and in this CF case, the PAM may contain a NGG or a NNAGAAW motif.
[00244] Accordingly, in the case of CF, the present method comprises manipulation of a target sequence in a genomic locus of interest comprising
delivering a non-naturaliy occurring or engineered composition comprising a viral vector system comprising one or more viral vectors operably encoding a composition for expression thereof, wherein the composition comprises:
a non-naturaliy occurring or engineered composition comprising a vector system comprising one or more vectors comprising
I. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) a guide sequence capable of hybridizing to the CF target sequence in a suitable mammalian cell,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
II. a second regulator}' element operably linked to an enzyme -coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences, wherein (a), (b) and (c) are arranged in a 5' to 3 ' orientation,
wherein components I and II are located on the same or different vectors of the system, wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence directs sequence-specific binding of a CRISPR complex to the target sequence, and
wherein the CRISPR complex comprises the CRISPR enzyme complexed with (1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence. In respect of CF, preferred target DNA sequences comprise the CFTRdeIta508 mutation. A preferred PAM is described above. A preferred CRISPR enzyme is any Cas (described herein, but particularly that described in Example 22).
[0Θ245] Alternatives to CF include any genetic disorder and examples of these are well known. Another preferred method or use of the invention is for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease.
90.1 0Θ246] In some embodiments, a "guide sequence" may be distinct from "guide RNA", A guide sequence may refer to an approx. 20bp sequence, within the guide RNA, that specifies the target site.
[00247] In some embodiments, the Cas9 is (or is derived from) the SpCas9. In such embodiments, preferred mutations are at any or all or positions 10, 762, 840, 854, 863 and/or 986 of SpCas9 or corresponding positions in other Cas9s (which may be ascertained for instance by standard sequence comparison tools. In particular, any or all of the following mutations are preferred in SpCas9: DI0A, E762A, H840A, N854A, N863A and/or D986A; as well as conservative substitution for any of the replacement amino acids is also envisaged. The same (or conservative substitutions of these mutations) at corresponding positions in other Cas9s are also preferred. Particularly preferred are D10 and H840 in SpCas9. However, in other Cas9s, residues corresponding to SpCas9 D10 and H840 are also preferred. These are advantageous as they provide nicka.se activity, [00248] It will be readily apparent that a host of other diseases can be treated in a. similar fashion. Some examples of genetic diseases caused by mutations are provided herein, but many more are known. The above strategy can be applied to these diseases.
[00249] The invention uses nucleic acids to bind target DNA sequences. This is advantageous as nucleic acids are much easier and cheaper to produce and the specificity can be varied according to the length of the stretch where homology is sought. Complex 3-D positioning of multiple fingers, for example is not required,
[00250] The terms "polynucleotide", "nucleotide", "nucleotide sequence", "nucleic acid" and "oligonucleotide" are used interchangeably. They refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three dimensional structure, and may perform any function, known or unknown. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomai RNA, short interfering RNA (siRNA), short-hairpin RNA (shRNA), micro- RNA (iriiRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. The term also encompasses nucleic -acid-like structures with synthetic backbones, see, e.g., Eckstein, 1991; Baserga et al., 1992; Milligan, 1993; WO 97/03211 ; WO 96/39154; Mata, 1997; Strauss-Soukup, 1997; and Samstag, 1996. A polynucleotide may comprise one or more modified nucleotides, such
90.1 as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nueleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component,
[00251] As used herein the term "wild type" is a term of the art understood by skilled persons and means the typical form of an organism, strain, gene or characteristic as it occurs in nature as distinguished from mutant or variant forms.
[0Θ252] As used herein the term "variant" should be taken to mean the exhibition of qualities that have a pattern that deviates from what occurs in nature,
|00253] The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate the involvement of the hand of man. The terms, when referring to nucleic acid molecules or polypeptides mean that the nucleic acid molecule or the polypeptide is at least substantially free from at least one other component with which they are naturally associated in nature and as found in nature.
[0Θ254] "Complementarity" refers to the ability of a nucleic acid to form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick base pairing or other non-traditional types. A percent complementarity indicates the percentage of residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence. "Substantially complementary" as used herein refers to a degree of complementarity that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 1 8, 19, 20, 21 , 22, 23, 24, 25, .30, 35, 40, 45, 50, or more nucleotides, or refers to two nucleic acids that hybridize under stringent conditions.
[00255] As used herein, "stringent conditions" for hybridization refer to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes with the target sequence, and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent, and vary depending on a number of factors, in general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in detail in Tijssen (1993), Laboratory Techniques In Biochemistry And Molecular Biology-Hybridization With Nucleic Acid Probes Part X, Second Chapter "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, N,Y. Where reference is made to a polynucleotide sequence, then complementary or partially complementary sequences are also envisaged. These are preferably capable of hybridising to the reference sequence under highly stringent conditions. Generally, in order to maximize the hybridization rate, relatively low- stringency hybridization conditions are selected: about 20 to 25° C. lower than the thermal melting point (T m ). The T m is the temperature at which 50% of specific target sequence hybridizes to a perfectly complementary probe in solution at a defined ionic strength and pH. Generally, in order to require at least about 85% nucleotide complementarity of hybridized sequences, highly stringent washing conditions are selected to be about 5 to 15° C. lower than the T m . In order to require at least about 70% nucleotide complementarity of hybridized sequences, moderately-stringent washing conditions are selected to be about 15 to 30° C. lower than the T m . Highly permissive (very low stringency) washing conditions may be as low as 50° C, below the T m , allowing a high level of mis-matching between hybridized sequences. Those skilled in the art will recognize that other physical and chemical parameters in the hybridization and wash stages can also be altered to affect the outcome of a detectable hybridization signal from a specific level of homology between target and probe sequences. Preferred highly s tringent conditions comprise incubation in 50% formamide, 5><SSC, and 1% SDS at 42° C, or incubation in 5xSSC and 1% SDS at 65° C, with wash in 0.2xSSC and 0.1% SDS at 65° C.
[0Θ256] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson Crick base pairing, Hoogstem binding, or in any other sequence specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of PGR, or the cleavage of a polynucleotide by an enzyme. A sequence capable of hybridizing with a given sequence is referred to as the "complement" of the given sequence.
[00257] As used herein, the term "genomic locus" or "locus" (plural loci) is the specific location of a gene or DNA sequence on a chromosome. A "gene" refers to stretches of DNA or RNA that encode a polypeptide or an RNA chain that has functional role to play
74
90.1 In an organism and hence Is the molecular unit of heredity in living organisms. For the purpose of this invention it may be considered that genes include regions which regulate the production of the gene product, whether or not such regulatory sequences are adjacent to coding and/or transcribed sequences. Accordingly, a gene includes, but Is not necessarily limited to, promoter sequences, terminators, translational regulator}' sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, replication origins, matrix attachment sites and locus control regions.
[0Θ258] As used herein, "expression of a genomic locus" or "gene expression" is the process by which information from a gene is used in the synthesis of a functional gene product. The products of gene expression are often proteins, but in non-protein coding genes such as rRNA genes or tRNA genes, the product is functional RNA. The process of gene expression is used by ail known life - eukaryotes (including multicellular organisms), prokaryotes (bacteria and archaea) and viruses to generate functional products to survive. As used herein "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context. As used herein, "expression" also refers to the process by which a polynucleotide is transcribed from a D A template (such as into and mRNA or other RNA transcript) and/or the process by which a transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. Transcripts and encoded polypeptides may be collectively referred to as "gene product." If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.
[0Θ259] The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. The polymer may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non amino acids. The tenns also encompass an amino acid polymer that has been modified; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component. As used herein the term "amino acid" includes natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
|00260] As used herein, the term "domain" or "protein domain" refers to a part of a protein sequence that may exist and function independently of the rest of the protein chain. [00261 ] As described in aspects of the invention, sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. In some preferred embodiments, the capping region of the dTALEs described herein have sequences that are at least 95% identical or share identity to the capping region amino acid sequences provided herein.
[0Θ262] Sequence homologies may be generated by any of a number of computer programs known in the art, for example BLAST or FASTA, etc. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A; Devereux et al,, 1984, Nucleic Acids Research 12:387). Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 ibid - Chapter 18), FASTA (Atsclml et al., 1 990, I Mol. Biol, 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al, 1999 ibid, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.
[00263] Percentage (%) sequence homology may be calculated over contiguous sequences, i.e., one sequence is aligned with the other sequence and each amino acid or nucleotide in one sequence is directly compared with the corresponding amino acid or nucleotide in the other sequence, one residue at a time. This is called an "un gapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.
|00264] Although this is a ver simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion may cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without unduly penalizing the overall homology or identity score. This is achieved by inserting "gaps" in the sequence alignment to try to maximize local homology or identity,
[00265] However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence
76
90.1 alignment with, as few gaps as possible - reflecting higher relatedness between the two compared sequences - may achieve a higher score than one with many gaps. "Affinity gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties may, of course, produce optimized alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example, when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.
[00266] Calculation of maximum % homology therefore first requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (Devereux et al., 1984 Nuc. Acids Research 12 p387). Examples of other software than may perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al, 1999 Short Protocols in Molecular Biology, 4th Ed. - Chapter 18), FASTA (Altschul et al, 1990 J. Mol. Biol 403-410) and the GE EWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999, Short Protocols in Molecular Biology, pages 7-58 to 7-60). However, for some applications, it is preferred to use the GCG Bestfit program. A new tool, called BLAST 2 Sequences is also available for comparing protein and nucleotide sequences (see FEMS Microbiol Lett. 1999 174(2): 247-50; FEMS Microbiol Lett. 1999 177(1 ): 1 87-8 and the website of the National Center for Biotechnology information at the website of the National Institutes for Health).
[00267] Although the final % homology may be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pair- wise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs, GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table, if supplied (see user manual for further details). For some applications, it is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
90.1 [00268] Alternatively, percentage homologies may be calculated using the multiple alignment feature in DNASIS1M (Hitachi Software), based on an algorithm, analogous to CLUSTAL (Higgins DG & Sharp PM (1988), Gene 73(1), 237-244), Once the software has produced an optimal alignment, it is possible to calculate % homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result,
[00269] The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent substance. Deliberate amino acid substitutions may be made on the basis of similarity in amino acid properties (such as polarity, charge, solubility, hydrophobic ity, hydrophilicity, and/or the amphipathic nature of the residues) and it is therefore useful to group amino acids together in functional groups. Amino acids may be grouped together based on the properties of their side chains alone. However, it is more useful to include mutation data, as well. The sets of amino acids thus derived are likely to be conserved for stractural reasons. These sets may be described in the form of a Venn diagram (Livingstone CD, and Barton G.J. (1993) "Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation" Comput. Appl Biosci. 9: 745-756) (Taylor W.R. (1986) "The classification of amino acid conservation" J. Theor. Biol. 1 19; 205-218). Conservative substitutions may be made, for example according to the table below which describes a generally accepted Venn diagram grouping of amino acids.
Figure imgf000079_0001
polypeptide) which may comprise homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue or nucleotide, with an alternative residue or nucleotide) that may occur i.e., like-for-like substitution in the case of amino acids such as basic for basic, acidic for acidic, polar for polar, etc. Non-homologous substitution may also occur i.e., from one class of residue to another or alternatively involving the inclusion of unnatural amino acids such as ornithine (hereinafter referred to as Z), diaminobutyric acid ornithine (hereinafter referred to as B), norieucine ornithine (hereinafter referred to as Q), pyriylalanine, ihienylalanine, naphthylalanine and phenylgiycine.
[0Θ271] Variant amino acid sequences may include suitable spacer groups that may be inserted between any two amino acid residues of the sequence including alkyl groups such as methyl, ethyl or propyl groups in addition to amino acid spacers such as glycine or β- alanine residues. A further form of variation, which involves the presence of one or more amino acid residues in peptoid form, may be well understood by those skilled in the art. For the avoidance of doubt, "the peptoid form" is used to refer to variant amino acid residues wherein the a-carbon substituent group is on the residue's nitrogen atom rather than the a-carbon. Processes for preparing peptides in the peptoid form are known in the art, for example Simon RJ et al., PNAS (1992) 89(20), 9367-9371 and Horweli DC, Trends Biotechnol. (1995) 13(4), 132-134.
[00272] The practice of the present invention employs, unless otherwise indicated, conventional techniques of immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA, which are within the skill of the art. See Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS I MOLECULAR BIOLOGY (F. M. Ausubel, et ai. eds., (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.): PCR 2: A PRACTICAL APPROACH (M.J. MacPherson, B.D, Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) ANTIBODIES, A LABORATORY MANUAL, and ANIMAL CELL CULTURE (R.I. Freshney, ed. (1987)).
[00273] In one aspect, the invention provides for vectors that are used in the engineering and optimization of CRISPR-Cas systems.
[00274] A used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. It is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment may be inserted so as to bring about the replication of the inserted segment. Generally, a vector is capable of replication when associated with the proper control elements. In general, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Vectors include, but are not limited to, nucleic acid molecules that are single- stranded, double-stranded, or partially double-stranded; nucleic acid molecules that comprise one or more free ends, no free ends (e.g. circular); nucleic acid molecules that comprise DNA, RNA, or both; and other varieties of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, wherein virally-derived DNA or RNA sequences are present in the vector for packaging into a virus (e.g. retroviruses, replication defective retroviruses, adenoviruses, replication defective adenoviruses, and adeno-associated viruses (AAVs)), Viral vectors also include polynucleotides carried by a. virus for transfection into a host ceil. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g. bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non- episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors." Common expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
[0Θ275] Recombinant expression vectors can comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory elements, which may be selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory element(s) in a manner that allows for expression of the nucleotide sequence (e.g. in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host ceil). With regards to recombination and cloning methods, mention is made of U.S. patent application 10/815,730, published September 2, 2004 as US 2004-0171156 Al , the contents of which are herein incorporated by reference in their entirety. [00276] Aspects of the invention relate to bicistronic vectors for chimeric RNA and Cas9. Bicistronic expression vectors for chimeric RNA and Cas9 are preferred. In general and particularly in this embodiment Cas9 is preferably driven by the CBh promoter. The chimeric RNA may preferably be driven by a Pol III promoter such as a HI or a U6 promoter. Ideally the two are combined. The chimeric guide RNA typically consists of a 20bp guide sequence (Ns) and this may be joined to the tracr sequence (mnning from the first "U" of the lower strand to the end of the transcript). The tracr sequence may be tnincaied at various positions as indicated. The guide and tracr sequences are separated by the tracr-mate sequence, which may be GUUUUAGAGCUA. This may be followed by the loop sequence GAAA as shown. Both of these are preferred examples. Applicants have demonstrated Cas9-mediated indels at the human EMX1 and PVALB loci by SURVEYOR assays. ChiRNAs are indicated by their "+n" designation, and crRNA refers to a hybrid RNA where guide and tracr sequences are expressed as separate transcripts. Throughout this application, chimeric RNA may also be called single guide, or synthetic guide RNA (sgRNA). The loop is preferably GAAA, but it is not limited to this sequence or indeed to being only 4bp in length. Indeed, preferred loop forming sequences for use in hairpin structures are four nucleotides in length, and most preferably have the sequence GAAA. However, longer or shorter loop sequences may be used, as may alternative sequences. The sequences preferably include a nucleotide triplet (for example, AAA), and an additional nucleotide (for example C or G). Examples of loop forming sequences include CAAA and AAAG.
[00277] The term "regulatory element" is intended to include promoters, enhancers, internal ribosornal entry sites (IRES), and other expression control elements (e.g. transcription termination signals, such as polyadenylation signals and poiy-U sequences). Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif, (1990). Regulatory elements include those that direct constitutive expression of a. nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulator}' sequences), A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g. liver, pancreas), or particular cell types (e.g. lymphocytes). Regulatory elements may also direct expression in a temporal -dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In
81
90.1 some embodiments, a vector comprises one or more pol III promoter (e.g. 1, 2, 3, 4, 5, or more pol I promoters), one or more pol II promoters (e.g. 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g. 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and HI promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al, Cell, 41 :521-530 ( 1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphogiycerol kinase (PGK) promoter, and the EFl promoter. Also encompassed by the term "regulatory element" are enhancer elements, such as WPRE; CMV enhancers; the R-U5' segment in LTR of HTLV-I (Moi. Cell, Biol., Vol. 8(1 ), p. 466-472, 1988); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), p. 1527-31, 1981). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to thereby produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., clustered regularly interspersed short palindromic repeats (CRTSPR) transcripts, proteins, enzymes, mutant forms thereof, fusion proteins thereof, etc.). With regards to regulatory sequences, mention is made of U.S. patent application 10/491,026, the contents of which are incorporated by reference herein in their entirety. With regards to promoters, mention is made of PCT publication WO 201 1 /028929 and U.S. application 12/511,940, the contents of which are incorporated by reference herein in their entirety,
[00278] Vectors can be designed for expression of CRISPR transcripts (e.g. nucleic acid transcripts, proteins, or enzymes) in prokaryotic or eukaryotic cells. For example, CRISPR transcripts can be expressed in bacterial ceils such as Escherichia coii, insect cells (using baculovirus expression vectors), yeast ceils, or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.
[00279] Vectors may be introduced and propagated in a prokaryote or prokaryotic cell. In some embodiments, a prokaryote is used to amplify copies of a vector to be introduced
82
90.1 into a eukaryotic cell or as an intermediate vector in the production of a vector to be introduced into a eukaryotic cell (e.g. amplifying a plasmid as part of a viral vector packaging system). In some embodiments, a prokaryote is used to amplify copies of a vector and express one or more nucleic acids, such as to provide a source of one or more proteins for delivery to a host cell or host organism. Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, such as to the amino terminus of the recombinant protein. Such fusion vectors may serve one or more purposes, such as: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Example fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988, Gene 67: 31-40), pMAL (Mew England Biolabs, Beverly, Mass.) and pRlT5 (Pharmacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.
[00280] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amrann et al., (1988) Gene 69:301 -315) and pET l i d (Studier et al, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).
0Θ281] In some embodiments, a vector is a yeast expression vector. Examples of vectors for expression in yeast Saccharornyces cerivisae include pYepSec l (Baldari, et al,, 1987. EMBO J. 6: 229-234), pMFa ( uijan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).
[0Θ282] In some embodiments, a vector drives protein expression in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell, Biol. 3 : 2156-21 65) and the pVL series (Lucklow and Summers, 1989, Virology 170: 31-39).
83
90.1 0Θ283] In some embodiments, a vector is capable of driving expression of one or more sequences in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are typically provided by one or more regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, simian virus 40, and others disclosed herein and known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g.. Chapters 16 and 17 of Sambrook, et al, MOLECULAR CLONING: A LABORATORY MAN UAL. 2nd ed,, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.
[00284] In some embodiments, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue- specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al, 1987. Genes Dev. 1 : 268-277), lymphoid-specific promoters (Caiame and Eaton, 1988. Adv. Immunol 43 : 235-275), in particular promoters of T ceil receptors (Winoto and Baltimore, 1989. EMBO J. 8: 729-733) and immunoglobulins (Baneiji, et al., 1983. Cell 33 : 729-740; Queen and Baltimore, 1983. Cell 33 : 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. Proc. Nail. Acad. Set USA 86: 5473-5477), pancreas-specific promoters (Edlund, et al, 1985. Science 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264, 166). Developmentaily-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessei and Grass, 1990. Science 249: 374-379) and the α-fetoprotem promoter (Campes and Tilghman, 1989. Genes Dev. 3 : 537-546). With regards to these prokaryotic and eukaryotic vectors, mention is made of U.S. Patent 6,750,059, the contents of which are incorporated by reference herein in their entirety. Other embodiments of the invention may relate to the use of viral vectors, writh regards to which mention is made of U.S. Patent application 13/092,085, the contents of which are incorporated by reference herein in their entirety. Tissue-specific regulatory elements are known in the art and in this regard, mention is made of U.S. Patent 7,776,321, the contents of which are incorporated by reference herein in their entirety.
84
90.1 0Θ285] In some embodiments, a regulatory element is operably linked to one or more elements of a CRISPR system so as to drive expression of the one or more elements of the CR1SPR system. In general, CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats), also known as SPIDRs (SPacer Interspersed Direct Repeats), constitute a family of DNA loci that are usually specific to a particular bacterial species. The CRISPR locus comprises a distinct class of interspersed short sequence repeats (SSRs) that were recognized in E. coli (Ishino et al, J. Bacterial, 169:5429-5433 [1987]; and Nakata et al, J. Bacterid, 171 :3553-3556 [1989]), and associated genes. Similar interspersed SSRs have been identified in Haloferax mediterranei, Streptococcus pyogenes, Anabaena, and Mycobacterium tuberculosis (See, Groenen et al, Mol. Microbiol, 10: 1057-1065 [ 1993]; Hoe et at Emerg. Infect. Dis., 5:254-263 [1999]; Masepohl et al, Biochim. Biophys. Acta 1307:26-30 [1996]; and Mojica et al, Mol. Microbiol, 17:85-93 [1995]). The CRISPR loci typically differ from other SSRs by the structure of the repeats, which have been termed short regularly spaced repeats (SRSRs) (Janssen et al, OMICS J. Meg. Biol, 6:23-33 [2002]; and Mojica et al, Mol Microbiol, 36:244-246 [2000]). In general, the repeats are short elements that occur in clusters that are regularly spaced by unique intervening sequences with a substantially constant length (Mojica et al, [2000], supra). Although the repeat sequences are highly conserved between strains, the number of interspersed repeats and the sequences of the spacer regions typically differ from strain to strain (van Embden et al, J. Bacteriol, 182:2393- 2401 [2000]). CRISPR loci have been identified in more than 40 prokaryotes (See e.g., Jansen et al, Mol Microbiol, 43: 1 565-1575 [2002]; and Mojica et al, [2005]) including, but not limited to Aeropyrum, Pyrobacuiurn, Sulfolobus, Archaeogiobus, Halocarcula, Methanobacterium, Methanococcus, Methanosarcina, Methanopyrus, Pyrococcus, Picrophiius, Thermoplasma, Corynebacterium, Mycobacterium, Streptomyces, Aquifex, Porphyromonas, Chlorobmm, Thermus, Bacillus, Listeria, Staphylococcus, Clostridium, Thermoanaerobacter, Mycoplasma, Fusobacterium, Azarcus, Chromobacterium, Neisseria, Nitrosomonas, Desuifovibrio, Geobacter, Myxococeus, Campylobacter, Wolinella, Acinetobacter, Erwinia, Escherichia, Legionella, Methyiococcus, Pasteurella, Photobaeterium, Salmonella, Xanthomonas, Yersinia, Treponema, and T ermotoga.
[00286] In general, "CRISPR system" refers collectively to transcripts and other elements involved in the expression of or directing the activity of CRISPR-associated ("Cas") genes, including sequences encoding a Cas gene, a tracr (trans -activating CRISPR) sequence (e.g. tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing a "direct repeat" and a tracrRNA-processed partial direct repeat in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or other sequences and transcripts from a CRISPR locus. In embodiments of the invention the terms guide sequence and guide RNA are used interchangeably. In some embodiments, one or more elements of a CRISPR system is derived from a type I, type IL or type III CRISPR system. In some embodiments, one or more elements of a CRISPR system is derived from a particular organism comprising an endogenous CRISPR system, such as Streptococcus pyogenes. In general, a CRISPR system is characterized by elements that promote the formation of a CRISPR complex at the site of a target sequence (also referred to as a protospacer in the context of an endogenous CRISPR system). In the context of formation of a CRISPR complex, "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, where hybridization between a. target sequence and a. guide sequence promotes the formation of a CRJSPR complex. A target sequence may comprise any polynucleotide, such as DNA or RNA polynucleotides. In some embodiments, a target sequence is located in the nucleus or cytoplasm of a cell .
[00287] In some embodiments, direct repeats may be identified in silico by searching for repetitive motifs that fulfill any or all of the following criteria:
1. found in a 2Kb window of genomic sequence flanking the type II CRJSPR locus;
2. span from 20 to 50 bp; and
3. interspaced by 20 to 50 bp.
[00288] In some embodiments, 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.
[00289] In some embodiments, candidate tracrRNA may be subsequently predicted by sequences that fulfill any or all of the following criteria:
1. sequence homology to direct repeats (motif search in Geneious with up to 18-bp mismatches);
2. presence of a predicted Rho-independent transcriptional terminator in direction of transcription; and
3. stable hairpin secondary structure between tracrRNA and direct repeat.
[00290] In some embodiments, 2 of these criteria may be used, for instance 1 and 2, 2 and 3, or 1 and 3. In some embodiments, all 3 criteria may be used.
[00291] In some embodiments, chimeric synthetic guide RNAs (sgRNAs) designs may incorporate at least 12 bp of duplex structure between the direct repeat and tracrRNA.
86
90.1 0Θ292] In preferred embodiments of the invention, the CRJSPR system is a type II CRISPR system and the Cas enzyme is Cas9, which catalyzes DNA cleavage. Enzymatic action by Cas9 derived from Streptococcus pyogenes or any closely related Cas9 generates double stranded breaks at target site sequences which hybridize to 20 nucleotides of the guide sequence and that have a protospacer- adjacent motif (PAM) sequence (examples include NGG/NRG or a PAM that can be determined as described herein) following the 20 nucleotides of the target sequence. CRISPR activity through Cas9 for site-specific DNA recognition and cleavage is defined by the guide sequence, the tracr sequence that hybridizes in pari, to the guide sequence and the PAM sequence. More aspects of the CRISPR system are described in Karginov and Hannon, The CRISPR system: small RNA- guided defence in bacteria and archaea, Mole Cell 2010, January 15; 37( 1): 7.
[00293] The type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Cas l, Cas2, and Csnl, as well as two non -coding RJS!A elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non -repetitive sequences (spacers, about 30bp each). In this system, targeted DNA double-strand break (DSB) is generated in four sequential steps (Fig. 2A). First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of pre-crRNA, which is then processed into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:traerRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer (Fig. 2A). Fig. 2B demonstrates the nuclear localization of the codon optimized Cas9. To promote precise transcriptional initiation, the RNA polymerase Ill- based U6 promoter was selected to drive the expression of tracrRNA (Fig. 2C). Similarly, a U6 promoter-based construct was developed to express a pre-crRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr- mate sequences"; Fig. 2C). The initial spacer was designed to target a 33-base-pair (bp) target site (30-bp protospacer plus a 3 -bp CRISPR motif (PAM) sequence satisfying the NGG recognition motif of Cas9) in the human EMX1 locus (Fig. 2C), a key gene in the development of the cerebral cortex.
[00294] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and
87
90.1 complexed with one or more Cas proteins) results in cleavage of one or both strands in or near (e.g. within 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50, or more base pairs from) the target sequence. Without wishing to be bound by theoiy, the tracr sequence, which may comprise or consist of all or a portion of a wild-type tracr sequence (e.g. about or more than about 20, 26, 32, 45, 48, 54, 63, 67, 85, or more nucleotides of a wild-type tracr sequence), may also form part of a CRISPR complex, such as by hybridization along at least a portion of the tracr sequence to all or a portion of a tracr mate sequence that is operably linked to the guide sequence. In some embodiments, one or more vectors driving expression of one or more elements of a CRISPR system are introduced into a host cell such that expression of the elements of the CRISPR system direct formation of a CRISPR complex at one or more target sites. For example, a Cas enzyme, a guide sequence linked to a tracr-mate sequence, and a tracr sequence could each be operably linked to separate regulatory elements on separate vectors. Alternatively, two or more of the elements expressed from the same or different regulatory elements, may be combined in a single vector, with one or more additional vectors providing any components of the CRISPR system not included in the first vector. CRISPR system elements that are combined in a single vector may be arranged in any suitable orientation, such as one element located 5' with respect to ("upstream" of) or 3' with respect to ("downstream" of) a second element. The coding sequence of one element may be located on the same or opposite strand of the coding sequence of a second element, and oriented in the same or opposite direction. In some embodiments, a single promoter drives expression of a transcript encoding a CRISPR enzyme and one or more of the guide sequence, tracr mate sequence (optionally operably linked to the guide sequence), and a tracr sequence embedded within one or more intron sequences (e.g. each in a different intron, two or more in at least one intron, or ail in a single intron). In some embodiments, the CRISPR enzyme, guide sequence, tracr mate sequence, and tracr sequence are operably linked to and expressed from the same promoter.
[00295] In some embodiments, a vector comprises one or more insertion sites, such as a restriction endomiclease recognition sequence (also referred to as a "cloning site"). In some embodiments, one or more insertion sites (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more insertion sites) are located upstream and/or downstream of one or more sequence elements of one or more vectors. In some embodiments, a vector comprises an insertion site upstream of a tracr mate sequence, and optionally downstream of a regulatory element operably linked to the tracr mate sequence, such that, following
88
90.1 Insertion of a guide sequence into the insertion site and upon expression the guide sequence directs sequence-specific binding of a CRISPR complex to a target sequence in a eukaryotie cell. In some embodiments, a. vector comprises two or more insertion sites, each insertion site being located between two tracr mate sequences so as to allow insertion of a guide sequence at each site. In such an arrangement, the two or more guide sequences may comprise two or more copies of a single guide sequence, two or more different guide sequences, or combinations of these. When multiple different guide sequences are used, a single expression construct may be used to target CRISPR activity to multiple different, corresponding target sequences within a cell. For example, a single vector may comprise about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, or more guide sequences. In some embodiments, about or more than about I, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more such guide-sequence-containing vectors may be provided, and optionally delivered to a cell [00296] In some embodiments, a vector comprises a. regulatory element operably linked to an enzyme-coding sequence encoding a. CRISPR enzyme, such as a. Cas protein. Non- limiting examples of Cas proteins include Casl , Cas IB, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csnl and Csxl2), Cas 10, Csyl , Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, CsO, Csf4, homologues thereof, or modified versions thereof. In some embodiments, the unmodified CRISPR enzyme has DNA cleavage activity, such as Cas9. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands at the location of a target sequence, such as within the target sequence and/or within the complement of the target sequence. In some embodiments, the CRISPR enzyme directs cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence. In some embodiments, a vector encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a. target polynucleotide containing a target sequence. For example, an aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. As a further example, two or more catalytic domains of Cas 9 (RuvC I, RuvC II, and RuvC III or the ΕΓΝΗ domain) may be mutated to produce a mutated Cas9 substantially lacking all UN cleavage activity. In some embodiments, a D10A mutation Is combined with one or more of H840A, N854A, or N863A mutations to produce a Cas9 enzyme substantially lacking all DNA cleavage activity. In some embodiments, a. CRISPR enzyme is considered to substantially lack ail DNA cleavage activity when the DNA cleavage activity of the mutated enzyme is less than about 25%, 10%, 5%, 1 %, 0.1 %, 0.01 %, or lower with respect to its non-mutated form.
[00297] An aspartate-to-alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 was engineered to convert the nuclease into a nickase (SpCas9n) (see e.g. Sapranauskas et al, 2011, Nucleic Acis Research, 39: 9275; Gasiunas et al, 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), such that nicked genomic DNA undergoes the high- fidelity homology-directed repair (HDR). Surveyor assay confirmed that SpCas9n does not generate indels at the EMX1 protospacer target. Co-expression of EMX.1 -targeting chimeric crRNA (having the tracrRNA component as well) with SpCas9 produced indels in the target site, whereas co-expression with SpCas9n did not (n=3). Moreover, sequencing of 327 amplicons did not detect any indels induced by SpCas9n. The same locus was selected to test CRISPR-mediated HR by co-transfecting HEK 293FT cells with the chimeric RNA targeting EMX1, hSpCas9 or hSpCas9n, as well as a HR template to introduce a pair of restriction sites (Hindlll and Nhel) near the protospacer.
[00298] Preferred orthologs are described herein, A Cas enzyme may be identified Cas9 as this can refer to the general class of enzymes t at share homology to the biggest nuclease with multiple nuclease domains from the type 11 CRISPR system. Most preferably, the Cas9 enzyme is from, or is derived from, spCas9 or saCas9. By derived, Applicants mean that the derived enzyme is largely based, in the sense of having a high degree of sequence homology with, a wildtype enzyme, but that it has been mutated (modified) in some way as described herein.
[00299] It will be appreciated that the terms Cas and CRISPR enzyme are generally used herein interchangeably, unless otherwise apparent. As mentioned above, many of the residue numberings used herein refer to the Cas9 enzyme from the type II CRISPR locus in Streptococcus pyogenes. However, it will be appreciated that this invention includes many more Cas9s from other species of microbes, such as SpCas9, SaCa9, StlCas9 and so forth,
[00300] An example of a codon optimized sequence, in this instance optimized for humans (i.e. being optimized for expression in humans) is provided herein, see the SaCas9 human codon optimized sequence. Whilst this is preferred, it will be appreciated that. other examples are possible and codon optimization for a host speeIes. oiher than human, or for codon optimization for specific organs such as the brain, is known.
[00301] In some embodiments, an enzyme coding sequence encoding a CRISPR enzyme is codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a mammal, including but not limited to human, mouse, rat, rabbit, dog, or non-human mammal or primate. In some embodiments, processes for modifying the germ line genetic identity of human beings and/or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes, may be excluded,
|00302] In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about I, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that axe more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RN (tJRNA) molecules. The predominance of selected tJRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the "Codon Usage Database" available at www.kazusa. orjp/codon/ (visited Jul. 9, 2002), and these tables can be adapted in a number of ways. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000"Nucl. Acids Res, 28:292 (2000), Computer algorithms for codon optimizing a particular sequence for expression in a particular host ceil are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available. In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a CRISPR enzyme correspond to the most frequently used codon for a particular amino acid.
[00303] In some embodiments, a vector encodes a CRISPR enzyme comprising one or more nuclear localization sequences (NLSs), such as about or more than about I, 2, 3, 4, 5,
91
90.1 6, 7, 8, 9, 10, or more NLSs. In some embodiments, the CRISPR enzyme comprises about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the ammo-terminus, about or more than about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more NLSs at or near the carboxy - terminus, or a combination of these (e.g. one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus). When more than one NLS is present, each may be selected independently of the others, such that a single NLS may be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies. In a preferred embodiment of the invention, the CRISPR enzyme comprises at most 6 NLSs. In some embodiments, an NLS is considered near the N- or C-terminus when the nearest amino acid of the NLS is within about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N- or C-terminus. Non- limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV (SEQ ID NO: ); the NLS from nucleoplasmin (e.g. the nucleoplasmin bipartite NLS with the sequence
KRPAATKKAGQAKKKK) (SEQ ID NO: ); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: ) or RQRRNELKRSP (SEQ ID NO: ); the hRNPAl M9 NLS having the sequence
NQSSNFGPMKGGNFGGRSSGPYGGGGQYFA PRNQGGY (SEQ ID NO: ); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELR AKKDEQILKRR.NV (SEQ ID
NO: ) of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ ID
NO: ) and PPK ARED (SEQ ID NO: ) of the myoma T protein; the sequence
POPKKKPL (SEQ ID NO: ) of human p53; the sequence SALIKKKKKMAP (SEQ ID
NO: ) of mouse c-abl IV; the sequences DRLRR (SEQ ID NO: ) and PKQKKRK
(SEQ ID NO: ) of the influenza virus NS1 ; the sequence RKLKK IKKL (SEQ ID NO: ) of the Hepatitis virus delta antigen; the sequence REKKKFLKRR (SEQ ID
NO: ) of the mouse Mxl protein; the sequence KRKGDEVDGVDEVAKKKSKK
(SEQ ID NO: ) of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK (SEQ ID NO: ) of the steroid hormone receptors (human) glucocorticoid.
[0Θ304] In general, the one or more NLSs are of sufficient strength to drive accumulation of the CRISPR enzyme in a. detectable amount in the nucleus of a eukaryotic cell. In general, strength of nuclear localization activity may derive from the number of NLSs in the CRISPR enzyme, the particular NLS(s) used, or a combination of these factors. Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the CRISPR enzyme, such that location within a cell may be visualized, such as in combination with, a means for detecting the location of the nucleus (e.g. a stain specific for the nucleus such as DAPI). Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay for the effect of CRISPR complex formation (e.g. assay for D A cleavage or mutation at the target sequence, or assay for altered gene expression activity affected by CRISPR complex formation and/or CRISPR. enzyme activity), as compared to a control no exposed to the CRISPR enzyme or complex, or exposed to a. CRISPR enzyme lacking the one or more NLSs.
[00305] In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific binding of a CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences, non-limiting example of which include the Smith- Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows- Wheeler Transform (e.g. the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign ( ovocraft Technologies; available at www.novocraft.com), ELAND (Iilumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net). In some embodiments, a guide sequence is about or more than about 5, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, a guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12, or fewer nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence may be assessed by any suitable assay. For example, the components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, may be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the CRISPR sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay as described herein. Similarly, cleavage of a target polynucleotide sequence may be
93
90.1 evaluated in a test tube by providing the target sequence, components of a CRISPR complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. Other assays are possible, and will occur to those skilled in the art.
[00306] A guide sequence may be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. Exemplary target sequences include those that are unique in the target genome. For example, for the S. pyogenes Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXGG (SEQ ID NO: ) where
NNNNNNNNNNNNXGG (N is A, G, T, or C; and X can be anything) (SEQ ID NO: ) has a single occurrence in the genome. A unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form MMMMMMMMMNNNNNNNNNNNXGG where NNNTNNNNNNNNXGG (N is A, G,
T, or C; and X can be anything) (SEQ ID NO: ) has a single occurrence in the genome.
For the S. thermophilus CRISPR1 Cas9, a unique target sequence in a genome may include a Cas9 target site of the form MMMMMMMMNNNNNNNNNNNNXXAGAAW
(SEQ ID NO: ) where NNNNNNNNNNNNXXAGAAW (N is A, G, T, or C; X can be anything; and W is A or T) (SEQ ID NO: ) has a single occurrence in the genome. A unique target sequence in a genome may include an S. thermophilus CRISPR I Cas9 target site of the form MMMMMMMMMNN NNN NNN XXAGAAW (SEQ ID NO: ) where NNWNWNWNW NXXAG A A W (N is A, G, T, or C; X can be anything; and W is
A or T) (SEQ ID NO: ) has a single occurrence in the genome. For the S, pyogenes
Cas9, a unique target sequence in a genome may include a Cas9 target site of the form
MMMMMMMMNNNNNNNNNNNNXGGXG (SEQ ID NO: ) where mm NN XGGXG (N is A, G, T, or C; and X can be anything) (SEQ ID NO: ) has a single occurrence in the genome. A unique target sequence in a genome may include an S. pyogenes Cas9 target site of the form
MMMMMMM^INmmm XGGXG (SEQ ID NO: ) where
NNNNNNNNNNNXGGXG (N is A, G, T, or C; and X can be anything) (SEQ ID NO: ) has a single occurrence in the genome. In each of these sequences "M" may be A, G, T, or C, and need not be considered in identifying a sequence as unique.
[00307] In some embodiments, a guide sequence is selected to reduce the degree secondary structure within the guide sequence. In some embodiments, about or less than
94
90.1 about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or fewer of the nucleotides of the guide sequence participate in self-complementary base pairing when optimally folded. Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133 - 148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A.R. Gruber et al , 2008, Cell 106(1): 23-24; and PA Can- and GM Church, 2009, Nature Biotechnology 27(12): 1 151-62).
|00308] In general, a tracr mate sequence includes any sequence that has sufficient complementarity with a tracr sequence to promote one or more of: (1) excision of a guide sequence flanked by tracr mate sequences in a cell containing the corresponding tracr sequence; and (2) formation of a CR1SPR complex at a target sequence, wherein the CRISPR complex comprises the tracr mate sequence hybridized to the tracr sequence. In general, degree of complementarity is with reference to the optimal alignment of the tracr mate sequence and tracr sequence, along the length of the shorter of the two sequences. Optimal alignment may be determined by any suitable alignment algorithm, and may further account for secondary stmctures, such as self-complementarity within either the tracr sequence or tracr mate sequence. In some embodiments, the degree of complementarity between the tracr sequence and tracr mate sequence along the length of the shorter of the two when optimally aligned is about or more than about 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97.5%, 99%, or higher. In some embodiments, the tracr sequence is about or more than about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, or more nucleotides in length. In some embodiments, the tracr sequence and tracr mate sequence are contained within a single transcript, such that hybridization between the two produces a transcript having a secondary structure, such as a hairpin. In an embodiment of the invention, the transcript or transcribed polynucleotide sequence has at least two or more hairpins. In preferred embodiments, the transcript has two, three, four or five hairpins. In a further embodiment of the invention, the transcript has at most five hairpins. In a hairpin structure the portion of the sequence 5' of the final "N" and upstream of the loop corresponds to the tracr mate sequence, and the portion of the sequence 3 ' of the loop corresponds to the tracr sequence Further non-limiting examples of single polynucleotides comprising a guide sequence, a tracr mate sequence,
95
90.1 and a tracr sequence are as follows (listed 5' to 3 '), where "N" represents a base of a guide sequence, the first block of lower case letters represent the tracr mate sequence, and the second block of lower case letters represent the tracr sequence, and the final poly-T sequence represents the transcription terminator: (1) a ggcttcatgccgaaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (SEQ ID NO: );
(2) NN NNNNNNN NNNNNNNNgittttgtactctca GAAA igcagaagctacaaagata aggcttcatgccg aaatcaacaccctgtcattttatggcagggtgttttcgttatttaaTTTTTT (SEQ ID NO: );
(3 ) NNNNNN^NNNNNNNNNNNNNgtttttgtactctcaGAA tgcagaagctacaaaga taaggcttcatgccg aaatcaacaccctgtcattttatggcagggtgtTTTTTT (SEQ ID NO: ); (4) NNMNNNNNNNNNNNNNNNNM gttttagagctaGAAA tagcaagttaaaataa ggctagtccgttatca actt gaaaaagtggcaccgagtcggtgcTTTTTT (SEQ ID NO: ); (5) NNNNNNNN
MNNNMNNNNNNgttttagagctaGAAATAG caagttaaaataaggctagtccgttat caac ttgaaaaagtg
TTTTTTT (SEQ ID NO: ); and (6) NNNNNNNNNN NNNNNNNNNgtttta gagctagAAATAGcaagttaaaataaggctagtccgttatcaTT TTTTTT (SEQ ID NO: ). In some embodiments, sequences (1) to (3) are used in combination with Cas9 from S. thermophilus CRISPRl. In some embodiments, sequences (4) to (6) are used in combination with Cas9 from S. pyogenes. In some embodiments, the tracr sequence is a separate transcript from a transcript comprising the tracr mate sequence.
[00309] In some embodiments, a recombination template is also provided. recombination template may be a component of another vector as described herein, contained in a separate vector, or provided as a separate polynucleotide. In some embodiments, a recombination template is designed to serve as a template in homologous recombination, such as within or near a target sequence nicked or cleaved by a CRISPR enzyme as a pari of a CRISPR complex. A template polynucleotide may be of any suitable length, such as about or more than about 10, 15, 20, 25, 50, 75, 100, 150, 200, 500, 1000, or more nucleotides in length. In some embodiments, the template polynucleotide is complementary to a portion of a polynucleotide comprising the target sequence. When optimally aligned, a template polynucleotide might overlap with one or more nucleotides of a target sequences (e.g. about or more than about 1, 5, 10, 15, 20, or more nucleotides). In some embodiments, when a template sequence and a polynucleotide comprising a target sequence are optimally aligned, the nearest nucleotide of the template polynucleotide is within about 1, 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 5000, 10000, or more nucleotides from the target sequence.
96
90.1 [0Θ310] In some embodiments, the CRISPR enzyme is part of a fusion protein comprising one or more heterologous protein domains (e.g. about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more domains in addition to the CRISPR enzyme). A CRISPR enzyme fusion protein may comprise any additional protein sequence, and optionally a linker sequence between any two domains. Examples of protein domains that may be fused to a CRISPR enzyme include, without limitation, epitope tags, reporter gene sequences, and protein domains having one or more of the following activities: meihylase activity, demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, RNA cleavage activity and nucleic acid binding activity. Non-limiting examples of epitope tags include histidine (His) tags, V5 tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. Examples of reporter genes include, but are not limited to, glutathione- S -transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT) beta-galactosidase, beta-giucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP), and autofiuorescent proteins including blue fluorescent protein (BFP). A CRISPR enzyme may be fused to a gene sequence encoding a protein or a fragment of a protein that bind D A molecules or bind other cellular molecules, including but not limited to maltose binding protein (MBP), S-tag, Lex A DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP 16 protein fusions. Additional domains that may form part of a fusion protein comprising a CRISPR enzyme are described in US201 10059502, incorporated herein by reference. In some embodiments, a tagged CRISPR enzyme is used to identify the location of a target sequence.
[00311] In some embodiments, a CRISPR enzyme may form a component of an inducible system. The inducible nature of the system would allow for spatioiemporal control of gene editing or gene expression using a form of energy. The form of energy may include but is not limited to electromagnetic radiation, sound energy, chemical energy and thermal energy. Examples of inducible system include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or light inducible systems (Phytoehrome, LOV domains, or cryptochrome).In one embodiment, the CRISPR enzyme may be a part of a Light Inducible Transcriptional Effector (LITE) to direct changes in transcriptional activity in a sequence-specific manner. The components of a light may include a CRISPR enzyme, a light-responsive cytochrome heterodimer (e.g. from Arabidopsis thaliana), and a transcriptional activation/repression domain. Further examples of inducible DNA binding proteins and methods for their use are provided in US 61/736465 and LIS 61/721,283, which is hereby incorporated by reference in its entirety.
[00312] In some aspects, the invention provides methods comprising delivering one or more polynucleotides, such as or one or more vectors as described herein, one or more transcripts thereof, and/or one or proteins transcribed therefrom, to a host cell. In some aspects, the invention further provides cells produced by such methods, and animals comprising or produced from such cells. In some embodiments, a CRISPR enzyme in combination with (and optionally complexed with) a guide sequence is delivered to a cell. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding components of a CRISPR system to cells in culture, or in a host organism. Non-viral vector delivery systems include DNA plasmids, RNA (e.g. a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell For a review of gene therapy procedures, see Anderson, Science 256:808-813 (1992); Nabel & Feigner, TIBTECH 1 1 :21 1 -217 (1993); Mitani & Caskey, TIBTECH 11 : 162-166 (1993); Dillon, TIBTECH 11: 167-175 (1993); Miller, Nature 357:455-460 ( 1992); Van Brunt, Biotechnology 6(10): 1149-1 154 ( 1988); Vigne, Restorative Neurology and Neuroscience 8:35-36 (1995); Kremer & Perricaudet, British Medical Bulletin 51 (l ):3 I-44 (1995); Haddada et ai, in Current Topics in Microbiology and Immunology Doerfler and Bohm (eds) (1995); and Yu et ai, Gene Therapy 1 : 13-26 (1994).
|00313] Methods of non-viral delivery of nucleic acids include lipofection, microinjection, hiolistics, virosomes, liposomes, immunoliposom.es, polycation or lipidmucieic acid conjugates, naked DNA, artificial virions, and agent-enhanced uptake of DNA. Lipofection is described in e.g., U.S. Pat. Nos. 5,049,386, 4,946,787; and 4,897,355) and lipofection reagents are sold commercially (e.g., Transfectam™ and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor- recognition lipofection of polynucleotides include those of Feigner, WO 91/17424; WO 91/16024. Delivery can be to cells (e.g. in vitro or ex vivo administration) or target tissues (e.g. in vivo administration).
98
90.1 [0Θ314] The preparation of lipid:rmcleic acid complexes, including targeted liposomes such as immunolipid complexes, is well known to one of skill in the art (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther. 2:291-297 (1995); Behr et al., Bioconjugate Chera. 5:382-389 (1994); Remy et al., Bioconjugate Chera. 5:647-654 (1994); Gao et al, Gene Therapy 2:710-722 (1995); Ahmad et al, Cancer Res. 52:4817- 4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787).
[0Θ315] The use of RNA or DNA viral based systems for the delivery of nucleic acids take advantage of highly evolved processes for targeting a virus to specific cells in the body and trafficking the viral payload to the nucleus. Viral vectors can be administered directly to patients (in vivo) or they can be used to treat cells in vitro, and the modified cells may optionally be administered to patients (ex vivo). Conventional viral based systems could include retroviral, lentivirus, adenoviral, adeno-associated and herpes simplex virus vectors for gene transfer. Integration in the host genome is possible with the retrovirus, lentivirus, and adeno-associated virus gene transfer methods, often resulting in long term expression of the inserted transgene. Additionally, high transduction efficiencies have been observed in many different cell types and target tissues,
|00316] The tropism of a retrovirus can be altered by incorporating foreign envelope proteins, expanding the potential target population of target cells. Lenti viral vectors are retroviral vectors that are able to transduce or infect non-dividing cells and typically produce high viral titers. Selection of a retroviral gene transfer system would therefore depend on the target tissue. Retroviral vectors are comprised of cis -acting long terminal repeats with packaging capacity for up to 6-10 kb of foreign sequence. The minimum cis- acting LTRs are sufficient for replication and packaging of the vectors, which are then used to integrate the therapeutic gene into the target cell to provide permanent transgene expression. Widely used retroviral vectors include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immune deficiency virus (S1V), human immuno deficiency virus (HIV), and combinations thereof (see, e.g., Buchscher et al, I Virol 66:2731-2739 (1992); Johann et al, J. Virol 66: 1635-1640 (1992); Sommnerfelt et al, Virol 176:58-59 (1990); Wilson et al, I Virol. 63 :2374-2378 (1989); Miller et al, J. Virol. 65:2220-2224 (1991); PCT/US94/05700).
|00317] In applications where transient expression is preferred, adenoviral based systems may be used. Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer
99
90.1 and levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system.
[00318] Adeno-associated vims ("AAV") vectors may also be used to transduce cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and for in vivo and ex vivo gene therapy procedures (see, e.g., West et al, Virology 160:38-47 (1987): U.S. Pat. No. 4,797,368: WO 93/24641; otin, Human Gene Therapy 5:793-801 ( 1994); Muzyczka, J. Clin. Invest. 94: 1351 ( 1994). Construction of recombinant AAV vectors are described in a number of publications, including U.S. Pat, No. 5, 173,414; Tratschm et al, Mo3. Cell. Biol. 5:3251 -3260 (1985); Tratschin, et al., Mol. Cell. Biol. 4:2072-2081 (1984); Hermonat & Muzyczka, PNAS 81 :6466-6470 (1984); and Samuiski et al, J. Virol 63:03822-3828 (1989).
[00319] Packaging cells are typically used to form virus particles that are capable of infecting a host cell. Such ceils include 293 cells, which package adenovirus, and ψ2 cells or PA317 ceils, which package retrovirus. Viral vectors used in gene therapy are usually generated by producer a cell line that packages a nucleic acid vector into a viral particle. The vectors typically contain the minimal viral sequences required for packaging and subsequent integration into a host, other viral sequences being replaced by an expression cassette for the polyniicleotideis ) to be expressed. The missing viral functions are typically supplied in trans by the packaging ceil line. For example, AAV vectors used in gene therapy typically only possess TTR sequences from the AAV genome which are required for packaging and integration into the host genome. Viral DMA is packaged in a cell line, which contains a helper plasmid encoding the other AAV genes, namely rep and cap, but lacking ITR sequences. The cell line may also infected with adenovirus as a helper. The helper virus promotes replication of the AAV vector and expression of AAV genes from the helper plasmid. The helper plasmid is not packaged in significant amounts due to a lack of ITR sequences. Contamination with adenovirus can be reduced by, e.g., heat treatment to which adenovirus is more sensitive than AAV.
[00320] Accordingly, AAV is considered an ideal candidate for use as a transducing vector. Such AAV transducing vectors can comprise sufficient cis-acting functions to replicate in the presence of adenovirus or herpesvirus or poxvirus (e.g., vaccinia vims) helper functions provided in trans. Recombinant AAV (rAAV) can be used to cany exogenous genes into cells of a variety of lineages. In these vectors, the AAV cap and/or rep genes are deleted from the viral genome and replaced with a DNA segment of choice. Current AA V vectors may accommodate up to 4300 bases of inserted DNA.
100
90.1 0Θ32Ϊ ] There are a number of ways to produce rAAV, and the invention provides rAA V and methods for preparing rAAV. For example, plasmid(s) containing or consisting essentially of the desired viral construct are transfected into AAV-infected ceils. In addition, a second or additional helper plasmid is cotransfected into these cells to provide the AAV rep and'Or cap genes which are obligator}' for replication and packaging of the recombinant viral construct Under these conditions, the rep and/or cap proteins of AAV act in trans to stimulate replication and packaging of the rAAV construct. Two to Three days after transfection, rAAV is harvested. Traditionally rAAV is harvested from the cells along with adenovirus. The contaminating adenovirus is then inactivated by heat treatment. In the instant invention, rAAV is advantageously harvested not from the cells themselves, but from cell supernatant. Accordingly, in an initial aspect the invention provides for preparing rAAV, and in addition to the foregoing, rAAV can be prepared by a method that comprises or consists essentially of: infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, and helper vims (e.g., adenovirus, herpesvirus, poxvirus such as vaccinia virus) wherein the rAAV lacks functioning cap and/or rep (and the helper vims (e.g., adenovirus, herpesvirus, poxvirus such as vaccinia vims) provides the cap and/or rev function that the rAAV lacks); or infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, wherein the recombinant lacks functioning cap and'Or rep, and transfecting said cells with a plasmid supplying cap and/or rep function that the rAAV lacks; or infecting susceptible cells with a rAAV containing exogenous DNA including DNA for expression, wherein the recombinant lacks functioning cap and'Or rep, wherein said cells supply cap and/or rep function that the recombinant lacks; or transfecting the susceptible cells with an AAV lacking functioning cap and'Or rep and piasmids for inserting exogenous DNA into the recombinant so that the exogenous DNA is expressed by the recombinant and for supplying rep and/or cap functions whereby transfection results in an rAAV containing the exogenous DNA including DNA for expression that lacks functioning cap and/or rep.
[00322] The rAAV can be from an AAV as herein described, and advantageously can be an rAAV I , r.AAV2, AAV5 or rAAV having hybrid or capsid which may comprise AAV 1, AAV2, AAV5 or any combination thereof. One can select the AAV of the rAAV with regard to the cells to be targeted by the rAAV; e.g., one can select AAV serotypes 1 , 2, 5 or a hybrid or capsid A AVI , AA\/T2, AAV5 or any combination thereof for targeting brain or neuronal cells; and one can select AAV4 for targeting cardiac tissue.
101
90.1 [0Θ323] In addition to 293 cells, other cells that can be used in the practice of the invention and the relative infectivity of certain AAV serotypes in vitro as to these cells (see Grimm, D. et al, J, Virol. 82: 5887-591 1 (2008)) are as follows:
Figure imgf000103_0001
[0Θ324] The invention provides rAAV that contains or consists essentially of an exogenous nucleic acid molecule encoding a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) system, e.g., a plurality of cassettes comprising or consisting a first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding a CRISPR-associated (Cas) protein (putative nuclease or helicase proteins), e.g., Cas9 and a terminator, and a two, or more, advantageously up to the packaging size limit of the vector, e.g., in total (including the first cassette) five, cassettes comprising or consisting essentially of a promoter, nucleic acid molecule encoding guide RNA (gRNA) and a terminator (e.g., each cassette schematically represented as Promoter-gRNAl- terminator, Promoter-gRNA2-terminator ... Promoter-gRNA(N)-terminator (where N is a number that can be inserted that is at an upper limit of the packaging size limit of the vector), or two or more individual rAAVs, each containing one or more than one cassette of a CRISPR system, e.g., a first rAAV containing the first cassette comprising or consisting essentially of a promoter, a nucleic acid molecule encoding Cas, e.g., Cas9 and a terminator, and a second rAAV containing a plurality, four, cassettes comprising or
102
90.1 consisting essentially of a promoter, nucleic acid molecule encoding guide RNA (gRNA) and a terminator (e.g., each cassette schematically represented as Promoter-gRN A 1 - terminator, Promoter-gRNA2-terminator ... Promo ter-gRNA(N}-temiina or (where N is a number that can be inserted that is at an upper limit of the packaging size limit of the vector). As rAAV is a DNA virus, the nucleic acid molecules in the herein discussion concerning AAV or rAAV are advantageously DNA, The promoter is in some embodiments advantageously human Synapsin I promoter (hSyn).
[0Θ325] Lentiviruses are complex retroviruses that have the ability to infect and express their genes in both mitotic and post-mitotic cells. The most commonly known lentivirus is the human immunodeficiency virus (HIV), which uses the envelope glycoproteins of other viruses to target a broad range of cell types.
[00326] Lentiviruses may be prepared as follows. After cloning pCasESlO (which contains a lentivirai transfer plasmid backbone), HEK293FT at low passage (p=5) were seeded in a T-75 flask to 50% confluence the day before transfection in DMEM with 10% fetal bovine serum and without antibiotics. After 20 hours, media was changed to OptiMEM (serum-free) media and transfection was done 4 hours later. Cells were transfected with 10 ^ig of lentivirai transfer plasmid (pCasESlO) and the following packaging plasmids: 5 μg of pMD2.G (VSV-g pseudoiype), and 7.5ug of psPAX2 (gag/pol/rev/tat). Transfection was done in 4mL OptiMEM with a cationic lipid delivery agent (50uL Lipofectamine 2000 and lOOul Plus reagent). After 6 hours, the media was changed to antibiotic-tree DMEM with 10% fetal bovine serum. Preparation of lentivirai vectors of the invention is further described in Example 36.
[0Θ327] Lentivirus may be purified as follows. Viral supernatants were harvested after 48 hours. Supernatants were first cleared of debris and filtered through a. 0.45um low- protein binding (PVDF) filter. They were then spun in a uitracentrifuge for 2 hours at 24,000 rpm. Viral pellets were resuspended in 50ui of DMEM overnight at 4C. They were then aliquotted and immediately frozen at -80C.
[00328] In another embodiment, minimal non-primate lentivirai vectors based on the equine infectious anemia virus (EIAV) are also contemplated, especially for ocular gene therapy (see, e.g., Balagaan, J Gene Med 2006; 8: 275 - 285, Published online 21 November 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: l().1002/jgm.845). In another embodiment, RetinoStai®, an equine infectious anemia virus-based lentivirai gene therapy vector that expresses angiostatic proteins endostain and angiostatin that is delivered via a subretinal injection for the treatment of the web form of
103
90.1 age-related macular degeneration is also contemplated (see, e.g., Bi ley et al., HUMAN GENE THERAPY 23:980-991 (September 2012)) may be modified for the CRISPR-Cas system of the present invention.
[00329] In another embodiment, self-inactivating lentiviral vectors with an siRNA targeting a common exon shared by HTV tat/rev, a nucleolar-locaiizing TAR decoy, and an anti--CCR5-specific hammerhead ribozyme (see, e.g., DiGiusto et ai. (2010) Sci Transi Med 2:36ra43) may be adapted to the CRISPR-Cas system of the present invention. A minimum of 2,5 x 106 CD34+ cells per kilogram patient weight may be collected and prestimulated for 16 to 20 hours in X-VTVO 1 medium (Lonza) containing 2mM.L- giutamine, stem cell factor (100 ng ml), Fit -3 ligand (Flt-3L) (100 ng ml), and thrombopoietin ( 10 ng/ml) (CellGenix) at a density of 2 x 106 cells/ml. Prestimulated cells may be transduced with lentiviral at a multiplicity of infection of 5 for 16 to 24 hours in 75-cm2 tissue culture flasks coated with fibronectin (25 mg/cm2) (RetroNectin,Takara Bio Inc.).
[0Θ330] Lentiviral vectors have been disclosed as in the treatment for Parkinson's Disease, see, e.g., US Patent Publication No. 20120295960 and US Patent Nos. 7303910 and 7351585. Lentiviral vectors have also been disclosed for the treatment of ocular diseases, see e.g., US Patent Publication Nos. 20060281 180, 20090007284, US201 10! 17189; US20090017543; US2007005496L US20100317109. Lentiviral vectors have also been disclosed for delivery to the train, see, e.g., US Patent Publication Nos. US20110293571; US20110293571, US20040013648, US20070025970, US200901 11 106 and US Patent No. US7259015.
[0Θ331] Additional methods for the delivery of nucleic acids to cells are known to those skilled in the art. See, for example, US20030087817, incorporated herein by reference, |00332] In some embodiments, a host cell is transiently or non-trans iently transfected with one or more vectors described herein. In some embodiments, a cell is transfected as it naturally occurs in an organism. In some embodiments, a cell that is transfected is taken from an organism. In some embodiments, the cell is derived from cells taken from a an organism, such as a cell line. A wide variety of ceil lines for tissue culture are known in the art. Examples of cell lines include, but are not limited to, C8161, CCRF-CEM, MOLT, mIMCD-3, NHDF, 1 lei . a -S3. Huhl, Huh4, Huh7, HUVEC, HASMC, HEKn, HEKa, MiaPaCell, Panel , PC-3, TF1 , CTLL-2, C1R, Rat6, CVT, RPTE, A10, T24, J82, A375, ARH-77, Calu l, SW480, SW620, SKOV3, SK-UT, CaCo2, P388D1 , SEM-K2, WEHI-231 , HB56, TIB55, Jurkat, J45.01 , LRMB, Bcl-1, BC-3, IC2 I, DLD2, Raw264.7,
104
90.1 NRK, NRK-52E, MRC5, MEF, Hep G2, HeLa B, HeLa T4, COS, COS- ! , COS-6, COS- M6A, BS-C-1 monkey kidney epithelial, BALB/ 3T3 mouse embryo fibroblast, 3T3 Swiss, 3T3-L1, 132-d5 human fetal fibroblasts; 10, 1 mouse fibroblasts, 293 -T, 3T3, 721, 9L, A2780, A2780ADR, A2780cis, A 172, A20, A253, A431 , A-549, ALC, B16, B35, BCP-1 cells, BEAS-2B, bEnd.3, BHK-21, BR 293, BxPC3, C3H-10T1/2, C6/36, Cal-27, CHO, CHO -7, CHO-IR, CHO- 1, CHO-K2, CHO-T, CHO Dhfr -/-, COR-L23, COR- L23/CPR, COR-L23/5010, COR-L23/R23, COS-7, COV-434, CML ΊΊ , CMT, CT26, D17, DH82, DU145, DuCaP, EL4, EM2, EM3, EMT6/AR1 , EMT6/AR10.0, FM3, H1299, H69, HB54, HB55, HCA2, HEK-293, HeLa, Hepalclc7, HL-60, HMEC, HT-29, Jurkat, JY cells, K562 cells, Ku812, KCL22, KG1, KYOl, LNCap, Ma-Mel 1-48, MC-38, MCF-7, MCF-IOA, MDA-MB-231, MDA-MB-468, MDA-MB-435, MDCK II, MDCK II, MOR/0.2R, MONO-MAC 6, MTD-1 A, MyEnd, NCI-H69/CPR, NCI-H69/LX10, NCI- H69/LX20, NCI-H69/LX4, NIH-3T3, NALM-1, NW-145, OPCN / OPCT cell lines, Peer, PNT-1A / PNT 2, RenCa, RIN-5F, RMA/RMAS, Saos-2 cells, Sf-9, SkBr3, T2, T--47D, T84, THP1 cell line, U373, U87, U937, VCaP, Vero cells, WM39, WT-49, X63, YAC-i , YAR, and transgenic varieties thereof. Cell lines are available from a variety of sources known to those with skill in the art (see, e.g., the American Type Culture Collection (ATCC) (Manassus, Va.)). In some embodiments, a cell transfected with one or more vectors described herein is used to establish a new cell line comprising one or more vector-derived sequences. In some embodiments, a cell transiently transfected with the components of a CRISPR system as described herein (such as by transient transiection of one or more vectors, or transiection with RNA), and modified through the activity of a CRISPR complex, is used to establish a new cell line comprising cells containing the modification but lacking any other exogenous sequence. In some embodiments, cells transiently or non-transiently transfected with one or more vectors described herein, or cell lines derived from such cells are used in assessing one or more test compounds,
[00333] In some embodiments, one or more vectors described herein are used to produce a non-human transgenic animal. In some embodiments, the transgenic animal is a. mammal, such as a mouse, rat, or rabbit. Methods for producing transgenic animals are known in the art, and generally begin with a method of cell transiection, such as described herein.
|00334] In one aspect, the invention provides for methods of modifying a target polynucleotide in a eukaryotic cell, which may be in vivo, ex vivo or in vitro. In some embodiments, the method comprises sampling a cell or population of cells from a human
105
90.1 or non-human animal, and modifying the cell or cells. Cu3 luring may occur at any stage ex vivo. The cell or cells may even be re-introduced into the non-human animal. For reintroduced cells it is particularly preferred that the cells are stem cells.
[00335] In some embodiments, the method comprises allowing a CRISPR complex to bind to the target polynucleotide to effect cleavage of said target polynucleotide thereby modifying the target polynucleotide, wherein the CRISPR complex comprises a CRISPR enzyme compiexed with a guide sequence hybridized to a target sequence within said target polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence.
[00336] In one aspect, the invention provides a. method of modifying expression of a polynucleotide in a eukaryotic cell. In some embodiments, the method comprises allowing a CRISPR complex to bind to the polynucleotide such that said binding results in increased or decreased expression of said polynucleotide; wherein the CRISPR complex comprises a CRISPR enzyme compiexed with a guide sequence hybridized to a target sequence within said polynucleotide, wherein said guide sequence is linked to a tracr mate sequence which in turn hybridizes to a tracr sequence. Similar considerations and conditions apply as above for methods of modifying a target poiynucieotide. In fact, these sampling, culturing and re-introduction options apply across the aspects of the present invention.
[00337] Indeed, in any aspect of the invention, the CRISPR complex may comprise a CRISPR enzyme compiexed with a guide sequence hybridized lo a target sequence, wherein said guide sequence may be linked to a tracr mate sequence which in turn may hybridize to a tracr sequence. Similar considerations and conditions apply as above for methods of modifying a target polynucleotide.
[00338] In one aspect, the invention provides kits containing any one or more of the elements disclosed in the above methods and compositions. Elements may be provided individually or in combinations, and may be provided in any suitable container, such as a. vial, a bottle, or a tube. In some embodiments, the kit includes instructions in one or more languages, for example in more than one language.
[0Θ339] In some embodiments, a kit comprises one or more reagents for use in a process utilizing one or more of the elements described herein. Reagents may be provided in any suitable container. For example, a kit may provide one or more reaction or storage buffers. Reagents may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g. in
106
90.1 concentrate or lyophilized form). A buffer can be any buffer, , including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In some embodiments, the buffer has a pH from about 7 to about 10. In some embodiments, the kit comprises one or more oligonucleotides corresponding to a guide sequence for insertion into a vector so as to operably link the guide sequence and a regulatory element. In some embodiments, the kit comprises a homologous recombination template polyn uc3 eoti de.
[0Θ340] In one aspect, the invention provides methods for using one or more elements of a. CRISPR system. The CRISPR complex of the invention provides an effective means for modifying a target polynucleotide. The CRISPR complex of the invention has a wide variety of utility including modifying (e.g., deleting, inserting, translocating, inactivating, activating) a target polynucleotide in a multiplicity of cell types. As such the CRISPR complex of the invention has a broad spectrum of applications in, e.g., gene therapy, drug screening, disease diagnosis, and prognosis. An exemplar)' CRISPR complex comprises a CRISPR enzyme complexed with a guide sequence hybridized to a target sequence within the target polynucleotide. The guide sequence is linked to a tracr mate sequence, which in turn hybridizes to a tracr sequence.
[00341] In one embodiment, this invention provides a method of cleaving a target polynucleotide. The method comprises modifying a target polynucleotide using a CRISPR complex that binds to the target polynucleotide and effect cleavage of said target polynucleotide. Typically, the CRISPR complex of the invention, when introduced into a cell, creates a break (e.g., a single or a double strand break) in the genome sequence. For example, the method can be used to cleave a disease gene in a ceil.
|00342] The break created by the CRISPR complex can be repaired by a repair processes such as the error prone non-homologous end joining (NHE.T) pathway or the high fidelity homology-directed repair (HDR) (Fig. 29). During these repair process, an exogenous polynucleotide template can be introduced into the genome sequence. In some methods, the HDR process is used modify genome sequence. For example, an exogenous polynucleotide template comprising a sequence to be integrated flanked by an upstream sequence and a downstream sequence is introduced into a cell. The upstream and downstream sequences share sequence similarity with either side of the site of integration in the chromosome.
107
90.1 [00343] Where desired, a donor polynucleotide can be DNA, e.g., a DNA plasmid, a bacterial artificial chromosome (BAG), a yeast artificial chromosome (YAC), a viral vector, a linear piece of DNA, a. PGR fragment, a naked nucleic acid, or a nucleic acid complexed with a delivery vehicle such as a liposome or poioxamer.
[00344] The exogenous polynucleotide template comprises a sequence to be integrated (e.g., a. mutated gene). The sequence for integration may be a. sequence endogenous or exogenous to the cell. Examples of a sequence to be integrated include polynucleotides encoding a protein or a non-coding RNA (e.g., a microRNA). Thus, the sequence for integration may be operably linked to an appropriate control sequence or sequences. Alternatively, the sequence to be integrated may provide a. regulatory function.
[00345] The upstream and downstream sequences in the exogenous polynucleotide template are selected to promote recombination between the chromosomal sequence of interest and the donor polynucleotide. The upstream sequence is a nucleic acid sequence that shares sequence similarity with the genome sequence upstream of the targeted site for integration. Similarly, the downstream sequence is a nucleic acid sequence that shares sequence similarity with the chromosomal sequence downstream of the targeted site of integration. The upstream and downstream sequences in the exogenous polynucleotide template can have 75%, 80%, 85%, 90%, 95%, or 100% sequence identity with the targeted genome sequence. Preferably, the upstream and downstream sequences in the exogenous polynucleotide template have about 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the targeted genome sequence. In some methods, the upstream and downstream sequences in the exogenous polynucleotide template have about 99% or 100% sequence identity with the targeted genome sequence.
[00346] An upstream or downstream sequence may comprise from about 20 bp to about 2500 bp, for example, about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 bp. In some methods, the exemplary upstream or downstream sequence have about 200 bp to about 2000 bp, about 600 bp to about 1000 bp, or more particularly about 700 bp to about 1000 bp.
[0Θ347] In some methods, the exogenous polynucleotide template may further comprise a marker. Such a marker may make it easy to screen for targeted integrations. Examples of suitable markers include restriction sites, fluorescent proteins, or selectable markers. The exogenous polynucleotide template of the invention can be constructed using
108
90.1 recombinant techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996).
[00348] In an exemplary method for modifying a target polynucleotide by integrating an exogenous polynucleotide template, a double stranded break is introduced into the genome sequence by the CRISPR complex, the break is repaired via homologous recombination an exogenous polynucleotide template such that the template is integrated into the genome. The presence of a double-stranded break facilitates integration of the template,
[00349] In other embodiments, this invention provides a method of modifying expression of a polynucleotide in a eukaryotic cell The method comprises increasing or decreasing expression of a target polynucleotide by using a CRISPR complex that binds to the polynucleotide.
[00350] In some methods, a target polynucleotide can be inactivated to effect the modification of the expression in a cell. For example, upon the binding of a CRISPR complex to a target sequence in a cell, the target polynucleotide is inactivated such that the sequence is not transcribed, the coded protein is not produced, or the sequence does not function as the wild-type sequence does. For example, a protein or microRNA coding sequence may be inactivated such that the protein or microRNA or pre-microRNA transcript is not produced.
[00351] In some methods, a control sequence can be inactivated such that it no longer functions as a control sequence. As used herein, "control sequence" refers to any nucleic acid sequence that effects the transcription, translation, or accessibility of a nucleic acid sequence. Examples of a control sequence include, a promoter, a transcription terminator, and an enhancer are control sequences.
[00352] The inactivated target sequence may include a deletion mutation (i.e., deletion of one or more nucleotides), an insertion mutation (i.e., insertion of one or more nucleotides), or a nonsense mutation (i.e., substitution of a single nucleotide for another nucleotide such that a stop codon is introduced). In some methods, the inactivation of a. target sequence results in "knock-out" of the target sequence.
[00353] A method of the invention may be used to create a plant, an animal or cell that may be used as a disease model. As used herein, "disease" refers to a disease, disorder, or indication in a subject. For example, a method of the invention may be used to create an animal or cell that comprises a modification in one or more nucleic acid sequences associated with a disease, or a plant, animal or cell in which the expression of one or more
109
90.1 nucleic acid sequences associated with a disease are altered. Such a nucleic acid sequence may encode a disease associated protein sequence or may be a disease associated control sequence. Accordingly, it is understood that in embodiments of the invention, a plant, subject, patient, organism or cell can be a non-human subject, patient, organism or cell. Thus, the invention provides a plant, animal or cell, produced by the present methods, or a progeny thereof. The progeny may be a clone of the produced plant or animal, or may result from sexual reproduction by crossing with other individuals of the same species to introgress further desirable traits into their offspring. The cell may be in vivo or ex vivo in the cases of multicellular organisms, particularly animals or plants. In the instance where the cell is in cultured, a ceil line may be established if appropriate culturing conditions are met and preferably if the cell is suitably adapted for this purpose (for instance a stem cell). Bacterial cell lines produced by the invention are also envisaged. Hence, cell lines are also envisaged.
[00354] In some methods, the disease model can be used to study the effects of mutations on the animal or cell and development and/or progression of the disease using measures commonly used in the study of the disease. Alternatively, such a disease model is useful for studying the effect of a pharmaceutically active compound on the disease.
[00355] In some methods, the disease model can be used to assess the efficacy of a potential gene therapy strategy. That is, a disease-associated gene or polynucleotide can be modified such that the disease development and/or progression is inhibited or reduced. In particular, the method comprises modifying a disease-associated gene or polynucleotide such that an altered protein is produced and, as a result, the animal or cell has an altered response. Accordingly, in some methods, a genetically modified animal may be compared with an animal predisposed to development of the disease such that the effect of the gene therapy event may be assessed.
[00356] In another embodiment, t is invention provides a method of developing a biologically active agent that modulates a cell signaling event associated with a disease gene. The method comprises contacting a. test compound with a cell comprising one or more vectors that drive expression of one or more of a CRISPR enzyme, a guide sequence linked to a tracr mate sequence, and a tracr sequence; and detecting a change in a readout that is indicative of a reduction or an augmentation of a ceil signaling event associated with, e.g., a mutation in a disease gene contained in the cell.
[00357] A cell model or animal model can be constructed in combination with the method of the invention for screening a cellular function change. Such a model may be
110
90.1 used to study the effects of a genome sequence modified by the CRJSPR complex of the invention on a cellular function of interest. For example, a cellular function model may be used to study the effect of a modified genome sequence on intracellular signaling or extracellular signaling. Alternatively, a cellular function model may be used to study the effects of a modified genome sequence on sensor}' perception. In some such models, one or more genome sequences associated with a signaling biochemical pathway in the model are modified.
[00358] Several disease models have been specifically investigated. These include de novo autism risk genes CHD8, KATNAL2, and SCN2A; and the syndromic autism (Angelman Syndrome) gene UBE3A. These genes and resulting autism models are of course preferred, but serve to show the broad applicability of the invention across genes and corresponding models.
[00359] An altered expression of one or more genome sequences associated with a signaling biochemical pathway can be determined by assaying for a difference in the mRNA levels of the corresponding genes between the test model cell and a control cell, when they are contacted with a candidate agent. Alternatively, the differential expression of the sequences associated with a signaling biochemical pathway is determined by detecting a difference in the level of the encoded polypeptide or gene product.
[00360] To assay for an agent-induced alteration in the level of mRNA transcripts or corresponding polynucleotides, nucleic acid contained in a sample is first extracted according to standard methods in the art. For instance, mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook et al. (1989), or extracted by nucleic-acid-binding resins following the accompanying instructions provided by the manufacturers. The mRNA contained in the extracted nucleic acid sample is then detected by amplification procedures or conventional hybridization assays (e.g. Northern blot analysis) according to methods widely known in the art or based on the methods exemplified herein.
[00361] For purpose of this invention, amplification means any method employing a. primer and a polymerase capable of replicating a target sequence with reasonable fidelity. Amplification may be carried out by natural or recombinant DNA polymerases such as TaqGold™, 17 DNA polymerase, Kienow fragment of E.coii DNA polymerase, and reverse transcriptase. A preferred amplification method is PGR. In particular, the isolated RNA can be subjected to a reverse transcription assay that is coupled with a quantitative
1 11
90.1 polymerase chairs reaction (RT-PCR) In order to quantify the expression level of a sequence associated with a signaling biochemical pathway.
[00362] Detection of the gene expression level can be conducted in real time in an amplification assay. In one aspect, the amplified products can be directly visualized with fluorescent DNA-binding agents including but not limited to DNA intercalators and DNA groove binders. Because the amount of the intercalators incorporated into the double- stranded DNA molecules is typically proportional to the amount of the amplified DNA products, one can conveniently determine the amount of the amplified products by quantifying the fluorescence of the intercalated dye using conventional optical systems in the art, DNA-binding dye suitable for this application include SYBR green, SYBR blue, DAP1, propidium iodine, Hoesie, SYBR gold, ethidium bromide, acridines, proflavine, acridine orange, acriflavine, fiuorcoumanin, ellipticine, daunomycin, chloroquine, distamycin D, ehromomyein, homidium, mithramycin, ruthenium polypyridyls, anthramycin, and the like.
[00363] In another aspect, other fluorescent labels such as sequence specific probes can be employed in the amplification reaction to facilitate the detection and quantification of the amplified products. Probe-based quantitative amplification relies on the sequence - specific detection of a desired amplified product, it utilizes fluorescent, target-specific probes (e.g., TaqMan® probes) resulting in increased specificity and sensitivity. Methods for performing probe-based quantitative amplification are well established in the art and are taught in U.S. Patent No. 5,210,015.
0Θ364] In yet another aspect, conventional hybridization assays using hybridization probes that share sequence homology with sequences associated with a signaling biochemical pathway can be performed. Typically, probes are allowed to form stable complexes with the sequences associated with a signaling biochemical pathway contained within the biological sample derived from the test subject in a hybridization reaction. It will be appreciated by one of skill in the art that where antisense is used as the probe nucleic acid, the target polynucleotides provided in the sample are chosen to be complementary to sequences of the antisense nucleic acids. Conversely, where the nucleotide probe is a sense nucleic acid, the target polynucleotide is selected to be complementary to sequences of the sense nucleic acid.
|00365] Hybridization can be performed under conditions of various stringency. Suitable hybridization conditions for the practice of the present invention are such that the recognition interaction between the probe and sequences associated with a signaling
1 12
90.1 biochemical pathway is both sufficiently specific and sufficiently stable. Conditions that increase the stringency of a hybridization reaction are widely known and published in the art. See, for example, (Sambrook, et ai, (1989); Nonradioactive In Situ Hybridization Application Manual, Boehringer Mannheim, second edition). The hybridization assay can be formed using probes immobilized on any solid support, including but are not limited to nitrocellulose, glass, silicon, and a variety of gene arrays. A preferred hybridization assay is conducted on high-density gene chips as described in U.S. Patent No. 5,445,934.
[0Θ366] For a convenient detection of the probe-target complexes formed during the hybridization assay, the nucleotide probes are conjugated to a detectable label. Detectable labels suitable for use in the present invention include any composition detectable by photochemical, biochemical, spectroscopic, immunochemical, electrical, optical or chemical means. A wide variety of appropriate detectable labels are known in the art, which include fluorescent or chemiluminescent labels, radioactive isotope labels, enzymatic or other ligands. In preferred embodiments, one will likely desire to employ a fluorescent label or an enzyme tag, such as digoxigenin, β-galactosidase, urease, alkaline phosphatase or peroxidase, avidin/biotin complex.
[00367] The detection methods used to detect or quantify the hybridization intensity will typically depend upon the label selected above. For example, radiolabels may be detected using photographic film or a phosphoimager. Fluorescent markers may be detected and quantified using a pbotodetector to detect emitted fight. Enzymatic labels are typically detected by providing the enzyme with a substrate and measuring the reaction product produced by the action of the enzyme on the substrate; and finally colorimetric labels are detected by simply visualizing the colored label.
[00368] An agent-induced change in expression of sequences associated with a signaling biochemical pathway can also be determined by examining the corresponding gene products. Determining the protein level typically involves a) contacting the protein contained in a biological sample with an agent that specifically bind to a protein associated with a signaling biochemical pathway; and (b) identifying any agenfcprotein complex so formed. In one aspect of this embodiment, the agent that specifically binds a protein associated with a signaling biochemical pathway is an antibody, preferably a monoclonal antibody.
[00369] The reaction is performed by contacting the agent with a sample of the proteins associated with a signaling biochemical pathway derived from the test samples under conditions that will allow a complex to form between the agent and the proteins associated
1 13
90.1 with a signaling biochemical pathway. The formation of the complex can be detected directly or indirectly according to standard procedures in the art. In the direct detection method, the agents are supplied with a detectable label and unreacted agents may be removed from the complex; the amount of remaining label thereby indicating the amount of complex fonned. For such method, it is preferable to select labels that remain attached to the agents even dining stringent washing conditions. It is preferable that the label does not interfere with the binding reaction. In the alternative, an indirect detection procedure may use an agent that contains a label introduced either chemically or enzymatically. A desirable label generally does not interfere with binding or the stability of the resulting agentpolypeptide complex. However, the label is typically designed to be accessible to an antibody for an effective binding and hence generating a detectable signal.
[00370] A wide variety of labels suitable for detecting protein levels are known in the art. Non-limiting examples include radioisotopes, enzymes, colloidal metals, fluorescent compounds, bioluminescent compounds, and chemiluminescent compounds.
0Θ37Ϊ ] The amount of agentpolypeptide complexes formed during the binding reaction can be quantified by standard quantitative assays. As illustrated above, the formation of agentpolypeptide complex can be measured directly by the amount of label remained at the site of binding. In an alternative, the protein associated with a signaling biochemical pathway is tested for its ability to compete with a labeled analog for binding sites on the specific agent. In this competitive assay, the amount of label captured is inversely proportional to the amount of protein sequences associated with a signaling biochemical pathway present in a test sample.
[0Θ372] A number of techniques for protein analysis based on the general principles outlined above are available in the art. They include but are not limited to radioimmunoassays, ELISA (enzyme linked immunoradiometric assays), "sandwich" immunoassays, immunoradiometric assays, in situ immunoassays (using e.g., colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assays, immunofluorescent assays, and SDS-PAGE.
[0Θ373] Antibodies that specifically recognize or bind to proteins associated with a signaling biochemical pathway are preferable for conducting the aforementioned protein analyses. Where desired, antibodies that recognize a. specific type of post-translational modifications (e.g., signaling biochemical pathway inducible modifications can be used. Post-translational modifications include but are not limited to glycosyiation, lipidation, acerylation, and phosphorylation. These antibodies may be purchased from commercial
1 14
90.1 vendors. For example, anti-phosphotyrosme antibodies that specifically recognize tyrosme-phosphorylated proteins are available from a number of vendors including Invitrogen and Perkin Elmer. Anti-phosphotyrosine antibodies are particularly useful in detecting proteins that are differentially phosphorylated on their tyrosine residues in response to an ER stress. Such proteins include but are not limited to eukaryotic translation initiation factor 2 alpha (eIF-2a). Alternatively, these antibodies can be generated using conventional polyclonal or monoclonal antibody technologies by immunizing a host animal or an antibody-producing cell with a target protein that exhibits the desired post-translational modification.
[00374] In practicing the subject method, it may be desirable to discern the expression pattern of an protein associated with a signaling biochemical pathway in different bodily tissue, in different cell types, and/or in different subcellular structures. These studies can be performed with the use of tissue-specific, cell-specific or subcellular structure specific antibodies capable of binding to protein markers that are preferentially expressed in certain tissues, cell types, or subcellular structures.
[00375] An altered expression of a gene associated with a signaling biochemical pathway can also be determined by examining a. change in activity of the gene product relative to a control cell. The assay for an agent-induced change in the activity of a protein associated with a signaling biochemical pathway will dependent on the biological activity and/or the signal transduction pathway that is under investigation. For example, where the protein is a kinase, a change in its ability to phosphorylate the downstream substrate(s) can be determined by a variety of assays known in the art. Representative assays include but are not limited to immunoblotting and immunopreeipitation with antibodies such as anti-phosphotyrosine antibodies that recognize phosphorylated proteins, in addition, kinase activity can be detected by high throughput chemiluminescent assays such as AlphaScreen™ (available from Perkin Elmer) and eTag™ assay (Chan-Hui, et al. (2003) Clinical Immunology 1 11 : 162- 174).
[00376] Where the protein associated with a signaling biochemical pathway is part of a signaling cascade leading to a fluctuation of intracellular pH condition, pFT sensitive molecules such as fluorescent pH dyes can be used as the reporter molecules. In another example where the protein associated with a signaling biochemical pathway is an ion channel, fluctuations in membrane potential and'Or intracellular ion concentration can be monitored. A number of commercial kits and high-throughput devices are particularly- suited for a rapid and robust screening for modulators of ion channels. Representative
1 15
90.1 Instruments Include FLIPRTM (Molecular Devices, Inc.) and VIPR (Aurora Biosciences), These instruments are capable of detecting reactions in over 1000 sample wells of a microplate simultaneously, and providing real-time measurement and functional data within a second or even a minisecond.
[00377] In practicing any of the methods disclosed herein, a suitable vector can be introduced to a cell or an embryo via one or more methods known in the art, including without limitation, microinjection, electroporation, sonoporation, biohsties, calcium phosphate-mediated transfectkm, cationic transfection, liposome transfection, dendrimer transfection, heat shock transfection, nucleofection transfection, magnetofection, lipofection, impalefection, optical transfection, proprietary agent -enhanced uptake of nucleic acids, and delivery via liposomes, immunoliposomes, virosomes, or artificial virions. In some methods, the vector is introduced into an embryo by microinjection. The vector or vectors may be microinjected into the nucleus or the cytoplasm of the embryo. In some methods, the vector or vectors may be introduced into a cell by nucleofection. 0Θ378] The target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide can be a polynucleotide residing in the nucleus of the eukaryotic ceil The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA).
[00379] Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway-associated gene or polynucleotide. Examples of target polynucleotides include a disease associated gene or polynucleotide. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease-affected tissues compared with tissues or cells of a non disease control. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease. The transcribed or translated products may be kno wn or unknown, and may be at a normal or abnormal level.
[00380] The target polynucleotide of a CRISPR complex can be any polynucleotide endogenous or exogenous to the eukaryotic cell. For example, the target polynucleotide
1 16
90.1 can be a polynucleotide residing in the nucleus of the eukaryotic cell. The target polynucleotide can be a sequence coding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a junk DNA).
[00381] The target polynucleotide of a CRISPR complex may include a number of disease-associated genes and polynucleotides as well as signaling biochemical pathway- associated genes and polynucleotides as listed in US provisional patent applications 61/736,527 and 61/748,427 having Broad reference BI-2011/008/WSGR Docket No. 44063-701.101 and BI-2011/008/WSGR Docket No. 44063-701.102 respectively, both entitled SYSTEMS METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION filed on December 12, 2012 and January 2, 2013, respectively, the contents of all of which are herein incorporated by reference in their entirety.
[00382] Examples of target polynucleotides include a sequence associated with a signaling biochemical pathway, e.g., a signaling biochemical pathway- associated gene or polynucleotide. Examples of target polynucleotides include a disease associated gene or polynucleotide. A "disease-associated" gene or polynucleotide refers to any gene or polynucleotide which is yielding transcription or translation products at an abnormal level or in an abnormal form in cells derived from a disease -affected tissues compared with tissues or cells of a non disease control. It may be a gene that becomes expressed at an abnormally high level; it may be a gene that becomes expressed at an abnormally low level, where the altered expression correlates with the occurrence and/or progression of the disease. A disease-associated gene also refers to a gene possessing mutation(s) or genetic variation that is directly responsible or is in linkage disequilibrium with a gene(s) that is responsible for the etiology of a disease. The transcribed or translated products may be known or unknown, and may be at a normal or abnormal level.
[00383] Examples of disease-associated genes and polynucleotides are listed in Tables A and B, Disease specific information is available from McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Betliesda, Md.), available on the World Wide Web. Examples of signaling biochemical pathway-associated genes and polynucleotides are listed in Table C.
[00384] Mutations in these genes and pathways can result in production of improper proteins or proteins in improper amounts which affect function. Further examples of genes, diseases and proteins are hereby incorporated by reference from US Provisional applications 61 /736,527 filed on December 12, 2012 and 61/748,427 filed on January 2,
1 17
90.1 2013. Such genes, proteins and pathways may be the target polynucleotide of a CRISPR complex.
Table A
Figure imgf000119_0001
1 18
90.1 [Parkinson's Disease [x-Synuc3ein; DJ-1; LRRK2; Parkin; PLNK1
Table B:
Figure imgf000120_0001
119
90.1 CD45, LCA, IL7R, CD3D, T3D, IL2RG, SCIDX1, SCIDX, IMD4),
Metabolic, liver, Amyloid neuropathy (TTR, PALB); Amyloidosis (APOA1, APP, AAA, kidney and protein CVAP, ADl, GSN, FGA, LYZ, TTR, PALB); Cirrhosis (KRT18, KRT8, diseases and disorders C1RH1A, NAIC, TEX292, K1AA1988); Cystic fibrosis (CFTR, ABCC7,
CF, MRP7); Glycogen storage diseases (SLC2A2, GLUT2, G6PC, G6PT, G6PT1, GAA, LAMP2, LAMPB, AGL, GDE, GBE1, GYS2, PYGL, PFKM); Hepatic adenoma, 142330 (TCF1, HNFIA, MODY3), Hepatic failure, early onset, and neurologic disorder (SCQD1, SCOl), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer and carcinomas (CTNNB1, PDGFRL, PDGRL, PRLTS, ΑΧΓΝ1, ΑΧΓΝ, CTNNBl, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5; Medullary cystic kidney disease (UMOD, HNFJ, FJHN, MCKD2, ADMCKD2); Phenylketonuria (PAH, PKU1, QDPR, DHPR, PTS); Polycystic kidney and hepatic disease (FCYT, PKHD1, ARPKD, PKD1, P D2, PKD4, PKDTS, PRKCSH, G19P1, PCLD, SI 6 1.
Muscular / Skeletal Becker muscular dystrophy (DMD, BMD, MYF6), Duehenne Muscular diseases and disorders Dystrophy (DMD, BMD); Emery-Dreifuss muscular dystrophy (LMNA,
LMN1, EMD2, FPLD, CMD1A*HGPS, LGMD1B, LMNA, LMN1, EMD2, FPLD, CMD1A); Facioscapulohumeral muscular dystrophy (FSHMDIA, FSHD1A); Muscular dystrophy (FKRP, MDC C,
LGMD21, LAMA2, LAMM, LARGE, KL\A0609, MDC1D, FCMD, TTID, MYOT, CAPN3, CA P3, DYSF, LGMD2B, SGCG, LGMD2C, DMD A1, SCG3, SGCA, ADL, DAG2, 1.GMD2D, DMDA2, SGCB, LGMD2E, SGCD, SGD, LGMD2F, CMD1L, TCAP, LGMD2G, CMDIN, TRTM32, HT2A, LGMD2H, FKRP, MDCIC, LGMD2I, TTN, CMD1G, TMD, LGMD2J, POMT1, CAV3, LGMD1C, SEP 1, SEEN, RSMD1, PLEC!, PLTN, EBS1); Osteopetrosis (LRP5, BMND!, LRP7, LR3, OPPG, VBCH2, CLCN7, CLC7, OPTA2, OSTM1, GL, TCIRG1, TIRC7, OC116, OPTBl); Muscular atrophy (VAPB, VAPC, ALS8, SMN1, SMA1, SMA2, SMA3, SMA4, BSCL2, SPG 17, GARS, SMADl, CMT2D, HEXB, IGHMBP2, SMUBP2, CATF1, SMARD1).
Neurological and ALS (SODl, ALS2, STEX, FUS, TARDBP, VEGF (VEGF-a, VEGF-b, neuronal diseases and VEGF-c); AMieimer disease (APP, AAA, CVAP, ADl, APOE, AD2, disorders PSEN2, AD4, STM2, APBB2, FE65L1, NOS3, PLAU, URK, ACE,
DCP1, ACE1, MPO, PACIP1, PAXIP1L, PTIP, A2M, BLMH, BMH, PSEN1, ADS); Autism (Mecp2, BZRAP1, MDGA2, SemaSA, Neurexin 1, GLOl, MECP2, RTT, PPMX, MRX16, MRX79, NLGN3, NLGN4, KIAA1260, AUTSX2); Fragile X Syndrome (FMR2, FXR1, FXR2, mGLURS); Huntington's disease and disease like disorders (HD, IT 15, PRNT, PRIP, JPH3, JP3, HDL2, TBP, SCA17); Parkinson disease (NR4A2, NURR1, NOT, TINT J R, SNCAIP, TBP, SCA17, SNCA, NACP, PARK!. PARK4, DJ1, PARK7, LRR.K2, PARKS, PINK1, PARK6, IJCHLl , PARK5, SNCA, NACP, PARK1, PAR 4, PRKN, PARK2, PDJ, DBH, NDUFV2); Rett syndrome (MECP2, RTT, PPMX, MR 16, MRX79, CDKL5, STK9, MECP2, RTT, PPMX, MRX16, MRX79, x-Synuclein, DJ-1); Schizophrenia (Neuregulinl (Nrgl), Erb4 (receptor for Neuregulin), Complexinl (Cpixl), Tphl Tryptophan
120
90.1 hydroxylase, Tph2, Tryptophan hydroxylase 2, Neurexin 1, GSK3, GSK3a, GSK3b, 5-HTT (Slc6a4), COMT, DRD (Drdla), SLC6A3, DA OA, DTNBPl, Dao (Daol )); Secretase Related Disorders (APH-1 (alpha and beta), Presenilin (Pse ! ), nicastrin, (Ncstn), PEN-2, Nosl , Parpl , NatL Nat2); Trinucleotide Repeat Disorders (HIT (Huntington's Dx), SBMA/SMAX!/AR (Kennedy's Dx), FX /X25 (Friedrich's Ataxia), ATX3 (Machado- Joseph's Dx), ATX 1 and ATXN2
(spinocerebellar ataxias), DMPK (myotonic dystrophy), Atrophin-1 and Atnl (DRPLA Dx), CBP (Creb-BP■■ global instability), VLDLR
(Alzheimer's), Atxn7, AtxnlO).
Occular diseases and Age-related macular degeneration (Abcr, CcS2, Cc2, cp (ceruloplasmin), disorders Timp3, cathepsinD, Vldlr, Ccr2); Cataract (CRYAA, CRYA1, CRYBB2,
CRYB2, ΡΓΤΧ3, BFSP2, CP49, CP47, CRYAA, CRYA 1, PAX6, AN2, MGDA, CRYBAl, CRYB1, CRYGC, CRYG3, CCL, L1M2, MP19, CRYGD, CRYG4, BFSP2, CP49, CP47, HSF4, CTM, ITSF4, CTM, ΜΪΡ, AQPO, CRYAB, CRYA2, CTPP2, CRYBB1, CRYGD, CRYG4, CRYBB2, CRYB2, CRYGC, CRYG3, CCL, CRYAA, CRYAl, GJA8, CX50, CAE1, GJA3, CX46, CZP3, CAE3, CCM1, CAM, RIT1); Corneal clouding and dystrophy (APOA l, TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, TACSTD2, TROP2, M1S1, VSX1 , RINX, PPCD, PPD, KTCN, COL8A2, FECD, PPCD2, PIP5K3, CFD); Cornea plana congenital (KERA, CNA2); Glaucoma (MYOC, TIGR, GLCIA, JOAG, GPOA, OPTN, GLCIE, FIP2, FfYPL, NRP, CYP1B1, GLC3A, OPAL NTG, NPG, CYP1B1, GLC3A); Leber congenital amaurosis (CRB1, RP12, CRX, CORD2, CRD, RPGRJPl , LCA6, ( OR 1)9. RPE65, RP20, AIPL1 , LCA4, GUCY2D, GUC2D, LCA1, CORD6, RDH12, LCA3 ); Macular dystrophy (ELOVL4, ADMD, STGD2, STGD3, RDS, RP7, PRPH2, PRPH, AVMD, AOFMD, VMD2).
Table C:
Figure imgf000122_0001
121
90.1
Figure imgf000123_0001
122
90.1
Figure imgf000124_0001
Acute Phase Response IRAKI; SOD2; MYD88; TRAF6; ELK1; MAPKl; PTPNll;
123
90.1
Figure imgf000125_0001
124
90.1
Figure imgf000126_0001
125
90.1 CHUK; NR1H2; TJP2; NFKB1; ESR1 ; SREBF1 ; FGFR4;
JUN; ILIRI; PRKCA; 11.6
IGF-l Signaling IGF1; PRKCZ; ELKl; MAPKl; PTPNll; NEDD4; AKT2;
PIK3CA; PRKCl; PTK2; FOS; PIK3CB; P1K3C3; MAPK8;
IGF1R; IRS1; MAPK3; IGFBP7; KRAS; PIK3C2A;
YWHAZ; PXN; RAF1; CASP9; MAP2K2; AKT1; PIK3R1;
PDPK1; MAP2K1; IGFBP2; SFN; JUN; CYR61; AKT3;
FOXOl; SRF; CTGF; RPS6KB1
NRF2 -mediated PRKCE; EP300; SOD2; PRKCZ; MAPKl; SQSTM1;
Oxidative
Stress Response NQOl; PIK3CA; PRKCl; FOS; PIK.3CB; PTK3C3; MAPK8;
PRKD1; MAPK3; KRAS; PRKCD; GSTPl; MAPK9; FTL;
NFE2L2; PIK3C2A; MAPKl 4; RAF1; MAP3K7; CREBBP;
MAP2K2; AKT1; PTK3R1; MAP2K1; PPIB; JUN; KEAP1;
GSK3B; ATF4; PRKCA; EIF2AK3; F1SP90AA1
Hepatic Fibrosis/Hepatic EDM; IGF1; KDR; FLT1; SMAD2; FGFR1; MET; PGF;
Stellate Cell Activation SMAD3; EGFR; FAS; CSFl; NFKB2; BCL2; MYH9;
IGF1R; IL6R; RELA; TLR4; PDGFRB; TNF; RELB; IL8;
PDGFRA; NFKB1; TGFBR1; SMAD4; VEGFA; BAX;
IL1R1; CCL2; HGF; MMPl; STAT I; TL6; CTGF; MMP9
PPAR Signaling EP300; INS; TRAF6; PPARA; RXRA; MAPKl ; IKBKB;
NCOR2; FOS; NFKB2; MAP3K14; STAT5B; MAPK3;
NRIPl; KRAS; PPARG; RELA; STAT5A; TRAF2;
PPARGC1A; PDGFRB; TNF; INSR; RAF1; IKBKG;
RELB; MAP3K7; CREBBP; MAP2K2; CHUK; PDGFRA;
MAP2K1 ; NFKB1 ; JUN; ILIRI; HSP90AA1
Fc Epsilon RI Signaling PRKCE; RAC1; PRKCZ; LYN; MAPKl; RAC2; PTPN11;
AKT2; PIK3CA; SYK; PRKCl; PIK3CB; PIK3C3; MAPK8;
PRKD1; MAPK3; MAPK10; KRAS; MAPKl 3; PRKCD;
MAPK9; PIK3C2A; BTK; MAPKl 4; TNF; RAF1; FYN;
MAP2K2; ΑΚΠ; PIK3R1; PDPKl; MAP2K1; AKT3;
VAV3; PRKCA
G -Protein Coupled PRKCE; RAPIA; RGS16; MAPKl; GNAS; AKT2; IKBKB;
Receptor Signaling PIK3CA; CREB1; GNAQ; NFKB2; CAMK2A; PIK3CB;
PIK3C3; MAPK3; KRAS; RELA; SRC; PIK3C2A; RAF1 ;
IKBKG; RELB; FYN; MAP2K2; AKT1; P1K3R1; CHUK;
PDPKl; STAT3; MAP2K1; NFKB1; BRAF; ATF4; AKT3;
PRKCA
Inositol Phosphate PRKCE; IRAKI; PRKAA2; E1F2AK2; PTEN; GRK6;
Metabolism MAPKl; PLKl; AKT2; PIK3CA; CDK8; PIK3CB; P1K3C3;
MAPK8; MAPK3; PRKCD; PRKAAl; MAPK9; CDK2;
PIM1; PIK3C2A; DYRK1A; MAP2K2; PIP5K1A; PIK3R1;
MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK
PDGF Signaling E1F2AK2: ELKl; ABL2; MAPKl; PIK3CA; FOS; PIK3CB;
PIK3C3; MAPK8; CAV1; ABL1; MAPK3; KRAS; SRC;
PIK3C2A; PDGFRB; RAF1; MAP2K2; JAK1; JAK2;
PIK3R1; PDGFRA; STAT3; SPHKl; MAP2K1; MYC;
JUN; CRKL; PRKCA; SRF; STAT1; SPHK2
126
90.1
Figure imgf000128_0001
127
90.1
Figure imgf000129_0001
128
90.1
Figure imgf000130_0001
129
90.1
Figure imgf000131_0001
130
90.1 Citrate Cycle 1DH2; IDHI
Fatty Acid Metabolism ALDHIAI ; CYP1B1
Glycerophosphoiipid PRDX6; CHKA
Metabolism
Histidine Metabolism PRMT5; ALDH1A1
Inositol Metabolism EROIL: APEX1
Metabolism of GSTPI ; CYP1B1
Xenobiotics
by Cytochrome p450
Methane Metabolism PRDX6; PRDX1
Phenylalanine PRDX6; PRDX1
Metabolism
Propanoate Metabolism ALDHIAI; LDHA
Seienoamino Acid PRMT5; AHCY
Metabolism
Sphingolipid Metabolism SPHK1; SPHK2
Aminophosphonate PRMT5
Metabolism
Androgen and Estrogen PRMT5
Metabolism
Ascorbate and Aldarate ALDHIAI
Metabolism
Bile Acid Biosynthesis ALDHIAI
Cysteine Metabolism LDHA
Fatty Acid Biosynthesis FASN
Glutamate Receptor GNB2L1
Signaling
NRF2-mediated PRDX1
Oxidative
Stress Response
Pentose Phosphate GPI
Pathway
Pentose and Glucuronate UCHLl
Interconversions
Retinol Metabolism ALDHI AI
Riboflavin Metabolism TYR.
Tyrosine Metabolism PRMT5, TYR.
Ubiquinone Bi osynthesis PRMT5
Valine, Leucine and ALDHI AI
Iso3 eucine Degradati on
Glycine, Serine and CHKA
Threonine Metabolism
Lysine Degradation ALDHI AI
Pain/Taste TRPM5; TRPAl
Pain TRPM7; TRPC5; TRPC6; TRPC 1; Cnrl ; cnr2; Grk2;
Trpal; Pome: Cg ; Crf; Pka; Era; Nr2b; TRPM5; Prkaca;
Prkacb; Prkarla: Prkar2a
Mitochondrial Function AIF; CytC; SMAC (Diablo); Aifm- 1; Aifm-2
Developmental BMP-4; Chordin (Chrd); Noggin (Nog); WNT (Wnt2;
131
90.1 Neurology
Wnt2b; Wnt3a; Wnt4; WntSa; Wnt6; Wnt7b; WntSb;
Wnt9a; Wnt9b; WntlOa; WntlOb; Wntl6); beta-catenin;
Dkk-1; Frizzled related proteins; Otx-2; Gbx2; FGF-8;
Reelin; Dab I; unc-86 (Pou4fl or Brn3a); Numb; Rein
[00385] Embodiments of the invention also relate to methods and compositions related to knocking out genes, amplifying genes and repairing particular mutations associated with DNA repeat instability and neurological disorders (Robert D. Wells, Tetsuo Ashizawa, Genetic Instabilities and Neurological Diseases, Second Edition, Academic Press, Oct 13, 201 1 - Medical). Specific aspects of tandem repeat sequences have been found to be responsible for more than twenty human diseases (New insights into repeat instability: role of RNA»DNA hybrids. Mclvor EI, Polak U, Napierala M. RNA Biol. 2010 Sep-Oct;7(5):551-8). The CRISPR-Cas system may be harnessed to correct these defects of genomic instability.
[00386] A further aspect of the invention relates to utilizing the CRISPR-Cas system for correcting defects in the EMP2A and EMP2B genes that have been identified to be associated with Lafora disease. Lafora disease is an autosomal recessive condition which is characterized by progressive myoclonus epilepsy which may start as epileptic seizures in adolescence. A few cases of the disease may be caused by mutations in genes yet to be identified. The disease causes seizures, muscle spasms, difficulty walking, dementia, and eventually death. There is currently no therapy that has proven effective against disease progression. Other genetic abnormalities associated with epilepsy may also be targeted by the CRISPR-Cas system and the underlying genetics is further described in Genetics of Epilepsy and Genetic Epilepsies, edited by Giuliano Avanzini, Jeffrey L. Noebels, Mariani Foundation Paediatric Neurology:20; 2009).
[0Θ387] In yet another aspect of the invention, the CRISPR-Cas system may be used to correct ocular defects that arise from several genetic mutations further described in Genetic Diseases of the Eye, Second Edition, edited by Elias L Traboulsi, Oxford University Press, 2012.
[00388] Several further aspects of the invention relate to correcting defects associated with a wide range of genetic diseases which are further described on the website of the National Institutes of Health under the topic subsection Genetic Disorders (website at health.nih.gov/topic/GeneticDisorders). The genetic brain diseases may include but are not limited to Adrenoleukodystrophy, Agenesis of the Corpus Caliosum, Aicardi Syndrome, Alpers' Disease, Alzheimer's Disease, Barfh Syndrome, Batten Disease, CADASIL,
132
90.1 Cerebellar Degeneration, Fabry's Disease, Gerstmann-Straussler-Scheinker Disease, Huntington's Disease and other Triplet Repeat Disorders, Leigh's Disease, Lesc -Nyhan Syndrome, Menkes Disease, Mitochondrial Myopathies and NINDS Colpocephaly. These diseases are further described on the website of the National Institutes of Health under the subsection Genetic Brain Disorders.
[00389] In some embodiments, the condition may be neoplasia. In some embodiments, where the condition is neoplasia, the genes to be targeted are any of those listed in Table A (in this case PTEN and so forth). In some embodiments, the condition may be Age-related Macular Degeneration. In some embodiments, the condition may be a Schizophrenic Disorder. In some embodiments, the condition may be a Trinucleotide Repeat Disorder. In some embodiments, the condition may be Fragile X Syndrome. In some embodiments, the condition may be a Secretase Related Disorder. In some embodiments, the condition may be a Prion■■ related disorder. In some embodiments, the condition may be ALS, In some embodiments, the condition may be a drug addiction. In some embodiments, the condition may be Autism, In some embodiments, the condition may be Alzheimer's Disease. In some embodiments, the condition may be inflammation. In some embodiments, the condition may be Parkinson's Disease.
|00390] Examples of proteins associated with Parkinson's disease include but are not limited to a-symiclein, DJ-1 , LRRK2, PINKl , Parkin, UCHL1, Synphilin-1 , and NURR1.
[00391] Examples of addiction-related proteins may include ABAT for example.
[00392] Examples of inflammation-related proteins may include the monocyte chemoattractant protein-! (MCP! ) encoded by the Ccr2 gene, the C-C chemokine receptor type 5 (CCR.5) encoded by the Cer5 gene, the IgG receptor ΠΒ (FCGR2b, also termed CD32) encoded by the Fegr2b gene, or the Fc epsilon Rig (FCERlg) protein encoded by the Fcerl g gene, for example.
[00393] Examples of cardiovascular diseases associated proteins may include IL1B (interleukin 1, beta), XDH (xanthine dehydrogenase), TP53 (tumor protein p53), PTGIS (prostaglandin 12 (prostacyclin) synthase), MB (myoglobin), IL4 (interleukin 4), ANGPT1 (angiopoietin 1), ABCG8 (AT -binding cassette, sub-family G (WHITE), member 8), or CTSK (cathepsin K), for example.
[00394] Examples of Alzheimer's disease associated proteins may include the very low density lipoprotein receptor protein (VLDLR) encoded by the VLDLR gene, the ubiquitin- like modifier activating enzyme 1 (UBA1 ) encoded by the UBA1 gene, or the NEDD8-
133
90.1 activating enzyme El catalytic subunit protein (UBE1 C) encoded by the UBA3 gene, for example.
[00395] Examples of proteins associated Autism Spectmm Disorder may include the benzodiazapine receptor (peripheral) associated protein 1 (BZRAPl) encoded by the BZRAPl gene, the AF4/FMR2 family member 2 protein (AFF2) encoded by the AFF2 gene (also termed MFR2), the fragile X mental retardation autosomal homolog 1 protein (FXR1) encoded by the FXR1 gene, or the fragile X mental retardation autosomal homolog 2 protein (FXR2) encoded by the FXR2 gene, for example.
[00396] Examples of proteins associated Macular Degeneration may include the ATP- binding cassette, sub-family A (ABC1) member 4 protein (ABCA4) encoded by the ABCR gene, the apolipoproiein E protein (APOE) encoded by the APOE gene, or the chemoldne (C-C motif) Ligand 2 protein (CCL2) encoded by the CCL2 gene, for example.
[00397] Examples of proteins associated Schizophrenia may include NRGl, ErbB4, CPLXL TPH1, TPH2, NRXN L GSK3A, BDNF, DISC I, GSK3B, and combinations thereof.
[00398] Examples of proteins involved in tumor suppression may include ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch 1, Notch2, Notch 3, or Notch 4, for example.
[00399] Examples of proteins associated with a secretase disorder may include PSENEN (presenifin enhancer 2 homolog (C. efegans)), CTSB (cathepsin B), PSEN1 (presenilin 1 ), APP (amyloid beta (A4) precursor protein), APH1B (anterior pharynx defective 1 homolog B (C. elegans)), PSEN2 (presenilin 2 (Alzheimer disease 4)), or BACE1 (beta-site APP-cleaving enzyme 1 ), for example.
[00400] Examples of proteins associated with Amyotrophic Lateral Sclerosis may include SOD1 (superoxide dismutase 1), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A), VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof.
[00401] Examples of proteins associated with prion diseases may include SOD1 (superoxide dismutase 1 ), ALS2 (amyotrophic lateral sclerosis 2), FUS (fused in sarcoma), TARDBP (TAR DNA binding protein), VAGFA (vascular endothelial growth factor A),
134
90.1 VAGFB (vascular endothelial growth factor B), and VAGFC (vascular endothelial growth factor C), and any combination thereof,
[00402] Examples of proteins related to neurodegenerative conditions in prion disorders may include A2M (Alpha-2-Maeroglobulin), AATF (Apoptosis antagonizing transcription factor), ACPP (Acid phosphatase prostate), ACTA2 (Actin alpha 2 smooth muscle aorta), ADAM22 (ADAM metallopeptidase domain), ADORA3 (Adenosine A3 receptor), or AD RAI D (Alpha- I D adrenergic receptor for Alpha- ID adrenoreceptor), for example.
[0Θ403] Examples of proteins associated with Immunodeficiency may include A2M [alpha-2-maerogiobulin]; AANAT [arylalkylamine N-aeetyltransferase]; ABCA I [ATP- binding cassette, sub-family A (ABC1), member 1]; ABCA2 [ATP -binding cassette, subfamily A (ABCl ), member 2]; or ABCA3 [ATP-binding cassette, sub-family A (ABCl), member 3]; for example.
[00404] Examples of proteins associated with Trinucleotide Repeat Disorders include AR (androgen receptor), FMR1 (fragile X mental retardation 1), HTT (huntingtin), or DMPK (dystrophia myotonica-protein kinase), FXN (frataxin), ATX 2 (ataxin 2), for example.
[00405] Examples of proteins associated with Neurotransmission Disorders include SST (somatostatin), NOS1 (nitric oxide synthase 1 (neuronal)), ADRA2A (adrenergic, alpha-2A-, receptor), ADRA2C (adrenergic, aipha~2C-, receptor), TACR1 (tachykinin receptor 1), or HTR2c (5-hydroxyt.ryptamine (serotonin) receptor 2C), for example.
[00406] Examples of neurodevelopmental-associated sequences include A2BP1 [ataxin 2-binding protein I], AADAT [aminoadipate aminotransferase], AANAT [arylalkylamine N-acetyltransferase], ABAT [4-aminobutyrate aminotransferase], ABCAI [ATP-binding cassette, sub-family A (ABCl ), member 1], or ABCA13 [ATP-binding cassette, subfamily A (ABCl), member 13], for example.
[00407] Further examples of preferred conditions treatable with the present system include may be selected from: Aieardi-Goutieres Syndrome; Alexander Disease; Allan- Herndon-Dudley Syndrome; POLG-Related Disorders; Alpha-Mannosidosis (Type II and III); Alstrom Syndrome; Angelman; Syndrome; Ataxia-Telangiectasia; Neuronal Ceroid- Lipofuscinoses; Beta-Thalassemia; Bilateral Optic Atrophy and (Infantile) Optic Atrophy Type 1 ; Retinoblastoma (bilateral); Canavan Disease; Cerebrooculofacioskeletal Syndrome 1 [COFS1 ]; Cerebrotendinous Xanthomatosis; Cornelia de Lange Syndrome; MAPT-Related Disorders; Genetic Prion Diseases; Dravet Syndrome; Early-Onset Familial Alzheimer Disease; Friedreich Ataxia [FRDA]; Fryns Syndrome; Fucosidosis; Fukuyama Congersiial Muscular Dystrophy; Galactosialidosis; Gaucher Disease; Organic Acidemias; Heme-phagocytic Lymphohistiocytosis; Hutc nson-Gilford Progeria Syndrome; Mucolipidosis II; Infantile Free Sialic Acid Storage Disease; PLA2G6- Associated Neurodegeneration; Jervell and Lange -Nielsen Syndrome; Junctional Epidermolysis Bullosa; Huntington Disease; Krabbe Disease (Infantile); Mitochondrial DNA -Associated Leigh Syndrome and N ARP; Lesch-Nyhan Syndrome; LIS 1 -Associated Lissencephaly; Lowe Syndrome; Maple Syrup Urine Disease; MECP2 Duplication Syndrome; ATP7A-Related Copper Transport Disorders; LAMA2-Related Muscular Dystrophy; Arylsulfatase A Deficiency; Mucopolysaccharidosis Types I, II or ΙΠ; Peroxisome Biogenesis Disorders, Zellweger Syndrome Spectrum; Neurodegeneration with Brain Iron Accumulation Disorders; Acid Sphingomyelinase Deficiency; Niemann - Pick Disease Type C; Glycine Encephalopathy; ARX-Related Disorders; Urea Cycle Disorders; COLlAl/2 -Related Osteogenesis Imperfecta; Mitochondrial DNA Deletion Syndromes; PLP1 -Related Disorders; Perry Syndrome; Phelan-McDermid Syndrome; Glycogen Storage Disease Type II (Pompe Disease) (Infantile); MAPT-Related Disorders; MECP2-Related Disorders; Rhizomelic Chondrodysplasia Punctata Type 1 ; Roberts Syndrome; Sandhoff Disease; Schindler Disease - Type 1; Adenosine Deaminase Deficiency; Smiih-Lemli-Qpitz Syndrome; Spinal Muscular Atrophy; Infantile-Onset Spinocerebellar Ataxia; Hexosaminidase A Deficiency; Thanatophoric Dysplasia Type 1 ; Collagen Type VI-Related Disorders; Usher Syndrome Type I; Congenital Muscular Dystrophy; Wolf-Hirschhorn Syndrome; Lysosomal Acid Lipase Deficiency; and Xeroderma Pigmentosum.
[0Θ408] As will be apparent, it is envisaged that the present system can be used to target any polynucleotide sequence of interest. Some examples of conditions or diseases that might be usefully treated using the present system are included in the Tables above and examples of genes currently associated with those conditions are also provided there. However, the genes exemplified are not exhaustive.
[00409] For example, "wild type StCas9" refers to wild type Cas9 from S thermophilus, the protein sequence of which is given in the SwissProt database under accession number G3ECR1. Similarly, S pyogenes Cas9 is included in SwissProt under accession number Q99ZW2.
[00410] The ability to use CRISPR-Cas systems to perform efficient and cost effective gene editing and manipulation will allow the rapid selection and comparison of single and and multiplexed genetic manipulations to transform such genomes for improved
136
90.1 production and enhanced traits. In this regard reference is made to US patents and publications: US Patent No. 6,603,061 - Agrobacterium-Mediated Plant Transformation Method; US Patent No. 7,868, 149 ■· Plant Genome Sequences and Uses Thereof and US 2009/0100536 - Transgenic Plants with Enhanced Agronomic Traits, all the contents and disclosure of each of which are herein incorporated by reference in their entirety. In the practice of the invention, the contents and disclosure of Morrell et al "Crop genomics:advances and applications" Nat Rev Genet. 201 1 Dec 29; 13(2):85-96 are also herein incorporated by reference in their entirety.
[0Θ411 ] Examples of genes to be targeted include the genes provided in Lawrence et al; Nature 23 Jan. 2014; Vol 505, pages 495 -503 (incorporated herein by reference) as provided in Figure 2, and Supplementary Figures 2, 3, 4, and 5. Examples of genes to be targeted include the genes provided in loannidis et al., JNCT, Vol. 102, Issue 12, June 16, 2010 (incorporated herein by reference), Table 1.
[00412] Examples of genes to be targeted include the genes encoding the proteins involved in tumor suppression or any tumor suppressor gene(s), as that term is used herein, including, for example, any gene of the TS GENE TUMOR SUPPRESSOR GENE DATABASE, ]ittp: /biomfo.mc,vanderbili.edu/riSGene/indexJiimi, on the filing day of this application (incorporated herein by reference), including 716 human genes (637 coding and 79 non-coding genes), 628 mouse genes, and 567 rat genes, involved in "loss- of-function" or is a tumor suppressor gene consistent with the use of the term in this disclosure, or ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch 1, Notch2, Notch 3, or Notch 4.
[00413] Examples of genes to be targeted include any gene of the TS GENE TUMOR SUPPRESSOR GENE DATABASE, http://bioinfo.mc.vanderbiit.edu/TSGene/index.html, on the filing day of this application (incorporated herein by reference), including 716 human genes (637 coding and 79 non-coding genes), 628 mouse genes, and 567 rat genes, involved in "loss-of-function" or is a tumor suppressor gene consistent with the use of the term in this disclosure, or Tet2, Rimxl, Dnmt3a, Nfl, Ezh2, Smc3 genes.
[00414] The current invention further comprises cells and non-human animals obtainable by the methods of the invention which include genomic modifications for expression of CRISPR enzyme for generation of complex disease models, including
137
90.1 proliferative conditions including the further administration to said cells / animals three or more sgRNA targeting genes of the invention, including the genes of Tables A, B, and C, as well genes provided in Lawrence et al; Nature 23 Jan. 2014; Vol 505, pages 495-503 as provided in Figure 2, and Supplementary Figures 2, 3, 4, and 5.; genes provided in loannidis et al, JNCI, Vol. 102, Issue 12, June 16, 2010, Table 1 ; gene(s) encoding the protein(s) involved in tumor suppression or any tumor suppressor gene, as that term is herin understood in view of the foregoing discussion of "loss-of-function gene(s)", including, for example, any gene of the TS GENE TUMOR SUPPRESSOR GENE DATABASE, http://bioMo.mc.vanderbilt.edu/TSGene/index.html, on the filing day of this application (incorporated herein by reference), including 716 human genes (637 coding and 79 non-coding genes), 628 mouse genes, and 567 rat genes, involved in "loss- of-function" or is a tumor suppressor gene consistent with the use of the term in this disclosure, or ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene hornolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene hornolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene hornolog 4), Notch 1, Notch2, Notch 3, or Notch 4.
|004i5] The current invention is further defined, inter alia, by the following items:
1) A vector system comprising one or more vectors, wherein said vector system comprises:
Component I comprising a first regulatory element operably linked to a CRISPR- Cas system chimeric RNA (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises:
(a) three or more guide sequences capable of hybridizing to three or more target sequences in the genome of an organism,
(b) a tracr mate sequence, and
(c) a tracr sequence, and wherein (a) the guide sequences, (b) tracr mate sequence and (c) tracr sequence are arranged in a 5 ' to 3 ' orientation; and
138
90.1 Component II comprising a second regulatory element operably linked to an enzyme-coding nucleotide sequence encoding a CRISPR enzyme, wherein the enzyme-coding nucleotide sequence comprises at least one or more nuclear localization sequences (NLSs), such that when the vector or vectors are transcribed after having been transduced into a population of cells from the organism, the tracr mate sequence hybridizes to the tracr sequence and the guide sequences direct sequence-specific binding of CRISPR enzyme to the target sequences, thereby forming CRISPR complexes; wherein a CRISPR complex comprises the CRISPR enzyme compiexed with ( 1) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence; and such that the CRISPR enzyme alters the genome of the transduced cell to obtain a genetically altered population of cells.
) The vector system of item 1, wherein the population of cells is a. population of stem cells.
) The vector system of item 1 or 2, wherein the population of cells is a population of hematopoietic stem and progenitor cells.
) The vector system of any one of the above items, wherein the vector system is a lentivirai vector system.
) The vector system of any one of the above items, wherein the first regulatory element is a U6 promoter.
) The vector system of any one of the above items, wherein the second regulatory element is an EFS promoter.
) The vector system of any one of the above items, wherein the polynucleotide sequence comprises at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 guide sequences.
) The vector system of any one of the above items, wherein the polynucleotide sequence comprises 3, 4, 5, 6, 7, 8, 9 or 10 guide sequences,
) The vector system of item 8, wherein the polynucleotide sequence comprises 3 guide sequences.
139
90.1 ) The vector system of item 8, wherein the polynucleotide sequence comprises 4 guide sequences.
) The vector system of item 8, wherein the polynucleotide sequence comprises 5 guide sequences.
) The vector system of item 8, wherein the polynucleotide sequence comprises 6 guide sequences.
) The vector system of any one of the above items, wherein the target sequences are associated with tumor suppressor genes.
) The vector system of any one of the above items, wherein the target sequences are tumor suppressor genes.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of Tet2, Runx! , Dnmt.3a, Nfl , Ezh2, Sme.3 genes.
) The vector system of items 1 -12, wherein the target sequences are genes selected from the group consisting of Tet2, Runxl, Dnmt3a, Nfl, Ezh2, Smc3, F1, MED 12, NF2, CUL.3, TADA2B, TADA i, BCR, ABLi genes, and genes of the following proteins ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia, and Rad3 related), EGFR (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v- erb-b2 erythroblastic leukemia viral oncogene homolog .3), ERBB4 (v~erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch 1, Not.ch2, Notch 3, and Notch 4.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of those genes provided in Tables A, B, and C.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of genes of the following proteins ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), EGFR. (epidermal growth factor receptor), ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2), ERBB3 (v-erb-b2 erythroblastic leukemia, viral oncogene homolog 3), ERBB4 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 4), Notch 1, Noteh2, Notch 3, and Notch 4.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of ACOl (aconitase 1 , soluble); ACVR1B (activin A receptor, type IB); ACVR2B (activin A receptor, type TIB); ADNP (activity- dependent neuroprotector homeobox); AJUBA (jub, ajuba homolog (Xenopus laevis)); AKT1 (v-akt murine thymoma viral oncogene homolog I); ALK (anaplastic lymphoma receptor tyrosine kinase); ALKBH6 (alkB, alkylation repair homolog 6 (E. coli)); ALPK2 (alpha-kinase 2); ANK3 (ankyrin 3, node of Ranvier (ankyrin G)); APC (adenomatous polyposis coli); APOL2 (apolipoprotein L, 2); ARHGAP35 (glucocorticoid receptor DNA binding factor 1 ); ARID 1 A (AT rich interactive domain 1A (SWl-like)): AR1D2 (AT rich interactive domain 2 (ARID, RFX-like)); ARID5B (AT rich interactive domain 5B (MRFl-like)); ASXL1 (additional sex combs like 1 (Drosophila)); ASXL2 (additional sex combs like 2 (Drosophila)); ATM (ataxia telangiectasia mutated); ATP5B (ATP synthase, H+ transporting, mitochondrial Fl complex, beta polypeptide); ΑΧΓΝ2 (axin 2 (conductin, axil)); AZGP1 (alpha-2-glycoprotein 1, zinc -binding); B2M (beta-2- microglobulin); BAP ! (BRCA 1 associated protein- 1 (ubiquitin carboxy-terminal hydrolase)); BCLAF1 (BCL2-associated transcription factor 1); BCOR (BCL6 co- repressor); BHMT2 (betaine-homocysteine methyltransferase 2); BRAF (v-raf murine sarcoma viral oncogene homolog BI); BRCA1 (breast cancer 1 , early onset); BRE (brain and reproductive organ -expressed (TNFRSF1A modulator)); C3orf70 (chromosome 3 open reading frame 70); CAP2 (CAP, adenylate cyclase - associated protein, 2 (yeast)); CARD 1 1 (caspase recruitment domain family, member I I); CASP8 (caspase 8, apoptosis-related cysteine peptidase); CBFB (core-binding factor, beta subunit); CCDC1020 (coiled-eoil domain containing 120); CCDC6 (coiied-coil domain containing 6); CCND1 (cyciin Dl); CD1 D (CD Id molecule); CD70 (CD70 molecule); CD79B (CD79b molecule, immunoglobulin-associated beta); CDC27 (cell division cycle 27 homolog (S, cerevisiae)); CDH1 (cadherin 1, type 1, E-cadherin (epithelial)); CDK12 (cyciin- dependent kinase 12); CD 4 (cyclin-dependent kinase 4); CDKN1A (cyclin- dependent kinase inhibitor 1 A (p21, Cipl )); CDKN1B (cyclin-dependent kinase inhibitor IB (p27, Kipl)); CDKJSI2A (cyclin-dependent kinase inhibitor 2A (melanoma, pl6, inhibits CDK4)); CEBPA (CCAAT/enhancer binding protein (C/EBP), alpha); CEP76 (centrosomal protein 76kDa); CITD4 (chromodomain heficase DN binding protein 4); CHD8 (chromodomain helicase DNA binding protein 8); CNBDl (cyclic nucleotide binding domain containing 1 ); CNKSR1 (connector enhancer of kinase suppressor of Ras 1); COLS A 1 (collagen, type V, alpha 1 ); COL5A3 (collagen, type V, alpha 3); CREBBP (CREB binding protein (Rubinstein-Taybi syndrome)); CTCF (CCCTC-binding factor (zinc finger
141
90.1 protein)); CTNNB1 (catenin (cad erin-associated protein), beta 1 , 88kDa); CUL4B (cullin 4B); CUX1 (cut-like homeobox 1); DDX3X (DEAD (Asp -Ghi -A la-Asp) box polypeptide 3, X-linked); DDX5 (DEAD (Asp-Glu-Ala-Asp) box polypeptide 5); DIAPH1 (diaphanous homolog 1 (Drosophila)); DIS3 (DIS3 mitotic control homolog (S. cerevisiae)); DNAH12 (dynein, axonemal, heavy chain 12); DNER (delta/notch-like EGF repeat containing); DNMT3A (DNA (cytosine-5-)- methyltransferase 3 alpha); EGFR (epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)); EIF2S2 (eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa); ELF3 (E74-iike factor 3 (ets domain transcription factor, epithelial-specific )); EP300 (ElA binding protein p300); EPHA2 (EPH receptor A2); ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/giioblastoma derived oncogene homolog (avian)); ERBB3 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)); ERCC2 (excision repair cross -complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D)); EZH1 (enhancer of zeste homolog 1 (Drosophila)); EZH2 (enhancer of zeste homolog 2 (Drosophila)); EZR (ezrin); FAM166A (family with sequence similarity 166, member A); FAM46C (family with sequence similarity 46, member C);FAT1 (FAT tumor suppressor homolog 1 (Drosophila)); FBXW7 (F-box and WD repeat domain containing 7); FGFBP1 (fibroblast growth factor binding protein 1 ); FGFR2 (fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratmocyte growth factor receptor, craniofacial dysostosis 1 , Crouzon syndrome, Pfciffer syndrome, Jackson- Weiss syndrome)); FGFR.3 (fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism));FLG (filaggrin); FLT3 (fins- related tyrosine kinase 3 ); FOXA1 (forkhead box A l); FOXQ1 (forkhead box Ql); FRMD7 (FERM domain containing 7); GATA3 (GATA binding protein 3); GNA13 (guanine nucleotide binding protein (G protein), alpha 13); GNB1 (guanine nucleotide binding protein (G protein), beta polypeptide 1); GMPTAB (N- acetyl glucosamine- 1 -phosphate transferase, alpha and beta subunits); GOT! (glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)); GPS2 (G protein pathway suppressor 2); GUSB (glucuronidase, beta); HIST1H1E (histone cluster 1, Hi e); HIST1 H3B (histone cluster 1, H3b); HIST1 H4E (histone cluster 1 , H4e); HLA-A (major histocompatibility complex, class I, A); HLA-B (major histocompatibility complex, class I, B); HRAS (v-Ha-ras Harvey rat
142
90.1 sarcoma viral oncogene homolog); HSP90AB.1 (heat shock protein 90kDa alpha (cytosolic), class B member 1); IDH1 (isocitrate dehydrogenase 1 (NADP+), soluble); 1DH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial); IL7R (interleukin 7 receptor); I G1 (inhibitor of growth family, member 1 ); INPPL1 (inositol polyphosphate phosphatase-like 1 ); INTS12 (integrator complex subunit 12); 1P07 (importin 7); IRF4 (interferon regulatory factor 4); IRF6 (interferon regulatory factor 6); ITGB7 (iniegrin, beta 7); ITP B (inositol 1 ,4,5-trisphosphate 3 -kinase B); KDM5C (lysine (K)-specific demethylase 5C); KDM6A (lysine (K)- specific demethylase 6A); KEAP1 (kelch-like ECH-associated protein 1); KEL (Kell blood group, metallo-endopeptidase); KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog); KLHL8 (kelch-like 8 (Drosophila)); KRAS (v- Ki-ras2 Kirsten rat sarcoma viral oncogene homolog); LCTL (lactase-like); MAP2K1 (mitogen-activated protein kinase kinase 1); MAP2K4 (mitogen- activated protein kinase kinase 4); MAP3K1 (mitogen-activated protein kinase kinase kinase 1 ); MAP4K3 (mitogen-activated protein kinase kinase kinase kinase 3); MBDl (methyl -CpG binding domain protein 1); MED 12 (mediator complex subunit 12); MED23 (mediator complex subunit 23); MET (met proto-oncogene (hepatocyte growth factor receptor)); MAG (MAX gene associated); MICALCL (MICAL C-terminal like); MLL (myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)); MLL2 (myeloid/lymphoid or mixed-lineage leukemia 2); MLL3 (myeloid/lymphoid or mixed-lineage leukemia 3); MLL4 (myeloid/lymphoid or mixed-lineage leukemia 2); MORC4 (MORC family CW- type zinc finger 4); MPO (myeloperoxidase); MTOR (mechanistic target of rapamycin (serine/threonine kinase)); MUC17 (mucin 17, cell surface associated); MXRA5 (matrix-remodelling associated 5); MYB (v-myb myeloblastosis viral oncogene homolog (avian)); MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)); MYD88 (myeloid differentiation primary response gene (88)); MYOCD (myocardin); NBPF1 (neuroblastoma breakpoint family, member 1 ); NCOR1 (nuclear receptor co-repressor 1); NF1 (neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)); NFE2L2 (nuclear factor (erythroid-derived 2)-like 2); NOTCH 1 (Notch homolog 1, translocation-associated (Drosophila)); NPM1 (nucleophosmin (nucleolar phosphoprotein B23, numatrin)); NRAS (neuroblastoma RAS viral (v- ras) oncogene homolog); NSD1 (nuclear receptor binding SET domain protein 1 );
143
90.1 TN4 (netrin 4); NUP210L (nucleoporin 210kDa-like); ODAM (odontogenic, ameloblast asssociated); OMA l (OMA1 homolog, zinc metallopeptidase (S, cerevisiae)); OR4A16 (olfactory receptor, family 4, subfamily A, member 16); OR52 1 (olfactory receptor, family 52, subfamily , member 1 ); OTUD7A (OTU domain containing 7A); PAPD5 (PAP associated domain containing 5); PBRMi (polybromo 1); PCBPl (poly(rC) binding protein 1): PDAPl (PDGFA associated protein 1); PDCD2L (programmed ceil death 2 -like); PDSS2 (prenyl (decaprenvl) diphosphate synthase, subunit 2); PHF6 (PHD finger protein 6); PTK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide); PIK3R1 (phosphoinositide-3 -kinase, regulatory subunit 1 (alpha)); PLCG2 (phospholipase C, gamma 2 (phosphatidylinositol-specific)); POLE (polymerase (D A directed), epsilon); POU2AF1 (POU class 2 associating factor 1 ); POU2F2 (POU class 2 homeobox 2); PPM ID (protein phosphatase ID magnesium-dependent, delta isoform); PPP2R1A (protein phosphatase 2 (formerly 2A), regulatory subunit A , alpha isoform); PPP6C (protein phosphatase 6, catalytic subunit); PRDM1 (PR domain containing 1, with ZNF domain); PTEN (phosphatase and tensin homolog (mutated in multiple advanced cancers 1)); PTP H (protein tyrosine phosphatase, non-receptor type 1 1 (Noonan syndrome 1 )); QKI (quaking homolog, KH domain RNA binding (mouse)); RAB40A (RAB40A, member RAS oncogene family); RAC l (ras -related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Racl )); RAD21 (RAD21 homolog (S. pombe)); RASA1 (RAS p21 protein activator (GTPase activating protein) 1); RBI (retinoblastoma 1 (including osteosarcoma)); RBM10 (R. A binding motif protein 10); RHEB (Ras homolog enriched in brain); RHOA (ras homolog gene family, member A); R1T1 (Ras -like without CAAX 1 ); RPL5 (ribosomai protein L5); RPS15 (ribosomal protein S15); RPS2 (ribosomal protein S2); RSBNiL (round spermatid basic protein 1 - like); RUN 1 (runt-related transcription factor 1 (acute myeloid leukemia 1; amll oncogene)); RXRA (retinoid X receptor, alpha); SACS (spastic ataxia of Charlevoix-Saguenay (sacsin)); SELP (selectin P (granule membrane protein 140kDa, antigen CD62)); SEPT 12 (septin 12); SERP!NB 13 (serpin peptidase inhibitor, clade B (ovalbumin), member 13); SETD2 (SET domain containing 2); SETDB l (SET domain, bifurcated 1); SF3B 1 (splicing factor 3b, subunit 1, 155kDa); SFRS2 (splicing factor, arginine/serine-rich 2); SGK1 (serarn/glucocorticoid regulated kinase 1 ); SIRT4 (sirtuin (silent mating type
144
90.1 information regulation 2 homolog) 4 (S. cerevisiae)); SLC1 A3 (solute carrier family 1 (glial high affinity glutamate transporter), member 3); SLC26A3 (solute carrier family 26, member 3); SLC44A3 (solute carrier family 44, member 3); SLC4A5 (solute carrier family 4, sodium bicarbonate cotransporter, member 5); SMAD2 (SMAD family member 2); SMAD4 (SMAD family member 4); SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4); SMARCB 1 (SWI SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1); SMC! A (structural maintenance of chromosomes 1A); SMC3 (structural maintenance of chromosomes 3); S X25 (sorting nexin 25); SOS1 (son of sevenless homolog 1 (Drosophila)); SOX 17 (SRY (sex determining region YVbox 17); 8PEN (spen homolog, transcriptional regulator (Drosophila)); SPOP (speckle- type POZ protein); STAG2 (stromal antigen 2); STK11 (serine/threonine kinase 1 1); STK19 (serine/threonine kinase 19); STX2 (syntaxin 2); TAP1 (transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)); TBC1 D12 (TBCl domain family, member 12); TBLIXRI (transducin (beta)-like 1 X-finked receptor 1); TBX3 (T-box 3 (ulnar mammary syndrome)); TCEB1 (transcription elongation factor B (Sill), polypeptide 1 ( 15kDa, elongin C)); TCF7L2 (transcription factor 7- like 2 (T-cell specific, HMG-box)); TCP1 1L2 (t-complex 1 1 (mouse)-like 2); TDRD10 (tudor domain containing 10); TET2 (tet oncogene family member 2); TGFBR2 (transforming growth factor, beta receptor II (70/80kDa)); TIMM17A (translocase of inner mitochondrial membrane 17 homolog A (yeast)); TNF (tumor necrosis factor (TNF superfamily, member 2)); TNFRSF14 (tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator)); TP53 (tumor protein p53); TP53BP1 (tumor protein p53 binding protein 1); TPX2 (TPX2, microtubule-associated, homolog (Xenopus laevis)); TRAF3 (TNF receptor- associated factor 3); TRJM23 (tripartite motif-containing 23 ); TSC1 (tuberous sclerosis 1); TTLL9 (tubulin tyrosine ligase-like family, member 9); TXNDC8 (thioredoxin domain containing 8 (spermatozoa)); U2AFI (U2 small nuclear RNA auxiliary factor 1); VHL (von Hippel-Lindau tumor suppressor); WASF3 (WAS protein family, member 3); WT1 (Wilms tumor 1); X1R152 (xin aetin-binding repeat containing 2); XPOl (exportin 1 (CRM! homolog, yeast)); ZFHX3 (zinc finger homeobox 3); ZNF180 (zinc finger protein 180); ZNF471 (zinc finger protein 471); ZNF483 (zinc finger protein 483); ZNF620 (zinc finger protein 620);
145
90.1 ZNF750 (zinc finger protein 750); and ZRANB3 (zinc finger, RA -binding domain containing 3).
The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of FLT3, DNMT3A, NPM1, IDH2, IDH1 , TET2, NRAS, RUNX1, WT ! , U2AF1 , TP53, KRAS, PTPN1 1 , KIT, SMC3, STAG2, PHF6, RAD21, CEBPA, ASXL1, SFRS2, SMC1A, PAPD5, EZH2, PDSS2, MXRA5, and KDM6A.
The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of TP53, KDM6A, RBI, PIK3CA, ARID 1 A, MLL2, CDK 1A, ERCC2, STAG2, RXRA, TBC1D12, NFE2L2, C3orf70, ERBB3, ELF3, FBXW7, FGFR3, FOXQ1, CREBBP, HRAS, SNX25, TSC1, MGA, EZR, DDX5, MIX, RHOA, PFIF6, MIX3, BCLAF ! , TGFBR2, EPPTA2, SETD2, and CDKN2A.
The vector system of items 1 2, wherein the target sequences are genes selected from the group consisting of PIK3CA, TP53, GATA3, MAP3K1 , PTEN, AKT1 , CTCF, CBFB, MLL3, MAP2K.4, RUNX1, CDH1, SF3B 1 , PIK3R1, ARID 1 A, NCOR1, KRAS, SPEN, RB I, MLL, ERBB2, TBL1XR1 , CDKN 1B, HIST1H3B, FOXA1 , CASP8, MED23, TBX3, CUL4B, STAG 2. MYB, RAB40A, EP3G0, FGFR2, GNPTAB, ERBB3, and ACVRIB.
The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of CDKN IB, ALK, and SMARCBl .
The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of SF3B 1 , TP53, MYD88, XPOl, HISTXHIE, RPS15, RPS2 NRAS, DDX3X, SPEN, ATM, MED 12, IDH1, SETDB 1, and J AKL The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of APC, TP53, FBXW7, SMAD4, NRAS, SMAD2, TCF7L2, BRAF, KRAS, PIK3CA, PCBPl, ARID 1 A, ACVRIB, ERBB3, CASP8, ELF3, TRJM23, CDC27, B2M, NTN4, AXIN2, SIRT4, GOT1 RBM10, BCLAF1, BCOR, MAP2K4, IDH2, PTEN, ERBB2, ARID2, CTNNB 1, TRAF3, CNBD! , and CD70.
The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of TP53, MYD88, TNFRSF14, CD79B, MLL2, EZH2, CARD11, CREBBP, TNF, CD70, POU2F2, ITPKB, IILA-A, BRAF, GNA 13, POU2AF1 HIST1H3B, KRAS, B2M, NOTCH1, PTEN, and MAP2K1 , ZNF471. ) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of PTEN, PIK3CA, PIK3R1, TP53, KRAS, FBXW7, CTCF, ARID 1 A, ARHGAP35, ZFHX3, FGFR2, CCND1, PPP2R1A, INGL ZNF471 , ERBB3, CT NB1, BCOR, CUX1, SPOP, NRAS, FAT1, ARID5B, CCDC6, ZNF620, AKT1 , SIX 1 A3, EIF2S2, TCP1 1 L2, SGK1, DTAPHl, KLFTL8, SOX17, GNPTAB, SLC44A3, ADNP, POLE, TTLL9, SELP, CHD4, PPM1D, RSBNI L, MICALCL, SACS, AN 3, TBL1XR1, SOS1 , DNER, MORC4, MYC , TXNDC8, INPPL1 , ZRANB3, TAP1 , EP300, TPX2, CAP2, ALKBH6 CA8P8, RASA1 , MGA, PBRMl , ERBB2, MLL4, ATM, CDKN1B, RB I , NFE2L2, TP53BP1, COL5A1, FLT3, MTOR, and TDRD10.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of TP53, CDKN2A, FLG, SMARCA4, PIK3CA, SMARCB 1, 1L7R, COLS A 1 SMAD4, KRAS, ARID 1 A, SETDB1, ERBB2, SACS, and PIK3Rl .
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of TP53, EGFR, PIK3R1, PI 3CA, IDH1 , RBI , PTEN, NF1, STAG2, RPL5, SLC26A3, BRAF, MAP3K1, KEL, CD ID, CHD8, DDX5, MUC17, QKI, AZGP1 , SETD2, NUP210L 8M.C1A, BCOR, PTPN1 1 , and EZR.) The vector system of items 1 -12, wherein the target sequences are genes selected from the group consisting of TP53, CDKN2A, CASP8, FA'I'l , NFE2L2, NOTCH 1 , MLL2, NSD1, HRAS, EPHA2, PI 3CA, AJUBA, RAC1, ZNF750, RHOA, TGFBR2, PTEN, IILA-A, EP300, B2M, OTUD7A, HLA-B, CTCF, IP07, RASA1 , MAP4K3 RBI , KDM6A, SMAD4, AR1D2, ASXL1 , ARHGAP35, MLL3, NCOR1, and PBRM1.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of SETD2, BAPI, VHL, PBRM1, PTEN, KDM5C, TP53, MTOR, ARID 1 A, GUSB, RHEB, ATM, TCEBl, MPO, CCDC120, PIK3CA, EGFR, ARHGAP35, BRCA1, FGFR3, and COL5A3.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of TP53, KEAP1 , STK11, CDKN2A, KRAS, U2AF1, SMARCA4, EGFR, MET, NFL RIT1, BRAF, PIK3CA, RBM10, ERBB2, ARID 1 A, ATM, SLC4A5, NBPF1, STX2, MAP2K1, RBI, FAT! , APC, MLL3, NRAS, SMAD4, CDKN1 B, CTNNB 1 , ARHGAP35, ARID2, and CDK12. ) The vector system of hems 1-12, wherein the target sequences are genes selected from the group consisting of TP53, CDKN2A, MLL2, KEAPl, PIK3CA, NFE2L2, RB I, HRAS, HLA-A, ARID 1 A, FBXW7, PTEN, EP300, EGFR, ARHGAP35, RASA1 , FGFR3, NF1, NSD1 , ASXL1 , STK1 1, FAT1, NOTCH 1, and SERPINB13.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of DDX3X, CTNNB 1, and TP53.
) The vector system of hems 1-12, wherein the target sequences are genes selected from the group consisting of BRAF, NRAS, CDKN2A, TP53, BCLAF1 , RAC1, PTEN, PPP6C, FRMD7, CDK4, STK19, ACOl , XIRP2, LCTL, OR52N1, ALPK2, WASF3, OR4A16, MYOCD, CTNNBl, ZNF750, KIT, MXRA5, ARID2, ANK3, RXRA, PIK3CA, and NCORl .
) The vector system of items 1 -12, wherein the target sequences are genes selected from the group consisting of KRAS, NRAS, TP53, DIS3, BRAF, FAM46C, INTS12, TRAF3, PRDM.1 , IRF4, IDH1, FGFR3, PTPN1 1 , and EZR.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of TP53, BRCA1, RB I, CDK12, NF1, SMARCBl, KRAS, NRAS, CREBBP, and ERBB2.
) The vector system of items 1-12, wherein the target sequences are genes selected from the group consisting of SPOP, TP53, ATM, MED 12, FOXA1 , and COL5A1.) The vector system of any one of items 1-38, wherein components I and 11 are located on the same vector of the vector system.
) The vector system of any one of items 1-38, wherein components I and II are located on different vectors of the vector system.
) The vector system of any one of items 1-38, wherein the vector system does not comprise component I
) The vector system of any one of items 1-38, wherein the vector system does not comprise component II.
) The vector system of any one of items 1-38, wherein the guide sequences are located on different vectors of the vector system.
) The vector system of any one of items 1-38, wherein the guide sequences are located on the same vector of the vector system.
148
90.1 ) A method for producing a genetically altered population of cells, wherein said method comprises transducing a population of cells from an organism with a vector system according to any one of items 1-44.
) The method for producing a genetically altered population of cells of item 45, wherein the method is performed on non-humans.
) The method for producing a genetically altered population of cells of items 45 or 46, wherein the population of cells is isolated from an organism.
) The method for producing a genetically altered population of cells of item 45, wherein the method is performed in vitro.
) A use of the vector system a vector system according to any one of items 1 -44 for producing a genetically altered population of cells from an organism.
) The use of the vector system according to item 49, wherein the use is performed in non-human animals.
) The use of the vector system according to item 49, wherein the use is performed in vitro.
) A genetically altered population of cells obtainable by a method according to any one of items 45-48.
) A method for producing a non-human animal, wherein said method comprises the use of the vector system of any one of items 1 -44.
) A method for producing a non-human animal, wherein said method comprises the delivery of the vector system of any one of items 1 -44 to a non-human animal.) A method for producing a non-human animal, wherein said method comprises the delivery of the genetically altered population of cells of item 52 to a non-human animal
) A method for producing a non-human animal, wherein said method comprises the delivery of the vector system of any one of items 1 -44 to the pronucleus of a zygote from a pseudo pregnant female.
) The method for producing a. non-human animal of item 56, wherein the pseudo pregnant female is selected from the group consisting of mice, rats and rabbits.) The method for producing a non-human animal of item 56 or item 57, wherein the pseudo pregnant female is a mouse.
) A non-human animal obtainable by a method according to any one of items 53-58.
149
90.1 ) The non-human animal according to item 59, wherein the non-human animal comprises a proliferative condition resulting from a method according to any one of items 53-58.
) A non-human animal comprising the vector system of any one of items 1 -44.
) The non-human animal according to item 61, wherein the non-human animal comprises a proliferative condition resulting from the vector system of a ny one of items 1-44.
) A non-human animal comprising a genetically altered population of cells of item 52.
) The non-human animal according to item 63, wherein the non-human animal comprises a proliferative condition resulting from the genetically altered population of cells of item 52,
) The non-human animal according to any one of items 60, 62, or 64, wherein the proliferative condition is a proliferative disorder.
) The non-human animal according to any one of items 60, 62, or 64, wherein the proliferative condition is a cancer.
) The non-human animal according to any one of items 60, 62, or 64, wherein the proliferative condition is a myeloid malignancy.
The non-human animal according to any one of items 60, 62, or 64, wherein the proliferative condition is selected from the group consisting of acute myeloid leukemia, bladder cancer, breast cancer, carcinoid cancer, chronic lymphocytic leukemia cancer, colorectal cancer, diffuse large B-cell lymphoma cancer, endometrial cancer, esophageal adenocarcinoma cancer, glioblastoma multiforme cancer, head and neck cancer, kidney clear cell cancer, lung adenocarcinoma cancer, lung squamous cell carcinoma cancer, medulloblastoma cancer, melanoma cancer, multiple myeloma cancer, neuroblastoma cancer, ovarian cancer, prostate cancer, and rhabdoid tumor/cancer
) A method for inducing a proliferative condition, wherein said method comprises transducing a population of cells with a vector system according to any one of items 1-44.
) The method for inducing a proliferative condition according to item 69, wherein said method comprises transducing a population of non-human cells with a vector system according to any one of items 1 -44.
150
90.1 71 ) The method for inducing a proliferative condition according to item 69 or item 70, wherein said method is performed in vitro,
72) The method for inducing a proliferative condition according to any one of items 69-71 , wherein said proliferative condition is proliferative disorder.
73) The method for inducing a proliferative condition according to any one of items 69-71 , wherein said proliferative condition is a cancer.
74) The method for inducing a proliferative condition according to any one of items 69-71, wherein said proliferative condition is a myeloid malignancy.
75 The method for inducing a proliferative condition according to any one of items 69-71, wherein the proliferative condition is selected from the group consisting of acute myeloid leukemia, bladder cancer, breast cancer, carcinoid cancer, chronic lymphocytic leukemia cancer, colorectal cancer, diffuse large B-cell lymphoma cancer, endometrial cancer, esophageal adenocarcinoma cancer, glioblastoma, multiforme cancer, head and neck cancer, kidney clear cell cancer, lung adenocarcinoma cancer, lung squamous cell carcinoma cancer, medulloblastoma cancer, melanoma cancer, multiple myeloma cancer, neuroblastoma cancer, ovarian cancer, prostate cancer, and rhabdoid tumor/cancer .
76) A vector system according to any one of items 1 -44 for the use of inducing a proliferative condition in an organism.
77) The vector system according to item 76, wherein the organism is a. non-human animal.
78) The vector system according to item 76 or item 77, wherein said proliferative condition is proliferative disorder.
79) The vector system according to item 76 or item 77, wherein said proliferative condition is a cancer.
80) The vector system according to to item 76 or item 77, wherein said proliferative condition is a myeloid malignancy.
81) The vector system according to item 76 or item 77, wherein the proliferative condition is selected from the group consisting of acute myeloid leukemia, bladder cancer, breast, cancer, carcinoid cancer, chronic lymphocytic leukemia cancer, colorectal cancer, diffuse large B-cell lymphoma cancer, endometrial cancer, esophageal adenocarcinoma cancer, glioblastoma multiforme cancer, head and neck cancer, kidney clear cell cancer, lung adenocarcinoma cancer, lung squamous cell carcinoma cancer, medulloblastoma cancer, melanoma cancer, multiple myeloma cancer, neuroblastoma cancer, ovarian cancer, prostate cancer, and rhabdoid tumor/cancer
A genetically altered population of ceils according to item 52, for the use of inducing a proliferative condition in an organism.
The genetically altered population of cells according to item 82, wherein the organism is a non-human animal.
The genetically altered population of cells according to item 82 or item 83, wherein said proliferative condition is proliferative disorder.
The genetically altered population of cells according to item 82 or item 83 , wherein said proliferative condition is a cancer.
The genetically altered population of ceils according to item 82 or item 83, wherein said proliferative condition is a myeloid malignancy.
The genetically altered population of ceils according to item 82 or item 83, wherein said proliferative condition is selected from the group consisting of acute myeloid leukemia, bladder cancer, breast cancer, carcinoid cancer, chronic lymphocytic leukemia cancer, colorectal cancer, diffuse large B-cell lymphoma cancer, endometrial cancer, esophageal adenocarcinoma cancer, glioblastoma multiforme cancer, head and neck cancer, kidney clear cell cancer, lung adenocarcinoma cancer, lung squamous cell carcinoma cancer, medulloblastoma cancer, melanoma cancer, multiple myeloma cancer, neuroblastoma cancer, ovarian cancer, prostate cancer, and rhabdoid tumor/cancer.
A method of interrogating function of one or more genes of cells in a proliferative condition induced according to any one of items 69-75 comprising determining changes in expression of one or more genes of ceils in the proliferative condition thereby interrogating the function of one or more genes.
A method of interrogating function of one or more genes of cells in a proliferative condition in a non-human animal according to any one of items 60, 62, 64, or 65- 68 comprising determining changes in expression of one or more genes of ceils in the proliferative condition thereby interrogating the function of one or more genes.
152
90.1 EXAMPLES
[00416] The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.
Example I: CRISPR Complex Activity in the Nucleus of a Eukaryotic Cell
[00417] An example type If CRISPR system is the type II CRISPR locus from Streptococcus pyogenes SF370, which contains a cluster of four genes Cas9, Cas l, Cas2, and Csnl, as well as two non-coding RNA elements, tracrRNA and a characteristic array of repetitive sequences (direct repeats) interspaced by short stretches of non -repetitive sequences (spacers, about 30bp each), in this system, targeted DNA double-strand break (DSB) is generated in four sequential steps (Fig, 2A). First, two non-coding RNAs, the pre-crRNA array and tracrRNA, are transcribed from the CRISPR locus. Second, tracrRNA hybridizes to the direct repeats of pre-crRNA, which is then processed into mature crRNAs containing individual spacer sequences. Third, the mature crRNA:tracrRNA complex directs Cas9 to the DNA target consisting of the protospacer and the corresponding PAM via heteroduplex formation between the spacer region of the crRNA and the protospacer DNA. Finally, Cas9 mediates cleavage of target DNA upstream of PAM to create a DSB within the protospacer (Fig. 2A). This example describes an example process for adapting this RN A -programmable nuclease system to direct CRISPR complex activity in the nuclei of eukaryotic cells.
[00418] Cell culture and transfection
[00419] Human embryonic kidney (HEK) cell line HEK 293FT (Life Technologies) was maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (HyClone), 2mM GiutaMAX (Life Technologies), lOOU/mL penicillin, and 100}ig<'mL streptomycin at 37"C with 5% C02 incubation. Mouse neuro2A (N2A) cell line (ATCC) was maintained with DMEM supplemented with 5% fetal bovine serum (HyClone), 2mM GiutaMAX (Life Technologies), lOOU/mL penicillin, and !00μ¾''ηιΙ. streptomycin at 37°C with 5% C02. [00420] HEK 293FT or N2A ceils were seeded into 24-well plates (Corning) one day prior to transfeetion at a density of 200,000 cells per well. Cells were transfected using Lipofectamine 2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24-well plate a total of 800ng of plasmids were used.
[00421] Surveyor assay and sequencing analysis for genome modification
[00422] HEK 293FT or N2A cells were transfected with plasmid DNA as described above. After transfection, the cells were incubated at 37°C for 72 hours before genomic DNA extraction. Genomic DNA was extracted using the QuickExtract DNA extraction kit (Epicentre) following the manufacturer's protocol. Briefly, cells were resuspended in QuickExtract solution and incubated at 65°C for 15 minutes and 98°C for 10 minutes. Extracted genomic DNA was immediately processed or stored at -2()°C.
[00423] The genomic region surrounding a CRISPR target site for each gene was PGR amplified, and products were purified using QiaQuick Spin Column (Qiagen) following manufacturer's protocol. A total of 400ng of the purified PGR products were mixed with 2μ1 10X Taq polymerase PGR buffer (Enzymatics) and ultrapure water to a final volume of 20μ1, and subjected to a re-annealing process to enable eteroduplex formation: 95°C for lOmin, 95°C to 85°C ramping at - 2°C/s, 85°C to 25°C at - 0.25°C/s, and 25°C hold for 1 minute. After re-annealing, products were treated with Surveyor nuclease and Surveyor enhancer S (Transgenomics) following the manufacturer's recommended protocol, and analyzed on 4-20% Novex TBE poly-acrylamide gels (Life Technologies). Gels were stained with SYBR Gold DNA stain (Life Technologies) for 30 minutes and imaged with a Gel Doc gel imaging system (Bio-rad). Quantification was based on relative band intensities, as a measure of the fraction of cleaved DNA. Fig. 7 provides a schematic illustration of this Surveyor assay.
[00424] Restriction fragment length polymorphism assay for detection of homologous recombination.
[00425] HEK 293FT and N2A cells were transfected with plasmid DNA, and incubated at 37°C for 72 hours before genomic DNA extraction as described above. The target genomic region was PGR amplified using primers outside the homology arms of the homologous recombination (HR) template. PGR. products were separated on a 1% agarose gel and extracted with MinElute GelExtraction Kit (Qiagen). Purified products were digested with Hindlll (Fermentas) and analyzed on a 6% Novex TBE poly-acrylamide gel (Life Technologies),
[00426] RN secondary structure prediction and analysis
154
90.1 [0Θ427] RNA secondary structure prediction was performed using the online webserver RNAfold developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g. A.R. Gruber et al, 2008, Cell 106( 1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27( 12): 1 151 - 62).
[00428] RNA purification
[00429] HEK 293FT cells were maintained and transfected as stated above. Cells were harvested by trypsinization followed by washing in phosphate buffered saline (PBS). Total cell RNA was extracted with TRI reagent (Sigma) following manufacturer's protocol. Extracted total RNA was quantified using Naonodrop (Thermo Scientific) and normalized to same concentration.
[00430] Northern blot analysis of crRNA and tracrRNA expression in mammalian cells [00431] RNAs were mixed with equal volumes of 2X loading buffer (Ambion), heated to 95°C for 5 min, chilled on ice for 1 min, and then loaded onto 8% denaturing polyacrylamide gels (SequaGel, National Diagnostics) after pre-running the gel for at least 30 minutes. The samples were eiectrophoresed for 1.5 hours at 40W limit. Afterwards, the RNA was transferred to Hybond N+ membrane (GE Healthcare) at 300 mA in a semi- dry transfer apparatus (Bio-rad) at room temperature for 1.5 hours. The RNA was crosslinked to the membrane using autocrosslmk button on Stratagene UV Crosslinker the Stratalinker (Stratagene). The membrane was pre -hybridized in ULTRAhyb-Oligo Hybridization Buffer (Ambion) for 30 min with rotation at 42°C, and probes were then added and hybridized overnight. Probes were ordered from IDT and labeled with [gamma-32P] ATP (Perkin Elmer) with T4 polynucleotide kinase (New England Biolabs). The membrane was washed once with pre -warmed (42°C) 2xSSC, 0.5% SDS for 1 min followed by two 30 minute washes at 42°C. The membrane was exposed to a phosphor screen for one hour or overnight at room temperature and then scanned with a phosphorimager (Typhoon).
[00432] Bacterial CRISPR system construction and evaluation
[00433] CRISPR locus elements, including tracrRNA, Cas9, and leader were PGR. amplified from Streptococcus pyogenes SF370 genomic DNA with flanking homology arms for Gibson Assembly. Two Bsal type IIS sites were introduced in between two direct repeats to facilitate easy insertion of spacers (Fig. 8). PGR products were cloned into EcoRV-digested pA CYC 184 downstream of the tet promoter using Gibson Assembly Master Mix (NEB). Other endogenous CRTSPR system elements were omitted, with the exception of the last 50bp of Csn2. Oligos (Integrated DNA Technology) encoding spacers with complimentary overhangs were cloned into the J¾al-digested vector pDCOOO (NEB) and then ligated with T7 ligase (Enzymatics) to generate pCRISPR plasrnids. Challenge plasrnids containing spacers with PAM
[00434] expression in mammalian cells (expression constructs illustrated in Fig. 6A, with functionality as determined by results of the Surveyor assay shown in Fig. 6B). Transcription start sites are marked as +1, and transcription terminator and the sequence probed by northern blot are also indicated. Expression of processed tracrRNA was also confirmed by Northern blot. Fig. 6C shows results of a Northern blot analysis of total RNA extracted from 293FT cells transfected with U6 expression constructs carrying long or short tracrRNA, as well as SpCas9 and DR-EMX1 1)-DR. Left and right panels are from 293FT cells transfected without or with SpRNase 111, respectively. U6 indicate loading control blotted with a probe targeting human U6 snRNA. Transfection of the short tracrRNA expression construct led to abundant levels of the processed form of tracrRNA (~75bp). Very low amounts of long tracrRNA are detected on the Northern blot.
|00435] To promote precise transcriptional initiation, the RNA polymerase Ill-based U6 promoter was selected to drive the expression of tracrRNA (Fig. 2C). Similarly, a U6 promoter-based construct was developed to express a pre-erRNA array consisting of a single spacer flanked by two direct repeats (DRs, also encompassed by the term "tracr- mate sequences"; Fig, 2C). The initial spacer was designed to target a 33-base-pair (bp) target site (30-bp protospacer plus a 3 -bp CRTSPR motif (PAM) sequence satisfying the NGG recognition motif of Cas9) in the human EMX1 locus (Fig. 2C), a key gene in the development of the cerebral cortex.
[00436] To test whether heterologous expression of the CRISPR system (SpCas9, SpRNase III, tracrRNA, and pre-crR A) in mammalian cells can achieve targeted cleavage of mammalian chromosomes, HEK 293FT cells were transfected with combinations of CRTSPR components. Since DSBs in mammalian nuclei are partially repaired by the non-homologous end joining (NHEJ) pathway, which leads to the formation of indels, the Surveyor assay was used to detect potential cleavage activity at the target EMX1 locus (Fig. 7) (see e.g. Guschin et al, 2010, Methods Mol Biol 649: 247). Co-transfection of all four CRTSPR components was able to induce up to 5.0% cleavage in the protospacer (see Fig. 2D). Co-transfection of all CRISPR components minus
156
90.1 SpRNase III also Induced up to 4.7% indel in the protospacer, suggesting that there may be endogenous mammalian RNases that are capable of assisting with crRNA maturation, such as for example the related Dicer and Drosha enzymes. Removing any of the remaining three components abolished the genome cleavage activity of the CRISPR system (Fig. 2D). Sanger sequencing of ampHcons containing the target locus verified the cleavage activity: in 43 sequenced clones, 5 mutated alleles (11.6%) were found. Similar experiments using a variety of guide sequences produced indel percentages as high as 29% (see Figs. 3-6, 10, and 1 1 ). These results define a three-component system for efficient CRISPR-mediated genome modification in mammalian cells. To optimize the cleavage efficiency, Applicants also tested whether different isoforms of tracrRNA affected the cleavage efficiency and found that, in this example system, only the short (89 -bp) transcript form was able to mediate cleavage of the human EMX1 genomic locus (Fig. 6B).
[00437] Fig. 12 provides an additional Northern blot analysis of crRNA processing in mammalian cells. Fig. I2A illustrates a schematic showing the expression vector for a single spacer flanked by two direct repeats (DR-EMX1 (l)-DR). The 30bp spacer targeting the human EMX1 locus protospacer 1 (see Fig. 6) and the direct repeat sequences are shown in the sequence beneath Fig. 12A. The line indicates the region whose reverse-complement sequence was used to generate Northern blot probes for EMX1(1) crRNA detection. Fig. 12B shows a Northern blot analysis of total RNA. extracted from 293FT cells transfected with U6 expression constructs carrying DR- EMX1(1 )-DR. Left and right panels are from 293FT cells transfected without or with SpRNase HI respectively. DR-EMX1(1)-DR was processed into mature crRNAs only in the presence of SpCas9 and short tracrRNA and was not dependent on the presence of SpRNase III. The mature crRNA detected from transfected 293FT total RNA is ~33bp and is shorter than the 39-42bp mature crRNA from S. pyogenes. These results demonstrate that a. CRISPR system can be transplanted into eukaryotic cells and reprogrammed to facilitate cleavage of endogenous mammalian target polynucleotides.
[00438] Fig, 2 illustrates the bacterial CRISPR system described in this example. Fig. 2A illustrates a schematic showing the CRISPR locus 1 from Streptococcus pyogenes SF370 and a proposed mechanism of CRISPR-mediated DNA cleavage by this system. Mature crRNA processed from the direct repeat-spacer array directs Cas9 to genomic targets consisting of complimentary protospacers and a protospacer-adjacent motif (P AM). Upon target-spacer base pairing, Cas9 mediates a double-strand break in the target DN A.
157
90.1 Fig. 2B illustrates engineering of S. pyogenes Cas9 (SpCas9) and RNase III (SpRNase III) with nuclear localization signals (NLSs) to enable import into the mammalian nucleus. Fig. 2C illustrates mammalian expression of SpCas9 and SpRNase III driven by the constitutive EFl a promoter and tracrRNA and pre-crRNA array (DR-Spacer-DR) driven by the RNA Pol III promoter U6 to promote precise transcription initiation and termination. A protospaeer from the human EMX1 locus with a satisfactory PAM sequence is used as the spacer in the pre-crRNA array. Fig. 2D illustrates surveyor nuclease assay for SpCas9-mediated minor insertions and deletions. SpCas9 was expressed with and without SpRNase III, tracrRNA, and a pre-crRNA array carrying the JEMX -target spacer. Fig. 2E illustrates a. schematic representation of base pairing between target locus and i? ¾7-targeting crRNA, as well as an example chromatogram showing a micro deletion adjacent to the SpCas9 cleavage site. Fig, 2F illustrates mutated alleles identified from sequencing analysis of 43 clonal amplicons showing a variety of micro insertions and deletions. Dashes indicate deleted bases, and non-aligned or mismatched bases indicate insertions or mutations. Scale bar = ΙΟμηΊ.
[0Θ439] To further simplify the three-component system, a chimeric crRNA-tracrRNA hybrid design was adapted, where a mature crRNA (comprising a guide sequence) may be fused to a partial tracrRNA via a stem-loop to mimic the natural crRNA: tracrRNA duplex. To increase co-delivery efficiency, a bicistronic expression vector was created to drive co- expression of a chimeric RNA and SpCas9 in transfected cells. In parallel, the bicistronic vectors were used to express a pre-crRNA (DR-guide sequence-DR) with SpCas9, to induce processing into crRNA with a separately expressed tracrRNA (compare Fig. 11B top and bottom). Fig. 8 provides schematic illustrations of bicistronic expression vectors for pre-crRNA array (Fig. 8A) or chimeric crRNA (represented by the short line downstream of the guide sequence insertion site and upstream of the EFl a promoter in Fig, 8B) with hSpCas9, showing location of various elements and the point of guide sequence insertion. The expanded sequence around the location of the guide sequence insertion site in Fig. 8B also shows a partial DR sequence (GTTTAGAGCTA) and a. partial tracrRNA sequence (TAGCAAGTTAAAATAAGGCTAGTCCGTTTTT). Guide sequences can be inserted between Bbsl sites using annealed oligonucleotides. Sequence design for the oligonucleotides are shown below the schematic illustrations in Fig, 8, with appropriate ligation adapters indicated. WPRE represents the Woodchuck hepatitis virus post-transcriptional regulatory element. The efficiency of chimeric RNA-mediated cleavage was tested by targeting the same EMX1 locus described above. Using both
158
90.1 Surveyor assay and Sanger sequencing of amplicons, Applicants confirmed that the chimeric RNA design facilitates cleavage of human EMXl locus with approximately a 4.7% modification rate (Fig. 3).
[00440] Generalizability of CRXSPR-mediated cleavage in eukaryotic cells was tested by targeting additional genomic loci in both human and mouse cells by designing chimeric RNA targeting multiple sites in the human EMXl and PVALB, as well as the mouse Th loci. Fig. 13 illustrates the selection of some additional targeted protospacers in human PVALB (Fig. 13 A) and mouse Th (Fig. 13B) loci. Schematics of the gene loci and the location of three protospacers within the last exon of each are provided. The underlined sequences include 30bp of protospacer sequence and 3bp at the 3' end corresponding to the PAM sequences. Protospacers on the sense and anti-sense strands are indicated above and below the DNA sequences, respectively. A modification rate of 6,3% and 0.75% was achieved for the human PVALB and mouse Th loci respectively, demonstrating the broad applicability of the CRJSPR system in modifying different loci across multiple organisms (Fig. 5). While cleavage was only detected with one out of three spacers for each locus using the chimeric constructs, all target sequences were cleaved with efficiency of indel production reaching 27% when using the co-expressed pre-crRNA arrangement (Figs, 6 and 13 ).
[00441] Fig. 1 1 provides a further illustration that SpCas9 can be reprogrammed to target multiple genomic foci in mammalian cells. Fig. 1 1A provides a schematic of the human EMXl locus showing the location of five protospacers, indicated by the underlined sequences. Fig. 1 1B provides a schematic of the pre-crRNA/trcrRNA complex showing hybridization between the direct repeat region of the pre-crRNA and tracrR_NA (top), and a schematic of a chimeric RNA design comprising a 20bp guide sequence, and tracr mate and tracr sequences consisting of partial direct repeat and tracrRNA sequences hybridized in a hairpin structure (bottom). Results of a Surveyor assay comparing the efficacy of Cas9-mediated cleavage at five protospacers in the human EMXl locus is illustrated in Fig, l lC. Each protospacer is targeted using either processed pre-crRNA/tracrRNA complex (crRNA) or chimeric RNA (chiRNA).
[0Θ442] Since the secondary structure of RNA can be crucial for intermolecular interactions, a structure prediction algorithm based on minimum free energy and Boiizmann-weighted structure ensemble was used to compare the putative secondary structure of all guide sequences used in the genome targeting experiment (see e.g. Gruber et at , 2008, Nucleic Acids Research, 36: W70). Analysis revealed that in most cases, the
159
90.1 effective guide sequences in the chimeric crRNA context were substantially free of secondary structure motifs, whereas the ineffective guide sequences were more likely to form internal secondary structures that could prevent base pairing with the target protospacer DNA. It is thus possible that variability in the spacer secondary structure might impact the efficiency of CRISPR -mediated interference when using a chimeric crRNA.
[00443] Further vector designs for SpCas9 are shown in Fig. 22, which illustrates single expression vectors incorporating a U6 promoter linked to an insertion site for a guide oligo, and a Cb promoter linked to SpCas9 coding sequence. The vector shown in Fig, 22b includes a tracrRNA coding sequence linked to an HI promoter.
[00444] In the bacterial assay, all spacers facilitated efficient CRISPR interference (Fig. 3C), These results suggest that there may be additional factors affecting the efficiency of CRISPR activity in mammalian cells,
[00445] To investigate the specificity of CRISPR-mediated cleavage, the effect of single-nucleotide mutations in the guide sequence on protospacer cleavage in the mammalian genome was analyzed using a series of EMXJ -targeting chimeric crRNAs with single point mutations (Fig. 3A), Fig. 3B illustrates results of a Surveyor nuclease assay comparing the cleavage efficiency of Cas9 when paired with different mutant chimeric RNAs, Single-base mismatch up to 12-bp 5' of the PAM substantially abrogated genomic cleavage by SpCas9, whereas spacers with mutations at farther upstream positions retained activity against the original protospacer target (Fig. 3B). In addition to the PAM, SpCas9 has single-base specificity within the last 1 2-bp of the spacer. Furthermore, CRISPR is able to mediate genomic cleavage as efficiently as a pair of TALE nucleases (TALEN) targeting the same EMX1 protospacer. Fig, 3C provides a schematic showing the design of TALENs targeting EMX1, and Fig. 3D shows a Surveyor gel comparing the efficiency of TALEN and Cas9 (n=3).
[00446] Having established a set of components for achieving CRISPR-mediated gene editing in mammalian cells through the error-prone NHEJ mechanism, the ability of CRISPR to stimulate homologous recombination (HR), a high fidelity gene repair pathway for making precise edits in the genome, was tested. The wild type SpCas9 is able to mediate site-specific DSBs, which can be repaired through both NHEJ and HR. In addition, an aspartaie-to-alanine substitution (D10A) in the RuvC I catalytic domain of SpCas9 was engineered to convert the nuclease into a nickase (SpCas9n; illustrated in Fig. 4A) (see e.g. Sapranausaks et al , 201 1, Nucleic Acids Research, 39: 9275; Gasiunas et aL' ,
160
90.1 2012, Proc. Natl. Acad. Sci. USA, 109:E2579), such that nicked genomic DNA undergoes the high-fidelity honiology-directed repair (HDR). Surveyor assay confirmed that SpCas9n does not generate indels at the EMXI protospacer target. As illustrated in Fig. 4B, co-expression of EMXI -targeting chimeric crRNA with SpCas9 produced indels in the target site, whereas co-expression with SpCas9n did not (n=3). Moreover, sequencing of 327 amplicons did not detect any indels induced by SpCas9n. The same locus was selected to test CRISPR-mediated HR by co-transfecting HE 293FT cells with the chimeric RNA targeting EMXI, hSpCas9 or hSpCas9n, as well as a HR template to introduce a pair of restriction sites (HmdIII and Nhel) near the protospacer. Fig. 4C provides a schematic illustration of the HR strategy, with relative locations of recombination points and primer annealing sequences (arrows). SpCas9 and SpCas9n indeed catalyzed integration of the HR template into the EMXI locus, PGR amplification of the target region followed by restriction digest with ΗίηάΙΪΙ revealed cleavage products corresponding to expected fragment sizes (arrows in restriction fragment length polymorphism gel analysis shown in Fig. 4D), with SpCas9 and SpCas9n mediating similar levels of HR efficiencies. Applicants further verified HR using Sanger sequencing of genomic amplicons (Fig. 4E). These results demonstrate the utility of CRISPR for facilitating targeted gene insertion in the mammalian genome. Given the 14-bp (12-bp from the spacer and 2 -bp from the PAM) target specificity of the wild type SpCas9, the availability of a nickase can significantly reduce the likelihood of off -target modifications, since single strand breaks are not substrates for the error -prone NHEJ pathway.
[00447] Expression constructs mimicking the natural architecture of CRISPR loci with arrayed spacers (Fig. 2A) were constructed to test the possibility of multiplexed sequence targeting. Using a single CRISPR array encoding a pair of EMXI- and PVALB-taxgetwg spacers, efficient cleavage at both loci was detected (Fig. 4F, showing both a schematic design of the crRNA array and a Surveyor blot showing efficient mediation of cleavage). Targeted deletion of larger genomic regions through concurrent DSBs using spacers against two targets within EMXI spaced by 119bp was also tested, and a 1.6% deletion efficacy (3 out of 1 82 amplicons; Fig. 4G) was detected. This demonstrates that the CRISPR system can mediate multiplexed editing within a single genome.
Example 2: CRISPR system modifications and alternatives
[00448] The ability to use RNA to program sequence-specific DNA cleavage defines a new class of genome engineering tools for a variety of research and industrial applications.
161
90.1 Several aspects of the CRISPR system can he further improved to increase the efficiency and versatility of CRISPR targeting. Optimal Cas9 activity may depend on the availability of free Mg/-+ at levels higher than that present in the mammalian nucleus (see e.g. jinek et al, 2012, Science, 337:816), and the preference for an NGG motif immediately downstream of the protospacer restricts the ability to target on average ever)' 12 -bp in the human genome (Fig, 9, evaluating both plus and minus strands of human chromosomal sequences). Some of these constraints can be overcome by exploring the diversity of CRISPR loci across the microbial metagenome (see e.g. Makarova et al , 201 1 , Nat Rev Microbiol, 9:467). Other CRISPR loci may be transplanted into the mammalian cellular milieu by a process similar to that described in Example 1. For example, Fig. 10 illustrates adaptation of the Type 11 CRISPR system from CRISPR 1 of Streptococcus thermophilics LMD-9 for heterologous expression in mammalian cells to achieve CRI8PR- mediated genome editing. Fig. 10A provides a Schematic illustration of CRISPR 1 from 5. thermophUus LMD-9. Figure 10B illustrates the design of an expression system for the S. thermophUus CRISPR system. Human codon-optimized hStCas9 is expressed using a constitutive EFla promoter. Mature versions of tracrRNA and crRNA are expressed using the U6 promoter to promote precise transcription initiation. Sequences from the mature crRNA and tracrRNA are illustrated. A single base indicated by the lower case "a" in the crRNA sequence is used to remove the polyU sequence, which serves as a RNA pollll transcriptional terminator. Fig. IOC provides a schematic showing guide sequences targeting the human EMXl locus. Fig. 10D shows the results of hSiCas9-mediated cleavage in the target locus using the Surveyor assay. RNA guide spacers I and 2 induced 14% and 6.4%, respectively. Statistical analysis of cleavage activity across biological replica at these two protospacer sites is also provided in Fig, 5. Fig. 14 provides a schematic of additional protospacer and corresponding PAM sequence targets of the S. thermophUus CRISPR system in the human EMXl locus. Two protospacer sequences are highlighted and their corresponding PAM sequences satisfying NNAGA AW motif are indicated by underlining 3 ' with respect to the corresponding highlighted sequence. Both protospacers target the anti-sense strand.
Example 3: Sample target sequence selection algorithm.
[00449] A software program is designed to identify candidate CRISPR target sequences on both strands of an input DNA sequence based on desired guide sequence length and a CRISPR motif sequence (PAM) for a specified CRISPR enzyme. For example, target
162
90.1 sites for Cas9 from S. pyogenes, with PAM sequences NGG, may be identified by searching for S'-Nx-NGG-S ' both on the input sequence and on the reverse-complement of the input. Likewise, target sites for Cas9 of 5. thermophiius CRJSPR1, with PAM sequence NNAGAAW, may be identified by searching for 5'-Nx-NNAGAAW-3' both on the input sequence and on the reverse-complement of the input. Likewise, target sites for Cas9 of 5. thermophiius CRISPR3, with PAM sequence NGGNG, may be identified by searching for 5'- x-NGGNG-3 ' both on the input sequence and on the reverse- complement of the input. The value "x" in Nx may be fixed by the program or specified by the user, such as 20.
[00450] Since multiple occurrences in the genome of the DMA target site may lead to nonspecific genome editing, after identifying all potential sites, the program filters out sequences based on the number of times they appear in the relevant reference genome. For those CRISPR enzymes for which sequence specificity is determined by a. 'seed' sequence, such as the 11 -12bp 5' from the PAM sequence, including the PAM sequence itself, the filtering step may be based on the seed sequence. Thus, to avoid editing at additional genomic loci, results are filtered based on the number of occurrences of the seed: PAM sequence in the relevant genome. The user may be allowed to choose the length of the seed sequence. The user may also be allowed to specify the number of occurrences of the seed:PAM sequence in a genome for purposes of passing the filter. The default is to screen for unique sequences. Filtration level is altered by changing both the length of the seed sequence and the number of occurrences of the sequence in the genome. The program may in addition or alternatively provide the sequence of a guide sequence complementary to the reported target sequence(s) by providing the reverse complement of the identified target sequence(s). An example visualization of some target sites in the human genome is provided in Fig. 18.
[00451] Further details of methods and algorithms to optimize sequence selection can be found in U.S. application Serial No. 61/064,798 (Attorney docket 44790.11.2022; Broad Reference BI-2012/084); incorporated herein by reference.
Example 4: Evaluation of multiple chimeric cr UNA- racr RN/i hybrids
[00452] This example describes results obtained for chimeric RNAs (chiRNAs; comprising a guide sequence, a tracr mate sequence, and a tracr sequence in a single transcript) having tracr sequences that incorporate different lengths of wild-type iracrRNA sequence. Fig.16a illustrates a schematic of a bicistronic expression vector for chimeric
163
90.1 RNA and Cas9. Cas9 is driven by the CBh promoter and the chimeric RNA is drivers by a U6 promoter. The chimeric guide RNA consists of a 20bp guide sequence (Ns) joined to the traer sequence (mnning from the first "U" of the lower strand to the end of the transcript), which is truncated at various positions as indicated. The guide and tracr sequences are separated by the tracr-mate sequence GIJUUUAGAGCUA followed by the loop sequence GAAA. Results of SURVEYOR assays for Cas9-mediated indels at the human EMXl and PVALB loci are illustrated in Figs. 16b and 16c, respectively. Arrows indicate the expected SURVEYOR fragments. ChiRNAs are indicated by their "+n" designation, and crRNA refers to a hybrid RNA where guide and tracr sequences are expressed as separate transcripts. Quantification of these results, performed in triplicate, are illustrated by histogram in Figs. 17a and 17b, corresponding to Figs. 16b and 16c, respectively ("N.D." indicates no indels detected). Proiospacer IDs and their corresponding genomic target, proiospacer sequence, PAM sequence, and strand location are provided in Table D, Guide sequences were designed to be complementary to the entire proiospacer sequence in the case of separate transcripts in the hybrid system, or only to the underlined portion in the case of chimeric RNAs.
Table D:
Figure imgf000165_0001
0Θ453] Further details to optimize guide sequences can be found in U.S. application Serial No. 61/836,127 (Attorney docket 44790.08.2022; Broad Reference BI-2013/004G); incorporated herein by reference.
[00454] Initially, three sites within the EMXl locus in human HEK 293FT cells were targeted. Genome modification efficiency of each chiRNA was assessed using the SURVEYOR nuclease assay, which detects mutations resulting from DNA double-strand breaks (DSBs) and their subsequent repair by the non-homologous end joining (NHEJ) DNA damage repair pathway. Constructs designated chiRN A(+n) indicate that up to the +n nucleotide of wild-type tracrRNA is included in the chimeric RNA construct, with values of 48, 54, 67, and 85 used for n. Chimeric RNAs containing longer fragments of wild-type tracrRNA (chiRNA(+67) and chiRNA(+85)) mediated DNA cleavage at all
164
90.1 three EMX1 target sites, with chiRNA(+85) irs particular demonstrating significantly higher levels of DNA cleavage than the corresponding erRNA/tracrRNA hybrids that expressed guide and tracr sequences in separate transcripts (Figs, 16b and 17a). Two sites in the PVALB locus that yielded no detectable cleavage using the hybrid system (guide sequence and tracr sequence expressed as separate transcripts) were also targeted using chiRNAs, chiRNA(+67) and chiRNA(+85) were able to mediate significant cleavage at the two PVALB protospacers (Figs. 16c and 17b).
For all five targets in the EMX1 and PVALB loci, a consistent increase in genome modification efficiency with increasing tracr sequence length was observed. Without wishing to be bound by any theory, the secondary structure formed by the 3' end of the tracrR A may play a role in enhancing the rate of CRISPR complex formation.
Example 5: Cas9 diversity
[00455] The CRISPR-Cas system is an adaptive immune mechanism against invading exogenous DNA employed by diverse species across bacteria and archaea. The type II CRISPR-Cas9 system consists of a set of genes encoding proteins responsible for the "acquisition" of foreign DNA into the CRISPR locus, as well as a set of genes encoding the "execution" of the DNA cleavage mechanism; these include the DNA nuclease (Cas9), a non-coding transactivating cr-RNA (tracrRNA), and an array of foreign DNA-derived spacers flanked by direct repeats (crRNAs). Upon maturation by Cas9, the tracRNA and crRNA duplex guide the Cas9 nuclease to a target DNA sequence specified by the spacer guide sequences, and mediates double-stranded breaks in the DNA near a short sequence motif in the target DNA that, is required for cleavage and specific to each CRISPR-Cas system. The type II CRISPR-Cas systems are found throughout the bacterial kingdom and highly diverse in in Cas9 protein sequence and size, tracrRNA and crRNA direct repeat sequence, genome organization of these elements, and the motif requirement for target cleavage. One species may have multiple distinct CRISPR-Cas systems.
[00456] Applicants evaluated 207 putative Cas9s from bacterial species identified based on sequence homology to known Cas9s and structures orthologous to known subdomains, including the HNH endonuclease domain and the RuvC endonuclease domains [information from the Eugene Koonin and Kira Makarova]. Phylogenetic analysis based on the protein sequence conservation of this set revealed five families of Cas9s, including three groups of large Cas9s (-1400 amino acids) and two of small Cas9s (~1 100 amino acids) (see Figs. 19 and 20A-F). [00457] Further details of Cas9s and mutations of the Cas9 enzyme to convert into a nickase or DNA binding protein and use of same with altered functionality can be found in U.S. application Serial Nos 61/836, 101 and 61/835,936 (Attorney docket 44790.09.2022 and 4790.07.2022 and Broad Reference BI-2013/004E and BI-2013/004F respectively) incorporated herein by reference.
Example 6: Cas9 orthologs
[0Θ458] Applicants analyzed Cas9 orthologs to identify the relevant PAM sequences and the corresponding chimeric guide RNA. Having an expanded set of PAMs provides broader targeting across the genome and also significantly increases the number of unique target sites and provides potential for identifying novel Cas9s with increased levels of specificity in the genome.
[00459] The specificity of Cas9 orthologs can be evaluated by testing the ability of each Cas9 to tolerate mismatches between the guide RNA and its DNA target. For example, the specificity of SpCas9 has been characterized by testing the effect of mutations in the guide RNA on cleavage efficiency. Libraries of guide RNAs were made with single or multiple mismatches between the guide sequence and the target DNA. Based on these findings, target sites for SpCas9 can be selected based on the following guidelines:
[00460] To maximize SpCas9 specificity for editing a particular gene, one should choose a target site within the locus of interest such that potential 'off -target' genomic sequences abide by the following four constraints: First and foremost, they should not be followed by a PAM with either 5'-NGG or NAG sequences. Second, their global sequence similarity to the target sequence should be minimized. Third, a maximal number of mismatches should lie within the PAM-proximal region of the off-target site. Finally, a maximal number of mismatches should be consecutive or spaced less than four bases apart,
[00461] Similar methods can be used to evaluate the specificity of other Cas9 orthologs and to establish criteria for the selection of specific target sites within the genomes of target species. As mentioned previously phylogenetic analysis based on the protein sequence conservation of this set revealed five families of Cas9s, including three groups of large Cas9s ( -1400 amino acids) and two of small Cas9s (-1 100 amino acids) (see Figs. 19 and 20A-F). Further details on Cas orthologs can be found in U.S. application Serial Nos 61/836, 101 and 61/835,936 (Attorney docket 44790.09.2022 and 4790.07.2022 and
166
90.1 Broad Reference BI-2013/004E and BI-2013/004F respectively) incorporated herein by reference.
Example 7: Methodological improvement to simplify cloning and delivery.
[00462] Rather than encoding the U6-promoter and guide RNA on a plasmid,
Applicants amplified the U6 promoter with a DNA oligo to add on the guide RNA. The resulting PGR product may be transfected into cells to drive expression of the guide RNA.
[00463] Example primer pair that allows the generation a PGR product consisting of
U6-promoter: :guideRNA targeting human Emxl locus:
[00464] Forward Primer: AAACTCTAGAgagggcctattteccatgattc
[00465] Reverse Primer (carrying the guide RNA, which is underlined): acctctagAAAAAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTA
GC
CTTATTTTAACTTGCTATGCTGTTTTGTTTCCAAAACAGCATAGCTCTAAAACC CC TAGTCATTGGAGGTGACGGTGTTTCGTCCTTTCCACaag
Example 8: Methodological improvement to improve activity:
[00466] Rather than use pol3 promoters, in particular RNA polymerase 111 (e.g. U6 or HI promoters), to express guide RNAs in eukaryotic cells, Applicants express the T7 polymerase in eukaryotic cells to drive expression of guide RN As using the T7 promoter.
[00467] One example of this system may invol ve introduction of three pieces of DNA:
[00468] 1. expression vector for Cas9
[0Θ469] 2. expression vector for T7 polymerase
[00470] 3. expression vector containing guideRNA fused to the 17 promoter
Example 9: Methodological improvement to reduce toxicity of Cas9: Deliver,) of ( 'a in the form ofmRNA.
[00471] Delivery of Cas9 in the form of mR A enables transient expression of Cas9 in cells, to reduce toxicity. For example, humanized SpCas9 may be amplified using the following primer pair:
[00472] Forward Primer (to add on T7 promoter for in vitro transcription): TAATACGACTCACTATAGGAAGTGCGCCACCATGGCCCCAAAGAAGAAGCGG
[00473] Reverse Primer (to add on polyA tail):
GGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTttcttaCTTTTTCTTTTTTGCCTGGCCG
167
90.1 [00474] Applicants transfect the Cas9 mRNA into cells with either guide RNA in the form of RN A or DNA cassettes to drive guide RNA expression in eukaryotic cells.
Example 10: Methodological improvement to reduce toxicity of Cas9: Use of an inducible promoter
[00475] Applicants transiently turn on Cas9 expression only when it is needed for carrying out genome modification. Examples of inducible system include tetracycline inducible promoters (Tet-On or Tet-Off), small molecule two-hybrid transcription activations systems (FKBP, ABA, etc), or fight inducible systems (Phytochrome, LOV domains, or cryptochrome).
Example 11: Improvement of the Cas9 system for in vivo application
[00476] Applicants conducted a Metagenomic search for a Cas9 with small molecular weight. Most Cas9 homologs are fairly large. For example the SpCas9 is around 1368aa long, which is too large to be easily packaged into viral vectors for delivery. A graph representing the length distribution of Cas9 homologs is generated from sequences deposited in GenBank (Fig. 23). Some of the sequences may have been mis-annotated and therefore the exact frequency for each length may not necessarily be accurate. Nevertheless it provides a glimpse at distribution of Cas9 proteins and suggest that there are shorter Cas9 homologs.
[00477] Through computational analysis, Applicants found that in the bacterial strain Campylobacter, there are two Cas9 proteins with less than 1000 amino acids. The sequence for one Cas9 from Campylobacter jejuni is presented below. At this length, CjCas9 can be easily packaged into AAV, lentiviruses, Adenoviruses, and other viral vectors for robust delivery into primary cells and in vivo in animal models. In a preferred embodiment of the invention, the Cas9 protein from S. aureus is used.
[00478] Campylobacter jejuni Cas9 (CjCas9)
[00479] MARILAFDIGlSSIGWAFSENDELKDCGVRIFTKVENPK'rGESLALPRRL AR
SAR.KRLARR ARLNHLKHLIANEFKLNYEDYQSFDESLAKAYKGSLISPYELRFR ALN
ELLS QDFARVILHIAKRRGYDDIKJN SDDKEKGAILKAI QNEEKLANYQSVGEY LYK
EYFQKFKENSKEFTNVRNK ESYER.CIAQSFLKDELKLIFKKQREFGFSFSK FEEE
168
90.1 VI,
SVAf^KRALKDFSHLVGNCSFFTDEK
1L
YTKDDLNALL EVLK GTLTYKQTKKLLGLSDDYEFKGEKGTYFIEF KYKEFTK AL
GEHN LSQDDLNEIAKDITLIKDEIKLKKALAKYDLN QNQID SLSKLEFKDHLN ISFK AL
KL-VTPLMLEGKKYDEAC ELNLKVAINEDKKDFLPAFlSrETYYKDEVTNPVVLRA IKE
Figure imgf000170_0001
EK
LGLKI SKNILKLRLFKEQKEFCAYSGEKIKISDLQDEKMLEIDHIYPYSRSFDDSY MN
KVLVFTKQNQEKLNQTl^FEAFGNDSAKVVQKIEVLAlOiLPTKKQKi lLDKNYKDK EQ
KNFKDRJ LNDTRYIARLVL YTKDYLDFLPLSDDENTKL DTQKGSKVHVEAKS
GM
LTSALRHTWGFSAKDRNNHLHHAIDAVUAYANNSIVKAFSDFKKEQESNSAELY AK
KISELDYKNKRKFFEPFSGFRQKVLDKIDEIFVSKPERKKPSGALHEETFRKEEEFY
QS
YGGKEGVLKALELGKTRKVNGKWKNGDMFRVDIFKHKKTNKFYAVPIYTMDFA LK
VLPNKAVARSKKGE1KDW1LMDENYEFCFSLYKDSLILIQTKDMQEPEFVYYNAF TSS
TVSLIVSKHDNKFETLSKNQKILFKNANEKEVIAKSIGIQNLKVFEKYIVSALGEVT KA EFRQREDFKK.
[00480] The putative traerRNA element for this CjCas9 is:
0Θ48Ϊ ] TATAATCTCATAAGAAATTTAAAAAGGGACTAAAATAAAGAGTTTG CG GGACTCTGCGGGGTTACAATCCCCTAAAACCGCTTTTAAAATT
[00482] The Direct Repeat sequence is:
[00483] ATTTTACCATAAAGAAATTTAAAAAGGGACTAAAAC
[00484] An example of a chimeric guideR A for CjCas9 is:
169
90.1 0Θ485] \mmmmmmmmm¾GlJlJT JAGIJCCCljAAAGGGAClJAAA AU
AAAGAGUUUGCGGGACUCUGCGGGGUUACAAUCCCCUAAAACCGCUUUU
Example 12: Cas9 optimization
[00486] For enhanced function or to develop new functions, Applicants generate chimeric Cas9 proteins by combining fragments from different Cas9 homologs. For example, two example chimeric Cas9 proteins:
[00487] For example. Applicants fused the N-term of St! Cas9 (fragment from this protein is in bold) with C-term of SpCas9 (fragment from this protein is underlined), [00488] >Stl(N)Sp(C)Cas9
[00489] MSDLVLGLDIGIGSVGVG1LNKVTGEI1HKNSRIFPAAQAENNLVRR
Figure imgf000171_0001
LFIALKNMVKHRGISYLDDASDDGNSSVGDYAQIVKENSKQLETKTPGQIQLE RY
QTYGQLRGDFTVEKDGKKHRLINVFPTSAYRSEALRILQTQQEFNPQITDEFI
NR
YLEBLTGKRKYYHGPG E SRTDYGRYRTSGETLD IFGILIGKCTFYPDEFR
Figure imgf000171_0002
LIPELYETSEEQMTILTRLGKQKTTSSSNKTKYIDEKLLTEEIYNPVVAKSVRQ AIK
IVNAAIKEYGDFD IVIEMARE QTTQKGO NSRE.RMKRIEEGIKELGSOILKEH PVE
NTOLO EKLYLYYLONGRDMYVDOELDI RLSDYDVDHIVPOSFLKDDSIDislKV
LL
RSDKNRG SD VPSEEVVK.KMK YWROLL AKLIT( RKFDNLT AERGGLSEL
170
90.1 DK
AGFI RQLVETRQl KHVAQILDSRlVr TKYDE D LI EV WLKSKLVSDFRKD
EQ
FYKVREINISTYHHAHDAYENAV^GTAU^
ΈΏ,
EIGKATAKYFFYSNIM>iFFKTEn ANGE]EJRPLIETNGETGElVWDKGRJ3FATVR KV
LSMPQVNIVKKTEVOTGGFSKESILPKRNSDKLIARKKDWPPKKYGGFDSPTVAY
sv
LVVAKVE GKS KL SV'KELLGrriMERSSFEKNPlDFLEAKGY EVKKDLllKLP YS
LFELENGR RMLASAGELOKGNELALPSKY FEYLASFIYEKLKGSPEDNEOKO LF
VEOH HYLDEUEQISEFSKRVILADA LDKVLSAY^KHRDKI^REQAEJ IIHLFTL TNL GAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
100490 j >Sp(N)Stl(C)Cas9
[00491] MDKKYSIGLDIGTNSVGWAVrrDEY VPS KFKVLGisl'rDRHSiKKNLI GA
LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFL YE
EDKXHERHPIFGNIVDEVAYHEKYPTIYHLRK VDSTDKADLRl-IYLALAHMIKF RG
HFLIEGDL PDNSDVDKLFIOLVOTY QLFEENPmASGVDAKAILSARLS SRRLE
NL
3AQLPGE KNGLFGNLLALSLGLTPNFKSNFDLAEDA LOLSKDTYDDDLDNLLA PIG
DOYADLFLAAKJNiLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHODLTLLKALV RQ
QLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFI PILEKMDGTEELLV LNRED
LL
RKQRTFDNGSIPHQIHLGELFiAILRROEDFYPFLKD RE JEKJLTFRIPYYVGPLAR GN
SRFAWMTRKSEETITP FEEVVD GASAOSFIERMTNFD LP EKVLPKFISLL YE YFTVY ELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKOLKEDYFK
K-TE
CFDSVEISGVEDRF'NASLGTYHDLLKIIKD FLDI EENEDILEDIVLTLTLFEDRE MIE
ERLKTYAHLFDDKVMKQLKRR.RYTGWGRLSRKLINGIRDKOSGKTILDFLKSDGF
AN
RNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAI KGILQTVKWDE LV
KVMGRHKPENrVTE ARETNEDDEKKAIQKIQKANKDEKDAAMLKAANOYN GKA
ELPHSVFHGHKQLATKIRLWHQQGERCLYTGKTISIHDLIN S QFEVDHILP
LSI
TFDDSLA KVLVYATANQEKGQRTPYQALDSMDDAWSFRELKAFVRESKTL SNK
KKEYLLTEEDISKFDVRKKFIERNLVDTRYASRWLNALQEHFRAHKIDTKVS VVR
GQFTSQLRRHWGIEKTRDTYHHHAVDALnAASSQL LWKKQK TLVSYSED
QL
LDIETGELISDDEYKESVFKAPYQHFVDTLKSKEFEDSILFSYQVDSKFNRKIS
DATI
YATRQAKVGKDKADETYVLGKIKDIYTQDGYDAFI IKIYKKDKSKFLI IYRH DPQT
FEKVIEPILENYP KQINEKGKEVPC PFLKYKEEHGYIRKYSK GNGPEIKS LKYY
DSKLGNfflDlTPKDSN KVVLQSVSPWRADVYFNKTTGKYElLGLKYADLQF
E G
TGTYKISQEKYNDIKKKEGVDSDSEFKFTLYKNDLLLVKDTETKEQQLFRFL
SRT
MPKQKHYVELKPYDKQ FEGGEALIKVLG1WANSGQCK GLGKSMSIYKV RTD VLGNQHIIKNEGDKPKLDF
[00492] The benefit of making chimeric Cas9 include:
[00493] reduce toxicity
[00494] improve expression in eukaryotic cells
[00495] enhance specificity
172
90.1 [00496] reduce molecular weight of protein, make protein smaller by combining the smallest domains from different Cas9 homo!ogs.
[00497] Altering the PAM sequence requirement
Example 13: Utilization of Cas9 as a generic DNA binding protein
[00498] Applicants used Cas9 as a generic DNA binding protein by mutating the two catalytic domains (DIO and H840) responsible for cleaving both strands of the DNA target. In order to upregulate gene transcription at a target locus Applicants fused the transcriptional activation domain (VP64) to Cas9. Applicants hypothesized that it would be important to see strong nuclear localization of the Cas9-VP64 fusion protein because transcription factor activation strength is a function of time spent at the target. Therefore, Applicants cloned a set of Cas9-VP64-GFP constructs, transfected them into 293 cells and assessed their localization under a fluorescent microscope 12 hours post-transfection.
[00499] The same constructs were cloned as a 2A-GFP rather than a direct fusion in order to functionally test the constructs without a bulky GFP present to interfere. Applicants elected to target the Sox2 locus with the Cas9 transactivator because it could be useful for cellular reprogram and the locus has already been validated as a. target for TALE-TF mediated transcriptional activation. For the Sox2 locus Applicants chose eight targets near the transcriptional start site (TSS). Each target was 20bp long with a neighboring GG protospacer adjacent motif (PAM). Each Cas9-VP64 construct was eo- transfected with each PCR generated chimeric crispr R A (chiRNA) in 293 cells. 72 hours post transfection the transcriptional activation was assessed using RT-qPCR.
[00500] To further optimize the transcriptional activator, Applicants titrated the ratio of chiRNA (Sox2.1 and Sox2.5) to Cas9 (NLS-VP64-NLS-hSpCas9-NLS-VP64-NLS), transfected into 293 cells, and quantified using RT-qPCR. These results indicate that Cas9 can be used as a generic DNA binding domain to upregulate gene transcription at a target locus.
[00501] Applicants designed a second generation of constructs. (Table below).
Figure imgf000174_0001
173
90.1 [ pLenti-EFla-GFP-2A-6xffis-NLS-NLS-hSpCsnl(D10A, H840A) |
[00502] Applicants use these constructs to assess transcriptional activation (VP64 fused constructs) and repression (Cas9 only) by RT-qPCR, Applicants assess the cellular localization of each construct using anti-His antibody, nuclease activity using a Surveyor nuclease assay, and D A binding affinity using a. gel shift assay. In a preferred embodiment of the invention, the gel shift assay is an EMS A gel shift assay.
Example 14: Cas9 transgenic and knock in mice
[00503] To generate a mouse that expresses the Cas9 nuclease Applicants submit two general strategies, transgenic and knock in. These strategies may be applied to generate any other model organism of interest, for e.g. Rat. For each of the general strategies Applicants made a constitutively active Cas9 and a Cas9 that is conditionally expressed (Cre recombinase dependent). The constitutively active Cas9 nuclease is expressed in the following context: pCAG-NLS-Cas9- LS-P2A-EGFP-WPRE-bGHpolyA. pCAG is the promoter, NLS is a nuclear localization signal, P2A is the peptide cleavage sequence, EGFP is enhanced green fluorescent protein, WPRE is the woodchuck hepatitis virus posttranscriptional regulator}' element, and bGHpolyA is the bovine growth hormone poly-A signal sequence (Figs. 25A-B). The conditional version has one additional stop cassette element, ioxP-SV4G polyA x3-ioxP, after the promoter and before NLS-Cas9- NLS (i.e. pCAG-loxP-SV40polyAx3-loxP-NLS-Cas9-NLS-P2A-EGFP-WPRE- bGHpolyA). The important expression elements can be visualized as in Fig. 26. The constitutive construct should be expressed in all cell types throughout development, whereas, the conditional construct will only allow Cas9 expression when the same cell is expressing the Cre recombinase. This latter version will allow for tissue specific expression of Cas9 when Cre is under the expression of a tissue specific promoter. Moreover, Cas9 expression could be induced in adult mice by putting Cre under the expression of an inducible promoter such as the TET on or off system.
[00504] Validation of Cas9 constructs: Each plasmid was functionally validated in three ways: 1) transient transfection in 293 cells followed by confirmation of GFP expression; 2) transient transfection in 293 ceils followed by immunofluorescence using an antibody recognizing the P2A sequence; and 3) transient transfection followed by Surveyor nuclease assay. The 293 cells may be 293FT or 293 T cells depending on the cells that are of interest. In a preferred embodiment the cells are 293FT cells. The results of the Surveyor were run out on the top and bottom row of the gel for the conditional and
174
90.1 constitutive constructs, respectively. Each was tested in the presence and absence of chimeric RNA targeted to the hEMX! locus (chimeric RNA liEMXl . l ). The results indicate that the constract can successfully target the hEMXl locus only in the presence of chimeric RNA (and Cre in the conditional case). The gel was quantified and the results are presented as average cutting efficiency and standard deviation for three samples.
00S05] Transgenic Cas9 mouse: To generate transgenic mice with constructs, Applicants inject pure, linear DNA into the pronucleus of a zygote from a pseudo pregnant CB56 female. Founders are identified, genotyped, and backcrossed to CBS 7 mice. The constructs were successfully cloned and verified by Sanger sequencing.
[00506] Knock in Cas9 mouse: To generate Cas9 knock in mice Applicants target the same constitutive and conditional constructs to the Rosa26 locus. Applicants did this by cloning each into a Rosa26 targeting vector with the following elements: Rosa26 short homology arm - constitutive/conditional Cas9 expression cassette - pPGK-Neo-Rosa26 long homology arm - pPGK-DTA. pPGK is the promoter for the positive selection marker Neo, which confers resistance to neomycin, a 1 kb short arm, a 4.3 kb long ann, and a negative selection diphtheria toxin (DTA) driven by PGK.
[00507] The two constructs were electroporated into Rl mESCs and allowed to grow for 2 days before neomycin selection was applied. Individual colonies that had survived by days 5-7 were picked and grown in individual wells. 5-7 days later the colonies were harvested, half were frozen and the other half were used for genotyping, Genotyping was done by genomic PCR, where one primer annealed within the donor plasmid (AttpF) and the other outside of the short homology arm (Rosa26~R) Of the 22 colonies harvested for the conditional case, 7 were positive (Left). Of the 27 colonies harvested for the constitutive case, zero were positive (Right), It is likely that Cas9 causes some level of toxicity in the mESC and for this reason there were no positive clones. To test this Applicants introduced a Cre expression plasmid into correctly targeted conditional Cas9 cells and found very low toxicity after many days in culture. The reduced copy number of Cas9 in correctly targeted conditional Cas9 cells (1-2 copies per cell) is enough to allow stable expression and relatively no cytotoxicity. Moreover, this data indicates that the Cas9 copy number determines toxicity. After electroporation each cell should get, several copies of Cas9 and this is likely why no positive colonies were found in the case of the constitutive Cas9 construct. This provides strong evidence that utilizing a conditional, Cre-dependent strategy should show reduced toxicity. Applicants inject correctly targeted
175
90.1 cells into a blastocyst and implant into a female mouse. Chimerics are identified and backcrossed. Founders are identified and genotyped.
[00508] Utility of the conditional Cas9 mouse: Applicants have shown in 293 cells that the Cas9 conditional expression construct can be activated by co-expression with Cre. Applicants also show that the correctly targeted Rl mESCs can have active Cas9 when Cre is expressed. Because Cas9 is followed by the P2A peptide cleavage sequence and then EGFP Applicants identify successful expression by observing EGFP. This same concept is what makes the conditional Cas9 mouse so useful. Applicants may cross their conditional Cas9 mouse with a mouse that ubiquitously expresses Cre (ACTB-Cre line) and may arrive at a mouse that expresses Cas9 in every cell. It should only take the deliver of chimeric RNA to induce genome editing in embryonic or adult mice. Interestingly, if the conditional Cas9 mouse is crossed with a mouse expressing Cre under a tissue specific promoter, there should only be Cas9 in the tissues that also express Cre. This approach may be used to edit the genome in only precise tissues by delivering chimeric RNA to the same tissue.
Example 15: Cas9 diversity and chimeric RNAs
|00509] The CRISPR-Cas system is an adaptive immune mechanism against invading exogenous DNA employed by diverse species across bacteria and archaea. The type II CRISPR-Cas system consists of a set of genes encoding proteins responsible for the "acquisition" of foreign DNA into the CRISPR locus, as well as a set of genes encoding the "execution" of the DNA cleavage mechanism; these include the DNA nuclease (Cas9), a non-coding transactivating cr-RNA (tracrRN A), and an array of foreign DNA-derived spacers flanked by direct repeats (crRJS!As). Upon maturation by Cas9, the tracrRNA and crRNA duplex guide the Cas9 nuclease to a target DNA sequence specified by the spacer guide sequences, and mediates double-stranded breaks in the DNA near a short sequence motif in the target DNA that is required for cleavage and specific to each CRISPR-Cas system. The type II CRISPR-Cas systems are found throughout the bacterial kingdom and highly diverse in in Cas9 protein sequence and size, tracrRNA and crRNA direct repeat sequence, genome organization of these elements, and the motif requirement for target cleavage. One species may have multiple distinct CRISPR-Cas systems.
jOOSIOj Applicants evaluated 207 putative Cas9s from bacterial species identified based on sequence homology to known Cas9s and structures orthologous to .known subdomains, including the HNH endonuclea.se domain and the RuvC endonuclease
176
90.1 domains [information from the Eugene oonin and Kira Makarova]. Phylogenetic analysis based on the protein sequence conservation of this set revealed five families of Cas9s, including three groups of large Cas9s ( -1400 amino acids) and two of small Ca.s9s (~1 100 amino acids) (Figs. l9A-D and 20A-F).
[00511] Applicants have also optimized Cas9 guide RNA using in vitro methods. Example 16: Cas9 mutations
[00512] In this example, Applicants show that the following mutations can convert SpCas9 into a nicking enzyme: Dl OA, E762A, H840A, N854A, N863A, D986A.
[00513] Applicants provide sequences showing where the mutation points are located within the SpCas9 gene (Fig. 24A-M). Applicants also show that the nickases are still able to mediate homologous recombination. Furthermore, Applicants show that SpCas9 with these mutations (individually) do not induce double strand break.
[00514] Cas9 orthologs all share the general organization of 3-4 RuvC domains and a HNH domain. The 5' most RuvC domain cleaves the non-complementary strand, and the HNH domain cleaves the complementary strand. All notations are in reference to the guide sequence.
[00515] The catalytic residue in the 5' RuvC domain is identified through homology comparison of the Cas9 of interest with other Cas9 orthologs (from S, pyogenes type TI CRISPR focus, S. thermophilics CRISPR locus 1 , S. thermophilus CRISPR locus 3, and Franciscilla novicida type II CRISPR locus), and the conserved Asp residue is mutated to alanine to convert Cas9 into a complementary-strand nicking enzyme. Similarly, the conserved His and Asn residues in the HNH domains are mutated to Alanine to convert Cas9 into a non-complementary-strand nicking enzyme.
Example 17: Cas9 Transcriptional Activation and Cas9 Repressor
[00516] Cas9 Transcriptional Activation
[00517] A second generation of constructs have been designed and are in the pipeline to be tested (Table 1 ). These constructs will be used to assess transcriptional activation (VP64 fused constructs) and repression (Cas9 only) by RT-qPCR. Applicants will also assess the cellular localization of each construct using anti-His antibody,, nuclease activity using a Surveyor nuclease assay, and DNA binding affinity using a gel shift assay.
[00518] Cas Repressor
177
90.1 0Θ519] It has beers shown previously thai dCas9 can be used as a generic DNA binding domain to repress gene expression. Applicants report an improved dCas9 design as well as dCas9 fusions to the repressor domains KRAB and SlD4x. From the plasmid library created for modulating transcription using Cas9 in Table 1 , the following repressor plasmids were functionally characterized by qPCR: pXRP27, pXRP28, pXRP29, pXRP48, pXRP49, pXRP50, pXRP51, pXRP52, pXRP53, pXRP56, pXRP58, pXRP59, pXRP61, and pXRP62.
[00520] Each dCas9 repressor plasmid was co-transfected with two guide RNAs targeted to the coding strand of the beta-eatenin gene. RNA was isolated 72 hours after transfection and gene expression was quantified by RT-qPCR, The endogenous control gene was GAPDH. Two validated shRNAs were used as positive controls. Negative controls were certain plasmids trans fected without gRNA, these are denoted as "pXRP## control". The plasmids pXRP28, pXRP29, pXRP48, and pXRP49 could repress the beta- catenin gene when using the specified targeting strategy. These plasmids correspond to dCas9 without a functional domain (pXRP28 and pXRP28) and dCas9 fused to SID4x (pXRP48 and pXRP49).
[00521] Further work investigates: repeating the above experiment, targeting different genes, utilizing other gRNAs to determine the optimal targeting position, and multiplexed repression.
[00522] Table 1
pXRP024-pLend2-EF!a-VP64- S-FLAG-Linker-dCas9- LS-gLuc-2A-GFP-WPRE
pXRP025-pLer l2-EFlaAT64-NLS-GGGGS:!Lit]ker-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP026-pLenti2-EFla-VP64-NLS-EAAA 3Linter-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP027-pLenii2-EF! a-NLS-FLAG-Linfcer-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP028-pL€nti2-EFla-NLS-GGGGS3Linlffir-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP029-pLenti2-EFla-NLS-EAAA 3Linker-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP030-pLend2-pSV40- 64-NLS-FLAG-Linkfir-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP03 i-pLeriti2-pPG A/P64-NLS ¾AG-Lmker-dCas9-NLS-gLiic-2A-GFP- PRE
pXRP032-pLenti2-LTR-VP64-NLS-FLAG-Lit±er-dCas9-M.S-gLuc-2A-GFP-WPRE
pXRP033-pLenii2-pSV40-VP64-NLS-GGGGS.,Linkfir-dCas9-NLS-gLuc-2A-GFP-WPRE
pXllP034-pLenti2-pPG -VP64-NLS-GGGGS3Liiiker-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP035-pLenti2-LTR-VP64-NLS-GGGGS3Litiker-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP036 )Lenii2-pSV40A^64-NLS-EAJAAK3Linker-dCas9-NLS-gLuc-2A-GFP-WPRE
pXRP037-pLenti2^PG AT64-NLS-EA.AA 3Linker-dCas9- LS-gLuc-2A-GFP-WPRE
pXRP038-pLenti2-LTR-VP64-NLS-EAAA 3Linte-d<¾s9-NLS-gLuc-2A-GFP-WPRE
pXRP048 )Lenii2-EFla-SID4x-NLS-FLAG-Linker-dCas9-NLS-gLuc-2A-GFP- RE pXRP049-pLenti2-EFla-S! 4X-NLS-GGGGS3Linker-dCas9-NLS-gLuc-2A-GFP-WPRE pXRP050-pLend2-EF!a-SID4X-NLS-EAAAK3Liriker-dCas9- LS-gLuc-2A-GFP-WPRE pXRP051-pLenti2-EFla-KEAB-NLS-FLAG-LirJier-dCas9-NLS-gLuc-2A-GFP-WPRE pXRP052-pLenti2-EFla- RAB-NLS-GGGGS3Linker-dQis9-NLS-gLuc-2A-GFP-WPRE pXRP053-pLend2-EF!a-KRAB- TLS-EAAAK3Linker-dCas9-NLS-gLuc-2A-GFP-WPRE pXRP054-pLenti2-EFla-dCas9-Linter-FLAG-NLS-VP64-gLuc-2A-GFP-WPRE pXRP055-pLenti2-EFla-dCas9-Linker-FLAG-NLS-SID4X-gLuc-2A-GFP-WPRE pXRP056-pLenii2-EF!a-dCas9-Linker-FLAG-NLS-KRAB-gLuc-2A-GFP-WPRE pXRP057-pLenti2-EFla-dCas9-GGGGGS3-NLS-VP64-gLuc-2A-GFP-WPRE pXRP058-pLenti2-EFla-dCas9-GGGGGS3-NLS-SID4X-gLuc-2A-GFP-WPRE pXRP059-pLenii2-EF!a-dCas9-GGGGGS3-NLS- RAB-gLuc-2A-GFP-WPRE pXRP060-pLeriti2-EFIa-dCas9-EAA K3-NLS-VP64-gLuc-2A-GFP-WPRE pXRP061 -pLenti2-EFla-dCas9-EAAA 3-NLS-SID4X-gLuc-2A-GFP-WPRE pXRP%2-pLend2-EF!a-dCas9-EAAA 3-NLS- RAB-gLuc-2A-GFP-WPRE pXRP024-pLend2-EF!a-VP64- LS-FLAG-Linker^'as9-NLS-gLuc-2A-GFP-WPRE pXRP025-pLenti2-EFla-VP64-NLS-GGGGS3Litiker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP026-pLeii!i2-EFla-VP64-NLS-EAAA 3Linker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP027-pLenii2-EFla-NLS-FLAG-Link;er-Cas9-NLS-gLuc-2A-GFP-\\7PRE pXRP028-pL€nti2-EFla-NLS-GGGGS3Linl∞r-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP029-pLend2-EF!a-NLS-EAAA 3Linker-Cas9- LS-gLuc-2A-GFP-WPRE pXRP030-pLenti2-pSV40-VP64-NLS-FLAG-Lin!a;r-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP031-pLeii!i2-pPG -VP64-NLS-FLAG-Linker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP032-pLenti2-LTR-VP64-NLS-FLAGiiiiker-Cas9-NLS-gLiic-2A-GFP-WPRE pXRP033-pL€nti2-pSV40- 64-NLS-GGGGS3Lhiiffir-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP034-pLend2-pPGK-VP64- LS-GGGGS3Linker^'as9-NLS-gL«c-2A-GFP-WPRE pXRP035-pLenti2-LTR-VP64-NLS-GGGGS3Litjker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP036-pLen!i2-pSV40-VP64-NLS-EAAA 3Lioker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP037-pLenti2-pPG -VP64-NLS-EAA„4 3Lmker-Cas9- LS-gLuc-2A-GFP-WPRE pXRP038-pLer l2-LTRA'P64-NLS-EAAAK3Linker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP048-pL∞d2-EF!a-Simx-NLS-FLAG-Linker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP049-pLenti2-EFla-Sn tX-NLS-GGGGS3Linkfir-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP050-pLen!i2-EFla-SID4X-NLS-EAAA 3Linker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP051^Lenti2-EFla-KJXAB-NLS-FLAG-Liiiker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP052-pLenti2-EFla-KRAB-OT.S-GGGGS3Linker-Cas9-NLS-gLuc-2A-GFP-WPRE pXRP053-pLenii2-EFla-KRAB-NLS-EAAAK3Liiiker-Cas9-NLS-gLuc-2A-GFP-\WRE pXRP054-p nti2-EFla-Cas9-Lhto-FLAG-NLS-VP64-gLuc-2A-GFP-WPRE pXRP055^Len!i2-EFla-Cas9-Linker-FLAG-NLS-SID4X-gLuc-2A-GFP-WPRE pXRP056-pLenti2-EFIa-Cas9-Linker-FLAG- LS- RAB-gLuc-2A-GFP-WPRE pXRP057-pLenti2-EFla-Cas9-GGGGGS3-NLS-VP64-gLuc-2A-GFP-WPRE pXRP058-pLenii2-EFla-Cas9-GGGGGS3-NLS-SID4X-gLuc-2A-GFP-WPRE pXRP059-pLenti2-EFla-Cas9-GGGGGS3-NLS- RAB-gLuc-2A-GFP-WPRE pXRP060-pLei!!i2-EFla-Cas9-EAAAK.3-NLS-VP64-gLuc-2A-GFP-WPRE pXRP061 -pLenti2-EFla-Cas9-EAAA 3-NLS-SiD4X-gLuc-2A-GFP-WPRE
179
90.1 pXRP062-pL€nti2-EFla-Cas9-EAAA 3-NLS-KRAB-gLuc-2A-GFP-WPRE
Example 18: Targeted deletion of genes involved in cholesterol biosynthesis, fatty acid biosynthesis, and other metabolic disorders, genes encoding mis-folded proteins involved in amyloid and other diseases, oncogenes leading to cellular transformation, latent viral genes, and genes leading to dominant-negative disorders, amongst other disorders.
[00523] Applicants demonstrate gene delivery of a CRISPR-Cas system in the liver, brain, ocular, epithelial, hematopoetic, or another tissue of an organism, a subject or a patient in need thereof, suffering from metabolic disorders, amyloidosis and protein- aggregation related diseases, cellular transformation arising from genetic mutations and translocations, dominant negative effects of gene mutations, latent viral infections, and other related symptoms, using either viral or nanoparticle deliver)' system,
[00524] Study Design: Organisms or subjects or patients in need thereof suffering from metabolic disorders, amyloidosis and protein aggregation related disease which include but are not limited to human, non-primate human, canine, feline, bovine, equine, other domestic animals and related mammals. The CRISPR-Cas system is guided by a chimeric guide RNA and targets a specific site of the human genomic loci to be cleaved. After cleavage and non-homologous end-joining mediated repair, frame-shift mutation results in knock out of genes.
[00525] Applicants select guide-RNAs targeting genes involved in above-mentioned disorders to be specific to endogenous loci with minimal off-target activity. Two or more guide RNAs may be encoded into a single CRISPR array to induce simultaneous double- stranded breaks in DNA leading to micro-deletions of affected genes or chromosomal regions.
[00526] Identification and design of gene targets
[00527] For each candidate disease gene, Applicants select DNA sequences of interest include protein-coding exons, sequences including and flanking known dominant negative mutation sites, sequences including and flanking pathological repetitive sequences. For gene-knockout approaches, early coding exons closest to the start codon offer best options for achieving complete knockout and minimize possibility of truncated protein products retaining partial function.
[00528] Applicants analyze sequences of interest for all possible targetable 20-bp sequences immediately 5' to a NGG motif (for SpCas9 system) or a NNAGAAW (for Stl Cas9 system). Applicants choose sequences for unique, single RNA-guided Cas9
180
90.1 recognition in the genome to minimize off-target effects based on computational algorithm to determine specificity,
[00529] Cloning of guide sequences into a delivery system
[00530] Guide sequences are synthesized as double-stranded 20-24 bp oligonucleotides. After 5 ' -phosp orylati on treatment of oligos and annealing to form duplexes, oligos are ligated into suitable vector depending on the delivery method:
[00531] Virus-based delivery methods
[0Θ532] AAV-based vectors (PX260, 330, 334, 335) have been described elsewhere [0Θ533] Lentiviraf-based vectors use a similar cloning strategy' of directly ligating guide sequences into a single vector carrying a U6 promoter-driven chimeric RNA scaffold and a EF la promoter-driven Cas9 or Cas9 nickase.
[00534] Vims production is described elsewhere,
[00535] Nanoparticle-based RNA deliver}' methods
[00536] 1. Guide sequences are synthesized as an oligonucleotide duplex encoding T7 promoter— guide sequence— chimeric RNA. A T7 promoter is added 5' of Cas9 by PGR method.
[00537] 2, T7"driven Cas9 and guide-chimeric RNAs are transcribed in vitro, and Cas9 mRNA is further capped and A-tailed using commercial kits. RNA products are purified per kit instructions.
[00538] Hydrodynamic tail vein delivery methods (for mouse)
[00539] Guide sequences are cloned into AAV plasmids as described above and elsewhere in this application.
[0Θ540] In vitro validation on cell lines
[00541] Transfection
[00542] 1. DNA plasmid transfection
[00543] Plasmids carrying guide sequences are transfected into human embryonic kidney (HEK293T) or human embryonic stem (hES) cells, other relevant cell types using lipid-, chemical-, or electroporation-based methods. For a 24-well transfection of ITEK293T cells (-260,000 cells), 500ng of total DNA is transfected into each single well using Lipofectamine 2000. For a 12-well transfection of hES cells, lug of total DNA is transfected into a single well using Fugene HD.
[00544] 2, RNA transfection
181
90.1 [0Θ545] Purified RNA described above is used for transfection into HEK293T cells. 1 - 2ug of RNA may be transfected into -260,000 using Lipofectamine 2000 per manufacturer's instruction. RNA deliver}' of Cas9 and chimeric RNA is shown in Fig, 28.
[00546] Assay of indel formation in vitro
[00547] Cells are harvested 72 -hours post-transfection and assayed for indel formation as an indication of double-stranded breaks.
[00548] Briefly, genomic region around target sequence is PGR amplified (-400-600 bp amplicon size) using high-fidelity polymerase. Products are purified, normalized to equal concentration, and slowly annealed from 95°C to 4°C to allow formation of DNA heteroduplexes. Post annealing, the Cel-I enzyme is used to cleave heteroduplexes, and resulting products are separated on a polyacrylamide gel and indel efficiency calculated.
[00549] In vivo proof of principle in animal
[00550] Delivery mechanisms
[00551] AAV or Lentivirus production is described elsewhere.
[0Θ552] Nanoparticle formulation: RNA mixed into nanoparticle formulation
[0Θ553] Hydrodynamic tail vein injections with DNA plasmids in mice are conducted using a commercial kit
[00554] Cas9 and guide sequences are delivered as vims, nanoparticle-coated RNA mixture, or DNA plasmids, and injected into subject animals. A parallel set of control animals is injected with sterile saline, Cas9 and GFP, or guide sequence and GFP alone.
[00555] Three weeks after injection, animals are tested for amelioration of symptoms and sacrificed. Relevant organ systems analyzed for indel formation, Phenotvpic assays include blood levels of HDL, LDL, lipids,
[00556] Assay for indel formation
[00557] DNA is extracted from tissue using commercial kits; indel assay will be performed as described for in vitro demonstration.
[00558] Therapeutic applications of the CRISPR-Cas system are amenable for achieving tissue-specific and temporally controlled targeted deletion of candidate disease genes. Examples include genes involved in cholesterol and fatty acid metabolism, amyloid diseases, dominant negative diseases, latent viral infections, among other disorders.
[00559] Examples of a single guide-RNA to introduce targeted indels at a gene locus
Mechani
Disease GENE SPACER PAM sm References
Hyperchol HMG- GCCAAATT P avastatin: a review of its esterolemi CR GGACGACC CGG Knockout pharmacology and use in the CTCG management of
hypercholesterolemia. ( Plosker GL et al. Drugs 1996, 51(3):433-459)
Potential role of non statin cholesterol lowering agents
Hyperchol CGAGGAGA (Trapani et al. IUBMB Life, esteroiemi CCCCCGTTT Volume 63, Issue 1 1, pages
SQLE CGG TGG Knockout 964-971 , November 201 ! )
DGAT1 inhibitors as anti- obesity and anti-diabetic agents. (Birch AM et al.
CCCGCCGC Current Opi ion in Drug
Hyperlipid DGAT CGCCGTGG Discovery & Development emia 1 CTCG AGG Knockout [2010, 13(4):489-496)
Killing of leukemic cells with a BCR/ABL fusion gene by RNA
TGAGCTCTA interference (RNAi).( Fuchs et
BCR- CGAGATCC al. Oncogene 2002,
Leukemia ABL ACA AGG Knockout 21(37):5716-5724)
Examples of a. pair of guide -RNA to introduce chromosomal microdeletion at gene locus
Median!
Disease GENE SPAC PAM srn
Perilipin-2 Null Mice are Protected Against Diet-Induced Obesity, Adipose Inflammation and Fatty Liver Disease (McManaman XL et al. The
CTCAAAATT J ournal of Lipid Research,
Hyperlipi PLFN2 CATACCGGT Microdel jlr.M035063. First Published on demia guide 1 TG TGG etion February 12, 2013)
CGTTAAACA
Hyperlipi PLIN2 ACAACCGG Microdel
demia guide2 ACT TGG etion
inhibition of SREBP by a Small Molecule, Betulin, Improves Hyperlipidemia and Insulin Resistance and Reduces Atherosclerotic Plaques (Tang J
TTCACCCCG et al. Cell Metabolism, Volume Hyperlipi SREBP CGGCGCTG Microdel 13, Issue 1, 44-56, 5 January demia guide 1 A AT etion 201 1)
ACCACTACC
Hyperlipi SREBP AGTCCGTCC Microdel
demia guide2 AC etion
183
90.1 Example 19: Targeted integration of repair for genes carrying disease-causing mutations: reconstitution of enzyme deficiencies and other related diseases.
[00561] Study design
I. Identification and design of gene targets
• Described in Example 22
II. Cloning of guide sequences and repair templates into a delivery system
• Described above in Example 22
• Applicants clone DNA repair templates to include homology arms with diseased allele as well a wild -type repair templ te
III. In vitro validation on cell lines
a. Transfection is described above in Example 22; Cas9, guide RNAs, and repair template are co-transfected into relevant cell types.
b. Assay for repair in vitro
i. Applicants harvest cells 72-liours post-transfection and assay for repair
ii. Briefly, Applicants amplify genomic region around repair template PGR using high-fidelity polymerase. Applicants sequence products for decreased incidence of mutant allele.
IV. In vivo proof of principle in animal
a. Delivery mechanisms are described above Examples 22 and 34.
b. Assay for repair in vivo
i. Applicants perform the repair assay as described in the in vitro demonstration.
V. Therapeutic applications
The CRISPR-Cas system is amenable for achieving tissue-specific and temporally controlled targeted deletion of candidate disease genes.
Examples include genes involved in cholesterol and fatty acid metabolism, amyloid diseases, dominant negative diseases, latent viral infections, among other disorders.
[00562] Example of one single missense mutation with repair template:
GEN PA
Disease E SPACER M
AGCCTTTCTGAACACATGC
Familial amyloid polyneuropathy TTR A CGG
184
90.1 Mechanism References
V30M Transthyretin mutations in health and disease (Joao et al. Human Mutation, repair Volume 5, Issue 3, pages 191-196, 1995)
V30M
allele CCTGCCATCAATGTGGCCATGCATGTGTTCAGAAAGGCT
WT
allele CCTGCCATCAATGTGGCCGTGCATGTGTTCAGAAAGGCT
Example 20: Therapeutic application, of the CRISPR-Cas system, in. Glaucoma,
Amyloidosis, and Huntington 's disease
[00563] Glaucoma: Applicants design guide R As to target the first exon of the mycilin (MYOC) gene. Applicants use adenovirus vectors (AdS) to package both Cas9 as well as a guide RNA targeting the MYOC gene. Applicants inject adenoviral vectors into the trabecular meshwork where cells have been implicated in the pathophysiology of glaucoma. Applicants initially test this out in mouse models carrying the mutated MYOC gene to see whether they improve visual acuity and decrease pressure in the eyes. Therapeutic application in humans employ a similar strategy.
[00564] Amyloidosis: Applicants design guide RNAs to target the first exon of the transthyretin (TTR) gene in the liver. Applicants use AAV8 to package Cas9 as well as guide RNA targeting the first exon of the TTR gene. AAV8 has been shown to have efficient targeting of the liver and will be administered intravenously. Cas9 can be driven either using liver specific promoters such as the albumin promoter, or using a constitutive promoter. A po33 promoter drives the guide RNA.
[0Θ565] Alternatively, Applicants utilize hydrodynamic deliver}' of plasmid DNA to knockout the TTR gene. Applicants deliver a plasmid encoding Cas9 and the guideRNA targeting Exon 1 of TTR.
[00566] As a further alternative approach. Applicants administer a combination of RNA (mRNA for Cas9, and guide RNA). RN can be packaged using liposomes such as Ii ivofectamine from Life Technologies and delivered intravenously. To reduce RNA- induced immunogenicity, increase the level of Cas9 expression and guide RNA stability, Applicants modify the Cas9 mRNA using 5' capping. Applicants also incorporate modified RNA nucleotides into Cas9 mRNA and guide RNA to increase their stability and reduce immunogenicity (e.g. activation of TLR). To increase efficiency, Applicants administer multiple doses of the virus, DNA, or RNA.
[00567] Huntington's Disease: Applicants design guide RNA based on allele specific mutations in the HTT gene of patients. For example, in a. patient who is heterozygous for ITTT with expanded CAG repeat, Applicants identify nucleotide sequences unique to the mutant HTT allele and use it to design guideRNA. Applicants ensure that the mutant base is located within the last 9 bp of the guide R A (which Applicants have ascertained has the ability to discriminate between single D A base mismatches between the target size and the guide R A).
[00568] Applicants package the mutant HTT allele specific guide R A and Cas9 into AAV9 and deliver into the striatum of Huntington's patients. Virus is injected into the striatum stereotactically via a craniotomy, AAV9 is known to transduce neurons efficiently. Applicants drive Cas9 using a neuron specific promoter such as human Synapsin I.
Example 21: Therapeutic application of the CRISPR-Cas system in HIV
[00569] Chronic viral infection is a source of significant morbidity and mortality. While there exists for many of these viruses conventional antiviral therapies that effectively target various aspects of viral replication, current therapeutic modalities are usually noncurative in nature due to "viral latency." By its nature, viral latency is characterized by a dormant phase in the viral life cycle without active viral production. During this period, the virus is largely able to evade both immune surveillance and conventional therapeutics allowing for it to establish long-standing viral reservoirs within the host from which subsequent re-activation can permit continued propagation and transmission of virus. Key to viral latency is the ability to stably maintain the viral genome, accomplished either through episomal or proviral latency, which stores the viral genome in the cytoplasm or integrates it into the host genome, respectively. In the absence of effective vaccinations which would prevent primary infection, chronic viral infections characterized by latent reservoirs and episodes of lytic activity can have significant consequences: human papilloma virus (HPV) can result in cervical cancer, hepatitis C virus (HCV) predisposes to hepatocellular carcinoma, and human immunodeficiency vims eventually destroys the host immime system resulting in susceptibility to opportunistic infections. As such, these infections require life-long use of currently available antiviral therapeutics. Further complicating matters is the high mutability of many of these viral genomes which lead to the evolution of resistant strains for which there exists no effective therapy.
[00570] The CRISPR-Cas system is a bacterial adaptive immune system able to induce double-stranded DNA breaks (DSB) in a multiplex -able, sequence-specific manner and has been recently re-constituted within mammalian cell systems. It has been shown that
186
90.1 targeting DNA with one or numerous guide-RNAs can result in both indels and deletions of the intervening sequences, respectively. As such, this new technology represents a means by which targeted and multiplexed DNA mutagenesis can be accomplished within a single cell with high efficiency and specificity. Consequently, delivery of the CRJSPR-Cas system directed against viral DNA sequences could allow for targeted disruption and deletion of latent viral genomes even in the absence of ongoing viral production.
[00571] As an example, chronic infection by HlV-1 represents a global health issue with .3.3 million individuals infected and an annual incidence of 2.6 million infections. The use of the multimodal highly active antiretroviral therapy (HAART), which simultaneously targets multiple aspects of viral replication, has allowed HIV infection to be largely managed as a chronic, not terminal, illness. Without treatment, progression of HIV to AIDS occurs usually within 9-10 years resulting in depletion of the host immune system and occurrence of opportunistic infections usually leading to death soon thereafter. Secondary to viral latency, discontinuation of HAART invariably leads to viral rebound. Moreover, even temporary disruptions in therapy can select for resistant strains of HIV uncontrollable by available means. Additionally, the costs of HAART therapy are significant: within the LIS $ 10,000- 15,0000 per person per year. As such, treatment approaches directly targeting the HIV genome rather than the process of viral replication represents a means by which eradication of latent reservoirs could allo for a curative therapeutic option.
[00572] Development and delivery of an HIV-1 targeted CRISPR-Cas system represents a unique approach differen liable from existing means of targeted DNA mutagenesis, i.e. ZFN and TALENs, with numerous therapeutic implications. Targeted dismption and deletion of the HIV-1 genome by CRISPR-mediated DSB and indels in conjunction with HAART could allo for simultaneous prevention of active viral production as well as depletion of latent viral reservoirs within the host.
[00573] Once integrated within the host immune system, the CRISPR-Cas system allows for generation of a HIV-1 resistant sub-population that, even in the absence of complete viral eradication, could allow for maintenance and re -constitution of host immune activity. This could potentially prevent primary infection by disruption of the viral genome preventing viral production and integration, representing a means to "vaccination". Multiplexed nature of the CRISPR-Cas system allows targeting of multiple aspects of the genome simultaneously within individual cells.
187
90.1 [0Θ574] As in HAART, viral escape by mutagenesis is minimized by requiring acquisition of multiple adaptive mutations concurrently. Multiple strains of HIV- 1 can be targeted simultaneously which minimizes the chance of super-infection and prevents subsequent creation of new recombinants strains. Nucleotide, rather than protein, mediated sequence-specificity of the CRISPR-Cas system allows for rapid generation of therapeutics without need for significantly altering delivery mechanism.
[00575] In order to accomplish this, Applicants generate CRISPR-Cas guide RNAs that target the vast majority of the HTV-i genome while taking into account HTV-i strain variants for maximal coverage and effectiveness. Sequence analyses of genomic conservation between HIV-1 subtypes and variants should allow for targeting of flanking conserved regions of the genome with the aims of deleting intervening viral sequences or induction of frame-shift mutations which would disrupt viral gene functions.
[00576] Applicants accomplish delivery of the CRISPR-Cas system by conventional adenoviral or lentiviral-mediated infection of the host immime system. Depending on approach, host immune ceils could be a) isolated, transduced with CRISPR-Cas, selected, and re-introduced in to the host or b) transduced in vivo by systemic deliver}' of the CRISPR-Cas system. The first approach allows for generation of a. resistant immune population whereas the second is more likely to target latent viral reservoirs within the host.
Examples of potential HIV-1 targeted spacers adapted from Mcintyre et al, which generated s RNAs against HiV-l optimized for maximal coverage of HIV-1 variants.
CACTGCTTAAGCCTCGCTCGAGG
TCACCAGCAATATTCGCTCGAGG
C ACCAGC A AT ATTCCG CTCG A GG
TAGCAACAGACATACGCTCGAGG
GGGCAGTAGTAATACGCTCGAGG CCAATTCCCATACATTATTGTAC
Example 22: Targeted correction of deltoFSOS or other mutations in cystic fibrosis
[00577] An aspect of the invention provides for a pharmaceutical composition that may comprise an CRISPR-Cas gene therapy particle and a biocompatible pharmaceutical carrier. According to another aspect, a method of gene therapy for the treatment of a subject having a mutation in the CFTR gene comprises administering a therapeutically effective amount of a CRISPR-Cas gene therapy particle to the cells of a subject
[00578] This Example demonstrates gene transfer or gene delivery of a CRISPR-Cas system in airways of subject or a patient in need thereof, suffering from cystic fibrosis or from cystic fibrosis related symptoms, using adeno-associated virus (AAV) particles,
188
90.1 [0Θ579] Study Design: Subjects or patients In need there of: Human, non-primate human, canine, feline, bovine, equine and other domestic animals, related. This study tests efficacy of gene transfer of a CRISPR-Cas system by a AAV vector. Applicants determine transgene levels sufficient for gene expression and utilize a CRISPR-Cas system comprising a Cas9 enzyme to target deltaF508 or other CFTR-inducing mutations.
[00580] The treated subjects receive pharmaceutically effective amount of aerosolized AAV vector system per lung endobronchially delivered while spontaneously breathing. The control subjects receive equivalent amount of a pseudotyped AAV vector system with an internal control gene. The vector system may be delivered along with, a pharmaceutically acceptable or biocompatible pharmaceutical carrier. Three weeks or an appropriate time interval following vector administration, treated subjects are tested for amelioration of cystic fibrosis related symptoms.
[00581] Applicants use an adenovirus or an AAV particle.
[00582] Applicants clone the following gene constructs, each operably linked to one or more regulatory sequences (Cbh or EFla promoter for Cas9, U6 or HI promoter for chimeric guide RNA), into one or more adenovirus or AAV vectors or any other compatible vector: A CFTRdelta508 targeting chimeric guide RNA (Fig. 3 IB), a repair template for deltaF508 mutation (Fig. 31 C) and a codon optimized Cas9 enzyme with optionally one or more nuclear localization signal or sequenee(s) (NLS(s)), e.g., two (2) NLSs.
[00583] Identification of Cas9 target site
[0Θ584] Applicants analyzed the human CFTR genomic locus and identified the Cas9 target site (Fig. 31 A). (PAM may contain a NGG or a NNAGAA W motif).
[00585] Gene Repair Strategy
[00586] Applicants introduce an adenovirus/ AAV vector system comprising a Cas9 (or Cas9 nickase) and the guide RNA along with a adenovirus/AAV vector system comprising the homology repair template containing the F508 residue into the subject via one of the methods of delivery discussed earlier. The CRISPR-Cas system is guided by the CFTRdelta 508 chimeric guide RNA and targets a specific site of the CFTR genomic locus to be nicked or cleaved. After cleavage, the repair template is inserted into the cleavage site via homologous recombination correcting the deletion that results in cystic fibrosis or causes cystic fibrosis related symptoms. This strategy to direct delivery and provide systemic introduction of CRJSPR systems with appropriate guide RNAs can be
189
90.1 employed t target genetic imi ations to edit or otherwise manipulate genes that cause metabolic, liver, kidney and protein diseases and disorders such as those in Table B.
Example 23: Generation of Gene Knockout Cell Library
[00587] This example demonstrates how to generate a library of cells where each cell has a single gene knocked out:
[00588] Applicants make a library of ES cells where each cell has a single gene knocked out, and the entire library of ES cells will have ever}' single gene knocked out. This library is useful for the screening of gene function in cellular processes as well as diseases,
|00589] To make this cell library, Applicants integrate Cas9 driven by an inducible promoter (e.g. doxycycline inducible promoter) into the ES cell. In addition, Applicants integrate a. single guide RNA targeting a specific gene in the ES cell. To make the ES cell library, Applicants simply mix ES cells with a. library of genes encoding guide RNAs targeting each gene in the human genome. Applicants first introduce a single BxBl attB site into the AAVS1 locus of the human ES cell. Then Applicants use the BxBl mtegrase to facilitate the integration of individual guide R A genes into the BxBl attB site in AAVS1 locus. To facilitate integration, each guide RNA gene is contained on a plasmid that carries of a single attP site. This way BxB l will recombine the attB site in the genome with the attP site on the guide RN containing plasmid.
[00590] To generate the cell library, Applicants take the library of cells that have single guide RNAs integrated and induce Cas9 expression. After induction, Cas9 mediates double strand break at sites specified by the guide RNA. To verify the diversity of this cell library, Applicants cany out whole exome sequencing to ensure that Applicants are able to observe mutations in every single targeted gene. This cell library can be used for a variety of applications, including who library-based screens, or can be sorted into individual cell clones to facilitate rapid generation of clonal cell lines with individual human genes knocked out.
Example 24: Engineering of Microalgae using Cas9
[0Θ591 ] Methods of delivering Cas9
[00592] Method 1 : Applicants deliver Cas9 and guide RNA using a vector that expresses Cas9 under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2-tubuHn.
190
90.1 [00593] Method 2: Applicants deliver Cas9 and T7 polymerase using vectors that expresses Cas9 and T7 polymerase under the control of a constitutive promoter such as Hsp70A-Rbc S2 or Beta2 --tubulin. Guide RNA will be delivered using a vector containing T7 promoter driving the guide RNA.
[00594] Method 3: Applicants deliver Cas9 mRNA and in vitro transcribed guide RNA to algae cells. RNA can be in vitro transcribed, Cas9 mRNA will consist of the coding region for Cas9 as well as 3'UTR from Co l to ensure stabilization of the Cas9 mRNA, 0Θ595] For Homologous recombination, Applicants provide an additional homology directed repair template.
[00596] Sequence for a cassette driving the expression of Cas9 under the control of beia-2 tubulin promoter, followed by the 3' UTR of Co l.
TCTTTCTTC TXJCTATGACACTTCCAGCAAAAGGTAGGGCGGGCTGCGA GACGGCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCCCCCGAAGC TC
CTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTAAA TA
GCCAGGCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCA
AAC
ACCTAGATCACTACCACTTCTACACAGGCCACTCGAGCTTGTGATCGCACTCC GC
TAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACATGTACCC ATA
CGATGTTCCAGATTA CGCTTCGCCGAA G AAA A AGCGCA AGGTCGAA GCGTCC GA
CAAGAAGTACAGCATCGGCCTGGACATCGGCACCAACTCTGTGGGCTGGGCC
GIG
ATCACCGACGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACA
cc
GACCGGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCG GC
GAAACAGCCGAGGCCACCCGGCTGAAGAGAACCGCCAGAAGAAGATACACC
AG
ACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAGATGGCC AA
191
90.1 GGTGGACGACAGCTTCTTCCACAGACTGGAAGAGTCCTTCCTGGTGGAAGAG
GAT
AAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCGTGGACGAGGTGGCCT AC
CACGAGAAGTACCCCACCATCTACCACCTGAGAAAGAAACTGGTGGACAGCA
cc
GACAAGGCCGACCTGCGGCTGATCTATCTGGCCCTGGCCCACATGATCAAGTT
CC
GGGGCCACTTCCTGATCGAGGGCGACCTGAACCCCGACAACAGCGACGTGGA
CA
AGCTGTTCATCCAGCTGGTGCAGACCTACAACCAGCTGTTCGAGGAAAACCCC AT
CAACGCCAGCGGCGTGGACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAG AG
CAGACGGCTGGAAAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGC
CT
GTTCGGCAACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCA AC
TTCGACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACG AC
GACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTTTCT GG
CCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAGAGTGAAC
AC
CGAGATCACCAAGGCCCCCCTGAGCGCCTCTATGATCAAGAGATACGACGAG
CA
CCACCAGGACCTGACCCTGCTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGA AG
TACAAAGAGATTTTCTTCGACCAGAGCAAGAACGGCTACGCCGGCTACATTGA
CG
GCGGAGCCAGCCAGGAAGAGTTCTACAAGTTCATCAAGCCCATCCTGGAAAA
GA
TGGACGGCACCGAGGAACTGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCG
GA
192
90.1 AGCAGCGGACCTTCGACAACGGCAGCATCCCCCACCAGATCCACCTGGGAGA
GC
TGCACGCCATTCTGCGGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAAC CG
GGAAAAGATCGAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTC TG
GCCAGGGGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACC ATC
ACCCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCT TCA
TCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCC CA
AGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTGACCAAAGTG AA
ATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAA AA
GGCCATCGTGGACCTGCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAG CT
GAAAGAGGACTACTTCAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCC
GGC
GTGGAAGATCGGTTCAACGCCTCCCTGGGCACATACCACGATCTGCTGAAAAT
TA
TCAAGGACAAGGACTTCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGA TA
TCGTGCTGACCCTGACACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCT
GA
AAACCTATGCCCACCTGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCG
GA
GATACACCGGCTGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGA
CA
AGCAGTCCGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAAC AG
AAACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCC AG
193
90.1 AAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATC TG
GCCGGCAGCCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGG AC
GAGCTCGTGAAAGTGATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAA TG
GCCAGAGAGAACCAGACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGA AT
GAAGCGGATCGAAGAGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGA
ACA
CCCCGTGGAAAACACCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTG
CAG
AATGGGCGGGATATGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCG AC
TACGATGTGGACCATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGA
CA
ACAAGGTGCTGACCAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGC CCT
CCGAAGAGGTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGC
CA
AGCTGATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGG CC
TGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCG
GC
AGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTA CG
ACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAA
GC
TGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAAC AA
CTACCACCACGCCCACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGA TC
AAAAAGTACCCTAAGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGT AC
194
90.1 GACGTGCGGAAGATGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCG cc
AAGTACTTCTTCTACAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCT GG
CCAACGGCGAGATCCGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGG
GG
AGATCGTGTGGGATAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAG CA
TGCCCCAAGTGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAG
CA
AAGAGTCTATCCTGCCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAA GG
ACTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCT GT
GCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTG
AA
AGAGCTGCTGGGGATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCC
AT
CGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATC AA
GCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTG GC
CTCTGCCGGCGAACTGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATAT GT
GAACTTCCTGTACCTGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGG
AT
AATGAGCAGAAACAGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGA TC
ATCGAGCAGATCAGCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCT
GG
ACAAAGTGCTGTCCGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCA GG
CCGAGAATATCATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCC CAAGTACTTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAG
GT
GCTGGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGG
AT
CGACCTGTCTCAGCTGGGAGGCGACAGCCCCAAGAAGAAGAGAAAGGTGGAG
GC
CAGCTAAGGATCCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCCC CTC
CCTAGTGTGTTTGGGGATGTGACTATGTATTCGTGTGTTGGCCAACGGGTCAA
cc
CGAACAGATTGATACCCGCCTTGGCATTTCCTGTCAGAATGTAACGTCAGTTG AT GOT ACT
[00597] Sequence for a cassette driving the expression of T7 polymerase under the control of beta-2 tubulin promoter, followed by the 3' UT of Cop 1:
TCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGGGCGGGCTGCGA GACGGCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCCCCCGAAGC TC
CTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGCTGTTTAAA
TA
GCCAGGCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCCATATTCA AAC
ACCTAGATCACTACCACTTCTACACAGGCCACTCGAGCTTGTGATCGCACTCC GC
TAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAACatgcctaagaaga aga
ggaaggttaacacgattaacatcgctaagaacgacttetetgacatcgaactggctgctatcccgttcaacactctggctgaccatt acggtgagcgtttagctcgcgaacagttggcccttgagca gagtcttacgagatgggtgaagcacgcttccgcaagatgtttga gcgtcaacttaaagctggtgaggttgcggataacgctgccgccaagcctctcatcactaccctactccctaagatgattgcacgc atcaacgactggtttgaggaagtgaaagctaagcgcggcaagcgcccgacagccttccagttcctgcaagaaatcaagccgga agccgtagcgtacatcaccattaagaccactctggcttgcctaaccagigctgacaatacaaccgttcaggctgtagcaagcgca atcggtcgggccattgaggacgaggctcgcttcggtcgtatccgtgaccttgaagctaagcacttcaagaaaaacgttgaggaa caactcaacaagcgcgtagggcacgtctacaagaaagcatttatgcaagttgtcgaggctgacatgctctctaagggtctactcg gtggcgaggcgtggtcttcgtggcataaggaagactctattcat^
aatggttagcttacaccgccaaaatgctggcgtagtaggtcaagactctgagactatcgaactcgcacctgaatacgctgaggct
196
90.1 atcgcaacccgigcaggtgcgciggctggcatctctecgatgttccaaccttgcgiagttccicctaagccgtggactggcattac tggiggtggctattgggctaacggicgicgicctctggcgctggtgcgtactcacagtaagaaagcactgatgcgctacgaagac gtttacatgcctgaggtgtacaaagcgattaacattgcgcaaaacaccgcatggaaaatcaacaagaaagtcctagcggtcgcc aacgtaateaccaagtggaagcattgiccggtcgaggacatccctgcgatigagcgtgaagaactcccgatgaaaccggaaga caicgacaigaatccigaggctctcaccgcgiggaaacgigcigccgctgcigtgiaccgcaaggacaaggcicgcaagictcg ccgtatcagccttgagttcatgcttgagcaagccaataagtttgctaa.ccataaggccatctggttccctta.caaca.tggactggcg cggtcgtgtttacgctgtgtcaatgttcaacccgcaaggtaacgatatgaccaaaggactgcttacgctggcgaaaggtaaacca atcggtaaggaaggtlactactggctgaaaatccacggtgcaaactgtgcgggtgtcgacaaggttccgtlccctgagcgcatca agttcattgaggaaaaccacgagaacatcatggcttgcgctaagictccactggagaacacttggtgggctgagcaagattctcc gttctgcttccttgcgttctgctttgagtacgctggggtacagcaccacggcctgagctataactgctcccttccgctggcgtttgac gggtcttgctctggcatccagcacttctccgcgatgctccgagatgaggtaggtggtcgcgcggttaacttgcttcctagtgaaac cgttcaggacatctacgggattgttgctaagaaagtcaacgagattctacaagcagacgcaaicaaigggaccgataacgaagta gttaccgtgaccgatgagaacactggtgaaatctctgagaaagtcaagctgggcactaaggcactggctggtcaatggctggct tacggtgttactcgcagtgtgactaagcgttcagtcatgacgctggcttacgggtccaaagagttcggcttccgtcaacaagtgct ggaagataccaticagccagciaitgattecggcaagggictgatgttcactcagccgaaicaggctgctggatacaiggctaag ctgatttgggaatctgigagcgtgacggiggtagctgcggttgaagcaatgaactggcttaagtcigctgctaagctgctggctgc tgaggtcaaagataagaagactggagagattcttcgcaagcgttgcgctgtgcattgggtaactcctga ggtttccctgtgtggc aggaatacaagaagcctattcagacgcgcttgaacctgatgttcctcggtcagttccgcttacagcctaccattaacaccaacaa agatagcgagatlgatgcacacaaacaggagtctggtaicgctectaactttgtacacagccaagacggiagccaccticgtaag actgtagigtgggcacacgagaagtacggaatcgaatcttttgcactgattcacgactccttcggtacgattccggctgacgctgc gaacctgttcaaagcagtgcgcgaaactatggttgacacatatgagtcttgtgatgtactggctgatttciacgaccagttcgctga ccagiigcacgagtctcaattggacaaaaigccagcacttccggciaaaggtaacttgaacciccgtgacatcttagagteggact tcgcgttcgcgtaaGGATCCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCC
C
CTCCCTAGTGTGTTTGGGGATGTGACTATGTATTCGTGTGTTGGCCAACGGGTC
A
ACCCGAACAGATTGATACCCGCCTTGGCATTTCCTGTCAGAATGTAACGTCAG TT GATGGTACT
[00598] Sequence of guide RNA driven by the T7 promoter (T7 promoter, s represent targeting sequence):
gaaatTAATACGACTCACTATANNNNNNNNNNNNNNNNNNN e tttagagc
taGAAAtagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgctittitt
[00599] Gene delivery:
197
90.1 0Θ600] Chlamydomonas reinhardtii strain CC-124 and CC-125 from the Chlamydomonas Resource Center will be used for electroporation. Electroporation protocol follows standard recommended protocol from the GeneArt Chlamydomonas Engineering kit.
[00601] Also, Applicants generate a line of Chlamydomonas reinhardtii that expresses Cas9 constitutively. This can be done by using pChlamyl (linearized using Pvul) and selecting for hygromycin resistant colonies. Sequence for pChlamy l containing Cas9 is below. In this way to achieve gene knockout one simply needs to deliver RNA for the guideRNA. For homologous recombination Applicants deliver guideRNA as well as a linearized homologous recombination template.
[00602] pChlamyl -Cas9:
TGCGGTATTTCACACCGCATCAGGTGGCACTTTTCGGGGAAATGTGC GCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCA
TGA
GATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTT AA
ATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAA
TC
AGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGA CT
CCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTG
CT
GCAATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAA A CC
AGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTC
CAT
CCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATA
GT
TTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTT GG
TATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCC CC
ATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAG TA
198
90.1 AGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTA CT
GTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC
ATT
CTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGG AT
AATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTC TT
CGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAA
cc
CACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGG
GT
GAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACAC
GG
AAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAG GG
TTATTGTCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTC
AG
ACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTA ATC
TGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGA TC
AAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATA CC
AAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTG
TA
GCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGTTGCCAGT
GG
C€JATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGG CG
CAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAA CG
ACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGC TTC
199
90.1 CCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG
GA
GAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGT
CG
GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
CGG
AGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTG
CTG
GCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCG TA
TTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGC
AG
CGAGTCAGTGAGCGAGGAAGCGGTCGCTGAGGCTTGACATGATTGGTGCGTA TGT
TTGTATGAAGCTACAGGACTGATTTGGCGGGCTATGAGGGCGGGGGAAGCTC TGG
AAGGGCCGCGATGGGGCGCGCGGCGTCCAGAAGGCGCCATACGGCCCGCTGG CG
GCACCCATCCGGTATAAAAGCCCGCGACCCCGAACGGTGACCTCCACTTTCAG CG
ACAAACGAGCACTTATACATACGCGACTATTCTGCCGCTATACATAACCACTC AG
CTAGCTTAAGATCCCATCAAGCTTGCATGCCGGGCGCGCCAGAAGGAGCGCA
GC
CAAACCAGGATGATGTTTGATGGGGTATTTGAGCACTTGCAACCCTTATCCGG AA
GCCCCCTGGCCCACAAAGGCTAGGCGCCAATGCAAGCAGTTCGCATGCAGCC CCT
GGAGCGGTGCCCTCCTGATAAACCGGCCAGGGGGCCTATGTTCTTTACTTTTTT AC
AAGAGAAGTCACTCAACATCTTAAAATGGCCAGGTGAGTCGACGAGCAAGCC CG
GCGGATCAGGCAGCGTGCTTGCAGATTTGACTTGCAACGCCCGCATTGTGTCG AC
200
90.1 GAAGGCTTTTGGCTCCTCTGTCGCTGTCTCAAGCAGCATCTAACCCTGCGTCGC CG
TTTCCATTTGCAGGAGATTCGAGGTACCATGTACCCATACGATGTTCCAGATT ACG
CTTCGCCGAAGAAAAAGCGCAAGGTCGAAGCGTCCGACAAGAAGTACAGCAT
CG
GCCTGGACATCGGCACCAACTCTGTGGGCTGGGCCGTGATCACCGACGAGTAC
AA
GGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACCGGCACAGCATC AA
GAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGCGAAACAGCCGAGGCC
AC
CCGGCTGAAGAGAACCGCCAGAAGAAGATACACCAGACGGAAGAACCGGAT CTG
CTATCTGCAAGAGATCTTCAGCAACGAGATGGCCAAGGTGGACGACAGCTTCT TC
CACAGACTGGAAGAGTCCTTCCTGGTGGAAGAGGATAAGAAGCACGAGCGGC AC
CCCATCTTCGGCAACATCGTGGACGAGGTGGCCTACCACGAGAAGTACCCCAC GA
TCTACCACCTGAGAAAGAAACTGGTGGACAGCACCGACAAGGCCGACCTGCG
GC
TGATCTATCTGGCCCTGGCCCACATGATCAAGTTCCGGGGCCACTTCCTGATC GA
GGGCGACCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTG
GT
GCAGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTG GA
CGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGAAAAT CT
GATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGCAACCTGATT GC
CCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCGACCTGGCCGAGG AT
201
90.1 GCCAAACTGCAGCTGAGCAAGGACACCTACGACGACGACCTGGACAACCTGC TG
GCCCAGATCGGCGACCAGTACGCCGACCTGTTTCTGGCCGCCAAGAACCTGTC
CG
ACGCCATCCTGCTGAGCGACATCCTGAGAGTGAACACCGAGATCACCAAGGC
ccc
CCTGAGCGCCTCTATGATCAAGAGATACGACGAGCACCACCAGGACCTGACC CTG
CTGAAAGCTCTCGTGCGGCAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTT CG
ACCAGAGCAAGAACGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGA AG
AGTTCTACAAGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGA
AC
TGCTCGTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGA CA
ACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGCGG CG
GCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATCGAGAAG AT
CCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGGGGAAACAGCA GA
TTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCACCCCCTGGAACTTCG
AG
GAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCTTCATCGAGCGGATGACCA
AC
TTCGATAAGAACCTGCCCAACGAGAAGGTGCTGCCCAAGCACAGCCTGCTGT
AC
GAGTACTTCACCGTGTATAACGAGCTGACCAAAGTGAAATACGTGACCGAGG
GA
ATGAGAAAGCCCGCCTTCCTGAGCGGCGAGCAGAAAAAGGCCATCGTGGACC T
GCTGTTCAAGACCAACCGGAAAGTGACCGTGAAGCAGCTGAAAGAGGACTAC TT
202
90.1 CAAGAAAATCGAGTGCTTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGG
TTC
AACGCCTCCCTGGGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGG
ACT
TCCTGGACAATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCT
GA
CACTGTTTGAGGACAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCA CC
TGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGCTG GG
GCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTCCGGCAA
GA
CAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAAACTTCATGCAG CT
GATCCACGACGACAGCCTGACCTTTAAAGAGGACATCCAGAAAGCCCAGGTG TC
CGGCCAGGGCGATAGCCTGCACGAGCACATTGCCAATCTGGCCGGCAGCCCC GC
CATTAAGAAGGGCATCCTGCAGACAGTGAAGGTGGTGGACGAGCTCGTGAAA GT
GATGGGCCGGCACAAGCCCGAGAACATCGTGATCGAAATGGCCAGAGAGAAC CA
GACCACCCAGAAGGGACAGAAGAACAGCCGCGAGAGAATGAAGCGGATCGA AG
AGGGCATCAAAGAGCTGGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAA CA
CCCAGCTGCAGAACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGA
TA
TGTACGTGGACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGA
CC
ATATCGTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTG AC
CAGAAGCGACAAGAACCGGGGCAAGAGCGACAACGTGCCCTCCGAAGAGGT
CG
203
90.1 TGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCTGATTAC cc
AGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCCTGAGCGAACT
GG
ATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACCCGGCAGATCACAAA
GC
ACGTGGCACAGATCCTGGACTCCCGGATGAACACTAAGTACGACGAGAATGA CA
AGCTGATCCGGGAAGTGAAAGTGATCACCCTGAAGTCCAAGCTGGTGTCCGA
TTT
CCGGAAGGATTTCCAGTTTTACAAAGTGCGCGAGATCAACAACTACCACCACG CC
CACGACGCCTACCTGAACGCCGTCGTGGGAACCGCCCTGATCAAAAAGTACC
CTA
AGCTGGAAAGCGAGTTCGTGTACGGCGACTACAAGGTGTACGACGTGCGGAA
GA
TGATCGCCAAGAGCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTT
CTA
CAGCAACATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGA
TC
CGGAAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGAGATCGTGTGGG
AT
AAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAGTGA AT
ATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAGTCTATCC TG
CCCAAGAGGAACAGCGATAAGCTGATCGCCAGAAAGAAGGACTGGGACCCTA
AG
AAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTCTGTGCTGGTGGTGGC
CA
AAGTGGAAAAGGGCAAGTCCAAGAAACTGAAGAGTGTGAAAGAGCTGCTGG GG
ATCACCATCATGGAAAGAAGCAGCTTCGAGAAGAATCCCATCGACTTTCTGGA
AG
204
90.1 CCAAGGGCTACAAAGAAGTGAAAAAGGACCTGATCATCAAGCTGCCTAAGTA CT
CCCTGTTCGAGCTGGAAAACGGCCGGAAGAGAATGCTGGCCTCTGCCGGCGA
AC
TGCAGAAGGGAAACGAACTGGCCCTGCCCTCCAAATATGTGAACTTCCTGTAC C
TGGCCAGCCACTATGAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAA
AC
AGCTGTTTGTGGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGAT
CA
GCGAGTTCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTG TC
CGCCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATC AT
CCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTACTTTGA
CA
CCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCTGGACGCCAC
CC
TGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGATCGACCTGTCTCAG
CT
GGGAGGCGACAGCCCCAAGAAGAAGAGAAAGGTGGAGGCCAGCTAACATAT GATTCGAATGTCTTTCTTGCGCTATGACACTTCCAGCAAAAGGTAGGGCG GGCTGCGAGACGGCTTCCCGGCGCTGCATGCAACACCGATGATGCTTCGACCC CC
CGAAGCTCCTTCGGGGCTGCATGGGCGCTCCGATGCCGCTCCAGGGCGAGCGC TG
TTTAAATAGCCAGGCCCCCGATTGCAAAGACATTATAGCGAGCTACCAAAGCC AT
ATTCAAACACCTAGATCACTACCACTTCTACACAGGCCACTCGAGCTTGTGAT CG
CACTCCGCTAAGGGGGCGCCTCTTCCTCTTCGTTTCAGTCACAACCCGCAAAC
AT
GACACAAGAATCCCTGTTACTTCTCGACCGTATTGATTCGGATGATTCCTACG
CG
205
90.1 AGCCTGCGGAACGACCAGGAATTCTGGGAGGTGAGTCGACGAGCAAGCCCGG
CG
GATCAGGCAGCGTGCTTGCAGATTTGACTTGCAACGCCCGCATTGTGTCGACG AA
GGCTTTTGGCTCCTCTGTCGCTGTCTCAAGCAGCATCTAACCCTGCGTCGCCGT TT
CCATTTGCAGCCGCTGGCCCGCCGAGCCCTGGAGGAGCTCGGGCTGCCGGTGC
CG
CCGGTGCTGCGGGTGCCCGGCGAGAGCACCAACCCCGTACTGGTCGGCGAGC
cc
GGCCCGGTGATCAAGCTGTTCGGCGAGCACTGGTGCGGTCCGGAGAGCCTCG
CG
TCGGAGTCGGAGGCGTACGCGGTCCTGGCGGACGCCCCGGTGCCGGTGCCCC GC
CTCCTCGGCCGCGGCGAGCTGCGGCCCGGCACCGGAGCCTGGCCGTGGCCCTA CC
TGGTGATGAGCCGGATGACCGGCACCACCTGGCGGTCCGCGATGGACGGCAC GA
CCGACCGGAACGCGCTGCTCGCCCTGGCCCGCGAACTCGGCCGGGTGCTCGGC CG
GCTGCACAGGGTGCCGCTGACCGGGAACACCGTGCTCACCCCCCATTCCGAGG TC
TTCCCGGAACTGCTGCGGGAACGCCGCGCGGCGACCGTCGAGGACCACCGCG
GG
TGGGGCTACCTCTCGCCCCGGCTGCTGGACCGCCTGGAGGACTGGCTGCCGGA
CG
TGGACACGCTGCTGGCCGGCCGCGAACCCCGGTTCGTCCACGGCGACCTGCAC GG
GACCAACATCTTCGTGGACCTGGCCGCGACCGAGGTCACCGGGATCGTCGACT TC
ACCGACGTCTATGCGGGAGACTCCCGCTACAGCCTGGTGCAACTGCATCTCAA CG
CCTTCCGGGGCGACCGCGAGATCCTGGCCGCGCTGCTCGACGGGGCGCAGTG GA
206
90.1 AGCGGACCGAGGACTTCGCCCGCGAACTGCTCGCCTTCACCTTCCTGCACGAC TT
CGAGGTGTTCGAGGAGACCCCGCTGGATCTCTCCGGCTTCACCGATCCGGAGG AA
CTGGCGCAGTTCCTCTGGGGGCCGCCGGACACCGCCCCCGGCGCCTGATAAGG AT
CCGGCAAGACTGGCCCCGCTTGGCAACGCAACAGTGAGCCCCTCCCTAGTGTG
TT
TGGGGATGTGACTATGTATTCGTGTGTTGGCCAACGGGTCAACCCGAACAGAT TG ATACCCGCCTTGGCATTTCCTGTCAGAATGTAACGTCAGTTGATGGTACT
|00603] For all modified Chlamydomonas reinhardtii cells, Applicants use PGR, SURVEYOR nuclease assay, and D A sequencing to verify successful modification.
Example 25: Use of Cas9 to target a variety of disease types
0Θ604] Diseases that involve mutations in protein coding sequence:
[0Θ605] Dominant disorders may be targeted by inactivating the dominant negative allele. Applicants use Cas9 to target a unique sequence in the dominant negative allele and introduce a mutation via NHEJ. The NHEJ-induced indel may be able to introduce a frame-shift mutation in the dominant negative allele and eliminate the dominant negative protein. This may work if the gene is haplo-sufficient (e.g. MYOC mutation induced glaucoma and Huntington's disease).
0Θ606] Recessive disorders may be targeted by repairing the disease mutation in both alleles. For dividing cells, Applicants use Cas9 to introduce double strand breaks near the mutation site and increase the rate of homologous recombination using an exogenous recombination template. For dividing cells, this may be achieved using multiplexed nickase activity to catalyze the replacement of the mutant sequence in both alleles via HEj -mediated ligation of an exogenous DNA fragment carrying complementary overhangs.
[00607] Applicants also use Cas9 to introduce protective mutations (e.g. inactivation of CCR5 to prevent HIV infection, inactivation of PCSK9 for cholesterol reduction, or introduction of the A673T into APP to reduce the likelihood of Alzheimer's disease).
[00608] Diseases that involve non-coding sequences
[00609] Applicants use Cas9 to disrupt non-coding sequences in the promoter region, to alter transcription factor binding sites and alter enhancer or repressor elements. For
207
90.1 example, Cas9 may be used to excise out the Klfl enhancer EITSl in hematopoietic stem cells to reduce BCL1 la levels and reactivate fetal globin gene expression in differentiated erythrocytes
[00610] Applicants also use Cas9 to disrupt functional motifs in the 5' or 3 ' untranslated regions. For example, for the treatment of myotonic dystrophy, Cas9 may be used to remove CTG repeat expansions in the DMPK gene.
Example 26: Multiplexed Nickase
[0Θ611 ] Aspects of optimization and the teachings of Cas9 detailed in this application may also be used to generate Cas9 nickases. Applicants use Cas9 nickases in combination with pairs of guide RNAs to generate DNA double strand breaks with defined overhangs. ie two pairs of guide RNAs are used, it is possible to excise an intervening DNA fragment. If an exogenous piece of DNA is cleaved by the two pairs of guide RNAs to generate compatible overhangs with the genomic DNA, then the exogenous DNA fragment may be ligated into the genomic DNA to replace the excised fragment. For example, this may be used to remove trinucleotide repeat expansion in the huntmtin (HIT) gene to treat Huntington's Disease,
[00612] If an exogenous DNA that bears fewer number of CAG repeats is provided, then it may be able to generate a fragment of DNA that bears the same overhangs and can be ligated into the HTT genomic focus and replace the excised fragment.
Figure imgf000209_0001
■■■ GaiACXXOXGCCCTCTGGC a¾¾33i4CACC
Hh CGftCOCTGGAAA. r educe d a r e peat s
[00613] The ligation of the exogenous DNA fragment into the genome does not require homologous recombination machineries and therefore this method may be used in postmitotic cells such as neurons.
Example 26: Delivery of CRISPR System
[00614] Cas9 and its chimeric guide RNA, or combination of tracrRNA and crRNA, can be delivered either as DNA or RNA, Delivery of Cas9 and guide RNA both as RNA
208 (normal or containing base or backbone modifications) molecules can be used to reduce the amount of time that Cas9 protein persist in the ceil. This may reduce the level of off- target cleavage activity in the target ceil Since delivery of Cas9 as mRNA takes time to be translated into protein, it might be advantageous to deliver the guide RNA several hours following the delivery of Cas9 mRNA, to maximize the level of guide RNA available for interaction with Cas9 protein.
[00615] In situations where guide RNA amount is limiting, it may be desirable to introduce Cas9 as mRNA and guide RNA in the form of a DNA expression cassette with a promoter driving the expression of the guide RNA. This way the amount of guide RNA available will be amplified via transcription.
[00616] A variety of delivery systems can be introduced to introduce Cas9 (DNA or RNA) and guide RNA (DNA or RNA) into the host cell. These include the use of liposomes, viral vectors, electr operation, nanoparticles , nano wires (Shalek et al, ano Letters, 2012), exosomes. Molecular trojan horses liposomes (Pardridge et al, Cold Spring Barb Protoc; 2010; doi: 10.1101/pdb.prot5407) may be used to deliver Cas9 and guide RNA across the blood brain barrier.
Example 28: Therapeutic strategies for Trinucleotide repeat disorders
[00617] As previously mentioned in the application, the target polynucleotide of a CRTSPR complex may include a number of disease-associated genes and polynucleotides and some of these disease associated gene may belong to a set of genetic disorders referred to as Trinucleotide repeat disorders (referred to as also trinucleotide repeat expansion disorders, triplet repeat expansion disorders or codon reiteration disorders).
[0Θ618] These diseases are caused by mutations in which the trinucleotide repeats of certain genes exceed the normal, stable threshold which may usually differ in a gene. The discovery of more repeat expansion disorders has allowed for the classification of these disorders into a number of categories based on underlying similar characteristics. Huntington's disease (HD) and the spinocerebellar ataxias that are caused by a CAG repeat expansion in protein-coding portions of specific genes are included in Category 1. Diseases or disorders with expansions that tend to make them phenotypieally diverse and include expansions are usually small in magnitude and also found in exons of genes are included in Category II, Category 111 includes disorders or diseases which are characterized by much larger repeat expansions than either Category 1 or II and are generally located outside protein coding regions. Examples of Category III diseases or
209
90.1 disorders include but are not limited to Fragile X syndrome, myotonic dystrophy, two of the spinocerebellar ataxias, juvenile myoclonic epilepsy, and Friedreich's ataxia,
[00619] Similar therapeutic strategies, like the one mentioned for Friedreich's ataxia below may be adopted to address other trinucleotide repeat or expansion disorders as well. For example, another triple repeat disease that can be treated using almost identical strategy is dystrophia myotonica Ϊ (DM1), where there is an expanded CTG motif in the 3' IJTR, in Friedreich's ataxia, the disease results from expansion of GAA trinucleotides in the first intron of frataxin (FXN), One therapeutic strategy using CRISPR is to excise the GAA repeat from the first intron. The expanded GAA repeat is thought to affect the D A structure and leads to recruit the formation of heterochromatin which turn off the frataxin gene (Fig, 32A),
[00620] Competitive Advantage over other therapeutic strategies are listed below:
[00621] si NA knockdown is not applicable in this case, as disease is due to reduced expression of frataxin. Viral gene therapy is currently being explored. HSV- 1 based vectors were used to deliver the frataxin gene in animal models and have shown therapeutic effect. However, long term efficacy of virus-based frataxin delivery suffer from several problems: First, it is difficult to regulate the expression of frataxin to match natural levels in health individuals, and second, long term over expression of frataxin leads to cell death.
[00622] Nucleases may be used to excise the GAA repeat to restore healthy genotype, but Zinc Finger Nuclease and TALFN strategies require delivery of two pairs of high efficacy nucleases, which is difficult for both delivery as well as nuclease engineering (efficient excision of genomic DNA by ZF or TA.LEN is difficult to achieve).
[00623] in contrast to above strategies, the CRISPR-Cas system has clear advantages. The Cas9 enzyme is more efficient and more muhiplexible, by which it is meant that one or more targets can be set at the same time. So far, efficient excision of genomic DNA > 30% by Cas9 in human cells and may be as high as 30%, and may be improved in the firture. Furthermore, with regard to certain trinucleotide repeat disorders like Huntington's disease (HD), trinucleotide repeats in the coding region may be addressed if there are differences between the two alleles. Specifically, if a. HD patient is heterozygous for mutant HTT and there are nucleotide differences such as SNPs between the wt and mutant HTT alleles, then Cas9 may be used to specifically target the mutant I ! allele. ZFN or TALENs will not have the ability to distinguish two alleles based on single base differences.
210
90.1 [00624] In adopting a strategy using the CRISPR-Cas 9 enzyme t address Friedreich's ataxia, Applicants design a number of guide ΝΛ:·· targeting sites flanking the GAA expansion and the most efficient and specific ones are chosen (Fig. 32B ;.
[00625] Applicants deliver a combination of guide RNAs targeting the intron 1 of FXN along with Cas9 to mediate excision of the GAA expansion region, AAV9 may be used to mediate efficient delivery of Cas9 and in the spinal cord,
[00626] if the Aiu element adjacent to the GAA expansion is considered important, there may be constraints to the number of sites that can be targeted but Applicants may adopt strategies to avoid disrupting it.
[00627] Alternative Strategies:
[00628] Rather than modifying the genome using Cas9, Applicants may also directly activate the FXN gene using Cas9 (nuclease activity deficientj-based DNA binding domain to target a transcription activation domain to the FXN gene. Applicants may have to address the robustness of the Cas9-mediated artificial transcription activation to ensure that it is robust enough as compared to other methods i'Trernbiay et ah, Transcription Activator-Like Effector Proteins Induce the Expression of the Frataxin Gene: Human Gene 'Therapy. August 2012, 23(8): 883 -890.)
Example 29: Strategies for minimizing off-target cleavage using Cas9 nickase
[00629] As previously mentioned in the application, Cas9 may be mutated to mediate single strand cleavage via one or more of the following mutations: D10A, E762A, and
IT840A.
[0Θ630] To mediate gene knockout via NHEJ, Applicants use a nickase version of Cas9 along with two guide RNAs. Off-target nicking by each individual guide RNA may be primarily repaired without mutation, double strand breaks (which can lead to mutations via NHEJ) only occur when the target sites are adjacent to each other. Since double strand breaks introduced by double nicking are not blunt, co -expression of end-processing enzymes such as TREXI will increase the level of NHEJ activity.
0Θ63Ϊ ] The following list of targets in tabular form are for genes involved in the following diseases:
[00632] Lafora's Disease - target GSY1 or PPP1R3C (PTG) to reduce glycogen in neurons.
[00633] Hypercholesterolemia - target PC8K.9
211
90.1 [00634] Target sequences are listed in pairs (L and R) with different number of nucleotides in the spacer (0 to 3bp), Each spacer may also be used by itself with the wild type Cas9 to introduce double strand break at the target locus.
GYS1 (human) GGCC-L ACCCTTGTTAGCCACCTCCC
GGCC-R GAACGCAGTGCTCTTCGAAG
GGNCC-L CTCACGCCCTGCTCCGTGTA
GGNCC-R G G C G AC AACTACTTC CTG G T
GGNNCC-L CTCACGCCCTGCTCCGTGTA
GGNNCC-R GGGCGACAACTACTTCCTGG
GGNNNCC-
L
GGNNNCC-
R GAG G ACCCAG GTGG AACTG C
PCSK9 (human) GGCC-L TCAGCTCCAGGCGGTCCTGG
GGCC-R AG C AG C AG GAG CAGTGGCAG
GGNCC-L TGGGCACCGTCAGCTCCAGG
GGNCC-R CAGCAGTGGCAGCGGCCACC
GGNNCC-L ACCTCTCCCCTGGCCCTCAT
GGNNCC-R CCAGGACCGCCTGGAGCTGA
GGNNNCC-
L CCGTCAGCTCCAGGCGGTCC
GGNNNCC- R AG G AG C AG CAG C AGTG GC AG
PPP1 R3C (PTG) (human) GGCC-L ATGTGCCAAGCAAAGCCTCA
GGCC-R TTCGGTCATGCCCGTGGATG
GGNCC-L GTCGTTGAAATTCATCGTAC
GGNCC-R ACCACCTGTGAAGAGTTTCC
GGNNCC-L CGTCGTTGAAATTCATCGTA
GGNNCC-R ACCACCTGTGAAGAGTTTCC
Gys1 (mouse) GGCC-L GAACGCAGTGCTTTTCGAGG
ACCCTTGTTGGCCACCTCCC
GGNCC-L GGTGACAACTACTATCTGGT GGNCC-R CTCACACCCTGCTCCGTGTA
GGNNCC-L G G G TG AC A ACTACTATCTG G GGNNCC-R CTCACACCCTGCTCCGTGTA GGNNNCC- L CGAGAACGCAGTGCTTTTCG
GGNNNCC- R ACCCTTGTTGGCCACCTCCC
PPP1 R3C (PTG) (mouse) GGCC-L ATG AG CCAAG CAAATCCTC A
GGCC-R TTCCGTCATGCCCGTGGACA GGNCC-L CTTCGTTGAAAACCATTGTA GGNCC-R CCACCTCTGAAGAGTTTCCT
GGNNCC-L CTTCGTTGAAAACCATTGTA GGNNCC-R ACCACCTGTGAAGAGTTTCC GGNNNCC- CTTCC ACTC ACTCTG CG ATT
212
90.1 L
GGNNNCC
R ACCATGTCTCAGTGTCAAGC
PCSK9 (mouse) GGCC-L GGCGGCAACAGCGGCAACAG
,f5PP R Δ ΤΓΐΡΤΡΤΠΡΓΐΤΠΗΡΤΠΡΓΐΡ,
GGNNCC-L CCGCAGCCACGCAGAGCAGT
GGNNCC-R GCACCTCTCCTCGCCCCGAT
[00635] Alternative strategies for improving stability of guide RNA and increasing specificity
[00636] 1 . Nucleotides in the 5' of the guide RNA may be linked via thiolester linkages rather than phosphoester linkage like in natural RNA. Thiolester linkage may prevent the guide RNA from being digested by endogenous RNA degradation machinery.
[0Θ637] 2. Nucleotides in the guide sequence (5' 20bp) of the guide RNA can use bridged nucleic acids (BNA) as the bases to improve the binding specificity.
Example 30: CRISPR-Cas for rapid, multiplex genome editing
[00638] Aspects of the invention relate to protocols and methods by which efficiency and specificity of gene modification may be tested within 3-4 days after target design, and modified clonal cell lines may be derived within 2-3 weeks.
[0Θ639] Programmable nucleases are powerful technologies for mediating genome alteration with high precision. The RNA -guided Cas9 nuclease from the microbial CR1SPR adaptive immune system can be used to facilitate efficient genome editing in eukar otic cells by simply specifying a 20-nt targeting sequence in its guide RNA. Applicants describe a set of protocols for applying Cas9 to facilitate efficient genome editing in mammalian cells and generate cell lines for downstream functional studies. Beginning with target design, efficient and specific gene modification can be achieved within 3-4 days, and modified clonal cell lines can be derived within 2-3 weeks.
[0Θ640] The ability to engineer biological systems and organisms holds enormous potential for applications across basic science, medicine, and biotechnology. Programmable sequence-specific endonucleases that facilitate precise editing of endogenous genomic loci are now enabling systematic interrogation of genetic elements and causal genetic variations in a broad range of species, including those that have not been genetically tractable previously. A number of genome editing technologies have emerged in recent years, including zinc finger nucleases (ZFNs), transcription activator- like effector nucleases (TALENs), and the RNA-guided CRISPR-Cas nuclease system. The first two technologies use a common strategy of tethering endonuciease catalytic
213
90.1 domains to modular DNA-binding proteins for inducing targeted DNA double stranded breaks (DSB) at specific genomic loci. By contrast, Cas9 is a nuclease guided by small R As through Watson-Crick base-pairing with target DNA, presenting a system that is easy to design, efficient, and well-suited for high-throughput and multiplexed gene editing for a variety of cell types and organisms. Here Applicants describe a set of protocols for applying the recently developed Cas9 nuclease to facilitate efficient genome editing in mammalian cells and generate cell lines for downstream functional studies.
[00641 ] Like ZFNs and TALENs, Cas9 promotes genome editing by stimulating DSB at the target genomic loci. Upon cleavage by Cas9, the target locus undergoes one of two major pathways for DNA damage repair, the error-prone non-homologous end joining (NHEJ) or the high-fidelity homology directed repair (HDR) pathway. Both pathways may be utilized to achieve the desired editing outcome.
[00642] NHEJ: In the absence of a repair template, the NHEJ process re-ligates DSBs, which may leave a scar in the form of indel mutations. This process can be harnessed to achieve gene knockouts, as indels occurring within a coding exon may lead to frameshift mutations and a premature stop codon. Multiple DSBs may also be exploited to mediate larger deletions in the genome.
|00643] HDR: Homology directed repair is an alternate major DNA repair pathway to NHEJ. Although HDR typically occurs at lower frequencies than NHEJ, it may be harnessed to generate precise, defined modifications at a target locus in the presence of an exogenously introduced repair template. The repair template may be either in the form of double stranded DNA, designed similarly to conventional DNA targeting constructs with homology arms flanking the insertion sequence, or single-stranded DNA oligonucleotides (ssODNs). The latter provides an effective and simple method for making small edits in the genome, such as the introduction of single nucleotide mutations for probing causal genetic variations. Unlike NHEJ, HDR is generally active only in dividing cells and its efficiency varies depending on the cell type and state.
[00644] Overview of CRISPR: The CRISPR-Cas system, by contrast, is at minimum a. two-component system consisting of the Cas9 nuclease and a short guide RNA. Retargeting of Cas9 to different loci or simultaneous editing of multiple genes simply requires cloning a different 20-bp oligonucleotide. Although specificity of the Cas9 nuclease has yet to be thoroughly elucidated, the simple Watson-Crick base-pairing of the CRISPR-Cas system is likely more predictable than that of ZFN or TALEN domains.
214
90.1 [00645] The type II CRISPR-Cas (clustered regularly interspaced short palindromic repeats) is a bacterial adaptive immune system that uses Cas9, to cleave foreign genetic elements. Cas9 is guided by a pair of non-coding RNAs, a variable crRNA and a required auxiliary tracrRNA. The crRNA contains a 20-nt guide sequence determines specificity by locating the target DNA via Watson-Crick base-pairing. In the native bacterial system, multiple crR As are co-transcribed to direct Cas9 against various targets. In the CRISPR- Cas system derived from Streptococcus pyogenes, the target DNA must immediately precede a 5'-NGG/NRG protospacer adjacent motif (PAM), which can vary for other CRISPR systems.
[00646] CRISPR-Cas is reconstituted in mammalian ceils through the heterologous expression of human codon-optimized Cas9 and the requisite RNA components. Furthermore, the crRNA and tracrRNA can be fused to create a chimeric, synthetic guide RNA (sgRNA). Cas9 can thus be re-directed toward any target of interest by altering the 20-nt guide sequence within the sgRNA.
[00647] Given its ease of implementation and multiplex capability, Cas9 has been used to generate engineered eukaryotic cells carrying specific mutations via both HEJ and HDR. In addition, direct injection of sgRNA and mRNA encoding Cas9 into embryos has enabled the rapid generation of transgenic mice with multiple modified alleles; these results hold promise for editing organisms that are otherwise genetically intractable.
[00648] A mutant Cas9 carrying a disruption in one of its catalytic domains has been engineered to nick rather than cleave DNA, allowing for single-stranded breaks and preferential repair through HDR, potentially ameliorating unwanted indei mutations from off-target DSBs. Additionally, a Cas9 mutant with both DNA-cleaving catalytic residues mutated has been adapted to enable transcriptional regulation in E. coil, demonstrating the potential of functionalizing Cas9 for diverse applications. Certain aspects of the invention relate to the construction and application of Cas9 for multiplexed editing of human cells.
[00649] Applicants have provided a human codon-optimized, nuclear localization sequence-flanked Cas9 to facilitate eukaryotic gene editing. Applicants describe considerations for designing the 20-nt guide sequence, protocols for rapid construction and functional validation of sgRNAs, and finally use of the Cas9 nuclease to mediate both NHEJ- and HDR-based genome modifications in human embryonic kidney (HEK-293FT) and human stem cell (HUES9) lines. This protocol can likewise be applied to other cell types and organisms.
215
90.1 [00650] Target selection for sgRNA: There are two main considerations in the selection of the 20-nt guide sequence for gene targeting: 1) the target sequence should precede the 5'--NGG PAM for S, pyogenes Cas9, and 2) guide sequences should be chosen to minimize off-target activity. Applicants provided an online Cas9 targeting design tool that takes an input sequence of interest and identifies suitable target sites. To experimentally assess off-target modifications for each sgRNA, Applicants also provide computationally predicted off-target sites for each intended target, ranked according to Applicants' quantitative specificity analysis on the effects of base-pairing mismatch identity, position, and distribution.
[00651] The detailed information on computationally predicted off -target sites is as follows:
[00652] Considerations for Off-target Cleavage Activities: Similar to other nucleases, Cas9 can cleave off-target DNA targets in the genome at reduced frequencies. The extent to which a given guide sequence exhibit off-target activity depends on a combination of factors including enzyme concentration, thermodynamics of the specific guide sequence employed, and the abundance of similar sequences in the target genome. For routine application of Cas9, it is important to consider ways to minimize the degree of off-target cleavage and also to be able to detect the presence of off-target cleavage.
[00653] Minimizing off-target activity: For application in cell lines. Applicants recommend following two steps to reduce the degree of off -target genome modification. First, using Applicants' online CRISPR target selection tool, it is possible to computationally assess the likelihood of a given guide sequence to have off-target sites. These analyses are performed through an exhaustive search in the genome for off -target sequences that are similar sequences as the guide sequence. Comprehensive experimental investigation of the effect of mismatching bases between the sgRNA and its target DNA revealed that mismatch tolerance is 1) position dependent - the 8-14 bp on the 3' end of the guide sequence are less tolerant of mismatches than the 5' bases, 2) quantity dependent - in general more than 3 mismatches are not tolerated, 3) guide sequence dependent - some guide sequences are less tolerant of mismatches than others, and 4) concentration dependent - off-target cleavage is highly sensitive to the amount of transfected DNA. The Applicants' target site analysis web tool (available at the website genome- engineering, org'' tools) integrates these criteria to provide predictions for likely off-target sites in the target genome. Second, Applicants recommend titrating the amount of Cas9 and sgRNA expression plasmid to minimize off-target activity.
216
90.1 [00654] Detection of off-target activities: Using Applicants' CRISPR targeting web tool, it is possible to generate a list of most likely off-target sites as well as primers performing SURVEYOR or sequencing analysis of those sites. For isogenic clones generated using Cas9, Applicants strongly recommend sequencing these candidate off- target sites to check for any undesired mutations. It is worth noting that there may be off target modifications in sites that are not included in the predicted candidate list and full genome sequence should be performed to completely verify the absence of off-target sites. Furthermore, in multiplex assays where several DSBs are induced within the same genome, there may be low rates of translocation events and can be evaluated using a variety of techniques such as deep sequencing.
[00655] The online tool provides the sequences for all oligos and primers necessary for 1) preparing the sgRNA constructs, 2) assaying target modification efficiency, and 3) assessing cleavage at potential off-target sites. It is worth noting that because the U6 RNA polymerase III promoter used to express the sgRNA prefers a guanine (G) nucleotide as the first base of its transcript, an extra G is appended at the 5' of the sgRNA where the 20- nt guide sequence does not begin with G.
[00656] Approaches for sgRNA construction and delivery: Depending on the desired application, sgRNAs may be delivered as either 1) PCR amplicons containing an expression cassette or 2) sgRNA-expressing plasmids. PCR-based sgRNA delivery- appends the custom sgRNA sequence onto the reverse PGR primer used to amplify a U6 promoter template. The resulting amplicon may be co-iransfected with a plasmid containing Cas9 (PXI65). This method is optimal for rapid screening of multiple candidate sgRNAs, as cell transfections for functional testing can be performed mere hours after obtaining the sgRNA-encoding primers. Because this simple method obviates the need for plasmid-based cloning and sequence verification, it is well suited for testing or co-transfecting a large number of sgRNAs for generating large knockout libraries or other scale-sensitive applications. Note that the sgRNA-encoding primers are over 100-bp, compared to the ~20-bp oligos required for plasmid-based sgRNA delivery.
[0Θ657] Construction of an expression plasmid for sgRNA is also simple and rapid, involving a single cloning step with a pair of partially complementary oligonucleotides. After annealing the oligo pairs, the resulting guide sequences may be inserted into a plasmid bearing both Cas9 and an invariant scaffold bearing the remainder of the sgRNA sequence (PX330). The transfection plasmids may also be modified to enable virus production for in vivo delivery.
217
90.1 [00658] In addition to PGR and plasmkl-based delivery methods, both Cas9 and sgRNA can be introduced into cells as RNA.
[00659] Design of repair template: Traditionally, targeted DNA modifications have required use of plasmid-based donor repair templates that contain homology arms flanking the site of alteration. The homology arms on each side can vary in length, but are typically- longer than 500 bp. This method can be used to generate large modifications, including insertion of reporter genes such as fluorescent proteins or antibiotic resistance markers. The design and construction of targeting plasmids has been described elsewhere.
[00660] More recently, single-stranded DNA oligonucleotides (ssODNs) have been used in place of targeting plasmids for short modifications within a defined locus without cloning. To achieve high HDR efficiencies, ssODNs contain flanking sequences of at least 40 bp on each side that are homologous to the target region, and can be oriented in either the sense or antisense direction relative to the target locus.
[00661] Functional testing
[00662] SURVEYOR nuclease assay: Applicants detected indel mutations either by the SURVEYOR nuclease assay (or PGR amplicon sequencing. Applicants online CRISPR target design tool provides recommended primers for both approaches. However, SURVEYOR or sequencing primers may also be designed manually to amplify the region of interest from genomic DNA and to avoid non-specific amplicons using NCBI Primer- BLAST. SURVEYOR primers should be designed to amplify 300-400 bp (for a 600-800 bp total amplicon) on either side of the Cas9 target for allowing clear visualization of cleavage bands by gel electrophoresis. To prevent excessive primer dimer formation, SURVEYOR primers should be designed to be typically under 25-nt long with melting temperatures of ~60°C. Applicants recommend testing each pair of candidate primers for specific PGR amplicons as well as for the absence of non-specific cleavage during the SURVEYOR nuclease digestion process.
[0Θ663] Plasmid- or ssODN-mediated HDR: HDR can be detected via PGR- amplification and sequencing of the modified region. PGR primers for this purpose should anneal outside the region spanned by the homology arms to avoid false detection of residual repair template (HDR Fwd and Rev, Fig. 30). For ssODN-mediated HDR, SURVEYOR PGR primers can be used.
[00664] Detection of indels or HDR by sequencing: Applicants detected targeted genome modifications by either Sanger or next-generation deep sequencing (NGS). For the former, genomic DNA from modified region can be amplified using either
218
90.1 SURVEYOR or HDR primers. Amplicons should be subcloned into a plasmid such as pUC19 for transformation; individual colonies can be sequenced to reveal clonal genotype.
[00665] Applicants designed next-generation sequencing (NGS) primers for shorter amplicons, typically in the 100-200 bp size range. For detecting NHEJ mutations, it is important to design primers with at least 10-20 bp between the priming regions and the Cas9 target site to allow detection of longer indels. Applicants provide guidelines for a two-step PGR method to attach barcoded adapters for multiplex deep sequencing. Applicants recommend the Ilium ina platform, due to its generally low levels of false positive indels. Off-target analysis (described previously) can then be performed through read alignment programs such as ClusialW, Geneious, or simple sequence analysis scripts.
[00666] Materials and Reagents
[00667] sgRNA preparation:
[00668] UltraPure DNaseRNase-free distilled water (Life Technologies, cat. no. 10977- 023)
[0Θ669] Herculase H fusion polymerase (Agilent Technologies, cat. no. 600679)
[00670] CRITICAL. Standard Taq polymerase, which lacks 3 '-5' exonuclease proofreading activity, has lower fidelity and can lead to amplification errors. Herculase II is a high-fidelity polymerase (equivalent fidelity to Pfu) that produces high yields of PGR product with minimal optimization. Other high-fidelity polymerases may be substituted.
[00671] Herculase II reaction buffer (5x; Agilent Technologies, included with polymerase)
[00672] dNTP solution mix (25 mM each; Enzymatics, cat. no. N205L)
[00673] MgC12 (25mM; ThermoScientific, cat. no. R0971)
[00674] QIAquick gel extraction kit (Qiagen, cat. no. 28704)
[00675] QIAprep spin rniniprep kit (Qiagen, cat. no. 27106)
[00676] UltraPure TBE buffer (10X; Life Technologies, cat. no. 15581 -028)
[00677] SeaKem LE agarose (Lonza, cat. no. 50004)
[0Θ678] SYBR Safe DNA stain (10,000x; Life Technologies, cat. no. S33102)
[00679] 1-kb Plus DNA ladder (Life Technologies, cat, no. 10787-018)
[00680] Tracklt CyanOrange loading buffer (Life Technologies, cat. no. 10482-
[00681] FastDigest Bbsl (Bpil) (Fermentas/ThermoScientific, cat. no. FD1014)
[00682] Fermentas Tango Buffer (Fermentas/ThermoScientific, cat. no. BY5)
[00683] DL-dithiothreitoI (DTT; Fermentas/ThermoScientific, cat, no. R0862)
219
90.1 [00684] T7 DNA ligase (Enzymatics, cat. no. L602L)
[00685] Critical :Do not substitute the more commonly used T4 ligase. T7 ligase has 1,000-fold higher activity on the sticky ends than on the blunt ends and higher overall activity than commercially available concentrated T4 ligases.
[00686] T7 2X Rapid Ligation Buffer (included with T7 DNA ligase, Enzymatics, cat. no. L602L)
[00687] T4 Polynucleotide Kinase (New England Biolabs, cat. no M0201 S)
[00688] T4 DNA Ligase Reaction Buffer (10X; New England Biolabs, cat. no B0202S)
[0Θ689] Adenosine 5 '-triphosphate (10 mM; New England Biolabs, cat. no. P0756S)
[00690] PlasmidSafe ATP-dependent DNase (Epicentre, cat. no. E3101K)
[00691] One Shot Stbl3 chemically competent Escherichia coli (E. coli) (Life
Technologies, cat. no. C7373-03)
[00692] SOC medium (New England Biolabs, cat. no. B9020S)
[00693] LB medium (Sigma, cat. no. L3022)
[00694] LB agar medium (Sigma, cat. no. L2897)
[00695] Ampieiliin, sterile filtered (100 mg ml-l ; Sigma, cat. no. A5354)
[00696] Mammalian cell culture:
[00697] HEK293FT ceils (Life Technologies, cat. no. R700-07)
[00698] Dulbecco's minimum Eagle's medium (DMEM, IX, high glucose; Life Technologies, cat. no. 10313-039)
[00699] Dulbecco's minimum Eagle's medium (DMEM, IX, high glucose, no phenol red; Life Technologies, cat, no. 31053-028)
[00700] Dulbecco's phosphate-buffered saline (DPBS, IX; Life Technologies, cat. no. 14190-250)
[00701] Fetal bovine serum, qualified and heat inactivated (Life Technologies, cat. no. 10438-034)
[00702] Opti-MEM I reduced-serum medium (FBS; Life Technologies, cat. no. 1 1058- 021)
[00703] Penicillin-streptomycin (lOOx; Life Technologies, cat. no. 15140-163)
[00704] TrypLE™ Express (IX, no Phenol Red; Life Technologies, cat, no. 12604- 013)
[00705] Lipofectamine 2000 transfection reagent (Life Technologies, cat. no. 1 1668027)
220
90.1 [00706] Amaxa SF Cell Line 4D-Nucleofector® X Kit S (32 RCT; Lonza, cat. no V4XC-2032)
[00707] HUES 9 cell line (HARVARD STEM CELL SCIENCE)
[00708] Geltrex LDEV-Free Reduced Growth Factor Basement Membrarse Matrix (Life
Technologies, cat. no. A14I3201)
0Θ7Θ9] mTeSRl medium (Stemcell Technologies, cat. no. 05850)
[00710] Accutase cell detachment solution (Stemcell Technologies, cat. no. 07920)
[00711 ] ROCK Inhibitor (Y-27632; illipore, cat. no. SCM075)
[0Θ712] Amaxa P3 Primary Cell 4D-Nuc1eofector® X Kit S (32 RCT; Lonza cat. no.
V4XP-3032)
[00713] Genotyping analysis:
[00714] QuickExtract DNA extraction solution (Epicentre, cat. no. QE09050)
[00715] PGR primers for SURVEYOR, RFLP analysis, or sequencing (see Primer table)
[00716] Herculase IT fusion polymerase (Agilent Technologies, cat. no. 600679)
[00717] CRITICAL. As Surveyor assay is sensitive to single-base mismatches, it is particularly important to use a. high-fidelity polymerase. Other high-fidelity polymerases may be substituted.
[00718] Herculase II reaction buffer (5x; Agilent Technologies, included with polymerase)
[00719] d TP solution mix (25 mM each; Enzymatics, cat. no. N205L)
[0Θ720] QIAquiek gel extraction kit (Qiage , cat. no, 28704)
[0Θ721 ] Taq Buffer (1 Ox; Genscript, cat, no. B0005)
[00722] SURVEYOR mutation detection kit for standard gel electrophoresis (Transgenomic, cat. no. 706025)
[00723] UltraPure TBE buffer (!Ox; Life Technologies, cat, no. 15581 -028)
0Θ724] SeaKem LE agarose (Lonza, cat. no. 50004)
0Θ725] 4-20% TBE Gels 1.0 mm, 15 Well (Life Technologies, cat. no. EC62255BOX) [0Θ726] Novex© Hi-Density TBE Sample Buffer (5X; Life Technologies, cat. no. LC6678)
[00727] SYBR Gold Nucleic Acid Gel Stain (10,000X: Life Technologies, cat. no. 8- 11494)
[00728] 1 -kb Plus DNA ladder (Life Technologies, cat. no. 10787-018)
[00729] Tracklt CyanOrange loading buffer (Life Technologies, cat. no. 10482-028)
221
90.1 [00730] FastDigest HindlU (Fermentas ThermoScientific, cat. no. FD0504)
[00731] Equipment
[00732] Filtered sterile pipette tips (Corning)
[00733] Standard 1.5ml microcentrifuge tubes (Eppendorf, cat. no. 0030 125.150)
[00734] Axyge 96-well PGR plates (VWR, cat. no. PC -96M2-HSC)
[00735] Axygen 8-Strip PGR tubes (Fischer Scientific, cat. no. 14-222-250)
[00736] Falcon tubes, polypropylene, 15 mi i'BD Falcon, cat. no. 352097)
[00737] Falcon tubes, polypropylene, 50 ml (BD Falcon, cat. no. 352070)
[0Θ738] Round-bottom Tube with ceil strainer cap, 5ml (BD Falcon, cat. no. 352235)
[00739] Petri dishes (60 mm * 15 mm; BD Biosciences, cat. no. 351007)
[00740] Tissue culture plate (24 well; BD Falcon, cat no. 353047}
[00741] Tissue culture plate (96 well, flat bottom; BD Falcon, cat. no. 353075)
[00742] Tissue culture dish ( 100 mm; BD Falcon. 353003)
[00743] 96-well thermocycler with programmable temperature stepping functionality
(Applied Biosystems Veriti, cat. no, 4375786).
[00744] Desktop microcentrifuges 5424, 5804 (Eppendorf)
[00745] Gel electrophoresis system (PowerPac basic power supply, Bio-Rad, cat. no. 164-5050, and Sub-Cell GT System gel tray, Bio-Rad, cat. no. 170-4401 )
[00746] Novex XCell SureLock Mini-Cell (Life Technologies, cat. no. EI0001 )
[00747] Digital gel imaging system (GelDoc EZ, Bio-Rad, cat, no. 170-8270, and blue sample tray, Bio-Rad, cat. no. 170-8273)
[00748] Blue light transilluminator and orange filter goggles (Safelmager 2,0; invitrogen, cat, no. G6600)
[00749] Gel quantification software (Bio-Rad, ImageLab, included with GelDoc EZ,or open-source imageJ from the National Institutes of Health, available at the website rsbweb.nih.gov/ij/) UV spectrophotometer (NanoDrop 2000c, Thermo Scientific) ΘΘ750] Reagent Setup
[00751] Tris-borate EDTA (TBE) electrophoresis solution Dilute TBE buffer in distilled water to IX working solution for casting agarose gels and for use as a buffer for gel electrophoresis. Buffer may be stored at room temperature (18 - 22 °C) for at least 1 year.
[00752] · ATP, 10 mM Divide 10 mM ATP into 50-μ1 aliquots and store at - 20 °C for up to 1 year; avoid repeated freeze-thaw cycles.
222
90.1 [00753] · DTT, 10 ίϊΐΜ Prepare 10 mM DTT solution in distilled water and store in 20-μί aliquots at - 70 °C for up to 2 years; for each reaction, use a new aliquot, as DTT is easily oxidized,
[00754] · D10 culture medium For culture of HEK293FT cells, prepare D10 culture medium by supplementing DMEM with IX GlutaMAX and 10% (vol/vol) fetal bovine serum. As indicated in the protocol, this medium can also be supplemented with I X penicillin-streptomycin . D10 medium can be made in advance and stored at 4 °C for up to 1 month.
|00755] * mTeSRl culture medium For culture of human embryonic stem cells, prepare m'TeSR l medium by supplementing the 5X supplement (included with mTeSRl basal medium), and 100 ug/mi Normocin.
0Θ756] Procedure
[00757] Design of targeting components and use of the online tool · Timing 1 d
[0Θ758] I j Input target genomic DNA sequence. Applicants provide an online Cas9 targeting design tool that takes an input sequence of interest, identifies and ranks suitable target sites, and computationally predicts off-target sites for each intended target. Alternatively, one can manually select guide sequence by identifying the 20-bp sequence directly upstream of any 5'-NGG.
[00759] 21 Order necessary oligos and primers as specified by the online tool. If the site is chosen manually, the oligos and primers should be designed.
[0Θ760] Preparation of sgRN A expression construct
[00761] 31 To generate the sgRNA expression construct, either the PGR- or plasmid- based protocol can be used.
[00762] (A) via PCR amplification · Timing 2 h
[00763] (i) Applicants prepare diluted U6 PCR template. Applicants recommend using PX330 as a PCR template, but any U6-containing plasmid may likewise be used as the PCR template. Applicants diluted template with ddH20 to a concentration of 10 ng/ul. Note that if a plasmid or cassette already containing an U6-driven sgRNA is used as a template, a. gel extraction needs to be performed to ensure that the product contains only the intended sgRNA and no trace sgRNA carryover from template.
[00764] (ii) Applicants prepared diluted PCR oligos. U6-Fwd and U6-sgRNA-Rev primers are diluted to a final concentration of 10 uM in ddH20 (add 10 uf of 100 uM primer to 90 ul dd¾0).
223
90.1 0Θ765] (iii) U6~sgRNA PGR reaction. Applicants set up the following reaction for each U6-sgRNA-Rev primer and mastermix as needed:
Component: Amount (ul) Final concentration
Herculase II PGR buffer, 5X 10 IX
d TP, lOOmM (25mM each) 0.5 1 mM
U6 template (PX330) 1 0.2 ng/ui
U6-Fwd primer 1 0.2 uM
U6-sgRNA-Rev primer (variable) 1 0.2 uM
Herculase II Fusion polymerase 0.5
Distilled water 36
Total 50
[00766] (iv) Applicants performed PGR reaction on the reactions from step (iii) using the following cycling conditions:
Cycle number Denature Anneal Extend
1 95°C, 2 m
2-31 95°Q 20 s 60°C, 20 s 72°C, 20 s
32 72°C, 3 m
[00767] (v) After the reaction is completed, Applicants ran the product on a gel to verify successful, single-band amplification. Cast a 2% (wt/vol) agarose gel in I TBE buffer with I X SYBR Safe dye. Run 5 ul of the PGR product in the gel at 15 V cm-1 for 20-30 min. Successful amplicons should yield one single 370-bp product and the template should be invisible, ft should not be necessary to gel extract the PGR amplicon.
[0Θ768] (vi) Applicants purified the PGR product using the QIAquick PGR purification kit according to the manufacturer's directions. Elute the ΌΝΑ in 35 ui of Buffer EB or water. Purified PGR products may be stored at 4°C or -20°C.
[00769] (B) Cloning sgRNA into Cas9-containing bicistronic expression vector *
[00770] (i) Prepare the sgRNA oligo inserts. Applicants resuspended the top and bottom strands of oligos for each sgRNA design to a final concentration of 100 uM. Pbosphorylate and anneal the oligo as follows:
Oligo I (100 uM) l ui
Oligo 2 (100 uM) l i
T4 Ligation Buffer, I OX 1 ul
T4 PN 1 ul
224
90.1 ddi 1■() 6 ul
Total 10 ul
[00771] (ii) Anneal in a thermocycler using the following parameters:
[00772] 37°C for 30 m
[00773] 95°C for 5 m
[00774] Ramp down to 25°C at 5°C per m
[00775] (iii) Applicants diluted phosphorvlated and annealed oligos 1 :200 by add lul of oli go to 199 ul room temperature ddH20.
[0Θ776] (iv) Clone sgRNA oligo into PX330. Applicants set up Golden Gate reaction for each sgRNA. Applicants recommend also setting up a no-insert, PX330 only negative control.
PX330 ( 100 ng) x ul
Diluted oligo duplex from step (iii) 2 ul
Tango Buffer, 10X 2 ul
DTT, lOmM 1 ul
ATP, iOniM 1 ul
FastDigest Bbsl 1 ul
T7 Ligase 0.5 ul
ddfl O x ul
Total 20 ul
[00777] (v) Incubate the Golden Gate reaction for a total of 1 h:
[00778] Cycle number Condition
[0Θ779] 1 -6 37°C for 5 m, 21 °C for 5 m
[00780] (vi) Applicants treated Golden Gate reaction with PlasmidSafe exonuclease to digest any residual linearized DNA. This step is optional but highly recommended.
Golden Gate reaction from step 4 1 1 ul
10X PlasmidSafe Buffer 1.5 ul
ATP, 10 mM 1.5 ul
PlasmidSafe exonuclease l_ul
[00781 ] Total 15 ul
[00782] (vii) Applicants incubated the PlasmidSafe reaction at 37°C for 30 min, followed by inactivation at 70°C for 30 min. Pause point: after completion, the reaction may be frozen and continued later. The circular DNA should be stable for at least I week.
225
90.1 0Θ783] (viii) Transformation. Applicants transformed the PlasmidSafe -treated plasmid into a competent E. coli strain, according to the protocol supplied with the cells. Applicants recommend Stbl3 for quick transformation. Briefly, Applicants added 5ul of the product from step (vii) into 20ul of ice-cold chemically competent Stbl3 cells. This is then incubated on ice for 10 m, heat shocked at 42°C for 30 s, returned immediately to ice for 2 m, 100 ul of SOC medium is added, and this is plated onto an LB plate containing 100 ug/'ml ampicillin with incubation overnight at 37°C.
[00784] (ix) Day 2: Applicants inspected plates for colony growth. Typically, there are no colonies on the negative control plates (ligation of Bbsl-digested PX330 only, no annealed sgRNA oligo), and tens to hundreds of colonies on the PX33G-sgR A cloning plates.
[00785] (x) From each plate. Applicants picked 2-3 colonies to check correct insertion of sgRNA. Applicants used a sterile pipette tip to inoculate a single colony into a 3 ml culture of LB medium with 100 ug ml ampicillin. Incubate and shake at 37°C overnight. 0Θ786] (xi) Day 3 : Applicants isolated plasmid DNA from overnight cultures using a QiAprep Spin miniprep kit according to the manufacturer's instructions,
[00787] (xii) Sequence validate CRISPR plasmid. Applicants verified the sequence of each colony by sequencing from the U6 promoter using the U6-Fwd primer. Optional: sequence the Cas9 gene using primers listed in the following Primer table.
Figure imgf000227_0001
226
90.1 Clone EMX1
EMX1- sgR A into bottom AAACCCCTAGTCATTGGAGGTGAC PX330
CAGAAGAAGAAGGGCTCCCATCACATCAACCGGTG
GCGCATTGCCACGAAGCAGGCCAATGGGGAGGACA TC
GATGTCACCTCCAATGACAAGCTTGCTAGCGGTGGG CAACCACAAACCCACGAGGGCAGAGTGCTGCTTGC EMX1 HDR
TG (sense;
ssODN- CTGGCCAGGCCCCTGCGTGGGCCCAAGCTGGACTCT insertion sense GGCCACTCCCT underlined)
AGGGAGTGGCCAGAGTCCAGCTTGGGCCCACGCAG GGGCCTGGCCAGCAGCAAGCAGCACTCTGCCCTCGT
i \"
GGTTTGTGGTTGCCCACCGCTAGCAAGCTTGTCATT GGAGGTGACATCGATGTCCTCCCCATTGGCCTGCTT EMX1 HDR
CG (antisense; ssODN- TGGCAATGCGCCACCGGTTGATGTGATGGGAGCCCT insertion antisense TCTTCTTCTG underlined)
EMXl
SURVEYOR
ΕΜΧΊ- assay PGR, SU V-F CCATCCCCTTCTGTGAATGT sequencing
EMXl
SURVEYOR
EMX1- assay PGR, SURV-R GGAGATTGGAGACACGGAGA sequencing
EMXl RFLP
EMXl- analysis PGR, HDR-F GGCTCCCTGGGTTCAAAGTA sequencing
EMXl RFLP
EMX1 - analysis PGR, HDR-R AGAGGGGTCTGGATGTCGTAA sequencing pUC19 multiple cloning site F primer, for Sanger pUC19-F CGCCAGGGTTTTCCCAGTCACGAC sequencing
[0Θ788] Applicants referenced the sequencing results against the PX330 cloning vector sequence to check that the 20 bp guide sequence was inserted between the U6 promoter and the remainder of the sgRNA scaffold. Details and sequence of the PX330 map in GenBank vector map format (*.gb file) can be found at the website crispr. genome- engineering, org.
0Θ789] (Optional) Design of ssODN template · Timing 3 d planning ahead
227
90.1 0Θ790] 3 J Design and order ssODN. Either the sense or antisense ssODN can be purchased directly from supplier. Applicants recommend designing homology arms of at least 40 bp on either side and 90 bp for optimal HDR efficiency. In Applicants' experience, antisense oiigos have slightly higher modification efficiencies.
[00791] 4j Applicants resuspended and diluted ssODN ultramers to a final concentration of 10 uM. Do not combine or anneal the sense and antisense ssODNs. Store at -20 ( .
0Θ792] 51 Note for HDR applications, Applicants recommend cloning sgRNA into the PX330 plasmid.
[00793] Functional validation of sgRNAs: cell culture and transfections * Timing 3-4 d
[00794] The CRISPR-Cas system has been used in a number of mammalian cell lines. Conditions may vary for each cell line. The protocols below details transiection conditions for HEK239FT cells. Note for ssODN-mediated HDR transfections, the Amaxa SF Cell Line Nucleofector Kit is used for optimal delivery of ssODNs. This is described in the next section.
[00795] 7| HEK293FT maintenance. Cells are maintained according to the manufacturer's recommendations. Briefly, Applicants cultured cells in D10 medium (GlutaMax DMEM supplemented with 10% Fetal Bovine Serum), at 37°C and 5% C02.
[00796] 8j To passage, Applicants removed medium and rinsed once by gently adding DPBS to side of vessel, so as not to dislodge cells. Applicants added 2 ml of TrypLE to a T75 flask and incubated for 5 m at 37°C. 10 ml of warm DI O medium is added to inactivate and transferred to a 50 ml Falcon tube. Applicants dissociated cells by triturating gently, and re-seeded new flasks as necessary. Applicants typically passage cells every 2-3 d at a split ratio of 1 :4 or 1 :8, never allowing cells to reach more than 70% confluency. Cell lines are restarted upon reaching passage number 15.
[00797] 9| Prepare cells for transfection. Applicants plated well-dissociated cells onto 24 -well plates in DIO medium without antibiotics 16-24 h before transiection at a seeding density of 1.3 x 10'' cells per well and a seeding volume of 500 ul. Scale up or down according to the manufacturer's manual as needed. It is suggested to not plate more cells than recommended density as doing so may reduce transfection efficiency.
[00798] lOj On the day of transfection, cells are optimal at 70-90% confluency. Cells may be transfected with Lipofectamme 2000 or Amaxa SF Cell Line Nucleofector Kit according to the manufacturers' protocols.
228
90.1 0Θ799] (A) For sgR As cloned into PX330, Applicants transfected 500 ng of sequence-verified CRJSPR plasmid; if transfecting more than one plasmid, mix at equimolar ratio and no more than 500 ng total
[00800] (B) For sgRNA amplified by PGR, Applicants mixed the following:
PX165 (Cas9 only) 200 ng
sgRNA amplicon (each) 40 ng
pUC 19 fill up total DNA to 500 ng
0Θ80Ϊ ] Applicants recommend transfecting in technical triplicates for reliable quantification and including transfection controls (e.g. GFP plasmid) to monitor transfection efficiency. In addition, PX330 cloning plasmid and/or sgRNA amplicon may be transfected alone as a negative control for downstream functional assays.
[00802] 1 1 j Applicants added Lipofectamine complex to cells gently as HEK293FT cells may detach easily from plate easily and result in lower transfection efficiency.
[00803] 12 j Applicants checked cells 24 h after transfection for efficiency by estimating the fraction of fluorescent cells in the control (e.g., GFP) transfection using a fluorescence microscope. Typically cells are more than 70% transfected.
[00804] 13 i Applicants supplemented the culture medium with an additional 500 ul of warm D10 medium. Add D10 very slowly to the side of the well and do not use cold medium, as cells can detach easily.
[00805] 14| Cells are incubated for a total of 48-72 h post-transfection before harvested for indel analysis. Indel efficiency does not increase noticeably after 48 h.
[0Θ806] (Optional) Co-transfection of CRISPR plasmids and ssODNs or targeting plasmids for MR * Timing 3-4 d
[00807] 15| Linearize targeting plasmid. Targeting vector is linearized if possible by cutting once at a restriction site in the vector backbone near one of the homology arms or at the distal end of either homology arm.
[00808] 16j Applicants ran a small amount of the linearized plasmid alongside uncut plasmid on a 0.8-1% agarose gel to check successful linearization. Linearized plasmid should run above the supercoiled plasmid.
[0Θ809] 17j Applicants purified linearized plasmid with, the QIA Quick PGR Purification kit.
[00810] 18| Prepare cells for transfection. Applicants cultured HEK293FT in T75 or T225 flasks. Sufficient cell count before day of transfection is planned for. For the Arnaxa strip-cuvette format, 2 x 10° cells are used per transfection.
229
90.1 [00811 ] 19j Prepare plates for transfection. Applicants added 1 ml of warm D10 medium into each well of a 12 well plate. Plates are placed into the incubator to keep medium warm.
[00812] 20| Nucleofection. Applicants transfected HEK293FT cells according to the Amaxa SF Cell Line Nucleofector 4D Kit manufacturer's instructions, adapted in the steps below.
[00813] a. For ssQDN and CRISPR cotransfection, pre-mix the following DNA in PGR tubes:
pCRISPR plasmid (Cas9 + sgRNA) 500 ng
ssOD'N template (lOuM) 1 ul
|00814] b. For HDR targeting plasmid and CRISPR cotransfection, pre-mix the following DNA in PGR tubes:
CRISPR plasmid (Cas9 + sgRJS!A) 500 ng
Linearized targeting plasmid 500 ng
[00815] For transfection controls, see previous section. In addition, Applicants recommend transfecting ssODN or targeting plasmid alone as a negative control.
[00816] 21 j Dissociate to single cells. Applicants removed medium and rinsed once gently with DPBS, taking care not to dislodge cells. 2 ml of TrypLE is added to a T75 flask and incubated for 5 m at 37°C. 10 ml of warm D10 medium is added to inactivate and triturated gently in a 50 ml Falcon tube. It is recommended that cells are triturated gently and dissociated to single cells. Large clumps will reduce transfection efficiency. Applicants took a 10 ul aliquot from the suspension and diluted into 90 ul of D10 medium for counting. Applicants counted cells and calculated the number of cells and volume of suspension needed for transfection. Applicants typically transfected 2 x 105 cells per condition using the Amaxa Niicieocuvette sirips, and recommend calculating for 20% more cells than required to adjust for volume loss in subsequent pipetting steps. The volume needed is transferred into a new Falcon tube.
[00817] 23 j Applicants spun down the new tube at 200 x g for 5 m.
[00818] Applicants prepared the transfection solution by mixing the SF solution and SI supplement as recommended by Amaxa. For Amaxa strip-cuvettes, a total of 20 ul of supplemented SF solution is needed per transfection. Likewise, Applicants recommend calculating for 20% more volume than required.
230
90.1 0Θ819] 25 j Applicants removed medium completely from pelleted cells from step 23 and gently resuspended in appropriate volume (20 ul per 2 x 105 cells) of SI -supplemented SF solution. Do not leave cells in SF solution for extended period of time,
[00820] 26i 20 ul of resuspended cells is pipetted into each DNA pre -mix from step 20. Pipette gently to mix and transfer to Nucleocuvette strip chamber. This is repeated for each transiection condition.
[00821] Electroporate cells using the Nucleofeeior 4D program recommended by Amaxa, CM- 1.30.
[00822] 28j Applicants gently and slowly pipetted 100 ul of warm D10 medium into each Nucleoeuvette strip chamber, and transferred all volume into the pre -warmed plate from step 19. CRITICAL. Cells are very fragile at this stage and harsh pipetting can cause cell death. Incubate for 24 h. At this point, transiection efficiency can be estimated from fraction of fluorescent cells in positive transiection control. Nucieofection typically results in greater than 70-80% transiection efficiency. Applicants slowly added 1 mi warm D10 medium to each well without dislodging the cells. Incubate cells for a total of 72 h.
[00823] Human embryonic stem cell (HUES 9) culture and transiection * Timing 3-4 d
[00824] Maintaining hESC (HUES9) line. Applicants routinely maintain HUES9 cell line in feeder-free conditions with mTesRl medium. Applicants prepared mTeSRl medium by adding the 5X supplement included with basal medium and 100 ug/ml Normocin. Applicants prepared a 10 ml aliquot of mTeSRl medium supplemented further with 10 uM Rock Inhibitor. Coat tissue culture plate. Dilute cold GelTrex 1 : 100 in cold DMEM and coat the entire surface of a 100 mm tissue culture plate,
[00825] Place plate in incubator for at least 30 m at 37°C. Thaw out a vial of cells at 37°C in a 15 ml Falcon tube, add 5 ml of mTeSRl medium, and pellet at 200 x g for 5 m. Aspirate off GelTrex coating and seed ~1 x 106 cells with 10 ml mTeSRl medium containing Rock Inhibitor, Change to normal mTeSRl medium 24 h after transiection and re-feed daily. Passaging cells. Re-feed cells with fresh mTeSRl medium daily and passage before reaching 70% confluency. Aspirate off mTeSRl medium and wash ceils once with DPBS, Dissociate cells by adding 2 ml Accutase and incubating at 37°C for 3 - 5 m. Add 10 ml mTeSRl medium to detached ceils, transfer to 15 ml Falcon tube and resuspend gently. Re-plate onto GelTrex-coated plates in mTeSRl medium with 10 uM Rock Inhibitor. Change to normal mTeSRl medium 24 h after plating.
231
90.1 [00826] Trans fecti on. Applicants recommend culturing cells for at least 1 week post- thaw before transfecting using the Amaxa P3 Primary Cell 4-D Nucleofector Kit (Lonza), Re-feed log-phase growing cells with fresh medium 2 h before transfection. Dissociate to single cells or small clusters of no more than 10 cells with accutase and gentle resuspension. Count the number of cells needed for nucleofection and spin down at 200 x g for 5 m. Remove medium completely and resuspend in recommended volume of SI - supplemented P3 nucleofection solution. Gently plate electroporated cells into coated plates in presence of I X Rock Inhibitor.
[0Θ827] Check transfection success and re-feed daily with regular mTeSRl medium beginning 24 h after nucleofection. Typically, Applicants observe greater than 70% transfection efficiency with Amaxa Nucleofection. Harvest DNA. 48-72 h post transfection, dissociate cells using accutase and Inactivate by adding 5 x volume of mTeSRl. Spin cells down at 200 x g for 5 m. Pelleted cells can be directed processed for DNA extraction with QuickExtract solution. It is recommended to not mechanically dissociate cells without accutase. It is recommended to not spin cells down without inactivating accutase or above the recommended speed; doing so may cause cells to lyse.
[00828] isolation of clonal cell lines by FACS, Timing · 2-3 h hands-on; 2-3 weeks expansion
[00829] Clonal isolation may be performed 24 h post-transfection by FACS or by serial dilution.
[00830] 54j Prepare FACS buffer. Cells that do not need sorting using colored fluorescence may be sorted in regular D10 medium supplemented with I X penicillin/streptinomycin. If colored fluorescence sorting is also required, a phenol-free DMEM or DPBS is substituted for normal DMEM, Supplement with IX penicillin/streptinomycin and filter through a .22 iim Steriflip filter.
[00831] 551 Prepare 96 well plates. Applicants added 100 ul of D10 media supplemented with IX penicillin.''streptinomycin per well and prepared the number of plates as needed for the desired number of clones.
[ΘΘ832] 56j Prepare cells for FACS. Applicants dissociated cells by aspirating the medium completely and adding 100 ul TrypLE per well of a 24-weIl plate. Incubate for 5 m and add 400 ul warm D 10 media.
[00833] 57j Resuspended cells are transferred into a 15 ml Falcon tube and gently triturated 20 times. Recommended to check under the microscope to ensure dissociation to single cells.
232
90.1 [0Θ834] 58| Spin down cells at 200 x g for 5 mi utes.
[0Θ835] 59j Applicants aspirated the media, and resuspended the cells in 200 ul of FACS media.
[00836] 60| Cells are filtered through a 35 urn mesh filter into labeled FACS tubes. Applicants recommend using the BD Falcon 12 x 75 mm Tube with Cell Strainer cap. Place cells on ice until sorting.
[00837] 61 J Applicants sorted single cells into 96-well plates prepared from step 55. Applicants recommend that in one single designated well on each plate, sort. 100 cells as a positive control.
[00838] NOTE. The remainder of the cells may be kept and used for genotyping at the population level to gauge overall modification efficiency.
[00839] 62 j Applicants returned cells into the incubator and allowed them to expand for 2-3 weeks. 100 ul of warm D10 medium is added 5 d post sorting. Change 100 ul of medium ever}' 3-5 d as necessary.
[00840] 63 j Colonies are inspected for "clonal" appearance 1 week post sorting: rounded colonies radiating from a central point. Mark off wells that are empty or may have been seeded with doublets or multiplets.
[00841] 641 When cells are more than 60% confluent, Applicants prepared a set of replica plates for passaging. 100 ul of D10 medium is added to each well in the replica plates. Applicants dissociated cells directly by pipetting up and down vigorously 2.0 times. 20% of the resuspended volume was plated into the prepared replica plates to keep the clonal lines. Change the medium ever}' 2-3 d thereafter and passage accordingly,
[0Θ842] 65 j Use the remainder 80% of cells for DNA isolation and genotyping.
[00843] Optional: Isolation of clonal cell lines by dilution. Timing * 2-3 h hands- on; 2-3 weeks expansion
[00844] 66| Applicants dissociated cells from 24-weil plates as described above. Make sure to dissociate to single cells. A cell strainer can be used to prevent clumping of cells, [00845] 67 j The number of ceils are counted in each condition. Serially dilute each condition in DIO medium to a final concentration of 0.5 cells per 100 ul. For each 96 well plate, Applicants recommend diluting to a final count of 60 cells in 12 ml of D10, Accurate count of cell number is recommended for appropriate clonal dilution. Ceils may be recounted at an intermediate serial dilution stage to ensure accuracy.
[00846] 68 j Multichannel pipette was used to pipette .100 ul of diluted cells to each well of a 96 well plate,
233
90.1 [0Θ847] NOTE. The remainder of the cells may be kept and used for genotyping at the population level to gauge overall modification efficiency.
[00848] 6 i Applicants inspected colonies for "clonal" appearance ~1 week post plating: rounded colonies radiating from a central point. Mark off wells that may have seeded with doublets or multiplets.
[00849] 70 j Applicants returned cells to the incubator and allowed them to expand for 2-3 weeks. Re-feed cells as needed as detailed in previous section.
[00850] SURVEYOR assay for CRiSJPR cleavage efficiency. Timing * 5-6 h
[00851 ] Before assaying cleavage efficiency of transfected cells, Applicants recommend testing each new SURVEYOR primer on negative (untransfected) control samples through the step of SURVEYOR nuclease digestion using the protocol described below. Occasionally, even single-band clean SURVEYOR PGR products can yield nonspecific SURVEYOR nuclease cleavage bands and potentially interfere with accurate indel analysis.
[ΘΘ852] 71 j Harvest cells for DNA. Dissociate cells and spin down at 200 x g for 5 m, NOTE. Replica plate at this stage as needed to keep transfected cell lines.
[00853] 72 j Aspirate the supernatant completely.
[00854] 73 j Applicants used QuickExtract DNA extraction solution according to the manufacturer's instructions. Applicants typically used 50 ul of the solution for each well of a 24 well plate and 10 ul for a 96 well plate.
[00855] 74j Applicants normalized extracted DNA to a final concentration of 100-200 ng/ul with ddH20. Pause point: Extracted DNA may be stored at -20°C for several months.
[00856] 75 j Set up the SUR VEYOR PCR. Master mix the following using SURVEYOR primers provided by Applicants online/computer algorithm tool:
Component: Amount (ul) Final concentration
Hercuiase II PCR buffer, 5X 10 IX
dNTP, lOOmM (25mM each) 1 1 mM
SURVEYOR Fwd primer (lOuM) 0.2 uM
SURVEYOR Rev primer (lOuM) 0.2 uM
Hercuiase 11 Fusion polymerase 1
MgCl2 (25mM) 2 1 mM
Distilled water
Total 49 (for each reaction)
234
90.1 [0Θ857] 76| Applicants added 100-200 ng of normalized genomic DNA template from step 74 for each reaction.
[00858] 771 PGR reaction was performed using the following cycling conditions, for no more than 30 amplification cycles:
Cycle number Denature Anneal Extend
1 95°C, 2 min
2-31 95°C, 20 s 60°C, 20 s 72°C, 30 s
32 72°C, 3 min
[00859] 78j Applicants ran 2-5 ul of PGR product on a 1% gel to check for single-band product. Although these PGR conditions are designed to work with most pairs of SURVEYOR primers, some primers may need additional optimization by adjusting the template concentration, MgCl2 concentration, and/or the annealing temperature.
[00860] 79 j Applicants purified the PGR reactions using the QIAQuick PGR purification kit and normalized eluant to 20 ng/ul. Pause point: Purified PGR product may be stored at -20°C.
[00861 ] 80 j DNA heteroduplex formation. The annealing reaction was set up as follows:
[00862] Taq PGR buffer, 10X 2 ul
[00863] Normalized DNA (20 ng ul) 18 ul
[00864] Total volume 20 a\
[00865] 81 j Anneal the reaction using the following conditions:
Cycle number Condition
1 95°C, 10 mn
2,
3 85°C, 1 min
4 85°C-75°C,
5 75°C, 1 min
6 75°C-65°C,
7 65 °C, 1 min
8 65°C-55°C,
9 55°C, 1 min
10 55°C-45°C,
11 45°C, 1 min
12 45°C-35°C,
13 35°C, 1 min
235
90.1 14 35°C-25°C, -0.3°C/s
15 25°C, 1 min
[00866] 82 j SUR VEYOR nuclease S digestion. Applicants prepared master-mix and added the following components on ice to annealed heteroduplexes from step 81 for a total final volume of 25 ul:
Component Amount (ul) Final Concentration
MgC32 solution, 0.15M Z. 15mM
dd¾0 0.5
SURVEYOR nuclease IX
SURVEYOR enhancer 1 IX
Total 5
[00867] 83 i Vortex well and spin down. Incubate the reaction at 42°C for 1 h.
[00868] 84j Optional: 2 ul of the Stop Solution from the SURVEYOR kit may be added. Pause point. The digested product may be stored at -20°C for analysis at a later time.
[0Θ869] 85j Visualize the SURVEYOR reaction. SURVEYOR nuclease digestion products may be visualized on a 2% agarose gel. For better resolution, products may be rim on a 4-20% gradient Polyacrylamide TBE gel. Applicants loaded 10 ul of product with the recommended loading buffer and ran the gel according to manufacturer's instructions. Typically, Applicants run until the bromophenol blue dye has migrated to the bottom of the gel. Include D A ladder and negative controls on the same gel
[0Θ870] 86j Applicants stained the gel with IX SYBR Gold dye diluted in TBE. The gel was gently rocked for 15 m.
[00871] 871 Applicants imaged the gel using a quantitative imaging system without overexposing the bands. The negative controls should have only one band corresponding to the size of the PGR product, but may have occasionally non-specific cleavage bands of other sizes. These will not interfere with analysis if they are different in size from target cleavage bands. The sum of target cleavage band sizes, provided by Applicants online/computer algorithm tool, should be equal to the size of the PGR produc t.
[0Θ872] 881 Estimate the cleavage intensity. Applicants quantified the integrated intensity of each band using Image! or other gel quantification software.
[00873] 89 j For each lane, Applicants calculated the fraction of the PGR product cleaved (jcm) using the following formula: fcu, = (b + c) / (a + b + c), where a is the integrated intensity of the undigested PGR. product and b and c are the integrated
236
90.1 Intensities of each cleavage product. 90| Cleavage efficiency may be estimated using the following formula, based on the binomial probability distribution of duplex formation:
[00874] 91 j indel (%) = 100 X (1 - <J(1 - /c¾:Sr}}
[00875] Sanger sequencing for assessing C ISPR cleavage efficiency. Timing « 3 d [00876] Initial steps are identical to Steps 71-79 of the SURVEYOR assay. Note: SURVEYOR primers may be used for Sanger sequencing if appropriate restriction sites are appended to the Forward and Reverse primers. For cloning into the recommended pUC 19 backbone, EcoRI may be used for the Fwd primer and Hindill for the Rev primer.
[00877] 92 j AmpUcon digestion. Set up the digestion reaction as follows:
Component Amount (ul)
Fast Digest buffer, 10X 3
FastDigest EcoRI 1
FastDIgest Hindill 1
Normalized DMA (20 ng/'ul) 10
ίίζΩ 15
Total volume 30
[00878] 931 pUC19 backbone digestion. Set up the digestion reaction as follows:
[00879] Component Amount (ul)
Fast Digest buffer, 1 OX 3
FastDigest EcoRI 1
FastDigest Hindill 1
FastAP Alkaline Phosphatase 1
pUC 19 vector (200 ng ul) 5
ddH2Q 20
Total volume 30
[00880] 94j Applicants purified the digestion reactions using the QIAQuick PGR purification kit, Pause point: Purified PGR product may be stored at -20°C.
[00881] 95 j Applicants ligated the digested pUC19 backbone and Sanger amplicons at a 1 :3 vectonmsert ratio as follows:
[00882] Component Amount (ul)
Digested pUC 19 x (50 ng)
Digested insert x (1 :3 vector: insert molar ratio)
T7 ligase 1
237
90.1 2X Rapid Ligation Buffer 10
ddPLQ X
Total volume 20
[00883] 96i Transformation. Applicants transformed the Plasm idSafe-treated plasmid into a competent E. co!i strain, according to the protocol supplied with the cells. Applicants recommend StbB for quick transformation. Briefly, 5ul of the product from step 95 is added into 20ul of ice-cold chemically competent StbB cells, incubated on ice for 10 m, heat shocked at 42°C for 30 s, returned immediately to ice for 2 m, 100 ul of SOC medium is added, and plated onto an LB plate containing 100 ug ml ampicillin. This is incubated overnight at 37°C.
|00884] 97 j Day 2: Applicants inspected plates for colony growth. Typically, there are no colonies on the negative control plates (ligation of EcoRI-Hindlll digested pUC19 only, no Sanger amplicon insert), and tens to hundreds of colonies on the pUC 19 -Sanger amplicon cloning plates.
0Θ885] 98| Day 3 : Applicants isolated plasmid DNA from overnight cultures using a QIAprep Spin miniprep kit according to the manufacturer's instructions.
[00886] 9 i Sanger sequencing. Applicants verified the sequence of each colony by sequencing from the pUC19 backbone using the pUC19-For primer. Applicants referenced the sequencing results against the expected genomic DNA sequence to check for the presence of Cas9-induced NHEJ mutations. % editing efficiency = (# modified clones)/(# total clones). It is important to pick a reasonable number of clones (>24) to generate accurate modification efficiencies.
[00887] Genotyping for microdeletion. Timing * 2-3 d hands on; 2-3 weeks expansion
[00888] lOOj Cells were transfected as described above with a pair of sgRNAs targeting the region to be deleted.
[00889] 101 1 24 h post-transfection, clonal lines are isolated by FACS or serial dilution as described above.
0Θ890] 102 j Cells are expanded for 2-3 weeks.
[0Θ891 ] 1031 Applicants harvested DNA from clonal lines as described above using 10 ui QuickExtract solution and normalized genomic DNA with ddH20 to a final concentration of 50-100 ng ui.
[00892] 104! PGR Amplify the modified region. The PGR reaction is set up as follows: Component: Amount (ul) Final concentration
238
90.1 Herculase II PGR buffer, 5X IX
dNTP, lOOmM (25mM each) 1 mM
Out Fwd primer (!OuM) 0.2 uM
Out Rev primer (! OuM) 0.2 uM
Herculase II Fusion polymerase
MgC12 (25mM) 1 mM
ddH?0 5Z
Total 48 (for each reaction)
[00893] Note: if deletion size is more than 1 kb, set up a parallel set of PGR reactions with In-Fwd and In-Rev primers to screen for the presence of the wt allele.
|00894] 1051 To screen for inversions, a PGR reaction is set up as follows:
Component: Amount (ul) Final concentration
Herculase II PGR buffer, 5X 10 IX
dNTP, lOOmM (25mM each) 1 1 mM
Out Fwd or Out-Rev primer ( 1 OuM) 1 0.2 uM
In Fwd or In-Rev primer ( 1 OuM) 1 0.2 uM
Herculase II Fusion polymerase 1
MgCl2 (25mM) 2 1 mM
ddHzO 32
Total 48 (for each reaction)
[00895] Note: primers are paired either as Out-Fwd + In Fwd, or Out-Rev + In-Rev.
[00896] 106j Applicants added 100-200 ng of normalized genomic DNA template from step 103 for each reaction.
[00897] 1071 PGR reaction was performed using the following cycling conditions: Cycle number Denature Anneal Extend
1 95 °C, 2 min
2-31 95°C, 20 s 60°C, 20 s 72°C, 30 s
32 72°C, 3 m
[00898] 1081 Applicants run 2-5 ul of PGR product on a 1-2% gel to check for product. Although these PGR conditions are designed to work with most primers, some primers may need additional optimization by adjusting the template concentration, MgCl2 concentration, and/or the annealing temperature.
[0Θ899] Geiiotypiiig for targeted modifications via HDR. Timing * 2-3 d, 2-3 h
239
90.1 [00900] 1091 Applicants harvested DNA as described above using QuickExtract solution and normalized genomic DNA with TE to a final concentration of 100-200 ng/ul.
[00901] HOj PCR Amplify the modified region. The PCR reaction is set up as follows:
Component: Amount (ul) Final concentration
Herculase Π PCR buffer, 5X 10 IX
dNTP, 100 mM (25 mM each) 1 1 mM
HDR Fwd primer ( 10 uM) 1 0.2 uM
HDR Rev primer (10 uM) 1 0.2 uM
Herculase II Fusion polymerase 1
MgCl2 (25mM) 2 1 mM
ddiiO 33
Total 49 (for each reaction)
0Θ902] 1 111 Applicants added 100-200 ng of genomic DNA template from step 109 for each reaction and am the following program.
Cycle number Denature Anneal Extend
1 95°C, 2 min
2-31 95°C, 20 s 60°C, 20 s 72°C, 30-60 s per kh
32 72°C, 3 min
[00903] 1 12! Applicants ran 5 ul of PCR product on a 0.8-1% gel to check for single- band product. Primers may need additional optimization by adjusting the template concentration, MgCl2 concentration, and/or the annealing temperature.
[00904] 1 13 ! Applicants purified the PCR reactions using the QIA Quick PCR purification kit,
[00905] 1 14| In the HDR example, a Hindlll restriction site is inserted into the EMX1 gene. These are detected by a restriction digest of the PCR amplicon:
Component Amount (ul)
Purified PCR amplicon (200-300ng) x
F.D. buffer, Green 1
Hindlll 0.5
ddH20 x
Total 10
[00906] i. The DNA is digested for 10 m at 37°C:
240
90.1 0Θ907] ii. Applicants ran 10 ul of the digested product with loading dye on a 4-20% gradient polyaerylaniide TBE gel until the xylene cyanol band had migrated to the bottom of the gel.
[00908] iii. Applicants stained the gel with I X SYBR Gold dye while rocking for 15 m.
[00909] iv. The cleavage products are imaged and quantified as described above in the SURVEYOR assay section. HDR efficiency is estimated by the formula.: (b + c)/(a. + b + c), where a is the integrated intensity for the undigested HDR PCR product, and b and c are the integrated intensities for the HindTII-cut fragments,
[0Θ910] 1 15| Alternatively, purified PCR amplicons from step 1 13 may be cloned and genotyped using Sanger sequencing or NGS.
[00911] Deep sequencing and off-target analysis * Timing 1 - 2 d
[00912] The online CRISPR target design tool generates candidate genomic off-target sites for each identified target site. Off-target analysis at these sites can be performed by SURVEYOR nuclease assay, Sanger sequencing, or next-generation deep sequencing. Given the likelihood of low or undetectable modification rates at many of these sites, Applicants recommend deep sequencing with the llfumina Miseq platform for high sensitivity and accuracy. Protocols will vary with sequencing platform; here, Applicants briefly describe a fusion PCR method for attaching sequencing adapters.
[00913] 1 16! Design deep sequencing primers. Next-generation sequencing (NGS) primers are designed for shorter amplicons, typically in the 100-200 bp size range. Primers may be manually designed using NCBI Primer-Blast or generated with online CRISPR target design tools (website at genome-engineering.org/tools).
[0Θ914] 1 17| Harvest genomic DNA from Cas 9 -targeted cells. Normalize QuickExtract genomic DNA to 100-200 ng ul with ddH20.
[00915] 1 18j Initial library preparation PCR. Using the NGS primers from step 116, prepare the initial library preparation PGR
[00916]
Component: Amount (ul) Final concentration
Herculase II PCR buffer, 5X 10 I X
dNTP, lOOmM (25mM each) 1 mM
NGS Fwd primer (!OuM) 1 0.2 uM
NGS Rev primer (l OuM) 1 0.2 uM
Herculase II Fusion polymerase I
MgC12 (25mM) 2 1 mM
241
90.1 ddH2Q 33
Total 49 (for each reaction)
[00917] 1 19j Add 100-200 ng of normalized genomic DNA template for each reaction,
[00918] 120! Perform PGR reaction using the following cycling conditions, for no more than 20 amplification cycles:
Cycle number Denature Anneal Extend
1 95°C, 2 min
2-21 95°C, 20 s 60°C, 20 s 72°C, 15 s
22. 72°C, 3 min
[00919] 1211 Run 2-5 ul of PGR product on a 1% gel to check for single -band product. As with all genomic DMA PCRs, MGS primers may require additional optimization by adjusting the template concentration, MgC32 concentration, and/or the annealing temperature.
[00920] 1221 Purify the PGR reactions using the QIAQuick PGR purification kit and normalize eluani to 20 ng/ul. Pause point: Purified PGR product may be stored at -20°C.
[00921 ] 123| Nextera XT DNA Sample Preparation Kit. Following the manufacturer's protocol, generate Miseq sequencing-ready libraries with unique barcodes for each sample.
[00922] 124! Analyze sequencing data. Off-target analysis may be performed through read alignment programs such as ClustalW, Geneious, or simple sequence analysis scripts.
[0Θ923] Timing
[0Θ924] Steps 1 - 2 Design and synthesis of sgRNA oligos and ssODNs: 1 -5 d, variable depending on supplier
[00925] Steps 3 - 5 Construction of CR1SPR piasmid or PGR expression cassette: 2 h to 3 d
[00926] Steps 6 - 53 Transfection into cell lines: 3 d (1 h hands-on time)
[00927] Steps 54 - 70 Optional derivation of clonal lines: 1 -3 weeks, variable depending on cell type
[0Θ928] Steps 71 - 91 Functional validation of NHEJ via SURVEYOR: 5-6 h
[00929] Steps 92 - 124 Genotyping via Sanger or next-gen deep sequencing: 2-3 d (3-4 h hands on time)
[00930] Addressing Situations Concerning Herein Examples
Figure imgf000243_0001
242
90.1 SURVEYOR or HDR PCR dirty Titrate MgC12; normalize and titrate template concentration;
or no amplification annealing temp gradient; redesign primers
Unequal amplification of alleles Set up separate PCRs to detect wildtype and deletion alleles;
in microdeletioti PCRs Redesign primers with similar sized amplicons
Colonies on negative control Increase Bbsl; increase Golden Gate reaction cycle number, cut i)laie PX330 separately with Antarctic Phosphate treatment
No sgRNA sequences or wrong
Screen additional colonies
sequences
Low Hpofec taurine trans fection Check cell health and density; titrate DNA; add GFP transfection efficiency control
Low nucleofection transfection
Check cell health and density; titrate DNA; suspend to single cell efficiency
Fitter cells before FACS; dissociate to single cells; resuspend in
Clumps or no ceils after FACS
appropriate density
Clumps or no cells in serial Recount cells; dissociate to single cells and filter through strainer; dilution check serial dilution
High SURVEYOR background
Redesign primers to prime from different locations
on negative sample
Puri fy PCR product; reduce input DNA; reduce 42°C incubation to 30
Dirty SURVEYOR result on gel
m
Purify and normalize PCR product; re-anneal with TaqB buffer;
No SURVEYOR cleavage
Redesign sgRNAs; sequence verify Cas9 on px330 backbone
Samples do not sink in TBE Supplement with MgC12 to a final concentration of 15mM or add acrylamide gel loading buffer containing glycerol
0Θ93Ϊ ] Discussion
[00932] CRTSPR-Cas may be easily multiplexed to facilitate simultaneous modification of several genes and mediate chromosomal microdeletions at high efficiencies. Applicants used two sgRNAs to demonstrate simultaneous targeting of the human GRIN2B and DYRK1A loci at efficiencies of up to 68% in HEK293FT cells. Likewise, a pair of sgRNAs may be used to mediate microdeletions, such as excision of an exon, which can be genotyped by PCR on a clonal level. Note that the precise location of exon junctions can vary. Applicants also demonstrated the use of ssODNs and targeting vector to mediate HDR with both wildtype and nickase mutant of Cas9 in HE 293FT and HUES9 cells (Fig. 30). Note that Applicants have not been able to detect HDR in HUES9 cells using the Cas9 nickase, which may be due to low efficiency or a potential difference in repair activities in HUES9 cells. Although these values are typical, there is some variability in the cleavage efficiency of a given sgRNA, and on rare occasions certain sgRNAs may not work for reasons yet unknown. Applicants recommend designing two sgRNAs for each locus, and testing their efficiencies in the intended cell type.
243
90.1 Example 31: NLSs
[0Θ933] Cas9 Transcriptional Modulator; Applicants set out to turn the Cas9/gRNA CR1SPR system into a generalized DNA binding system in which functions beyond DNA cleavage can be executed. For instance, by fusing functional domain(s) onto a catalytically inactive Cas9 Applicants have imparted novel functions, such as transcriptional activation/repression, methylation/demefhylation, or chromatin modifications. To accomplish this goal Applicants made a catalytically inactive Cas9 mutant by changing two residues essential for nuclease activity, D10 and H840, to alanine. By mutating these two residues the nuclease activity of Cas9 is abolished while maintaining the ability to bind target DNA. The functional domains Applicants decided to focus on to test Applicants' hypothesis are the transcriptional activator VP64 and the transcriptional repressors SID and KRAB.
[00934] Cas9 Nuclear localization: Applicants hypothesized that the most effective Cas9 transcriptional modulator would be strongly localized to the nucleus where it would have its greatest influence on transcription. Moreover, any residual Cas9 in the cytoplasm could have unwanted effects. Applicants determined that wild-type Cas9 does not localize into the nucleus without including multiple nuclear localization signals (NLSs) (although a CRISPR system need not have one or more NLSs but advantageously has at least one or more NLS(s)). Because multiple NLS sequences were required it was reasoned that it is difficult to get Cas9 into the nucleus and any additional domain that is fused to Cas9 could disrupt the nuclear localization. Therefore, Applicants made four Cas9-VP64-GFP fusion constructs with different NLS sequences (pXRP02- pLenti2-EF 1 a-NLS- hSpCsn 1 ( 1 OA ,840 A)-NLS-VP64-EGFP, pXRP04- pLenti2-EF 1 a-NLS- hSpCsn 1 ( 10A,840A)-NLS-VP64-2 A-EGFP-NLS, pXRP06 - pLenti2-EF 1 a-NLS-EGFP-- VP64-NLS-hSpCsnl(10A,840A)-NLS, pXRP08- pLenti2-EFla-NLS-VP64-NLS- hSpCsnl (10A,840A)-NLS- 64-EGFP-NLS). These constructs were cloned into a lenti backbone under the expression of the human EFla promoter. The WPRE element was also added for more robust protein expression. Each construct was transfected into HEK 293FT cells using Lipofectame 2000 and imaged 24 hours post-transfection. The best nuclear localization is obtained when the fusion proteins have NLS sequences on both the N- and C-term of the fusion protein. The highest observed nuclear localization occurred in the construct with four NLS elements.
[00935] To more robustly understand the influence of NLS elements on Cas9 Applicants made 16 Cas9-GFP fusions by adding the same alpha importin NLS sequence
244
90.1 on either the N- or C-tenn looking at zero to three tandem repeats. Each construct was transfeeted into HEK 293FT cells using Lipofectame 2000 and imaged 24 hours post- transfection. otably, the number of NLS elements does not directly correlate with the extent of nuclear localization. Adding an NLS on the C-tenn has a greater influence on nuclear localization than adding on the N-term.
[00936] Cas9 Transcriptional Activator: Applicants functionally tested the Cas9-VP64 protein by targeting the 8ox2 locus and quantifying transcriptional activation by RT- qPCR. Eight DNA target sites were chosen to span the promoter of Sox2. Each construct was transfeeted into HEK 293FT cells using Lipofectame 2000 and 72 hours post- transfection total RNA was extracted from the cells, 1 ug of RNA was reverse transcribed into cDNA (q Script Supermix) in a 40 ul reaction. 2 ul of reaction product was added into a single 20 ul TaqMan assay qPCR reaction. Each experiment was performed in biological and technical triplicates. No RT control and no template control reactions showed no amplification. Constructs that do not show strong nuclear localization, pXRP02 and pXRP04, result in no activation. For the construct that did show strong nuclear localization, pXRP08, moderate activation was observed. Statistically significant activation was observed in the case of guide RNAs Sox2.4 and Sox2.5.
Example 32: In Vivo Mouse Data
[00937] Material and reagents
Herculase II fusion polymerase (Agilent Technologies, cat. no. 600679)
lOx X L Buiier 4 (NEB, cat. No. B7004S)
Bsal HF (NEB, cat. No. R3535S)
T7 DNA ligase (Enzymatics, cat. no, L602L)
Fast Digest buffer, 10X (ThermoScientific, cat. No. B64)
FastDigest Notl (ThermoScientific, cat. No. FD0594)
FastAP Alkaline Phosphatase (ThermoScientific, cat. No, EF0651 )
Lipofectamine2000 (Life Technologies, cat. No. 11668-019)
Trypsin (Life Technologies, cat. No. 15400054)
Forceps #4 (Sigma, cat. No, ZI 68777-1EA)
Forceps #5 (Sigma, cat. No, F6521- 1EA)
lOx Hank's Balanced Salt Solution (Sigma, cat. No. H4641 -500ML)
Penicillin/Streptomycin solution (Life Technologies, cat. No. P4333)
Neurobasal (Life Technologies, cat. No. 21103049)
245
90.1 B27 Supplement (Life Technologies, cat. No. 17504044)
L-glutamine (Life Technologies, cat. No. 25030081 )
Glutamate (Sigma, cat. No. RES5G63G-A7)
β-mercaptoethanol (Sigma, cat. No. M6250-100ML)
HA rabbit antibody (Cell Signaling, cat, No, 3724S)
LIVE/DEAD© Cell Imaging Kit (Life Technologies, cat. No. R37601)
30G World Precision Instrument syringe (World Precision Instruments, cat. No.
NANOFIL)
Stereotaxic apparatus (Kopf Instruments)
UltraMicroPump3 (World Precision Instruments, cat. No. UMP3-4)
Sucrose (Sigma, cat. No. S7903 )
Calcium chloride (Sigma, cat. No. C10I6)
Magnesium acetate (Sigma, cat. No, M0631)
Tris-HCl (Sigma, cat. no T5941)
EDTA (Sigma, cat. No. E6758)
NP-40 (Sigma, cat. No. NP40)
Phenylmethanesulfonyi fluoride (Sigma, cat. No. 78830)
Magnesium chloride (Sigma, cat. No. M8266)
Potassium chloride (Sigma, cat. No. P9333)
β -glycerophosphate (Sigma, cat. No. G9422)
Glycerol (Sigma, cat. No. G9012)
Vybrant® DyeCycle™ Ruby Stain (Life technologies, cat. No. S4942)
FACS Aria Flu-act-cell sorter (Koch Institute of MIT, Cambridge US)
DNAeasy Blood & Tissue Kit (Qiagen, cat. No. 69504)
[00938] Procedure
[00939] Constructing gRNA multiplexes for using in vivo in the brain
Applicants designed and PCK amplified single gKNAs targeting mouse TET and DNMT family members (as described herein) Targeting efficiency was assessed in N2a ceil line (Fig. 33). To obtain simultaneous modification of several genes in vivo, efficient gRNA was multiplexed in AAV-packaging vector (Fig, 34), To facilitate further analysis of system efficiency applicants added to the system expression cassette consistent of GFP- KASH domain fusion protein under control of human Synapsin I promoter (Fig. 34). This modification allows for further analysis of system efficiency in neuronal population (more detail procedure in section Sorting nuclei and in vivo results),
246
90.1 [0Θ940] All 4 parts of the system were PGR amplified using Herculase II Fusion polymerase using following primers:
1st U6 Fw:
gagggtctcgtccttgcggccgcgctagcgagggcctatttcccatgattc 1st gRNA Rv:
etcggteteggtAAAAAAgcaccgactcggtgccactt111caagttgataacggactag c
cttattttaacttgctaTTTCtagctctaaaac N N N NNNNNNNNNNNN GGTGTTT C GTCCTTTCCA.C
2nd U6 Fw:
gagggtctcTTTaccggtgagggccta111cccatga11cc
2nd gRNA Rv:
ctcggtctcctcAAAAAAgcaccgactcggtgccac11111caagttgataacgg actage
c1.1a1111aac11gctaTTTCtagctctaaaac N N N N N N GGTGTTT C GTCCTTTCCAC
3rd U6 Fw:
gagggtctcTTTgagctcgagggcctatttcccatgattc
3rd gRNA R.v:
ctcggtctegegt A A Agcaccgactcggtgccactttttcaagttgataacg gactag
ccttattttaacttgctaTTTCtagctctaaaacNNN N NNNNNNNNNNNNNNGGTGTT T CGTCCTTTCCA hSyn GFP-kash Fw : gagggtctcTTacgcgtgtgtctagac
hSyn GFP-kash Rv: ctxggtctcAaggaCAGGGAAGGGAGCAG GGTTCACGCCTGTAATCCCAGCAAT TTGGGA GGCCAAGG GGGTAGATCACCTGAGAT AGGAGTTGC
{^NNNNNNNNNNNNNNNNNN is a reverse compliment targeted genomic sequence)
[00941] Applicants used Golden Gate strategy to assemble all parts (1:1 molecular ratio) of the system in a single step reaction:
LY> gR NA 18 ng
247
90.1 2aa U6_gRNA 1 8 ng
3rd U6_gRNA 1 8 ng
Syn_GFP-kash 100 ng
10x EBuffer 4 1.0 μΐ
ίθχ BSA 1.0 μΐ
10 mM ΑΤΡ 1.0 μΐ
Bsal HF 0.75 μί
Τ7 ligase 0.25 μί
d.dH20
Cycle number Condition
1-50 37°C for 5 m, 21°C for 5 ni
Golden Gate reaction product was PGR amplified using Herculase II fusion polymerase and following primers:
Fw 5 ' cctqtcc 1 gc g gccgcgctagcgagggcc
Rv 5' cacgcggccgcaaggacagggaagggagcag
[0Θ943] PGR product was cloned into AAV backbone, between ITR sequences using Notl restriction sites:
PGR product digestion:
Fast Digest buffer, 10X 3 μί
FastDigest Noll 1 μΐ
D A 1 μg
ddH?0 up to 30 ul
[0Θ944] AAV backbone di gestion :
Fast Digest buffer, 10X 3 μΐ
FastDigest Not! 1 μΐ
FastAP Alkaline Phosphatase 1 μί
AAV backbone 1 μg
d l I f . O up to 30 ul
0Θ945] After 20 min incubation in 37°C samples were purified using QTAQuick PGR purification kit. Standardized samples were ligated at a 1 :3 vectoninsert ratio as follows:
Digested pUC 19 50 ng
Digested insert 1 :3 vectoninsert molar ratio
T7 ligase 1 μί
2X Rapid Ligation Buffer 5 μΐ
248
90.1 ddi 1■() up to 10 μΐ
[0Θ946] After transformation of bacteria with ligation reaction product, applicants confirmed obtained clones with Sanger sequencing.
[00947] Positive DNA clones were tested in N2a cells after co-transfection with Cas9 construct (Figs. 35 and 36).
[00948] Design of new Cas9 constructs for AA V delivery
[00949] AAV delivery system despite its unique features has packing limitation - to successfully deliver expressing cassette in vivo it has to be in size < then 4,7 lib. To decrease the size of SpCas9 expressing cassette and facilitate delivery applicants tested several alteration: different promoters, shorter polyA signal and finally a. smaller version of Cas9 from Staphylococcus aureus (SaCas9) (Figs. 37 and 38). All tested promoters were previously tested and published to be active in neurons, including mouse Mecp2 (Gray et al., 201 1), rat Maplb and truncated rat Maplb (Liu and Fischer, 1996). Alternative synthetic polyA sequence was previously shown to be functional as well (Levitt et al, 1989; Gray et al., 201 1 ). All cloned constructs were expressed in N2a cells after transfection with Lipofectamine 2000, and tested with Western blotting method (Fig. 39).
[00950] Testing AA V multiplex system in primary neurons
[00951] To confirm functionality of developed system in neurons, Applicants use primary neuronal cultures in vitro. Mouse cortical neurons was prepared according to the protocol published previously by Banker and Goslin (Banker and Goslin, 1988).
[ΘΘ952] Neuronal cells are obtained from embryonic day 16. Embryos are extracted from the euthanized pregnant female and decapitated, and the heads are placed in ice-cold HBSS. The brains are then extracted from the slaills with forceps (#4 and #5) and transierred to another change of ice-cold HBSS. Further steps are performed with the aid of a stereoscopic microscope in a Petri dish filled with ice-cold HBSS and #5 forceps. The hemispheres are separated from each other and the brainstem and cleared of meninges. The hippocampi are then very carefully dissected and placed in a 15 ml conical tube filled with ice-cold HBSS. Cortices that remain after hippocampal dissection can be used for further cell isolation using an analogous protocol after removing the brain steam residuals and olfactory bulbs. Isolated hippocampi are washed three times with 10 ml ice-cold HBSS and dissociated by 15 min incubation with trypsin in HBSS (4 ml HBSS with the addition of 10 μΐ 2.5% trypsin per hippocampus) at 37°C. After trypsinization, the hippocampi are very carefully washed three times to remove any traces of trypsin with
249
90.1 ITBSS preheated to 37°C and dissociated in warm HBSS. Applicants usually dissociate cells obtained from 10-12 embryos in 1 ml HBSS using 1 ml pipette tips and dilute dissociated cells up to 4 ml. Ceils are piated at a density of 250 cells/mm2 and cultured at 37°C and 5% C02 for up to 3 week
[00953] HBSS
435 ml H20
50 ml lOx Hank's Balanced Salt Solution
16.5 mi 0.3M HEPES pH 7.3
5 ml penicillin-streptomycin solution
Filter (0.2 μηι) and store 4°C
[00954] Neuron Plating Medium (100 ml)
97 ml Neurobasal
2 ml B27 Supplement
1 ml penicillin-streptomycin solution
250 μΐ glutamine
125 μ! glutamate
[00955] Neurons are transduced with concentrated AAV 1/2 virus or AAV1 virus from filtered medium of HEK293FT cells, between 4-7 days in culture and keep for at least one week in culture after transduction to allow for delivered gene expression.
[00956] AA V-driven expression of the system
[00957] Applicants confirmed expression of SpCas9 and SaCas9 in neuronal cultures after AAV delivery using Western blot method (Fig. 42). One week after transduction neurons were collected in NuPage SDS loading buffer with β-mercaptoethanol to denaturate proteins in 95°C for 5 min. Samples were separated on SDS PAGE gel and transferred on PVDF membrane for WB protein detection. Cas9 proteins were detected with HA antibody.
[00958] Expression of SV«-GFP-kash from gRNA multiplex AAV was confirmed with fluorescent microscopy (Fig. 50).
ΘΘ959] Toxicity
[ΘΘ960] To assess the toxicity of AAV with CRISPR system Applicants tested overall morphology of neurons one week after vims transduction (Fig. 45). Additionally, Applicants tested potential toxicity of designed system with the LIVE/DEAD® Cell Imaging Kit, which allows to distinguish live and dead ceils in culture. It is based on the presence of intracellular esterase activity (as determined by the enzymatic conversion of
250
90.1 the non-fluorescent calcein AM to the intensely green fluorescent calcein). On the other hand, the red, eell-impermeant component of the Kit enters cells with damaged membranes only and bind to DMA generating fluorescence in dead cells. Both flourophores can be easily visualized in living cells with fluorescent microscopy. AAV- driven expression of Cas9 proteins and multiplex gRNA constructs in the primary cortical neurons was well tolerated and not toxic (Figs. 43 and 44), what indicates that designed AAV system is suitable for in vivo tests.
[00961] Virus production
[00962] Concentrated virus was produced according to the methods described in McClure et al, 201 1. Supernatant virus production occurred in HEK293FT cells.
[00963] Brain surgeries
[00964] For viral vector injections 10-15 week old male C57BL/6N mice were anesthetized with a Ketamine Xylazine cocktail (Ketamine dose of 100 mg kg and Xylazine dose of 10 mg/kg) by intraperitoneal injection. Intraperitonial administration of Buprenex was used as a pre-emptive analgesic ( 1 mg kg). Animals were immobilized in a Kopf stereotaxic apparatus using intra-aural positioning studs and tooth bar to maintain an immobile skull. Using a hand-held drill, a hole (l-2mm) at -3.0 mm posterior to Bregma and 3.5 mm lateral for injection in the CAl region of the hippocampus was made. Using 30G World Precision Instrument syringe at a depth of 2.5 mm, the solution of AAV viral particles in a total volume of 1 ul was injected. The injection was monitored by a 'World Precision Instruments UltraMicroPumpS ' injection pump at a flo rate of 0.5 uFmin to prevent tissue damage. When the injection was complete, the injection needle was removed slowly, at a rate of 0.5 mm/min. After injection, the skin was sealed with 6-0 Ethilon sutures. Animals wrere postoperatively hydrated with 1 niL iactated Ringer's (subcutaneous) and housed in a temperature controlled (37°C) environment until achieving an ambulatory recovery. 3 weeks after surgery animals were euthanized by deep anesthesia followed by tissue removal for nuclei sorting or with 4% paraformaldehyde perfusion for immunochemistry.
[00965] Sorting nuclei and in vivo results
[00966] Applicants designed a method to specifically genetically tag the gRNA targeted neuronal cell nuclei with GFP for Fluorescent Activated Cell Sorting (FACS) of the labeled cell nuclei and downstream processing of DNA, RMA and nuclear proteins. To that purpose the applicants' multiplex targeting vector was designed to express both a fusion protein between GFP and the mouse nuclear membrane protein domain KASH
251
90.1 (Starr DA, 201 1, Current biology) and the 3 gRNAs to target specific gene loci of interest (Fig. 34). GFP-KASH was expressed under the control of the human Synapsin promoter to specifically label neurons. The amino acid of the fusion protein GFP-KASH was:
MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFTCT TGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDD G
YKTRAEVKEEGDTLV RIELKGIDFKEDGNILGHKIEY YNSHNVYIMADKQKN GIK
VNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDH MV
LLEFVTAAGITLGMDELYKSGLRSREEEEETDSR PHLDSPGSSQPRRSFLSRVIRA
AL PLQLLLLLLLLLACLLPASEDDYSCTQA FARSFYPMLRYTNGPPPT
[00967] One week after AAV1/2 mediated deliver}' into the brain a robust expression of GFP-KASH was observed. For FACS and downstream processing of labeled nuclei, the hippocampi were dissected 3 weeks after surgery and processed for cell nuclei purification using a gradient centrifugation step. For that purpose the tissue was homogenized in 320 mM Sucrose, 5 mM CaCl, 3 mM Mg(Ac)2, 10 mM Tris pH 7.8, 0.1 mM EDTA, 0.1% NP40, 0.1 mM Phenylmethanesulfonyl fluoride (PMSF), 1 mM β-mercaptoethanol using 2ml Bounce homogenizes" (Sigma) The homogenisate was centrifuged on a 25% to 29% Optiprep® gradient according to the manufacture's protocol for 30 min at 3.500 φηι at 4 °C. The nuclear pellet was resuspended in 340 mM Sucrose, 2 mM MgC12, 25 mM KC1, 65 mM glycerophosphate, 5% glycerol, 0.1 mM PMSF, 1 mM β-mercaptoethanol and Vybrant® DyeCycle™ Ruby Stain (Life technologies) was added to label cell nuclei (offers near-infrared emission for DMA). The labeled and purified nuclei were sorted by FACS using an Aria Flu-aei-celi sorter and BDFACS Diva software. The sorted GFP+ and GFP- nuclei were finally used to purify genomic DNA using DNAeasy Blood & Tissue Kit (Qiagen) for Surveyor assay analysis of the targeted genomic regions. The same approach can be easily used to purify nuclear RNA or protein from targeted ceils for downstream processing. Due to the 2 -vector system (Fig. 34) the applicants using in this approach efficient Cas9 mediated DNA cleavage was expected to occur only in a small subset of cells in the brain (cells which were co-infected with both the multiplex targeting vector and the Cas9 encoding vector). The method described here enables the applicants to specifically purify DNA, RNA and nuclear proteins from the cell population expressing the 3 gRNAs of interest and therefore are supposed to undergo Cas9 mediated DNA
252
90.1 cleavage. By using this method the applicants were able to visualize efficient D A cleavage in vivo occurring only in a small subset of cells.
[00968] Essentially, what Applicants have shown here is targeted in vivo cleavage. Furthermore, Applicants used a multiple approach, with several different sequences targeted at the same time, but independently. Presented system can be applied for studying brain pathologic conditions (gene knock out, e.g. Parkinson disease) and also open a field for further development of genome editing tools in the brain. By replacing nuclease activity with gene transcription regulators or epigenetic regulators it will be possible to answer whole spectrum of scientific question about role of gene regulation and epigenetic changes in the brain in not only in the pathologic conditions but also in physiological process as learning and memory formation. Finally, presented technology can be applied in more complex mammalian system as primates, what allows to overcome current technology limitations.
Example 33: Model Data
[00969] Several disease models have been specifically investigated. These include de novo autism risk genes CHD8, KATNAL2, and SCN2A; and the syndromic autism (Angelman Syndrome) gene UBE3A. These genes and resulting autism models are of course preferred, but show that the invention may be applied to any gene and therefore any- model is possible.
[00970] Applicants have made these cells lines using Cas9 nuclease in human embryonic stem cells (hESCs). The lines were created by transient transfection of liESCs with Cbh-Cas9-2A-EGFP and pU6-sgRNA. Two sgRNAs are designed for each gene targeting most often the same exons in which patient nonsense (knock-out) mutations have been recently described from whole exome sequencing studies of autistic patients. The Cas9-2A-EGFP and pU6 plasmids were created specifically for this project.
Example 34: AAV production system or protocol
[0Θ97Ϊ ] An AAV production system or protocol that was developed for, and works particularly well with, high through put screening uses is provided herein, but it has broader applicability in the present invention as well. Manipulating endogenous gene expression presents various challenges, as the rate of expression depends on many factors, including regulatory elements, mRNA processing, and transcript stability. To overcome this challenge, Applicants developed an adeno-associated virus (AAV)-based vector for
253
90.1 the delivery. AAV has an ssDNA-based genome and is therefore less susceptible to recombination.
[00972] AAV 1/2 (serotype AAV1/2, i.e., hybrid or mosaic AAV 1 / AAV2 capsid
AAV) heparin purified concentrated virus protocol
[00973] Media: DIP + HEPES
500ml bottle DMEM high glucose + Glutamax (GIBCO)
50ml Hyclone FBS (heat-inactivated) (Thermo Fischer)
5.5ml HEPES solution (1 M, GIBCO)
Cells: low passage HEK293FT (passage <10 at time of virus production, thaw new cells of passage 2-4 for vims production, grow up for 3-5 passages)
[00974] Transfection reagent: Poivethylenimine (PEP "Max"
Dissolve 50mg PET "Max" in 50ml sterile Ultrapure H20
Adjust pH to 7.1
Filter with 0.22um fiiptop filter
Seal tube and wrap with parafilm
Freeze aliquots at -20°C (for storage, can also be used immediately)
[00 75] Cell (Mlnre
Culture low passage HEK293FT in D10 + HEPES
Passage everyday between 1 :2 and 1 :2.5
Advantageously do not allow cells to reach more than 85% confiuency
[00976] For T75
- Warm 10ml HBSS (-Mg2+, -C 'a2 - . GIBCO) + lml TrypLE Express (GIBCO) per flask to 37°C (Waterbath)
Aspirate media fully
- Add 10ml warm HBSS gently (to wash out media completely)
- Add lml TrypLE per Flask
- Place flask in incubator (37°C) for Imin
■· Rock flask to detach cells
- Add 9ml D10 + HEPES media (37°C)
- Pipette up and down 5 times to generate single cell suspension
■■ Split at 1 :2 - 1:2.5 (12ml media for T75) ratio (if cells are growing more slowly, discard and thaw a new batch, they are not in optimal growth)
- transfer to T225 as soon as enough cells are present (for ease of handling large amounts of cells)
254
90.1 [0Θ977] AAV production (5*15cm dish scale per construct):
Plate 10 million cells in 21.5 nil media into a 15cm dish
Incubate for 18-22 hours at 37°C
Transfection is ideal at 80% confluence
[00978] Per plate
Prewarm 22ml media (D10 + HEPES)
[00979] Prepare tube with DNA mixture (use endofree maxiprep DNA):
5.2 ug vector of interest plasmid
4.35 ug AAV 1 serotype plasmid
4.35 ug AAV 2 serotype plasmid
10.4 ug pDF6 plasmid (adenovirus helper genes)□ Vortex to mix
Add 434 uL DMEM (no serum!)
Add 130 ul PEI solution
Vortex 5- 10 seconds
Add DNA/DMEM/PEI mixture to prewarmed media
V ortex briefly to mix
Replace media in 15cm dish with DNA/DMEM/PEI mixture
Return to 37°C incubator
Incubate 48h before harvesting (make sure medium isn't turning too acidic)
[00980] Virus harvest:
1. aspirate media carefully from 15cm dish dishes (advantageously do not dislodge cells)
2. Add 25 ml RT DPBS (Invitrogen) to each plate and gently remove cells with a cell scraper. Collect suspension in 50 ml tubes.
3. Pellet cells at 800x g for 10 minutes.
4. Discard supernatant
[00981] pause point: freeze cell pellet at -80C if desired
5. resuspend pellet in 150 mM NaCI, 20 mM Tris pH 8.0, use 10 ml per tissue culture plate.
6. Prepare a fresh solution of 10% sodium deoxycholate in dH20. Add 1.25 ml of this per tissue culture plate for a final concentration of 0.5%. Add benzonase nuclease to a final concentration of 50 units per ml. Mix tube thoroughly.
7. Incubate at 37°C for 1 hour (Waterbath).
8. Remove cellular debris by centrifuging at 3000 x g for 15 mitts. Transfer to fresh 50 ml tube and ensure all cell debris has been removed to prevent blocking of heparin columns.
255
90.1 [0Θ982] Heparin, column purification of AAV1/2:
1. Set up HiTrap heparin columns using a peristaltic pump so that solutions flow through the column at 1 ml per minute. It is important to ensure no air bubbles are introduced into the heparin column.
2. Equilibrate the column with 10 ml 150 raM NaCl, 20 mM Tris, pH 8.0 using the peristaltic pump.
3. Binding of vir us: Apply 50 ml virus solution to column and allo to flow through.
4. Wash step i t column with 20 ml 100 mM NaC3, 20 mM Tris, pH 8.0. (using the peristaltic pump)
5. Wash step 2: Using a 3 ml or 5 ml syringe continue to wash the column with 1 ml 200 mM NaCl, 20 mM Tris, pH 8.0, followed by 1 ml 300 mM NaCl, 20 mM Tris, pH 8.0. Discard the flow-through.
(prepare the syringes with different buffers during the 50min flow through of virus solution above)
6. Elution Using 5 ml syringes and gentle pressure (flow rate of < Iml/min) eiute the vims from the column by applying:
1.5 ml 400 mM NaC 20 mM Tris, pH 8.0
3.0 mi 450 mM NaCl, 20 mM Tris, pH 8.0
1.5 ml 500 mM NaCl, 20 mM Tris, pH 8.0
Collect these in a 15 ml centrifuge tube.
[00983] Concentration of AAV1/2:
1. Concentration step 1 : Concentrate the eluted virus using Amicon ultra 15ml centrifugal filter units with a 100,000 molecular weight cutoff. Load column eluate into the concentrator and centrifuge at 2000x g for 2 minutes (at room temperature. Check concentrated volume - it should be approximately 500 μΐ. If necessary, centrifuge in Imin intervals until correct volume is reached.
2. buffer exchange: Add lml sterile DPBS to filter unit, centrifuge in Imin intervals until correct volume (500ul) is reached.
3. Concentration step 2: Add 500u3 concentrate to an Amicon Ultra 0.5ml 100K filter unit. Centrifuge at 6000g for 2min. Check concentrated volume - it should be approximately 100 μΐ. If necessary, centrifuge in Imin intervals until correct volume is reached.
4. Recovery: Invert filter insert and insert into fresh collection tube. Centrifuge at lOOOg for 2min.
256
90.1 Aliquot and freeze at ~80°C
luf is typically required per injection site, small aliquots (e.g. 5ul) are therefore recommended ( avoid freeze-thaw of virus).
determine DNasel-resistant GC particle titer using qPC (see separate protocol)
[00984] Materials
Amicon Ultra, 0.5ml, 100K; M1LLIPORE; UFC510024
Amicon Ultra, 15ml, 100K; MILLIPORE; UFC910024
Benzonase nuclease; Sigma-Aldrich, E1014
HiTrap Heparin cartridge; Sigma-Aldrich; 54836
Sodium deoxyeholate; Sigma-Aldrich; D5670
[00985] AAV1 supernatant production protocol
Media: D 10 + PTEPES
500ml bottle DMEM high glucose + Glutamax (Invitrogen)
50mi Hycione FBS (heat-inactivated) (Thermo Fischer)
5.5ml FIEPES solution (1 M, GIBCO)
Cells: low passage HEK293FT (passage <10 at time of virus production)
Thaw new ceils of passage 2-4 for virus production, grow up for 2-5 passages
Transfection reagent: Polyethylenimine (PEI) "Max"
Dissolve 50mg PEI "Max" in 50ml sterile Ultrapure H20
Adjust pH to 7.1
Filter with 0.22um fliptop filter
Seal tube and wrap with parafilm
Freeze aliquots at -20°C (for storage, can also be used immediately)
Cell Culture
Culture low passage HE 293FT in D 10 + HEPES Passage everyday between 1 :2 and 1 :2.5
Advantageously do let cells reach more than 85% con fluency
For T75
- Warm 10ml HBSS (-Mg2+, -Ca2+, GIBCO) + lml TrypLE Express (GIBCO) per flask to 37°C (Waterbath)
■- Aspirate media fully
- Add 10ml warm HBSS gently (to wash out media completely)
- Add 1 ml TrypLE per Flask
- Place flask in incubator (37°C) for Imin
257
90.1 - Rock flask to detach cells
- Add 9m! D10 + HEPES media (37°C)
■■ Pipette up and down 5 times to generate single cell suspension
- Split at 1 :2 - 1 :2.5 (12ml media for T75) ratio (if cells are growing more slowly, discard and thaw a new batch, they are not in optimal growth)
■· transfer to T225 as soon as enough cells are present (for ease of handling large amounts of cells)
AAV production (single 15cm dish scale)
Plate 10 million cells in 21.5 ml media into a 15cm dish
Incubate for 18-22 hours at 37°C
Transfection is ideal at 80% confluence per plate
Prewarm 22ml media (D 10 + HEPES)
Prepare tube with D A mixture (use endofree maxiprep DNA):
5.2 ug vector of interest plasmid
8.7 ug AAV 1 serotype plasmid
10.4 ug DF6 plasmid (adenovirus helper genes)
Vortex to mix
Add 434 uL DMEM (no serum!) Add 130 ul PEI solution
Vortex 5-10 seconds
Add DNA/DMEM/PEI mixture to prewarmed media
Vortex briefly to mix
Replace media in 15cm dish with DNA/DMEM/PEI mixture
Return to 37°C incubator
Incubate 48h before harvesting (advantageously monitor to ensure medium is not turning too acidic)
[00986] Virus harvest:
Remove supernatant from 15cm dish
Filter with 0.45 urn filter (low protein binding) Aliquot and freeze at -80°C
Transduction (primary neuron cultures in 24-well format, 5DIV)
Replace complete neurobasal media in each well of neurons to be transduced with fresh neurobasal (usually 400ul out of 500ul per well is replaced)
Tha AAV supernatant in 37°C waterbafh
Let equilibrate in incubator for 30min
Add 250 ul AAV supernatant to each well
258
90.1 Incubate 24h at 37°C
Remove media/supernatant and replace with fresh complete neurobasal
Expression starts to be visible after 48h, saturates around 6-7 Days Post Infection
Constructs for pAAV plasmid with GOI should not exceed 4.8kb including both ITRS.
[00987] Example of a human codon optimized sequence (i.e. being optimized for expression in humans) sequence : SaCas9 is provided below:
ACCGGTGCCACCATGTACCCATACGATGTTCCAGATTACGC TTCGCCGAAGAAAAAGCGCAAGGTCGAAGCGTCCATGAAAAGGAACTACATT CT
GGGGCTGGACATCGGGATTACAAGCGTGGGGTATGGGATTATTGACTATGAA AC
AAGGGACGTGATCGACGCAGGCGTCAGACTGTTCAAGGAGGCCAACGTGGAA AA
CAATGAGGGACGGAGAAGCAAGAGGGGAGCCAGGCGCCTGAAACGACGGAG AA
GGCACAGAATCCAGAGGGTGAAGAAACTGCTGTTCGATTACAACCTGCTGAC CG
ACCATTCTGAGCTGAGTGGAATTAATCCTTATGAAGCCAGGGTGAAAGGCCTG A
GTCAGAAGCTGTCAGAGGAAGAGTTTTCCGCAGCTCTGCTGCACCTGGCTAAG
C
GCCGAGGAGTGCATAACGTCAATGAGGTGGAAGAGGACACCGGCAACGAGCT
G
TCTACAAAGGAACAGATCTCACGCAATAGCAAAGCTCTGGAAGAGAAGTATG
TC
GCAGAGCTGCAGCTGGAACGGCTGAAGAAAGATGGCGAGGTGAGAGGGTCA ATT
AATAGGTTCAAGACAAGCGACTACGTCAAAGAAGCCAAGCAGCTGCTGAAAG
TG
CAGAAGGCTTACCACCAGCTGGATCAGAGCTTCATCGATACTTATATCGACCT GC
TGGAGACTCGGAGAACCTACTATGAGGGACCAGGAGAAGGGAGCCCCTTCGG
AT
GGAAAGACATCAAGGAATGGTACGAGATGCTGATGGGACATTGCACCTATTT
259
90.1 TCC
AGAAGAGCTGAGAAGCGTCAAGTACGCTTATAACGCAGATCTGTACAACGCC CT
GAATGACCTGAACAACCTGGTCATCACCAGGGATGAAAACGAGAAACTGGAA
TA
CTATGAGAAGTTCCAGATCATCGAAAACGTGTTTAAGCAGAAGAAAAAGCCT
AC
ACTGAAACAGATTGCTAAGGAGATCCTGGTCAACGAAGAGGACATCAAGGGC
TA
CCGGGTGACAAGCACTGGAAAACCAGAGTTCACCAATCTGAAAGTGTATCAC
GA
TATTAAGGACATCACAGCACGGAAAGAAATCATTGAGAACGCCGAACTGCTG GA
TCAGATTGCTAAGATCCTGACTATCTACCAGAGCTCCGAGGACATCCAGGAAG
AG
CTGACTAACCTGAACAGCGAGCTGACCCAGGAAGAGATCGAACAGATTAGTA
AT
CTGAAGGGGTACACCGGAACACACAACCTGTCCCTGAAAGCTATCAATCTGAT TC
TGGATGAGCTGTGGCATACAAACGACAATCAGATTGCAATCTTTAACCGGCTG AA
GCTGGTCCCAAAAAAGGTGGACCTGAGTCAGCAGAAAGAGATCCCAACCACA
CT
GGTGGACGATTTCATTCTGTCACCCGTGGTCAAGCGGAGCTTCATCCAGAGCA
TCAAAGTGATCAACGCCATCATCAAGAAGTACGGCCTGCCCAATGATATCATT
ATCGAGCTGGCTAGGGAGAAGAACAGCAAGGACGCACAGAAGATGATCAAT
GAGATGCAGAAACGAAACCGGCAGACCAATGAACGCATTGAAGAGATTATCC
GAACTACCGGGAAAGAGAACGCAAAGTACCTGATTGAAAAAATCAAGCTGCA
CGATATGCAGGAGGGAAAGTGTCTGTATTCTCTGGAGGCCATCCCCCTGGAGG
ACCTGCTGAACAATCCATTCAACTACGAGGTCGATCATATTATCCCCAGAAGC
GTGTCCTTCGACAATTCCTTTAACAACAAGGTGCTGGTCAAGCAGGAAGAGAA
CTCTAAAAAGGGCAATAGGACTCCTTTCCAGTACCTGTCTAGTTCAGATTCCA
AGATCTCTTACGAAACCTTTAAAAAGCACATTCTGAATCTGGCCAAAGGAAAG
GGCCGCATCAGCAAGACCAAAAAGGAGTACCTGCTGGAAGAGCGGGACATCA
260
90.1 ACAGATTCTCCGTCCAGAAGGATTTTATTAACCGGAATCTGGTGGACACAAGA
TACGCTACTCGCGGCCTGATGAATCTGCTGCGATCCTATTTCCGGGTGAACAA
TCTGGATGTGAAAGTCAAGTCCATCAACGGCGGGTTCACATCTTTTCTGAGGC
GCAAATGGAAGTTTAAAAAGGAGCGCAACAAAGGGTACAAGCACCATGCCGA
AGATGCTCTGATTATCGCAAATGCCGACTTCATCTTTAAGGAGTGGAAAAAGC
TGGACAAAGCCAAGAAAGTGATGGAGAACCAGATGTTCGAAGAGAAGCAGG
CCGAATCTATGCCCGAAATCGAGACAGAACAGGAGTACAAGGAGATTTTCAT
CACTCCTCACCAGATCAAGCATATCAAGGATTTCAAGGACTACAAGTACTCTC
ACCGGGTGGATAAAAAGCCCAACAGAGAGCTGATCAATGACACCCTGTATAG
TACAAGAAAAGACGATAAGGGGAATACCCTGATTGTGAACAATCTGAACGGA
CTGTACGACAAAGATAATGACAAGCTGAAAAAGCTGATCAACAAAAGTCCCG
AGAAGCTGCTGATGTACCACCATGATCCTCAGACATATCAGAAACTGAAGCTG
ATTATGGAGCAGTACGGCGACGAGAAGAACCCACTGTATAAGTACTATGAAG
AGACTGGGAACTACCTGACCAAGTATAGCAAAAAGGATAATGGCCCCGTGAT
CAAGAAGATCAAGTACTATGGGAACAAGCTGAATGCCCATCTGGACATCACA
GACGATTACCCTAACAGTCGCAACAAGGTGGTCAAGCTGTCACTGAAGCCAT
ACAGATTCGATGTCTATCTGGACAACGGCGTGTATAAATTTGTGACTGTCAAG
AATCTGGATGTCATCAAAAAGGAGAACTACTATGAAGTGAATAGCAAGTGCT
ACGAAGAGGCTAAAAAGCTGAAAAAGATTAGCAACCAGGCAGAGTTCATCGC
CTCCTTTTACAACAACGACCTGATTAAGATCAATGGCGAACTGTATAGGGTCA
TCGGGGTGAACAATGATCTGCTGAACCGCATTGAAGTGAATATGATTGACATC
ACTTACCGAGAGTATCTGGAAAACATGAATGATAAGCGCCCCCCTCGAATTAT
CAAAACAATTGCCTCTAAGACTCAGAGTATCAAAAAGTACTCAACCGACATTC
TGGGAAACCTGTATGAGGTGAAGAGCAAAAAGCACCCTCAGATTATCAAAAA
GGGCTAAGAATTC
Example 35: Minimizing off-target cleavage using Cas9 nickase and two guide RN/ls [00988] Cas9 is a. RNA-guided D A nuclease that may be targeted to specific locations in the genome with the help of a 20bp RNA guide. However the guide sequence may tolerate some mismatches between the guide sequence and the DNA-target sequence. The flexibility is undesirable due to the potential for off-target cleavage, when the guide R A targets Cas9 to a an off-target sequence thai has a few bases different from the guide sequence. For all experimental applications (gene targeting, crop engineering, therapeutic
261
90.1 applications, etc) it is important to be able to improve the specificity of Cas9 mediated gene targeting and reduce the likelihood of off -target modification by Cas9.
[00989] Applicants developed a method of using a. Cas9 nickase mutant in combination with two guide R As to facilitate targeted double strand breaks in the genome without off-target modifications. The Cas9 nickase mutant may be generated from a Cas9 nuclease by disabling its cleavage activity so that instead of both strands of the DNA duplex being cleaved only one strand is cleaved. The Cas9 nickase may be generated by inducing mutations in one ore more domains of the Cas9 nuclease, e.g. Ruvel or IfNH. These mutations may include but are not limited to mutations in a Cas9 catalytic domain, e.g in SpCas9 these mutations may be at positions D10 or H840. These mutations may include but are not limited to DIOA, E762A, H840A, N854A, 863A or D986A in SpCas9 but nickases may be generated by inducing mutations at corresponding positions in other CRISPR enzymes or Cas9 orthoiogs. In a most preferred embodiment of the invention the Cas9 nickase mutant is a SpCas9 nickase with a DIOA mutation,
[00990] The way this works is that each guide RNA in combination with Cas9 nickase would induce the targeted single strand break of a duplex DNA target. Since each guide RNA nicks one strand, the net result is a double strand break. The reason this method eliminates off-target mutations is because it is very unlikely to have an off-target site that has high degrees of similarity for both guide sequences (20bp+2bp(PAM) = 22bp specificity for each guide, and two guides means any off-target site will have to have close to 44bp of homologous sequence). Although it is still likely that individual guides may have off-targets, but those off-targets will only be nicked, which is unlikely to be repaired by the mutagenic NHEJ process. Therefore the multiplexing of DNA double strand nicking provides a powerful way of introducing targeted DNA double strand breaks without off-target mutagenic effects.
[00991] Applicants carried out experiments involving the co-transfection of HEK293FT cells with a plasmid encoding Cas9(D10A) nickase as well as DNA expression cassettes for one or more guides. Applicants transfected cells using Lipofectamine 2000, and transfected cells were harvested 48 or 72 hours after trartsfections. Double nicking- induced NHEJ were detected using the SURVEYOR nuclease assay as described previously herein (Figs. 51 , 52 and 53).
[00992] Applicants have further identified parameters that relate to efficient cleavage by the Cas9 nickase mutant when combined with two guide RNAs and these parameters include but are not limited to the lengt of the 5 ' overhang. Efficient cleavage is reported
262
90.1 for 5' overhang of at least 26 base pairs. In a preferred embodiment of the invention, the 5' overhang is at least 30 base pairs and more preferably at least 34 base pairs. Overhangs of up to 200 base pairs may be acceptable for cleavage, while 5' overhangs less than 100 base pairs are preferred and 5' overhangs less than 50 base pairs are most preferred (Figs. 54 and 55).
Example 36: Generation of in vivo murine models of myeloid malignancy with combinatorial genetic lesions using CRISPR/Cas genome editing (I)
[00993] Recent genome sequencing efforts have demonstrated that human malignancies commonly bear mutations in four or more driver genes. Murine models of these recurrent mutations have yielded insights into the biology and treatment of cancer, but it has not yet been possible to engineer primary cells that recapitulate the genetic complexity of human disease. Mice bearing combinations of three or more genetic lesions are exponentially more difficult to generate through breeding. Recent advances in genome editing technologies now offer the potential to overcome these limitations, but are restricted to cell types and organisms amendable to direct nucleic acid transfer. Applicants generated a lentiviral Clustered-Regularly-Interspaced-Sliort-Palindromatic-Repeats (CRISPR)- CRISPR-associated-system (Cas) delivery system and utilized it to modify murine hematopoietic stem cells (HSCs) in vivo at up to five genomic loci, leading to clonal outgrowth and myeloid malignancy. Lentiviru -delivered CRISPR-Cas genome editing is a powerful tool for the engineering of in vivo cancer models.
|00994] Transcriptional Activator Like Effector Nucleases (TALENs), and more recently the CRISPR-Cas system have been developed for the targeted editing of genomic loci. Both systems have been successfully used to engineer the genomes of multiple model organisms. A limitation of these technologies, however, is the efficient delivery of the required components into specific cell types. In particular, primary hematopoietic stem and progenitor cells (HSPC), the disease-initiating cell populations for myeloid malignancies, are difficult to target with commonly used gene transfer methods. Viral vectors derived from HIV-1 are currently the most efficient gene delivery tools, but their application for the deliver}' of TALENs has been restricted due to the highly repetitive nature of the introduced proteins, leading to recombination of the vectors. Type II CRISPR-Cas, which does not contain such highly repetitive sequences, has recently been
263
90.1 adapted for specific DNA targeting in mammalian cells, and is therefore amenable to expression from lentiviral vectors.
[00995] To perform genome editing with high efficiency in primary HSPCs, and to track the engineered cells in vivo. Applicants generated a modular lentiviral CRISPR-Cas vector (Figs. 56A and 59). This lentiviral vector simultaneously delivers both the Streptococcus pyogenes Cas9 gene and a chimeric small guide RNA (sgRNA) or a chimeric RNA polynucleotide sequence (chiR A). This single vector enables the targeting of any genomic locus in a broad range of cell types by a one-step exchange of the target site (spacer). To allow tracking or selection of transduced cells, a fluorescent protein or selectable marker was linked to the Cas9 gene with a picorna virus derived 2A protein cleavage site.
[00996] Since efficacy of the CRTSPR-Cas system may depend on the spacer sequence, Applicants developed an assay for rapid and quantitative evaluation of target site cleava ge. Standard assays such as those utilizing T7 endonuciease are time consuming, require optimization for individual target sites, and are challenging to use quantitatively. Fluorescent reporters are an alternative approach to quantify the efficacy of genome engineering tools or RNA interference. Applicants generated a. lentiviral reporter system in which Applicants introduced up to 20 target sequences into the coding sequence of a fluorescent protein (Fig. 56A, bottom). The vector confers puromycin resistance, enabling the rapid generation of stable cell fines for genomic testing of spacer efficacy. Transduction of these reporter cell lines with targeting CRISPR-Cas vectors leads to quantifiable loss of reporter fluorescence (Fig. 56B),
[0Θ997] To model myeloid malignancies in vivo. Applicants first developed lentiviral CRISPR-Cas vectors targeting 8 genes that are recurrently mutated in hematopoietic malignancies. Applicants tested an average of 3 spacers per gene and found that approximately 60% of the vectors achieved cleavage (>20% reduction of mean fluorescent intensity (MFT)) of their respective target genes (Fig. 56C). Results for two spacers were confirmed by the standard T7 endonuciea.se assay, demonstrating cutting at the genomic locus (Fig. 60). These findings demonstrate that the Applicants' lentiviral system achieves efficient cleavage of target sites, and that engineered fluorescent reporter cell lines can provide rapid, quantitative evaluation of spacer efficacy.
[00998] Having demonstrated the efficiency of the lentiviral delivery system in vitro. Applicants examined whether the genomes of primary murine HSPCs could be engineered in vivo. Applicants isolated Lineage-/Scal+/cKit+ (LSK) cells, which are enriched for
264
90.1 HSPC activity, from mice with knock-in of the Flt3 internal tandem duplication (F3t3- ITD) mutation. While Flt3-ITD mutations frequently occur in acute myeloid leukemia (AML), the Flt3-1TD knock-in mice have only a mild hematopoietic phenotype, and Applicants hypothesized that additional co-operating oncogenic lesions would induce a more aggressive disease. Heterozygous Flt3-ITD expressing LS cells were transduced with an eGFP-expressing CRISPR-Cas lentiviral vector with an sgRNA targeting the Runxl gene or a non-targeting sgRNA (Fig. 56A), and were then transplanted into lethally irradiated wild-type (WT) congenic recipient mice. In serial analysis of the peripheral blood of recipient mice, Applicants found that the population of cells expressing Cas9 and the Runxl sgRNA expanded significantly over a. period of 19 weeks in comparison to the population of cells expressing Cas9 and the non-targeting sgRNA (p=0.03; t-test, two- sided, unpaired), thus indicating that loss of Runxl may induce a growth advantage in heterozygous Flt3-ITD expressing cells in vivo (Figs. 56D, 61 A). Detection of eGFP- positive ceils at 19 weeks post- transplant indicated that Applicants transduced long-term repopulating HSCs (Figs. 56E, 61 B and 61 C).
[0Θ999] To demonstrate genome modification of HSCs, Applicants performed deep sequencing of the genomic sequence targeted in Runxl in peripheral blood at serial time points. At 19 weeks post-transplant, only long-term repopulating HSCs provide mature cells to hematopoiesis, and any unique mutation found at this time point is therefore expected to be in an HSC. Applicants identified at least 16 distinct insertions or deletions at the targeted Runxl site in peripheral blood harvested 5 weeks post-transplant that were also present in blood 19 weeks post-transplant (Fig. 62). These findings demonstrate that multiple distinct HSCs were genetically modified. Overall, these results demonstrate that lentiviral delivery of the CRISPR-Cas system in HSCs is feasible and well tolerated, and that this system can be employed to edit the genomes of HSCs to interrogate gene function in hematopoiesis.
[001000] Since myeloid malignancies, and cancer more broadly, are caused by multiple cooperating genetic lesions, Applicants next sought to target multiple cancer- associated genes simultaneously. To facilitate multiplex genome editing, Applicants generated a two-vector system in which Cas9, and an eGFP fluorescent marker, are delivered from one lentiviral vector, while additional sgRNAs and an RFP657 fluorescent marker are delivered by a second lentiviral vector (Fig. 57A). Multiple sgRNAs can thus be introduced into a single cell.
265
90.1 0Θ100Ϊ ] Applicants sought to perform multiplex gene editing by transducing LSK. cells from C57B1/6 wild-type mice with a pool of vectors providing sgRNAs, thereby enabling the simultaneous targeting of the Tet2, Rural, DnmtSa, Nfl, Ezh2, SmcS genes. Applicants found that all mice transplanted with LSK cells transduced with this pool developed significant myeloid skewing of hematopoiesis (p= .007; t-test; Welch corrected; two-sided; impaired) with reduction of B -cells (p=0.001; t-test, two-sided; unpaired), and some developed leukocytosis, as compared to the control group that received LSK cells transduced with control vectors expressing Cas9 and a non-targeting sgRNA (Fig. 57B).
[001002] To determine the efficacy of multiplex genome editing, Applicants examined the genetics of putative clones in the peripheral blood of mice. Two-dimensional flow cytometry analysis of eGFP and RFP657 allowed us to detect clonal hematopoietic expansion in vivo (Figs. 57C, 57D, 63), though some clonal, mutated populations were only GFP dim (Figs. 63 and 64). For two mice, Applicants purified clonal populations from peripheral blood based on their eGFP/RFP657 profile (red gated), by fluorescent activated cell sorting (FACS) (Figs. 57C and 57D). Applicants examined the mutated genes by PGR amplification, sub-cloning, and sequencing of targeted gene regions. In one mouse, a clone expanded gradually over 12 weeks that had mutations in Tell, DnmtSa, Runxl, and Nfl (Figs. 57C, 66A), while no mutations in Ezh2 and SmcS were detected. In a second mouse, a clone expanded rapidly after transplantation with mutations in Tet2, Rural, Nfl and Ezh2 (Figs. 57D, 66B), and no mutations in DnmtSa and SmcS. In both cases, the detected mutational pattern strongly suggests that a single cell was transduced with four separate sgRNAs, resulting in modification of one or both alleles of four tumor suppressor genes. Despite expansion of these clonal populations, no transformation to acute leukemia was observed in these mice during the observation period of up to 14 weeks.
[001003] Transformation to acute leukemia was observed in a different mouse transduced with the same pool of sgRNAs. A clonal population was detected at 4 weeks post-transplant, and the mouse was euthanized at 6 ½ weeks post-transplant with mild leukocytosis (white blood cell (WBC) count: 15.3xlQA6/ml; normal: 5-10x10A6/ml) and splenomegaly (436 mg: normal: 80-120mg). The bone marrow had a high disease burden, with 85% of cells expressing the CRISPR-Cas vectors (Fig. 58A). The cells were skewed to the myeloid lineage (GrHVCDl lb+). Analysis of the targeted genes revealed deletions in DnmtSa, Ezh2, SmcS and Nfl, confirming a clonal origin of the disease (Figs. 58A right
266
90.1 panel, 67). The peripheral blood from these mice had increased granulocytes and circulating blasts, which are signs of leukemic transformation (Fig. 58B, left panel). Bone marrow histology showed an excess of myeloid lineage ceils (>90%) with 20-30% blast cells, while other lineages were suppressed (Fig. 58B, right panel), consistent with acute myeloid leukemia (AML).
[001004] Applicants next confirmed thai the detected mutations had an impact on protein expression and cellular phenotype. Both Ezh2 and Smc3 protein expression were markedly reduced. Nfl is a negative regulator of the Ras pathway, and Applicants observed de-repression of the downstream targets, Erkl and Erk2, as expected for cells with inactivation of Nfl (Fig. 58C). Serial replating of FACS -purified, double positive eGFP/RFP657-expressing cells indicates increased self-renewal capacity compared to wild-type C57B1/6 BM cells (Fig. 58D). In transplant experiments, the GFP/RFP657 double positive mutated cells robustly engrafted in secondar recipient mice (Fig, 68A). At 8 weeks post-transplant two out of five recipient mice developed leukocytosis (Fig. 68B). Mutated cells in all mice had highly biased differentiation with >90% of the cells belonging to the myeloid lineage (Figs. 58E and F) similar to the phenotype of the primary disease (Fig. 58G). At 14 weeks post transplant a second primary mouse succumbed to myeloid leukemia characterized by splenomegaly (412mg), leukocytosis (WBC: 33.6x10A6/ml), excess myeloid cells in the BM (Fig. 69 A), and circulating blasts in peripheral blood (Fig. 69B). Clonal mutations were identified in Tet2, DnmtSa, Ruwcf Nfl, and Ezh2. None of the mice transplanted with non-targeting sgRNA expressing cells developed disease during the course of the experiment. These studies demonstrate that, using lentiviral delivered CRISPR-Cas components, Applicants have engineered novel models of myeloid malignancy bearing mutations in 4-5 different genes that can be propagated and studied through serial transplantation.
[001005] To examine an alternative set of co-operative mutations, the same pool of sgRNAs targeting leukemia tumor suppressor genes was used to transduce LSK cells from mice with heterozygous knock-in of the Fit3-ITD oncogene allele. Targeting of Runxl alone did not induce transformation of FU3-ITD heterozygous expressing cells (Fig, 56D). Consistent with the results of pooled tumor suppressor gene targeting in wild-type C57B1/6 mice, expansion of CRISPR/Cas -transduced, Flt3 -ITD-expressing cells was observed over time. In some mice, expression of the CRISPR/Cas vector was GFP-dim at 8-10 weeks (Fig. 70). A total of three out of nine (33%) mice developed disease at 10-12 weeks with leukocytosis (WBC: 15.4xlOA6/ml, 40.4xlQA6/ml, and 78.1xl0A6/ml) and
267
90.1 splenomegaly (326mg, 533mg, and 1036mg). Flow cytometry of the BM demonstrated that cells were myeloid biased (Figs. 71 A, 72A, 73 A). Myeloid differentiation bias and presence of blast cells were confirmed by histological analysis of blood smears (Figs. 7 IB, 72B, 73B), consistent with AML in these mice. Clonal mutations were detected in 3-5 genes in the three mice (Figs. 71 C, 72C, 73C). Since the mutations were engineered in the Flt3~ITD heterozygous background, AML was generated from primary ceils with mutations in 4 to 6 leukemia driver genes.
[001006] Taken together, these studies of lenti virus-delivered CRISPR/Cas with multiplex sgRNAs demonstrated highly efficient genome editing in murine HSPCs. Applicants simultaneously inactivated multiple tumor suppressor genes causing outgrowth of a myeloid clone and transformation to leukemia. Applicants described models with 4 and more genes modified, with editing of up to 10 individual alleles, when a pool of sgRNAs targeting 6 genes was introduced in primary HSPCs. While genetic models have recently been generated using CRISPR-Cas in whole organisms, Applicants' system enables tissue specific interrogation of gene function in adult organisms while avoiding potential developmental defects. The genetic complexity thus generated is beyond the capacities of current approaches for engineering murine malignancies and will allow rapid generation of novel disease models. Such models are critical for the functional interrogation of novel disease alleles and for the development and pre-clinical testing of targeted therapies.
[001007] The novel leukemia models generated reflect both the number and functional classes of co-occurring mutations that occur during the pathogenesis of human myeloid malignancies. All of the clones characterized had inactivating mutations in Nfl, a lesion that activates Ras signaling, and the only mutation in the screen that causes activated kinase signaling, a common feature of ieiikemias and other cancers. Applicants also identified mutations in Ezh2, a gene recently shown to be involved in the differentiation block in AML, in ail mice that presented with myeloid transformation. Inhibition of myeloid differentiation has also been reported DnmtS' a, Tet2, and Ru al each of which were successfully mutated in Applicants' models.
[001008] Overall, Applicants studies demonstrated a robust methodology to generate multiple genetic lesions via lentivirus -delivered CRISPR-Cas system in a broad range of cells, including the primary adult stem cells that are the disease-initiating population for leukemia. The use of viral-based CRISPR-Cas will enable the rapid and efficient generation of cancer models that reflect the complex genetics of human disease.
268
90.1 [001009] Vector construction and viral particle production: Lentiviral vectors were based on the pLKO_TRC005 lentiviral backbone. The codon optimized Streptococcus pyogenes Cas9 (SpCas9) cD A and small guide R A (sgRNA) have been described by Applicants, The sgRNA was amplified from the pLX330 backbone and placed behind the human U6 promoter of the pLKO_TRC005. Vectors expressing only Cas9 and no sgRNA were generated by deleting the hU6 promoter. Bbsl sites were replaced by BsmBI sites for insertion of the spacer sequence. The hPGK promoter of the pLKO TRC005 was replaced by a minimal size hEFla promoter (EFS). To generate vectors expressing Cas9 only, the hU6 promoter was deleted from the pLKO_TRC005 backbone by cutting PpuMI EcoRI followed by Klenow fragment fill-in reaction and ligation. SpCas9 cDNA was PGR amplified (Phusion DNA Polymerase, NEB) and placed behind the EFS promoter followed by addition of P2A-eGFP, P2A-tagRFP, P2A-PAC or P2A-BSD. Optimized picorna virus 2A sites were fused to respective cDNAs via PGR. The sgRNA -only vectors were generated by replacing the SpCas9 and respective marker gene with a fluorescent protein marker, or selection marker only. The RFP657 fluorescent protein was described previously in Morozova et. al (2010), incorporated herein by reference. Suitable protospacer sequences were identified with unique 13 bp seed sequence and a minimum of 3 mismatches to the mouse genome. Lentiviral reporter vectors were generated by replacing the eGFP fluorescent reporter gene in the RRL.PPT. SFFV.TRES. eGFP.pre with PAG, followed by insertion of the RFP657 fluorescent reporter gene 5' of the IRES. CRISPR'Cas target sites were introduced behind the start codon of the RFP657.
0Θ10Ϊ 0] Lentiviral particles were produced by transient transfection of 293T cells using the calcium-phosphate transfection method. Viral constructs were co-transfected with pMD2.G and psPAX2 , Lentiviral particles were concentrated using ultracentrifugation. Oligonucleotide sequences used for the cloning of CRISPR/Cas protospacers used in this study are shown in Table 1 below.
269
90.1 Targeted Gene # OMgo Sequence {5*>3*}
Rt xl 1 s C GC GGCAC G G GGGACGTC C CG GA as AAAC TC CGGGAC GTCCCCGA GTGCC
Rimxl 2 s CAGC GCCGGGTGAAATGGGTGTCGC as AAAC C GACACC CATTTCAC C C GGC
Ranx i 3 $ CACC GGGCTGGTCATGCCGCTGGCA as AAAC TGCCAGCGGCATGACCAGCCG
Te 2 i s CAGC GAATAGTATCCTAGTTCCGAC
as AAAC GTCGGAACTAGGATAGTATTC
Tet2 2 s CAGC GGAA C AAGCTCTAC ATCCCGT as AAAC ACGGGATGTAGAGCTTGTTGG
Tet2 3 5 CAGC GATGAGATGCGGTACTCTGCA as AAAC TGGAGAGTACCGCATC TC TC
Dnmt3a ? s CAGC GTGGGCATGG TGCG CACG A as AAAC TGG TGCGGCACG A TG GCC C
Dnmt3s 2 CACC GCATGATGCGCGGCCCAAGG
35 AAAC CCTTGGGCCGCGCATCATGC
DnmiSa 3 3 CACC GCTTACCAGTATGACGACSA
ss AAAC TCGTCGTCATAC GGIAAGC
Mil f s CACC 6AA GGAGC GGTCC C G GTAAC
35 AAAC GTTACCGGGACCGCTCCTTC
Mil 2 S CAGC GCAGATSAGCCGCCACATCGA as AAAC TC GATGTG GC GGCTCATCTGC
Nil 3 s CACC GCACTGACAGCGCCCATAGGT as AAAC ACGTATGGGCGG GTCAGTGC
Ezfrl 1 s CACC GCTGAGAAGGGACCGGTTTGT as AAAC AG AAAC C GGT G CC TTCTCAGC
Ezh2 2 s CAGC GACA CG GTTGCGGCAA CAAAC as AAAC GTTTGTGGG C GG AGCG TGTC
F .»; 3 s CACC GAAGACACCACCTAAACGCCC as AAAC G GGCG TIT GGTGG TGTCT TC
Smc'3 i s CACC GCTCC AGTC AGAGCAC C TCGA as AAAC TGGAGGTGCTGTGACTGGAGG
8mc3 2 s CACC GAAAAGCTGAiAAAGGGGCAAG as AAAC GTTGCCGCITTATCAGCTT i S C
Asxl1 1 s CACC GCAAGAG7GCCATTCGAGGCC as AAAC GGCCTCGAATGGCACTG7TGC
Asx!f 2 3 CACC GAIACTAAAACCGACTTAGC
as AAAC GCTAAGTGGGi TTTAG i ATC
Asx!l 3 3 CACC GAGCCCAAAGTCCCGCCCATC
35 AAAC GATGGGCGGGACTTTGGGCTC p53 ? 3 CACC GAGAAGAAAATTTCCGCAAAA
35 AAAC i S TTGCGGAAATTTIC :; s CTC p53 2 3 CACC GCGCTC C CTGGGG GCAGTTCA
35 AAAC TGAAGTGCCGCCAGGGAGCGC p53 3 S CAGC GCTATTACACATGTACTTGTAG
3S AAAC CIACAAGTACATGTGIAATAGC
#: Spacer number; s: sense; as: antisense;
[001011] Reporter based efficacy assessment of CRISPR-Cas spacer sequences: Fluorescent reporter vectors were constructed and produced as described above. HEL cells
270
90.1 (ATCC) were cultured in RPMI with 10% FBS and 100 U/ral Penicillin/Streptomycin. HEL cells were transduced with CRISPR/Cas reporter vectors in the presence of 4ug/ml hexadimethrine bromide (Poiybrene (Life Technologies)) and transduced cells wrere selected with 2ug ml Puromycin (Life Technologies) for 72h, starting 48h post transduction. Selection was verified by flow cytometry. Selected reporter cell lines were transduced with CRISPR-Cas vectors targeting the respective target sites and non- targeting controls. RFP657 reporter fluorescence was assessed by flow cytometry at 6 days post transduction in comparison to non-targeting controls and untransduced cells.
[001012] T7-endonueiease assay: Ba/F3 cells (DSMZ) were cultured in RPMI with 10% FBS, 100 U/ml Penicillin/Streptomycin and 5 ng ml 113 (Peprotech). Ba/F3 cells wrere transduced with CRISPR/Cas vectors, and transduced cells were purified by FACS 7 days post-infection. Genomic DNA was isolated according to manufacturers instruction with a DNA Micro Kit (Quiagen). Targeted loci were amplified by PGR (Phusion DNA Polymerase, NEB). CRISPR/Cas efficacy at the endogenous locus was assessed using the Surveyor Mutation Detection Kit (Transgenomic).
[0Θ1013] Mouse bone marrow transplant and analysis: Total BM was isolated from femurs and tibias from 6-10 week old female C57B1/6 mice or heterozygous 6-12 week old F3t3-1TD knock-in mice. BM was subjected to erythrocyte lysis (BD PharmLyse, BD Bioscience), followed by magnetic bead selection of cKit (CD 117) positive cells using CD1 17 MicroBeads (Milteny Biotech). GDI 17 selected cells were stained with APC labeled cKit (eBioscience), PE labeled Seal (BioLegend) PacificBlue labeled Grl, GDI lb, B220(CD45R), Terl l9, and CD3 (all BioLegend) and then flow sorted on a BD FACS Aria II. LSK cells were cultured in Stem Span SFEM (StemCell Technologies) supplemented with 50ng/ml murine Thpo and 50ng murine Scf (both Peprotech) for 48h and then transduced with concentrated lentiviral supernatant in presence of 2ug/ml Poiybrene. 24h post transduction ceils were collected and intravenously injected into lethaily irradiated (950 cGy) 6-10 week old female C57B1/6 mice. C57B1/6 mice were obtained from Taeonic. Flt3 -ITD mice were bred in local facilities.
[001014] All transplant experiments were performed with 4-5 mice per group. Statistical significance between groups was assessed using an unpaired t-test. Peripheral blood was sampled by retro-orbital bleeding. Bone marrow was harvested from femurs and tibias. Nucleated cells were obtained by erythrocyte lysis. To detect mature lineage markers, cells were stained with Grl -APC-eFluor780 (eBioscience), CD l ib- APC (BioLegend), B220(CD45R)-PE-Cy7 (BioLegend) and CD3e-PE (eBioscience). HSPCs were stained
271
90.1 with PacificBlue labeled Grl , GDI lb, B220(CD45R), Terl l9, and CD3 (all BioLegend), Scal-PE (BioLegend), CD150-PE-Cy7 (BioLegend), cKit-APC (eBioscience), CD48- PerCP-Cy5.5 (eBioscience), and CD34-AlexaFluor700 (eBioscience). Flow cytometry was performed on a BD LSR II flow cytometer. Cells expressing both the eGFP and RFP657 reporter gene were stained with Grl -PE-Cy7 (eBioscience) and CDl lb-PE (BioLegend) or B220(CD45R)-PE-Cy7 and CD3e-PE for mature lineage detection.
[001015] To assess mutations at targeted loci, peripheral blood nucleated cells were purified by FACS. Genomic DNA was isolated according to manufacturers instruction with a DNA Micro Kit (Quiagen). Targeted loci were amplified by PGR (Phusion DNA Polymerase, NEB). PGR products were cloned into pJetl .2 PGR cloning vector (Life Technologies). Plasniid DNA was isolated from individual bacterial clones with a DNA Plasmid Mini Kit (Quiagen) and sequences were assessed by Sanger sequencing.
[001016] Secondary transplant of leukemic mice was performed by transplanting 5χ10Λ6 primary BM cells into sub-lethally (650cGy) irradiated C57B1/6 mice. Peripheral blood semars were stained with May-Gruenwald/Giemsa stain. BM histology was assessed from paraffin embedded tissue sections stained with Hematoxilin and Eosin. Clonogenic colony assays were performed in cytokine-supplemented methylcelluiose (StemCeil Technoiogies ). 25,000 C57B1/6 BM wildtype BM cells or 25,000 ceils from leukemic mice were plated. Colony numbers were assessed 7 days post seeding. For re -plating experiments, cells were washed with PBS, counted, and plated as described above.
[001017] Immunoblots: Nucleated C57B1/6 wildtype BM ceils or leukemic BM ceils were lysed with RIPA buffer (Pierce) supplemented with Halt Protease Inhibitor (Pierce). Protein concentrations were determined using Bradford protein assay (Bio-Rad). Equal protein amounts were separated by SDS-PAGE and blotted on nitrocellulose membrane, blocked with fat free milk and incubated with primary antibodies (Cell Signaling; Ezh2 clone D2C9; Smc3 clone D47B5; phospho-Erkl/2 (phospho-p44/42) clone D13.14.4E; Erkl/2 (p44/42) clone 137F5). Mouse beta -actin was obtained from Satnta Cruz (clone C4). After washing blots were incubated with HRP -conjugated secondary antibody and developed using SuperSignai West Pico Chemiluminescent Substrate (Pierce).
[001018] Statistical analysis: Statistical analysis w¾s performed with GraphPad Prism software (Graphpad Software). Data is are shown as the mean with standard error of the mean. Groups were compared using an unpaired t-test. Normal distrib tion was assumed. Differences in variance were analyzed using an F-test. Welch correction for t-test was applied for unequal variances and is indicated.
272
90.1 [001019] Next Generation Sequencing to Assess Mutational Repertoire: gDNA was isolated using a DNA Blood Mini kit (Quiagen) according to manufacturers instructions. The genomic region flanking the CR1SPR target site for each region was amplified by a nested PGR to attach the Ulumina adapters in the first round and to add barcodes unique for each individual mouse in the second PGR. All libraries were pooled and purified using Agencourt AMPure XP system (Beckman Coulter), Single end, 300 cycle sequencing was performed using MiSeq (Illumina). Reads were adapter trimmed and aligned using BLAT to reference amplicon sequences. Indeis were surveyed using Integrative Genomics Viewer.
[001020] Generation of human isogenic cancer ceil lines is of particular interest for pharmaceutic industry and Applicants provide further data on the transformation of human cancer cell lines (Fig, 74). The lentiviral vectors for deliver}' of Cas9, sgRNA and marker gene have been described by applicants previously in this application. The GM-CSF dependent human erythroleukemia cell line was obtained from ATCC and grown in RPMI supplemented with 10% FBS and 2ng ml human GM-CSF. TF 1 cells were transduced with lentiviral CRISPR-Cas constructs in the presence of 4ug Polybrene. Seven days post transduction ceils were washed three times with DMEM to remove the GM-CSF. Washed cells were counted using a Beckman/Coulter Vi-Cell and seeded at a density of 2χ10Λ5 cells per ml in 12-well plates (2.5ml per well) in RPMI with 10% FBS. Control vector transduced cells were seeded in RPMI with 10% FBS and in RPMI with 10% FBS and 2ng/ml GM-CSF as positive control Cells were counted over time using a Beckman/Coulter Vi-Cell and cumulative cell count was assessed
[001021 ] A listing of targeted genes and the spacer ot guide sequences used are as follows:
Figure imgf000274_0001
273
90.1 Targeted Gene Spacer
TP53 GCCATTGTTCAATATCGTCCG
TP53 GCACCAGCAGCTCCTACACCGG
TP53 GACGGAAACCGTAGCTGCCC
ASXL1 GTTCTCGGGCTGCCACGCCGA
ASXL1 G CTG G G C AG CG CTG CTATTCG
ASXL1 GGAAGGTCCGAGAGTTGATC
N F1 G A ATTACAG G G CTCGTCCA AC
N F1 GTCTG G G CTTGTCG G CAAATCG
N F1 GAACCCTTACGTTCACTGAC
WT1 GTAGCTGGGCGTCCCGTCGA
WT1 GGTTGGGGAACTGCGCCGCA
WT1 GATGCCGACCGTACAAGAGTC
PTEN GAACTTGTCTTCCCGTCGTGT
RU NX1 GACTGATCGTAGGACCACGGT
RU X1 GGTAGGTGGCGACTTGCGGT
RU NX1 GCTCAGGTTTGTCGGTCGAAG
SMC3 GTCATCTTCGTCCAGAACAG
SMC3 GTAGAGTGTATGACGAACGAA
SMC3 GGTGACCAAGTCAGCCATCG
[001022] References:
1. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine 368, 2059-2074 (2013).
2. Jinek, M. et al. A programmable dual-RNA- guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
3. Cong, L. et al. Multiplex genome engineering using CRTSPR/Cas systems. Science 339, 819-823 (2013).
4. Mali, P. et ai RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
5. Bogdanove, A.J. & Voytas, D.F, TAL effectors: customizable proteins for DNA targeting. Science 333, 1843-1846 (201 1).
6. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome editing. Nature biotechnology 30, 460-465 (2012).
7. Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31, 227-229 (2013).
8. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013).
274
90.1 9. Friedland, A.E. et al. Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nature methods 10, 741 -743 (2013).
10. Shan, Q. et al. Targeted genome modification of crop plants using a CRISPR-Cas system. Nature biotechnology 31, 686-688 (2013).
1 1. Wood, A.J. et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (2011).
12. Sander, J.D. et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nature biotechnology 29, 697-698 (2011).
13. Holkers, M. et al. Differential integrity of TATE nuclease genes following adenoviral and lentivirai vector gene transfer into human cells. Nucleic acids research 41, e63 (2013).
14. Hsu, P.D. et al. DNA targeting specificity of RNA -guided Cas9 nucleases. Nature biotechnology 31, 827-832 (2013).
15. Fellmann, C. et ai. Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Molecular cell 41 , 733-746 (201 1).
16. Lee, B.H. et al. FLT3 mutations confer enhanced proliferation and survival properties to muitipotent progenitors in a murine model of chronic myeiomonocytic leukemia. Cancer ceil 12, 367-380 (2007).
17. Kelly, L.M. & Gilliland, D.G. Genetics of myeloid leukemias. Annual review of genomics and human genetics 3, 179-198 (2002).
18. Tanaka, S. et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107-11 17 (2012).
19. Challen, G.A. et al. Dnmtlia is essential for hematopoietic stem cell differentiation. Nature genetics 44, 23-31 (2012).
20. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self- renewal and myeloid transformation. Cancer cell 20, 1 1 -24 (201 1 ).
21. Quivoron, C. et al TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer cell 20, 25-38 (201 1 ).
22. Mead, A.J. et al. FLT3-TTDs instruct a myeloid differentiation and transformation bias in lymphomyeloid muitipotent progenitors. Ceil reports 3, 1766-1776 (2013).
23. Cong, L. et al Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
275
90.1 24. Hsu, P.D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827-832 (2.013).
25. Sehambaeh, A. et al. Equal potency of gammaretrovirai and lentiviral SIN vectors for expression of 06-methylguanine-DNA methyitransferase in hematopoietic cells. Molecular therapy : the journal of the American Society of Gene Therapy 13, 391 -400 (2006).
26. Kim, J.H. et al High cleavage efficiency of a 2A peptide derived from porcine teschovims-1 in human cell lines, zebrafish and mice. PloS one 6, el 8556 (201 1 ).
27. Morozova, K.S. et al. Far-red fluorescent protein excitable with red lasers for flow cytometry and superresolution STED nanoscopy. Biophysical journal 99, L 13 - 15 (2010).
28. Lee, B.H. et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer ceil 12, 367-380 (2007).
Example 37: Generation of in vivo murine models of myeloid malignancy with combinatorial genetic lesions using CRISPR/Cas genome editing (II)
[001023] Recent genome sequencing efforts have demonstrated that human malignancies commonly bear mutations in four or more driver genes. (Ref. 1) Murine models of these recurrent mutations have yielded insights into the biology and treatment of cancer, but it has not yet been possible to engineer primary cells that recapitulate the genetic complexity of human disease. Mice bearing combinations of three or more genetic lesions are exponentially more difficult to generate through breeding. Recent advances in genome editing technologies now offer the potential to overcome these limitations. (Ref. 2-4) Using a lentiviral small guide RNA (sgRNA):Cas9 deliver}' system Applicants modified up to five genes in a. single murine hematopoietic stem cell (HSC) in vivo, leading to clonal outgrowth and myeloid malignancy. sgRNA:Cas9 genome editing, e.g., vector-delivered, such as Lentivirus-delivered sgRNA:Cas9 is a powerful tool for the engineering of in vivo cancer models reflecting the complexity of human disease.
[001024] Transcriptional Activator Like Effector Nucleases (TALENs), and more recently CRISPR-Cas have been developed for the targeted editing of genomic loci (Ref. 2-6). E. REF 2 Both systems have been successfully used to engineer the genomes of multiple model organisms, (Ref. 7- 12) Primary hematopoietic stem and progenitor ceils (HSPC), the disease-initiating cell populations for myeloid malignancies, are difficult to
276
90.1 target with commonly used gene transfer methods. Viral vectors derived from HIV-1 are currently the most efficient gene delivery tools, but their application for the delivery of TALENs has been restricted due to the highly repetitive nature of the introduced proteins, leading to recombination of the vectors, (Ref. 13) The Streptococcus pyogenes cas9 gene (Cas9), which does not contain such highly repetitive sequences, has recently been adapted for specific DNA targeting in mammalian cells, (Ref. 2-4) and is therefore amenable to expression from lentiviral vectors.
[0ΘΤ025] Towards the goal of modeling myeloid malignancies using genome editing of primary HSPCs in vivo, Applicants generated a modular lentiviral sgRNA:Cas9 vector (Figure 75A and Figure 78). This lentiviral vector simultaneously delivers the Streptococcus pyogenes cas9 gene, a previously described chimeric sgRNA, and a fluorescent marker. (Ref. 2, 3, .14) This enables the targeting of any genomic locus in a broad range of cell types, and consequent NHEJ -mediated gene disruption, by a one-step exchange of the target site (spacer).
[0Θ1026] Applicants sought to model loss-of-function mutations in 8 genes that are recurrently inactivated in myeloid malignancies (Tet2, Runxl, Dnmt3a, Ezh2, Nfl , Smc3, p53 and Asxll) using lentiviral sgRNA:Cas9 vectors. Applicants validated the targeting efficacy using a fluorescent reporter harboring up to 20 sgRNA:Cas9 target sites as an alternative approach to commonly used endonuclease assays (Figure 75A/75B, and herein Data & Methods). At least one effective sgRNA was identified for 6 genes (Figure 75C). Results for two spacers were confirmed by the standard T7 endonuclease assay, validating efficient cutting at genomic loci (Figure 75D). These findings demonstrate that Applicants lentiviral system achieves efficient cleavage of target sites, and that engineered fluorescent reporter cell lines can provide rapid, quantitative evaluation of spacer efficacy.
1001027] Having demonstrated the efficiency of the lentiviral delivery system in vitro. Applicants examined whether Applicants could engineer the genomes of primary murine HSPCs in vivo. Applicants isolated Lineage-/Scal+/cKit+ (LSK) cells, which are enriched for HSPC activity, from mice with knock-in of the Flt3 internal tandem duplication (Fit.3-ITD) mutation. (Ref. 15) While FH3-ITD mutations frequently occur in acute myeloid leukemia (AML), Flt3-ITD knock-in is insufficient to cause AMI. in mice, and Applicants hypothesized that additional co-operating oncogenic lesions would induce transformation. Heterozygous Flt3-ITD expressing LSK cells were transduced with eGFP- expressing sgRNA:Cas9 lentiviral vectors targeting the Runxl gene or a non-targeting sgRNA (Figure 75.A), and were then transplanted into lethally irradiated wild-type (WT)
277
90.1 congenic recipient mice. In serial analysis of the peripheral blood of recipient mice. Applicants found that the population of cells expressing Cas9 and the Runxl sgRNA expanded significantly over a period of 19 weeks in comparison to the population of cells expressing Cas9 and the non-targeting sgRNA (p=0.03), thus indicating that loss of Runxl may induce a growth advantage in heterozygous FH3-ITD expressing cells in vivo (Figure 75E, Figure 79A).
[001028] Detection of eGFP -positive ceils at 19 weeks post-transplant in all HSPC compartments indicated that Applicants transduced long-term repopulating HSCs (Figure 75E and Figure 79B and 79C). Stable expression of Cas9-eGFP over the 19 weeks in HSPCs and normal differentiation capacity indicates that continuous Cas9 expression at the levels provided does not cause significant toxicity in hematopoietic ceils (Figure 80). As further validation of genome modification of HSCs, Applicants performed deep sequencing of the genomic sequence targeted in Runxl in peripheral blood at serial time points. Applicants identified at least 16 distinct insertions or deletions at the targeted Runxl site in peripheral blood harvested 5 weeks post-transplant that were also present in blood 19 weeks post-transplant (Figure 81). The majority of genome modifications were deletions ranging from l-251bp. Overall, these results demonstrate that lentiviral delivery of the sgRNA: Cas9 system in HSCs is feasible and well tolerated, and that this system can be employed to edit the genomes of HSCs to interrogate gene function in hematopoiesis.
[001029] Since myeloid malignancies, and cancer more broadly, are caused by multiple cooperating genetic lesions (at least 3-4 oncogenic lesions in AML(Ref. 1)), Applicants next sought to perform multiplex targeting of cancer-associated genes to induce myeloid malignancy. To facilitate multiplex genome editing, Applicants generated a two-vector system in which Cas9 and an eGFP are delivered from one lentiviral vector, while additional sgRNAs and a RFP657 fluorescent marker are delivered by a second lentiviral vector (Figure 76.A). The small size of the sgRNA-only vector enables high viral titers and introduction of multiple sgRNAs into a single LSK cell.
[001030] Applicants generated a pool of vectors with the single most effective sgRNA for the Tet2, Runxl, DnmtSa, Nfl, Ezh2, and Smc3 genes. Transduction of LSK ceils from C57BS/6 wild-type mice with the pooled virus, following transplantation into lethally irradiated recipient mice, caused significant myeloid skewing of hematopoiesis (p=0.007) with reduction of B-cells (p:O.()01) within the transduced cell population, and leukocytosis in some mice, as compared to the control group that received LSK cells transduced with control vectors expressing Cas9 and a non-targeting sgRNA (Figure 76B).
278
90.1 [0Θ1031 ] To detennine the efficacy of multiplex genome editing and to assess the selective pressure for combinations of mutations Applicants examined the genetics of putative clones in the peripheral blood of mice. Since Applicants used pooled vims expressing different sgRNAs, transduced cells bear different combinations of mutations, and cells with a genotype that drives a competitive advantage would gain a clonal dominance as occurs naturally during leukemogenesis. Two-dimensional flow cytometry analysis of eGFP and RFP657 allowed Applicants to detect putatively clonal hematopoietic expansion in vivo (Figures 76C and 76D, Figure 82), though some clonal, mutated populations were only GFP dim (Figure 83 and 84).
[001032] For two mice, Applicants purified populations from peripheral blood based on their eGFP/RFP657 density profile (red gated), by fluorescence-activated cell sorting (FACS) (Figure 76C and 76D). Applicants examined the targeted genes by PGR amplification, sub-cloning and sequencing of targeted gene regions. In one mouse, a. population expanded gradually over 12 weeks that had mutations in Tet2, DnmtSa, Runxl, and Nfl (Figure 76C, Figure 85A), while no mutations in Ezh2 and Smc3 were detected. In a second mouse, a population expanded rapidly after transplantation with mutations in Tei2, Runxl, Nfl and Ezh2 (Figure 76D, Figure 85B), and no mutations in DnmtSa and Smc3. In both cases, the detected mutational pattern (detection of two allele variants) strongly suggests that a single cell was transduced with four separate sgRNAs, resulting in modification of one or both alleles of four tumor suppressor genes. Despite expansion of these clonal populations, no transformation to acute leukemia was observed in these mice during the observation period of up to 30 weeks.
[001033] Transformation to acute leukemia was observed in a different mouse transduced with the same pool of sgRNAs. A clonal population was detected at 4 weeks post-transplant, and the mouse was euthanized at 6.5 weeks post-transplant with mild leukocytosis (white blood cell (WBC) count: 15.3xl 0 ml; normal: 5-!0xl06/ml) and splenomegaly (436 nig; normal: 80-120mg). The cells were skewed to the myeloid lineage (Grl+/CDl lb+) (Figure 77A left panel) with 85% of cells expressing the sgRNA:Cas vectors (Figure 77A right panel). Analysis of the targeted genes revealed deletions in DnmtSa, Ezh2, SmcS and Nfl (Figure 86). Leukemic cells showed enhanced re-plating capacity and analysis of methylceilulose colonies from the leukemia confirmed that all mutations occurred within a single clone (Figure 87, Example 37 Table 2). The peripheral blood from these mice revealed increased granulocytes and circulating blasts, indicative of leukemic transformation (Figure 77B, left panel). Bone marrow histology revealed greater
279
90.1 than 20% blast cells and suppression of normal differentiation (Figure 77B, right panel. Figure 88A, Figure 92), consistent with acute myeloid leukemia (AML).
[001034] Applicants next confirmed that the detected mutations had an impact on protein expression and cellular phenotype. Both Ezh2 and Smc3 protein expression were markedly reduced, consistent with the bi-allelie mutations detected in both genes. Nfl is a negative regulator of the Ras pathway, and Applicants observed de-repression of the downstream targets, Erkl and Erk2, as expected for cells with inactivation of Nil (Figure 77C). Serial re-plating of FACS-purified, double positive eGFP/RFP657-expressing cells indicates increased self-renewal capacity compared to wild-type C57B1/6 BM cells (Figure 87). Following transplantation into sub-Iethally irradiated secondary recipient mice Applicants observed robust engraftment of the GFP/RFP657 double positive mutated cells (Figure 88B). At 8 weeks post-transplant two out of five recipient mice developed leukocytosis and succumbed to leukemia at 1 1-12 weeks post transplant (Figure 88C/D). Mutated cells in ail mice showed a strong differentiation bias, with >90% of the cells belonging to the myeloid lineage (Figure 77D and E). Bone marrow pathology confirmed AMI, in the secondary recipients (Figure 77F, Figure 88E).
[001035] At 14 weeks following transplantation with the pool of tumor suppressor- targeting sgRNA pooled lentivirus, another primary mouse succumbed to a distinct myeloid leukemia characterized by splenomegaly (412mg), leukocytosis (WBC: 33.6xl 0°/ml), excess myeloid cells in the BM (Figure 89 A), circulating blasts in peripheral blood, and diagnostic features of AML in the bone marro (>20% blasts) (Figure 89B). Clonal mutations were identified in Tet2, DnmtSa, Runxl, Nfl, and E∑h2. None of the mice transplanted with non-targeting sgRNA expressing cells developed disease during the course of the experiment (Figure 90). These studies demonstrate that by- using lentiviral delivered sgRNA: Cas9 components, Applicants have engineered novel models of myeloid malignancy bearing mutations in 4-5 different genes that can be propagated and studied through serial transplantation.
[001036] To examine an alternative set of co-operative mutations, the same pool of sgRNAs targeting leukemia tumor suppressor genes was used to transduce LSK cells from mice with, heterozygous knock-in of the Fk3-ITD oncogene allele. Targeting of Rural alone did not induce transformation of FH3-ITD heterozygous expressing cells (Figure 75D). Consistent with the results of pooled tumor suppressor gene targeting in wild-type C57B1/6 mice, expansion of sgRNA:Cas9-transduced, Flt3-ITD-expressing cells was observed over time. In some mice, expression of the sgRNA :Cas9 vector was GFP-dim at
280
90.1 8-10 weeks (Figure 91). A total of five out of nine (55%) mice developed disease at 10-16 weeks with leukocytosis and splenomegaly (Figure 92). Three of the mice were analyzed further. Bone marrow flow cytometry demonstrated that cells were myeloid biased in each of these mice (Figures 93 A, 94A, 95 A). Diagnostic features of AML were evident with an excess of myeloblasts (>20%) in the bone marrow and circulating blast cells in the peripheral blood (Figures 93B, 94B, 95B). Clonal mutations were detected in 3 -5 genes in the three mice (Figures 93C, 94C, 95C). Since the mutations were engineered in the F 3- ITD heterozygous background, AML was generated from primary cells with mutations in 4 to 6 leukemia driver genes.
[001037] As off-target cleavage by Cas9:sgRNA could potentially contribute to leukemogenesis, Applicants examined leukemias Applicants generated for off-target genome editing. (R.ef. 14, 16) Applicants performed targeted sequencing of the top five off-target sites for each of the sgRJS!As in each of 4 leukemias. None of the off-target sequences had any mutations in any of the leukemias examined, indicating that off-target cleavages are unlikely to be a significant contributor to leukemogenesis in Applicants' studies (Example 37 Tables 3 and 4).
[001038] Taken together, these studies of ientivirus-delivered Cas9:sgRNA with multiplex sgRNAs demonstrate highly efficient genome editing in murine HSPCs. Applicants simultaneously inactivated multiple tumor suppressor genes causing outgrowth of a myeloid clone and transformation to acute leukemia. Applicants describe models with up to 5 genes modified, with editing of up to 10 individual alleles, when a pool of sgRMAs targeting 6 genes was introduced in primary HSPCs (Figure 77G), While genetic models have recently been generated using Cas9:sgRNA in whole organisms (Ref. 7-9), Applicants' system enables tissue specific interrogation of gene function in adult organisms while avoiding potential developmental defects. The genetic complexity thus generated is beyond the capacities of current approaches for engineering murine malignancies and will allow rapid generation of novel disease models beyond hematopoietic malignancies. Such models are critical for the functional interrogation of novel disease alleles and for the development and pre-clinical testing of targeted therapies.
[001039] The novel leukemia models generated reflect both the number and functional classes of co- occurring mutations that occur during the pathogenesis of human myeloid malignancies. (Ref. 1, 17) All of the clones characterized had inactivating mutations in Nil, a lesion that activates Ras signaling, and the only mutation in the screen that causes activated kinase signaling, a common feature of leukemias and other cancers. (Ref. 17)
281
90.1 Although NF1 mutations are not frequent in AML patients, it was chosen as an amendable target for NHEJ mediated gene editing and representative for cytokine activation in AML. Nfl inactivation in mice, however, is insufficient to cause AML and induces a long- latency myeloproliferativen disease.(Ref. 18) Applicants also identified mutations in Ezh2, a gene recently shown to be involved in the differentiation block in AMI. (Ref 19), in all mice that presented with myeloid transformation. Inhibition of myeloid differentiation has also been reported after deletion of Dnmt3a R.Qt 20), 7¾2(Ref. 21 , 22) and Runxl Re 23) each of which were successfully mutated in Applicants models,
[0Θ1040] Overall, Applicants studies demonstrate a robust methodology to generate multiple genetic lesions via lentivirus-delivered Cas9:sgRNA in a broad range of cells, including the primary adult stem cells that are the disease-initiating population for leukemia. The use of viral-based Cas9:sgRNA will enable the rapid and efficient generation of cancer models that reflect the complex genetics of human disea se.
[001041] Methods and Data
[0Θ1042] For evaluation of sgRNA~Cas9 efficacy Applicants developed a modular reporter system based on disruption of the reading frame of a fluorescent protein (RFP657) (Figure 75A). Reporter fluorescence is lost upon out-of-frame deletion/insertion after NHEJ thus not detecting all cleavage events, however, for studies based on NHEJ mediated gene disruption these out of frame deletions/insertions are relevant and the reporter therefore provides a precise measurement of gene disruption events.
[001043] Off note, similar approaches using disruption of a fluorescent protein coding sequence have been used before for evaluation of genome editing or RNA interference tools and allow more rapid and quantitative testing of cleavage efficiency than standard T7-endonuclea.se assays. (Ref. 24) In contrast, others have used homologous recombination to evaluate the cleavage efficacy of CRISPR-Cas9 or sgRNA-Cas9 systems, which is also limited in detection of cleavage efficacy, in particular when transfection rates are not provided.(Ref 25)
[001044] In Applicants' approach to model myeloid malignancy, Applicants used this reporter assay to establish high efficacy sgRNAs for 8 genes that are recurrently mutated in myeloid malignancies (Tet2, Runxl , Dnmt3a, Ezh2, Nfl , Smc3, p53 and Asxl l). The chosen genes have been described as leukemia promoting loss-of-function mutations and have been found co-mutated in various combinations.
[001045] Off note, Wang and colleagues used an efficient Tet2 target site to generate sgRNA:Cas9 based knock-out mice, which was located in the same exon as the one used
282
90.1 in Applicants' study. (Ref. 26) As its efficacy was proven, future studies may use sites described here or by Wang and colleagues.
[001046] Applicants tested an average of 3 spacers per gene and found that about 60% of the spacers could reduce the Mean Fluorescence Intensity (MFI) of the reporter by more than 20%. About 30% of the sgRNAs reduced the MFI by more than 50%, thereby- exceeding formerly published cleavage efficacies of TALENs (Figure 75C), Comparison of Applicants' results for Cas9 cleavage efficacy is hampered by differences in applied methods. Former studies mostly employed transient transfection with limited information about transfection efficacies. The use of lenti viral deliver}' may increase the efficacy of sgRNA:Cas9 genome editing due to prolonged expression. At the transduction rates achieved in Applicants' study (<30%) one can assume to be in a 1-2 vector copy number per cell. The employed EFS promoter delivers relatively low expression of the Cas9-eGFP cassette. This is in contrast to studies using transfection (which results in a high copy number per cell) and strong viral promoters.
[001047] Variance of efficacy between spacers as seen in Applicants' study has been observed before and may be attributed to recently published criteria on optimal spacer design.(Ref 27,28)
[001048] Beside variances detected, efficient cleavage for all pre -tested spacers was detected in-vivo (Figure 83,85,86,89,93,94,95). Analysis of mutations from mouse samples showed that NHEJ in murine hematopoietic cells primarily causes deletions. Deletion size was variable ranging from 1 bp to 251 bp. The majority of mutations were between 1-40 bp. The cell type used and its particular DNA repair preferences may however influence the spectrum of mutations that occur.
[001049] Larger deletions than the ones detected may occur but detection is limited with PGR based approaches.
[001050] Subsequent analysis of cleavage at off-target sites did not detect mutations at these sites in line with former publications showing abrogation of Cas9 cleavage when spacers have three or more mismatches to the genomic site.
[001051 ] One concern when using integrating viral vectors is the accidental activation of nearby oncogens, which may cause leukemia or contribute to leukemia development. (Ref. 29 ) In Applicants' study a self-inactivating lentiviral vector with a. eukaryotic EFS promoter was used. Both the use of self-inactivating vectors with internal promoters and the use of physiological promoters strongly reduces the risk of insertionai mutagenesis.
283
90.1 (Ref. 30) It is therefore unlikely that vector integration has contributed to leukemia development in Applicants' study.
[001052] Materials & Methods
[001053] Vector construction and viral particle production
[001054] Lenti viral vectors were based on the pLKO_TRC005 lentiviral backbone. The codon optimized Streptococcus pyogenes Cas9 (SpCas9) cDNA and small guide RNA (sgRNA) have been described before. (Ref. 28) The sgRNA was amplified from the pLX330 backbone and placed behind the human U6 promoter of the pLKO_TRC005. Vectors expressing only Cas9 and no sgRNA were generated by deleting the hU6 promoter. Bbsl sites were replaced by BsmBI sites for insertion of the spacer sequence. The hPGK promoter of the pLKO TRC005 was replaced by a minimal size hEFl a promoter (EFS).(Ref. 32) To generate vectors expressing Cas9 only, the hU6 promoter was deleted from the pLKO TRCG05 backbone by cutting PpuMl/EcoRI followed by Klenow fragment fill-in reaction and ligation. SpCas9 cDNA was PGR amplified (Phusion DNA Polymerase, NEB) and placed behind the EPS promoter followed by addition of P2A-eGFP, P2A-tagRFP, P2A-PAC or P2A-BSD. Optimized piconia virus 2A sites have been described before (Ref. 33) and were fused to respective cDNAs via PGR, The sgRNA-only vectors were generated by replacing the SpCas9 and respective marker gene with a fluorescent protein marker, or selection marker only. The RFP657 fluorescent protein was described before. (Ref. 34)
[001055] Suitable protospacer sequences were identified as described before with unique 13bp seed sequence and a minimum of .3 mismatches to the mouse genome. (Ref. 23) [0Θ1056] Lentiviral reporter vectors were generated by replacing the eGFP fluorescent reporter gene in the RRL.PPT.SFFV.IRES.eGFP.pre* (kindly provided by Christopher Baum and Axel Schambach, Hannover Medical School, Hannover, Germany) with PAG, followed by insertion of the RFP657 fluorescent reporter gene 5' of the IRES. CRISPR'Cas target sites were introduced behind the start codon of the RFP657.
[001057] Lentiviral particles were produced by transient transfection of 293T cells using the calcium-phosphate transfection method. Viral constructs were co-transfected with pMD2.G (Addgene plasmid 12259) and psPAX2 (Addgene plasmid 12260) (both kindly provided by Didier Trono., EPFL, Lausanne, Switzerland). Lentiviral particles were concentrated using ultracentrifugation.
[001058] Oligonucleotide sequences used for the cloning of CRISPR/Cas protospacers used in this study are shown in Example 37 Table 1.
284
90.1 [001059] Reporter based efficacy assessment of CRISPR/Cas spacer sequences
[0Θ1060] Fluorescent reporter vectors were constructed and produced as described above. EEL cells (ATCC) were cultured in RPMI with 10% FBS and 100 U/ml Penicillin/Streptomycin, HEL cells were transduced with CRISPR/Cas reporter vectors in the presence of 4ug/ml hexadimethrine bromide (Polybrene (Life Technologies)) and transduced ceils were selected with 2ug/mi Puromycin (Life Technologies) for 72h, starting 48h post transduction. Selection was verified by flow cytometry. Selected reporter cell lines were transduced with CRISPR/Cas vectors targeting the respective target sites and non-targeting controls. RFP657 reporter fluorescence was assessed by flow cytometry at 6 days post transduction in comparison to non-targeting controls and untransduced cells.
[001061] T7-endonuciease assay
[001062] Ba/F3 cells (DSMZ) were cultured in RPMI with 10% FBS, 100 U/ml Penicillin/Streptomycin and 5 ng ml 113 (Peprotech). Ba/F3 ceils were transduced with CRISPR/Cas vectors, and transduced cells were purified by FACS 7 days post-infection. Genomic D A was isolated according to manufacturers instruction with a DNA Micro Kit (Quiagen). Targeted loci were amplified by PGR (Phusion DNA Polymerase, NEB). CRISPR/Cas efficacy at the endogenous locus was assessed using the Surveyor Mutation Detection Kit (Transgenomic).
[001063] Mouse bone marrow transplant and analysis
[001064] Total BM was isolated from femurs and tibias from 6-10 week old female C57B1/6 mice or heterozygous 6-12 week old Flt3-ITD knock-in mice.35 BM was subjected to erythrocyte lysis (BD PharmLyse, BD Bioscience), followed by magnetic bead selection of cKit (GDI 17) positive cells using GDI 17 MicroBeads (Milteny Biotech). CD 1 17 selected ceils were stained with APC labeled cKit (eBioscience), PE labeled Seal (BioLegend) PacificBlue labeled Grl, GDI l b, B220(CD45R), Terl l9, and CD3 (all BioLegend) and then flow sorted on a BD FACS Aria II. LSK cells were cultured in StemSpan SFEM (StemCeil Technologies) supplemented with 50ng/ml murine Thpo and 50ng murine Scf (both Peprotech) for 48h and then transduced with concentrated lentiviral supernatant in presence of 2ug/mi Polybrene. 24h post transduction cells were collected and intravenously injected into lethaliy irradiated (950 cGy) 6-10 week old female C57B1/6 mice. C57B1/6 mice were obtained from Taconie. Fit3 -LTD mice were bred in local facilities.
[001065] All transplant experiments were performed with 4-5 mice per group. Statistical significance between groups was assessed using an unpaired t-test.
285
90.1 [0Θ1066] No blinding and no randomization were carried out.
[0Θ1067] Experiments and procedures were performed in the Children's Hospital Boston animal facility and were approved by the Children's Hospital Boston Institutional Animal Care and Use Committee.
[001068] Peripheral blood was sampled by retro-orbital bleeding. Bone marrow was harvested from femurs and tibias. Nucleated ceils were obtained by erythrocyte lysis, [001069] To detect mature lineage markers, cells were stained with Grl -APC-eFluor780 (eBioscience), CDl lb-APC (BioLegend), B220(CD45R)-PE-Cy7 (BioLegend) and CD3e- PE (eBioscience). HSPCs were stained with PacificBlue labeled Grl, GDI lb, B220(CD45R), Terl l9, and CD3 (all BioLegend), Scal-PE (BioLegend), CD15Q-PE-Cy7 (BioLegend), cKit-APC (eBioscience), CD48-PerCP-Cy5.5 (eBioscience), and CD34- AlexaFluor700 (eBioscience). Flow cytometry was performed on a ΒΓ) LSR II flow cytometer. Cells expressing both the eGFP and RFP657 reporter gene were stained with Grl-PE-Cy7 (eBioscience) and CDl l b-PE (BioLegend) or B220(CD45R)-PE-Cy7 and CD3e-PE for mature lineage detection.
[001070] To assess mutations at targeted loci, peripheral blood nucleated cells were purified by FAGS. Genomic DNA was isolated according to manufacturers instruction with a DNA Micro Kit (Quiagen). Targeted loci were amplified by PGR (Phusion DNA Polymerase, NEB). PGR products were cloned into pJetl .2 PGR cloning vector (Life Technologies). Plasmid DNA was isolated from individual bacterial clones with a DNA Plasmid Mini Kit (Quiagen) and sequences were assessed by Sanger sequencing.
[001071] Secondary transplant of leukemic mice was performed by transplanting 5χ10Λ6 primary BM cells into sub-lethally (650cGy) irradiated C57B1/6 mice.
[001072] Peripheral blood semars were stained with May-Gruenwald/Giemsa stain. BM histology was assessed from paraffin embedded tissue sections stained with Hematoxilin and Eosin.
[001073] Cionogenic colony assays were performed in cytokine-suppiemented methylcellulose (M3434; StemCell Technologies). 25,000 C57B3/6 BM wildtype BM cells or 25,000 cells from leukemic mice were plated. Colony numbers were assessed 7 days post seeding. For re-plating experiments, cells were washed with PBS, counted, and plated as described above.
[001074] Immunoblots
[001075] Nucleated C57B1/6 wildtype BM cells or leukemic BM ceils were iysed with RIP A buffer (Pierce) supplemented with Halt Protease Inhibitor (Pierce). Protein
286
90.1 concentrations were determined using Bradford protein assay (Bio-Rad). Equal protein amounts were separated by SDS-PAGE and blotted on nitrocellulose membrane, blocked with fat free milk and incubated with primary antibodies (Cell Signaling; Ezh2 clone D2C9; Smc3 clone D47B5; phospho-Erkl/2 (phospho-p44/42) clone D13.14.4E; Erkl /2 (p44/42) clone 137F5). Mouse beta actin was obtained from Santa Cruz (clone C4). After washing blots were incubated with HRP --conjugated secondary antibody and developed using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
[001076] Statistical analysis
[001077] Statistical analysis was performed with GraphPad Prism software (Graphpad Software). Data are shown as the mean with standard error of the mean. Groups were compared using an unpaired, two sided t-test. Normal distribution was assumed. Differences in variance were analyzed using an F-test. Welch correction for t-test was applied for unequal variances as indicated.
[001078] Next Generation Sequencing to Assess Mutational Repertoire
[001079] gDNA was isolated using a DNA Blood Mini kit (Quiagen) according to manufacturers instructions. The genomic region flanking the CRISPR target site for each region was amplified by a nested PGR to attach the lilumina adapters in the first round and to add barcodes unique for each individual mouse in the second PGR. Ail libraries were pooled and purified using Agencourt AMPure XP system (Beckman Coulter). Single end, 300 cycle sequencing was performed using MiSeq (lilumina). Reads were adapter trimmed and aligned using BEAT to reference amplicon sequences. Indels were surveyed using Integrative Genomics Viewer.
[001080] Example 37 Table 1 - Target sites and efficacies
Figure imgf000288_0001
287
90.1
Figure imgf000289_0001
[001081 ] Example 37 Table 2 - Genotyping of methylcellulose colonies
Figure imgf000289_0002
288
90.1 PATENT
BI-2013/092 PCT; VP Docket No. 44790.99.2048 - Off-target sites of sgRNA target sites used for in-vivo studies
Figure imgf000290_0001
289
NEWYORK/#345390. !
[001083] Example 37 Table 4 - Percentages of mutated sequencereads at off-target sites
Figure imgf000291_0001
[001084] Off-target sites (column 1) are listed in Example 37 Table 3. Top row indicates where respective leukemias are presented. A C57BI/6 (WT) control was included.
[001085] References Ref 1. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. The New England journal of medicine 368, 2059-2074 (2013); Ref 2. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012). Ref 3. Cong, L. et al. Multiplex genome engineering using CRiSPR/Cas systems. Science 339, 819-823 (2013). Ref. 4. Mali, P. et al. R A -guided human genome engineering via Cas9. Science 339, 823-826 (2013). Ref 5. Bogdanove, A.J. & Voytas, D.F. TAL effectors: customizable proteins for D'NA targeting. Science 333, 1843- 1846 (2011). Ref 6. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome editing. Nature biotechnology 30, 460-465 (2012). Ref 7. Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature biotechnology 31 , 227-229 (2013). Ref 8. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR Cas-mediated genome engineering. Cell 153, 910-918 (2013). Ref 9. Friedland, A.E, et al. Heritable genome editing in C. eiegans via a CR1SPR-Cas9 system. Nature methods 10, 741 -743 (2013). Ref 10. Shan, Q. et al. Targeted genome modification of crop plants using a CRISPR-Cas system. Nature biotechnology 31, 686-688 (2013). Ref I I . Wood, A.J. et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (201 1). Ref. 12. Sander, j.D. et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nature biotechnology 29, 697-698 (2011). Ref. 13. Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic acids research 41, e63 (2013). Ref. 14. Hsu, P.D. et al, D'NA targeting specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827-832 (2013). Ref. 15. Lee, B.H. et al. FLT3 mutations confer enhanced proliferation and survival properties to multi potent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer cell 12, 367-380 (2007). Ref. 16. Fu, Y. et al. High- frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature biotechnology 31 , 822-826 (2013). Ref. 17. Kelly, L.M. & Giliiland, D.G. Genetics of myeloid leukemias. Annual review of genomics and human genetics 3, 179-198 (2002). Ref. 18. Zhang, Y., Taylor, B.R., Shannon, K. & Clapp, D.W. Quantitative effects of Nfl inactivation on in vivo hematopoiesis. The Journal of clinical investigation 108, 709-715 (2001), Ref. 1 . Tanaka, S. et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107-1117 (2012). Ref. 20. Challen, G.A. et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nature genetics 44, 23-3 1 (2012). Ref. 21. Moran-Crasio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell 20, 11-24 (201 1). Ref. 22. Quivoron, C. et al. TET2 inactivation results in pieiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer cell 20, 25-38 (201 1). Ref. 23. Mead, A.J. et al. FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid muitipotent progenitors. Cell reports 3, 1766-1776 (2013), Ref 24. Reyon, 13. et al. FLASH assembly of TALENs for high-throughput genome editing. Nature biotechnology 30, 460-465 (2012); Ref 25, Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Ref 26. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRJSPR/Cas-mediated genome engineering. Cell 153, 910-918 (2013); Ref 27. Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014); Ref 28. Cong, L. et ai. Multiplex genome engineering using CRJSPR/Cas systems. Science 339, 819-823 (2013); Ref 29. Li, Z. et ai. Murine leukemia induced by retroviral gene marking. Science 296, 497 (2002); Ref 30. Zychlmski, D. et ai. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Molecular therapy : the journal of the American Society of Gene Therapy 16, 718-725 (2008); Ref 31. Hsu, P.D. et ai. DNA targeting specificity of RNA-guided Cas9 nucleases. Nature biotechnology 31, 827-832 (2013); Ref 32. Schambach, A. et al. Equal potency of gammaret.ro viral and lenti viral SIN vectors for expression of 06~methyiguanine~DNA methyltransferase in hematopoietic ceils. Molecular therapy : the journal of the American Society of Gene Therapy 13, 391-400 (2006); Ref 33, Kim, J.H. et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice, PloS one 6, el8556 (2011); Ref 34. Morozova, K.S, et al. Far-red fluorescent protein excitable with red lasers for flow cytometry and superresolution STED nanoscopy. Biophysical journal 99, LI 3-15 (2010); Ref 35. Lee, B.H. et ai. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer cell 12, 367-380 (2007).
[001086] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention.
References
1 , Ding, Q. et al. A TALEN genome-editing system for generating human stem cell- based disease models. Cell Stem Ceil 12, 238-251 (2013). 2. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Ceil 146, 318-331 (201 1).
3. Carlson, D.F. et al. Efficient TALEN-mediated gene knockout in livestock. Proc Natl Acad Sci U 8 A 109, 17382-17387 (2012).
4. Geurts, A.M. et al. Knockout Rats via Embryo Microinjection of Zinc -Finger Nucleases. Science 325, 433-433 (2009).
5. Takasu, Y. et al. Targeted mutagenesis in the silkworm Bombyx mori using zinc finger nuclease mRNA injection, insect Biochem Molec 40, 759-765 (2010).
6. Watanabe, T. et al. Non-transgenic genome modifications in a hemimetaboious insect using zinc-finger and TAL effector nucleases. Nat Commun 3 (2012).
7. Porteus, M.H. & Baltimore, D. Chimeric nucleases stimulate gene targeting in human ceils. Science 300, 763 (2003).
8. Miller, J.C. et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol 25, 778-785 (2007).
9. Sander, J.D. et al. Selection-free zinc-finger-nuc lease engineering by context- dependent assembly (CoDA). Nat Methods 8, 67-69 (2011).
10. Wood, A.J. et al. Targeted genome editing across species using ZFNs and TALENs, Science 333, 307 (2011).
11. Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757-761 (2010).
12. Zhang, F. et al. Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. Nat Biotechnol 29, 149-153 (2011).
13. Miller, J.C. et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 29, 143-148 (2011).
14. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30, 460-465 (2012).
15. Boch, j. et al. Breaking the code of DNA binding specificity of TAL-type ill effectors. Science 326, 1509-1512 (2009).
16. Moscou, M.J. & Bogdanove, A.J. A simple cipher governs D'NA recognition by TAL effectors. Science 326, 1501 (2009). 17. Sanjana, N.E. et al. A transcription activator-like effector toolbox for genome engineering. Nat Protoc 7, 171 -192 (2012).
18. Deveau, H., Garneau, J.E, & Moineau, S. CRISPR-Cas system and its role in phage- baeteria interactions. Annu Rev Microbiol 64, 475-493 (2010).
19. Horvath, P. & Barrangou, R. CRISPR-Cas, the immune system of bacteria and archaea. Science 327, 167-170 (2010).
20. Makarova, K.S, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9, 467-477 (201 1).
21. Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea; versatile small RNAs for adaptive defense and regulation. Annu Rev Genet 45, 273- 297 (2011).
22. Cong, L. et al. Multiplex genome engineering using CRISPR-Cas systems. Science 339, 819-823 (2013).
23. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823- 826 (2013).
24. Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).
25. Cho, S.W., Kim, S., Kim, J.M. & Kim, J.S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232 (2013).
26. Garneau, J.E. et al. The CRISPR-Cas bacterial immune system cleaves bacteriophage and lasmid DNA. Nature 468, 67-71 (2010).
27. Jinek, M, et al. A programmable dual -RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012),
28. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A 109, E2579-2586 (2012).
29. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat Rev Genet 11, 636-646 (2010).
30. Hsu, P.D. & Zhang, F. Dissecting neural function using targeted genome engineering technologies. ACS Cheni Neurosci 3, 603-610 (2012). 31. Perez, E.E. et al. Establishment of HIV-1 resistance in CD4(+) T cells by genome editing using zinc-finger nucleases. Nat Biotechnoi 26, 808-816 (2008).
32. Cong, L. et al. Multiplex Genome Engineering Using CRISPR-Cas Systems. Science 339, 819-823 (2013).
33. Chen, F.Q. et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods 8, 753-U796 (201 1 ).
34. Bedell, V.M. et al. In vivo genome editing using a high-efficiency TALEN system. Nature 491 , 1 144 133 (2012).
35. Saleh-Gohari, N. & Helleday, T. Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res 32, 3683-3688 (2004).
36. Deitcheva, E. et al. CRISPR R.NA. maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602-607 (2011).
37. Sapranauskas, R, et al. The Streptococcus thermophilus CRISPR-Cas system provides immunity in Escherichia coli. Nucleic Acids Res 39, 9275-9282 (2011).
38. Hwang, W.Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system, Nat Biotechnoi 31, 227-229 (2013).
39. Wang, H. et al. One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR-Cas-Mediated Genome Engineering, Cell 153, 910-918 (2013),
40. Shen, B. et al. Generation of gene -modified mice via Cas9 RNA-mediated gene targeting. Cell Res 23, 720-723 (2013).
41 . Qi, L.S. et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173-1183 (2013),
42. Tuschl, T. Expanding small RNA interference, Nat Biotechnoi 20, 446-448 (2002).
43. Smithies, O., Gregg, R.G., Boggs, S.S., Koralewski, M.A. & Kucherlapati, R.S. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317, 230-234 ( 1985).
44. Thomas, K.R., Folger, .R.. & Capecchi, M.R. High frequency targeting of genes to specific sites in the mammalian genome. Cell 44, 419-428 (1986).
45. Hasty, P., Rivera-Perez, J, & Bradley, A. The length of homology required for gene targeting in embryonic stem cells. Mo I Cell Biol 11 , 5586-5591 (1991). 46. Wu, 8., Ying, G.X., Wu, Q. & Capecehi, M.R. A protocol for constructing gene targeting vectors: generating knockout mice for the cadherin family and beyond. Nat Protoc 3, 1056-1076 (2008).
47. Guschin, D.Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol Biol 649, 247-256 (2010).
48. Oliveira, T.Y. et al. Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements. J Immunol Methods 375, 176-181 (2012).
49. Deltcheva, E. et al CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III . Nature 471 , 602-607 (2011).
50. Bogenhagen, D.F. & Brown, D.D. Nucleotide sequences in Xenopus 58 DNA required for transcription termination. Cell 24, 261-270 (1981).
51. Buitmann, 8. et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res 40, 5368-5377 (2012).'"
52. Valton, J. et al. Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J Biol Chem 287, 38427-38432 (2012).
53. Christian, M. et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186, 757-761 (2010).
54. Mussolino, C. et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic acids research 39, 9283-9293 (201 1 ).
55. Bobis-Wozowicz, S., Osiak, A., Rahman, S.H. & Cathomen, T. Targeted genome editing in pluripotent stem cells using zinc-finger nucleases. Methods 53, 339-346 (2011).
56. Jiang, W., Bikard, D., Cox, D., Zhang, F. & Marraffini, L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 31, 233-239 (2013).
57. Michaelis, L.M., Maud "Die kinetik der invertinwirkung." . Biochem. z (1913).
58. Mahfouz, M.M. et al. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci U S A 108, 2623-2628 (201 1 )/
59. Wilson, E.B. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22, 209-212 (1927).
60. Tangri S, et al,, Rationally engineered therapeutic proteins with reduced immimogenicity, J Immunol. 2005 Mar 15 ; 174(6) : 3187-96.
61. REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J. 1991) 62. Lopes, V.S., etc al., Retinal gene therapy with a large MY07A cDNA using adeno- assocaited virus. Gene Ther, 2013 Jan 24. doi: 10.1038/gt 2013.3.[Epub ahead of print]
63. Kaplitt, M.G., et al., Safety and tolerability of gene therapy with an adeno -associated vims (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet. 2007 Jun 23;369(9579):2097-105.
64. Nathwani, A.C., et al, Adeno virus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoal 108046. Epub 201 1 Dec 10.
65. Gray SJ, Fori SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J, Ehlers MD, Zylka MJ, McCovvn TJ, Samulski RJ. Optimizing promoters for recombinant adeno- associated vims-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther. 2011 Sep;22(9): 1143-53. doi:
10. 1089 hum.20 Hi.245.
66. Liu D, Fischer I. Two alternative promoters direct neuron-specific expression of the rat microtubule-associated protein IB gene. J Neurosci. 1996 Aug 15;16(16):5026-36.
67. Levitt N. Briggs D, Gil A. Pro dfoot N.J. Definition of an efficient synthetic poly(A) site. Genes Dev. 1989;3: 1019-1025.
68. McClure C, Cole KL, Wulff P, Klugmann M, Murray AJ. Production and titering of recombinant adeno-associated viral vectors. J Vis Exp. 2011 Nov 27;(57):e3348. doi:
10.3791/3348.
69. Banker G, Gosiiii K. Developments in neuronal cell culture. Nature. 1988 Nov 10;336(6195): 185-6.

Claims

What is claimed is:
1. A method of inducing a proliferative condition in an organism comprising:
isolating a first population of cells from the organism,
transducing the first population of cells with a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising
1. a first regulatory element operably linked to a CRISPR-Cas system chimeric RNA. (chiRNA) polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
Π. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising at least one or more nuclear localization sequences (NLSs),
wherein (a), (b) and (c) are arranged in a 5 ' to 3 ' orientation,
wherein components I and II are located on the same or different vectors of the system,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence,
wherein the CRISPR complex comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the CRISPR enzyme alters the genome of the first population of cells to obtain a second population of cells, and
transplanting the second population of cells into the organism thereby inducing the proliferative condition.
2. A method of interrogating function of one or more genes in a proliferative condition in an organism comprising:
inducing the proliferative condition by a method comprising
isolating a first population of cells from the organism, transducing the first population of ceils with a non-naturally occurring or engineered composition comprising a vector system comprising one or more vectors comprising
I. a first regulatory element operably linked to a CRISP -Cas system chiRNA polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
II. a second regulatory element operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising zero or at least one or more NLSs,
wherein (a), (b) and (c) are arranged in a 5 ' to 3 ' orientation,
wherein components I and II are located on the same or different vectors of the system,
wherem when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence,
wherem the CRISPR complex comprises the CRISPR enzyme complexed with (I) the guide sequence that is hybridizableto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
wherein the CRISPR enzyme alters the genome of the first population of cells to obtain a second population of ceils,
transplanting the second population of cells into the organism thereby inducing the proliferative condition; and
determining changes in expression of the one or more genes in the proliferative condition thereby interrogating the function of one or more genes.
3. The method of claim 1 or 2, wherein the proliferative condition is a cancer.
4. The method of claim 3, wherem the first population of cells is a population of stem cells.
5. The method of claim 1 or 2, wherem the proliferative condition is a myeloid malignancy.
6. The method of claim 5, wherem the first population of cells is a population of hematopoietic stem and progenitor cells.
7. The method of claim 1 or 2, wherem the vector system is a lentivirai vector system,
8. The method of claim 7, wherein the first regulatory element is a U6 promoter.
9. The method of claim 7, wherein the second regulatory element is an EFS promoter.
10. The method of claim 1 or 2, wherein the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences.
1 1. The method of claim 1 or 2, wherem the target sequences are associated with tumor suppressor gene(s).
12. A non-natural !y occurring or engineered composition for generating an in vivo, in vitro or ex vivo proliferative condition comprising multiple genetic lesions in a population of cells comprising a lentivirai vector system comprising one or more lentivirai vectors comprising
I. a U6 promoter operably linked to a CRISPR-Cas system chiRNA polynucleotide sequence, wherein the polynucleotide sequence comprises
(a) three or more guide sequences capable of hybridizing to three or more target sequences in genome of the organism,
(b) a tracr mate sequence, and
(c) a tracr sequence, and
Π. a EFS promoter operably linked to an enzyme-coding sequence encoding a CRISPR enzyme comprising zero or at least one or more NLSs,
wherein (a), (b) and (c) are arranged in a 5 ' to 3 ' orientation,
wherein components I and II are located on the same or different vectors of the system,
wherein when transcribed, the tracr mate sequence hybridizes to the tracr sequence and the guide sequence direct sequence-specific binding of CRISPR complexes to the target sequence, and wherein the CRJSPR complex comprises the CRI8PR enzyme com lexed with (1) the guide sequence that is hybridizabieto the target sequence, and (2) the tracr mate sequence that is hybridized to the tracr sequence,
13. The composition of claim 12, wherein the proliferative condition is a cancer.
14. The composition of claim 12, wherein the population of cells is a population of stem cells.
15. The composition of claim 12, wherein the proliferative condition is a myeloid malignancy.
16. The composition of claim 12, wherem the population of cells is a population of hematopoietic stem and progenitor cells.
17. The composition of claim 12, wherem the polynucleotide sequence comprises 4, 5, 6, 7, 8, 9 or 10 guide sequences.
18. The composition of claim 12, wherein the target sequences are associated with tumor suppressor gene(s).
PCT/US2014/041790 2013-06-17 2014-06-10 Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions WO2014204723A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP14738672.6A EP3011035B1 (en) 2013-06-17 2014-06-10 Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences
US14/971,459 US20160168594A1 (en) 2013-06-17 2015-12-16 Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
US16/003,085 US20190106710A1 (en) 2013-06-17 2018-06-07 Oncogenic Models Based on Delivery and Use of the CRISPR-Cas Systems, Vectors and Compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361836123P 2013-06-17 2013-06-17
US61/836,123 2013-06-17
US201361915397P 2013-12-12 2013-12-12
US61/915,397 2013-12-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/971,459 Continuation-In-Part US20160168594A1 (en) 2013-06-17 2015-12-16 Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions

Publications (2)

Publication Number Publication Date
WO2014204723A1 true WO2014204723A1 (en) 2014-12-24
WO2014204723A9 WO2014204723A9 (en) 2016-02-25

Family

ID=51176465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/041790 WO2014204723A1 (en) 2013-06-17 2014-06-10 Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions

Country Status (3)

Country Link
US (2) US20160168594A1 (en)
EP (1) EP3011035B1 (en)
WO (1) WO2014204723A1 (en)

Cited By (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
CN105400773A (en) * 2015-12-14 2016-03-16 同济大学 CRISPR/Cas9 enrichment sequencing method applied in large-scale screening of cancer genes
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
WO2016069591A2 (en) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, methods and use of synthetic lethal screening
WO2016086197A1 (en) 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016138488A2 (en) 2015-02-26 2016-09-01 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
WO2016154493A1 (en) * 2015-03-24 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for multi-scale, annotation-independent detection of functionally-diverse units of recurrent genomic alteration
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
WO2016205764A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
WO2017015637A1 (en) * 2015-07-22 2017-01-26 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
WO2017070605A1 (en) 2015-10-22 2017-04-27 The Broad Institute Inc. Type vi-b crispr enzymes and systems
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075294A1 (en) 2015-10-28 2017-05-04 The Board Institute Inc. Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
WO2017147196A1 (en) 2016-02-22 2017-08-31 Massachusetts Institute Of Technology Methods for identifying and modulating immune phenotypes
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017161325A1 (en) 2016-03-17 2017-09-21 Massachusetts Institute Of Technology Methods for identifying and modulating co-occurant cellular phenotypes
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
WO2017219027A1 (en) 2016-06-17 2017-12-21 The Broad Institute Inc. Type vi crispr orthologs and systems
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
WO2018170333A1 (en) 2017-03-15 2018-09-20 The Broad Institute, Inc. Novel cas13b orthologues crispr enzymes and systems
WO2018170515A1 (en) 2017-03-17 2018-09-20 The Broad Institute, Inc. Methods for identifying and modulating co-occurant cellular phenotypes
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
WO2018191388A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
WO2018175636A3 (en) * 2017-03-22 2018-11-22 Novartis Ag Compositions and methods for immunooncology
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
WO2019003193A1 (en) 2017-06-30 2019-01-03 Novartis Ag Methods for the treatment of disease with gene editing systems
WO2019005884A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation Compositions and methods for treating inflammatory bowel diseases
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh Tumor organoid model
WO2019060746A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2019087113A1 (en) 2017-11-01 2019-05-09 Novartis Ag Synthetic rnas and methods of use
EP3514246A1 (en) 2014-02-27 2019-07-24 The Broad Institute Inc. T cell balance gene expression and methods of use thereof
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US10385359B2 (en) 2013-04-16 2019-08-20 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
WO2019204585A1 (en) 2018-04-19 2019-10-24 Massachusetts Institute Of Technology Single-stranded break detection in double-stranded dna
US10457960B2 (en) 2014-11-21 2019-10-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
EP3560330A1 (en) 2018-04-24 2019-10-30 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
WO2020006049A1 (en) 2018-06-26 2020-01-02 The Broad Institute, Inc. Crispr/cas and transposase based amplification compositions, systems and methods
WO2020006036A1 (en) 2018-06-26 2020-01-02 Massachusetts Institute Of Technology Crispr effector system based amplification methods, systems, and diagnostics
WO2020028555A2 (en) 2018-07-31 2020-02-06 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2020033601A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
EP3686279A1 (en) 2014-08-17 2020-07-29 The Broad Institute, Inc. Genome editing using cas9 nickases
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
WO2020206036A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Novel nucleic acid modifier
WO2020229533A1 (en) 2019-05-13 2020-11-19 KWS SAAT SE & Co. KGaA Drought tolerance in corn
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243661A1 (en) 2019-05-31 2020-12-03 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2020239680A2 (en) 2019-05-25 2020-12-03 KWS SAAT SE & Co. KGaA Haploid induction enhancer
EP3579858A4 (en) * 2017-02-07 2020-12-23 The Regents of The University of California Gene therapy for haploinsufficiency
WO2021003432A1 (en) 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
US10912797B2 (en) 2016-10-18 2021-02-09 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021055874A1 (en) 2019-09-20 2021-03-25 The Broad Institute, Inc. Novel type vi crispr enzymes and systems
WO2021074367A1 (en) 2019-10-17 2021-04-22 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
US11001829B2 (en) 2014-09-25 2021-05-11 The Broad Institute, Inc. Functional screening with optimized functional CRISPR-Cas systems
US11072816B2 (en) 2017-05-03 2021-07-27 The Broad Institute, Inc. Single-cell proteomic assay using aptamers
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
US11098325B2 (en) 2017-06-30 2021-08-24 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
WO2021239986A1 (en) 2020-05-29 2021-12-02 KWS SAAT SE & Co. KGaA Plant haploid induction
US11214800B2 (en) 2015-08-18 2022-01-04 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11286478B2 (en) 2016-04-19 2022-03-29 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
US11345932B2 (en) 2018-05-16 2022-05-31 Synthego Corporation Methods and systems for guide RNA design and use
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
CN114946765A (en) * 2022-05-11 2022-08-30 华南理工大学 Zebra fish model with congenital thrombocytopenic syndrome and application thereof
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447527B2 (en) 2018-09-18 2022-09-20 Vnv Newco Inc. Endogenous Gag-based capsids and uses thereof
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11479761B2 (en) 2015-04-16 2022-10-25 Wageningen Universiteit Nuclease-mediated genome editing
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2023006933A1 (en) 2021-07-30 2023-02-02 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
US11578118B2 (en) 2017-10-20 2023-02-14 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
US11603544B2 (en) 2017-06-05 2023-03-14 Fred Hutchinson Cancer Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
US11634755B2 (en) 2015-06-18 2023-04-25 The Broad Institute, Inc. Crispr enzymes and systems
CN116083481A (en) * 2022-07-22 2023-05-09 湖北省农业科学院畜牧兽医研究所 Application of ACVR2B in regulation and control of pork production performance and method for improving pork production performance
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
EP4268831A2 (en) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
US11866697B2 (en) 2017-05-18 2024-01-09 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2024042199A1 (en) 2022-08-26 2024-02-29 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding
US11920128B2 (en) 2013-09-18 2024-03-05 Kymab Limited Methods, cells and organisms
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US12037583B2 (en) 2015-12-04 2024-07-16 Novartis Ag Compositions and methods for immunooncology
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
US12121524B2 (en) 2019-01-16 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US10940169B2 (en) 2015-11-30 2021-03-09 Joseph E. Kovarik Method for reducing the likelihood of developing cancer in an individual human being
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11191665B2 (en) 2011-02-04 2021-12-07 Joseph E. Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10111913B2 (en) 2011-02-04 2018-10-30 Joseph E. Kovarik Method of reducing the likelihood of skin cancer in an individual human being
US10583033B2 (en) 2011-02-04 2020-03-10 Katherine Rose Kovarik Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
US10010568B2 (en) 2011-02-04 2018-07-03 Katherine Rose Kovarik Method and system for reducing the likelihood of a spirochetes infection in a human being
US10085938B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for preventing sore throat in humans
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
DE202013012241U1 (en) 2012-05-25 2016-01-18 Emmanuelle Charpentier Compositions for RNA-directed modification of a target DNA and for RNA-driven modulation of transcription
ES2926021T3 (en) 2012-10-23 2022-10-21 Toolgen Inc Composition for cleaving a target DNA comprising a target DNA-specific guide RNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
JP2016528890A (en) * 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing using the CRISPR / Cas system
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11529379B2 (en) 2013-12-20 2022-12-20 Seed Health, Inc. Method and system for reducing the likelihood of developing colorectal cancer in an individual human being
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11213552B2 (en) 2015-11-30 2022-01-04 Joseph E. Kovarik Method for treating an individual suffering from a chronic infectious disease and cancer
US11642382B2 (en) 2013-12-20 2023-05-09 Seed Health, Inc. Method for treating an individual suffering from bladder cancer
US11672835B2 (en) 2013-12-20 2023-06-13 Seed Health, Inc. Method for treating individuals having cancer and who are receiving cancer immunotherapy
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11026982B2 (en) 2015-11-30 2021-06-08 Joseph E. Kovarik Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
EP3129485B2 (en) * 2014-04-09 2022-12-21 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating cystic fibrosis
EP3227462B1 (en) * 2014-12-01 2020-04-22 The Broad Institute, Inc. Method for in situ determination of nucleic acid proximity
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
CA2981715A1 (en) 2015-04-06 2016-10-13 The Board Of Trustees Of The Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods
AU2016316027B2 (en) * 2015-09-01 2022-04-07 Dana-Farber Cancer Institute Inc. Systems and methods for selection of gRNA targeting strands for Cas9 localization
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US10568916B2 (en) 2015-11-30 2020-02-25 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US10933128B2 (en) 2015-11-30 2021-03-02 Joseph E. Kovarik Method and system for protecting honey bees from pesticides
US10675347B2 (en) 2015-11-30 2020-06-09 Joseph E. Kovarik Method and system for protecting honey bees from fipronil pesticides
US11529412B2 (en) 2015-11-30 2022-12-20 Seed Health, Inc. Method and system for protecting honey bees from pesticides
US10086024B2 (en) 2015-11-30 2018-10-02 Joseph E. Kovarik Method and system for protecting honey bees, bats and butterflies from neonicotinoid pesticides
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
WO2018195073A2 (en) * 2017-04-18 2018-10-25 Yale University A platform for t lymphocyte genome engineering and in vivo high-throughput screening thereof
CN111182790A (en) 2017-07-31 2020-05-19 瑞泽恩制药公司 CRISPR reporter non-human animals and uses thereof
KR20200030594A (en) * 2017-10-16 2020-03-20 에프. 호프만-라 로슈 아게 Nucleic acid molecule for reducing PAPD5 and PAPD7 mRNA to treat hepatitis B infection
MA50858A (en) * 2017-11-01 2020-09-09 Editas Medicine Inc METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITION OF TGFBR2 IN T CELLS FOR IMMUNOTHERAPY
KR102439221B1 (en) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. Acoustic transducer actuators and controllers
CA3089731A1 (en) 2018-02-05 2019-08-08 Ibex Biosciences, Llc Use of pcbp1 to treat hyperproliferative disease
WO2019204766A1 (en) * 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN109852586B (en) * 2018-11-20 2019-10-08 广东医科大学 A method of establishing colorectal cancer HK2 reporter gene cell line
WO2020247654A1 (en) * 2019-06-06 2020-12-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Setbp1 and xpo1 inhibitors for the treatment of sickle cell disease and beta-thalassemia
CN114402072A (en) * 2019-08-07 2022-04-26 艾比克斯生物科学有限责任公司 Use of PCBP1 in generating induced pluripotent stem cells and inhibiting tumorigenesis
WO2021076744A1 (en) * 2019-10-15 2021-04-22 The Regents Of The University Of California Gene targets for manipulating t cell behavior
US20230201375A1 (en) * 2020-04-27 2023-06-29 Duke University Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)
US20230235319A1 (en) * 2020-06-12 2023-07-27 Bayer Aktiengesellschaft Crispr-cas12a directed random mutagenesis agents and methods
KR20240055811A (en) 2021-09-10 2024-04-29 애질런트 테크놀로지스, 인크. Guide RNA with chemical modifications for prime editing
CN115192714B (en) * 2022-07-08 2024-09-17 沈阳药科大学 Use of HDAC6 inhibitors in the manufacture of a medicament for the treatment of DNMT3A gene-deficient cancers

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
B. C. LEWIS: "The c-myc and PyMT oncogenes induce different tumor types in a somatic mouse model for pancreatic cancer", GENES & DEVELOPMENT, vol. 17, no. 24, 15 December 2003 (2003-12-15), pages 3127 - 3138, XP055049590, ISSN: 0890-9369, DOI: 10.1101/gad.1140403 *
GAJ THOMAS ET AL: "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 31, no. 7, 9 May 2013 (2013-05-09), pages 397 - 405, XP028571313, ISSN: 0167-7799, DOI: 10.1016/J.TIBTECH.2013.04.004 *
HSU PATRICK D ET AL: "Development and Applications of CRISPR-Cas9 for Genome Engineering", CELL, vol. 157, no. 6, 5 June 2014 (2014-06-05), pages 1262 - 1278, XP028849523, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2014.05.010 *
JANSSEN K P ET AL: "Mouse models of K-ras-initiated carcinogenesis", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1756, no. 2, 25 November 2005 (2005-11-25), pages 145 - 154, XP027829577, ISSN: 0304-419X, [retrieved on 20051125] *
L. CONG ET AL: "Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 3 January 2013 (2013-01-03), pages 819 - 823, XP055102030, ISSN: 0036-8075, DOI: 10.1126/science.1231143 *
L. CONG ET AL: "Supplementary Material to : Multiplex Genome Engineering Using CRISPR/Cas Systems", SCIENCE, vol. 339, no. 6121, 3 January 2013 (2013-01-03), pages 1 - 25, XP002730884, ISSN: 0036-8075, DOI: 10.1126/science.1231143 *
LOMBARDO ANGELO ET AL: "Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1298 - 1306, XP002465562, ISSN: 1087-0156, DOI: 10.1038/NBT1353 *
LUKE A. GILBERT ET AL: "CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes", CELL, vol. 154, no. 2, 1 July 2013 (2013-07-01), pages 442 - 451, XP055115843, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.06.044 *
P. MALI ET AL: "RNA-Guided Human Genome Engineering via Cas9", SCIENCE, vol. 339, no. 6121, 3 January 2013 (2013-01-03), pages 823 - 826, XP055111247, ISSN: 0036-8075, DOI: 10.1126/science.1232033 *
SHALEM OPHIR ET AL: "Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells", January 2014, SCIENCE (WASHINGTON D C), VOL. 343, NR. 6166, PAGE(S) 84-87, ISSN: 0036-8075(print), XP002723432 *
WANG HAOYI ET AL: "One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering", CELL, CELL PRESS, US, vol. 153, no. 4, 2 May 2013 (2013-05-02), pages 910 - 918, XP028538358, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2013.04.025 *

Cited By (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9322006B2 (en) 2011-07-22 2016-04-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10385359B2 (en) 2013-04-16 2019-08-20 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US10975390B2 (en) 2013-04-16 2021-04-13 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US12037596B2 (en) 2013-04-16 2024-07-16 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US10227581B2 (en) 2013-08-22 2019-03-12 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US11920128B2 (en) 2013-09-18 2024-03-05 Kymab Limited Methods, cells and organisms
US11390887B2 (en) 2013-11-07 2022-07-19 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10190137B2 (en) 2013-11-07 2019-01-29 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US10640788B2 (en) 2013-11-07 2020-05-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAs
US9834791B2 (en) 2013-11-07 2017-12-05 Editas Medicine, Inc. CRISPR-related methods and compositions with governing gRNAS
US9546384B2 (en) 2013-12-11 2017-01-17 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse genome
US10208317B2 (en) 2013-12-11 2019-02-19 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
US11820997B2 (en) 2013-12-11 2023-11-21 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
US10711280B2 (en) 2013-12-11 2020-07-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a mouse ES cell genome
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
EP3514246A1 (en) 2014-02-27 2019-07-24 The Broad Institute Inc. T cell balance gene expression and methods of use thereof
US11209440B2 (en) 2014-02-27 2021-12-28 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
EP3686279A1 (en) 2014-08-17 2020-07-29 The Broad Institute, Inc. Genome editing using cas9 nickases
US11197467B2 (en) 2014-09-24 2021-12-14 The Broad Institute, Inc. Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
US11459557B2 (en) 2014-09-24 2022-10-04 The Broad Institute, Inc. Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
US11001829B2 (en) 2014-09-25 2021-05-11 The Broad Institute, Inc. Functional screening with optimized functional CRISPR-Cas systems
WO2016069591A2 (en) 2014-10-27 2016-05-06 The Broad Institute Inc. Compositions, methods and use of synthetic lethal screening
US11697828B2 (en) 2014-11-21 2023-07-11 Regeneran Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
US10457960B2 (en) 2014-11-21 2019-10-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide RNAs
WO2016086197A1 (en) 2014-11-25 2016-06-02 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
EP3626832A2 (en) 2014-11-25 2020-03-25 The Brigham and Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US11234418B2 (en) 2014-12-10 2022-02-01 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US10993419B2 (en) 2014-12-10 2021-05-04 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US10278372B2 (en) 2014-12-10 2019-05-07 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US9888673B2 (en) 2014-12-10 2018-02-13 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3985115A1 (en) 2014-12-12 2022-04-20 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094867A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016100974A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
EP3702456A1 (en) 2014-12-24 2020-09-02 The Broad Institute, Inc. Crispr having or associated with destabilization domains
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
US12116619B2 (en) 2014-12-30 2024-10-15 The Broad Institute, Inc. CRISPR mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016108926A1 (en) 2014-12-30 2016-07-07 The Broad Institute Inc. Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
WO2016138488A2 (en) 2015-02-26 2016-09-01 The Broad Institute Inc. T cell balance gene expression, compositions of matters and methods of use thereof
US11427869B2 (en) 2015-02-26 2022-08-30 The Broad Institute, Inc. T cell balance gene expression, compositions of matters and methods of use thereof
WO2016154493A1 (en) * 2015-03-24 2016-09-29 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for multi-scale, annotation-independent detection of functionally-diverse units of recurrent genomic alteration
US11760985B2 (en) 2015-04-16 2023-09-19 Wageningen Universiteit CRISPR-Cas complex
US11479761B2 (en) 2015-04-16 2022-10-25 Wageningen Universiteit Nuclease-mediated genome editing
WO2016182893A1 (en) 2015-05-08 2016-11-17 Teh Broad Institute Inc. Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
US11643669B2 (en) 2015-06-17 2023-05-09 Massachusetts Institute Of Technology CRISPR mediated recording of cellular events
WO2016205728A1 (en) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Crispr mediated recording of cellular events
US11773412B2 (en) 2015-06-18 2023-10-03 The Broad Institute, Inc. Crispr enzymes and systems
US11781172B2 (en) 2015-06-18 2023-10-10 The Broad Institute, Inc. Crispr enzymes and systems
US11634755B2 (en) 2015-06-18 2023-04-25 The Broad Institute, Inc. Crispr enzymes and systems
US20180127745A1 (en) * 2015-06-18 2018-05-10 The Broad Institute Inc. Cell sorting
US11060115B2 (en) 2015-06-18 2021-07-13 The Broad Institute, Inc. CRISPR enzymes and systems
EP4159856A1 (en) 2015-06-18 2023-04-05 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3666895A1 (en) 2015-06-18 2020-06-17 The Broad Institute, Inc. Novel crispr enzymes and systems
US12091709B2 (en) 2015-06-18 2024-09-17 The Broad Institute, Inc. Crispr enzymes and systems
US11180751B2 (en) 2015-06-18 2021-11-23 The Broad Institute, Inc. CRISPR enzymes and systems
US11236327B2 (en) 2015-06-18 2022-02-01 The Broad Institute, Inc. Cell sorting
US11421250B2 (en) 2015-06-18 2022-08-23 The Broad Institute, Inc. CRISPR enzymes and systems
WO2016205764A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
US11773432B2 (en) 2015-06-18 2023-10-03 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2017015637A1 (en) * 2015-07-22 2017-01-26 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
US11642374B2 (en) 2015-07-31 2023-05-09 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US10406177B2 (en) 2015-07-31 2019-09-10 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11583556B2 (en) 2015-07-31 2023-02-21 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11147837B2 (en) 2015-07-31 2021-10-19 Regents Of The University Of Minnesota Modified cells and methods of therapy
US11903966B2 (en) 2015-07-31 2024-02-20 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11642375B2 (en) 2015-07-31 2023-05-09 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US11925664B2 (en) 2015-07-31 2024-03-12 Intima Bioscience, Inc. Intracellular genomic transplant and methods of therapy
US11266692B2 (en) 2015-07-31 2022-03-08 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
US11214800B2 (en) 2015-08-18 2022-01-04 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017070605A1 (en) 2015-10-22 2017-04-27 The Broad Institute Inc. Type vi-b crispr enzymes and systems
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
WO2017074788A1 (en) 2015-10-27 2017-05-04 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075294A1 (en) 2015-10-28 2017-05-04 The Board Institute Inc. Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
US11186825B2 (en) 2015-10-28 2021-11-30 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1
US11180730B2 (en) 2015-10-28 2021-11-23 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3
US11092607B2 (en) 2015-10-28 2021-08-17 The Board Institute, Inc. Multiplex analysis of single cell constituents
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
US11884717B2 (en) 2015-11-19 2024-01-30 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
US12037583B2 (en) 2015-12-04 2024-07-16 Novartis Ag Compositions and methods for immunooncology
CN105400773A (en) * 2015-12-14 2016-03-16 同济大学 CRISPR/Cas9 enrichment sequencing method applied in large-scale screening of cancer genes
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
WO2017114497A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
EP4219689A2 (en) 2015-12-30 2023-08-02 Novartis AG Immune effector cell therapies with enhanced efficacy
WO2017147196A1 (en) 2016-02-22 2017-08-31 Massachusetts Institute Of Technology Methods for identifying and modulating immune phenotypes
WO2017158153A1 (en) 2016-03-17 2017-09-21 Imba - Institut Für Molekulare Biotechnologie Gmbh Conditional crispr sgrna expression
US11427861B2 (en) 2016-03-17 2022-08-30 Massachusetts Institute Of Technology Methods for identifying and modulating co-occurant cellular phenotypes
EP3219799A1 (en) 2016-03-17 2017-09-20 IMBA-Institut für Molekulare Biotechnologie GmbH Conditional crispr sgrna expression
WO2017161325A1 (en) 2016-03-17 2017-09-21 Massachusetts Institute Of Technology Methods for identifying and modulating co-occurant cellular phenotypes
US11286478B2 (en) 2016-04-19 2022-03-29 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
US11788083B2 (en) 2016-06-17 2023-10-17 The Broad Institute, Inc. Type VI CRISPR orthologs and systems
WO2017219027A1 (en) 2016-06-17 2017-12-21 The Broad Institute Inc. Type vi crispr orthologs and systems
US12031150B2 (en) 2016-07-13 2024-07-09 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
EP4219462A1 (en) 2016-07-13 2023-08-02 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11154574B2 (en) 2016-10-18 2021-10-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
US10912797B2 (en) 2016-10-18 2021-02-09 Intima Bioscience, Inc. Tumor infiltrating lymphocytes and methods of therapy
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US11466271B2 (en) 2017-02-06 2022-10-11 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
EP3579858A4 (en) * 2017-02-07 2020-12-23 The Regents of The University of California Gene therapy for haploinsufficiency
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
EP4361261A2 (en) 2017-03-15 2024-05-01 The Broad Institute Inc. Novel cas13b orthologues crispr enzymes and systems
WO2018170333A1 (en) 2017-03-15 2018-09-20 The Broad Institute, Inc. Novel cas13b orthologues crispr enzymes and systems
US11739308B2 (en) 2017-03-15 2023-08-29 The Broad Institute, Inc. Cas13b orthologues CRISPR enzymes and systems
WO2018170515A1 (en) 2017-03-17 2018-09-20 The Broad Institute, Inc. Methods for identifying and modulating co-occurant cellular phenotypes
CN110832075A (en) * 2017-03-22 2020-02-21 诺华股份有限公司 Compositions and methods for immunooncology
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
WO2018175636A3 (en) * 2017-03-22 2018-11-22 Novartis Ag Compositions and methods for immunooncology
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018191520A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Respiratory and sweat gland ionocytes
WO2018191388A1 (en) 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
WO2018195486A1 (en) 2017-04-21 2018-10-25 The Broad Institute, Inc. Targeted delivery to beta cells
US11072816B2 (en) 2017-05-03 2021-07-27 The Broad Institute, Inc. Single-cell proteomic assay using aptamers
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11866697B2 (en) 2017-05-18 2024-01-09 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US11603544B2 (en) 2017-06-05 2023-03-14 Fred Hutchinson Cancer Center Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019005884A1 (en) 2017-06-26 2019-01-03 The Broad Institute, Inc. Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
US11098325B2 (en) 2017-06-30 2021-08-24 Intima Bioscience, Inc. Adeno-associated viral vectors for gene therapy
WO2019003193A1 (en) 2017-06-30 2019-01-03 Novartis Ag Methods for the treatment of disease with gene editing systems
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
WO2019018410A1 (en) * 2017-07-17 2019-01-24 The General Hospital Corporation Compositions and methods for treating inflammatory bowel diseases
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh Tumor organoid model
WO2019060746A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US11680296B2 (en) 2017-10-16 2023-06-20 Massachusetts Institute Of Technology Mycobacterium tuberculosis host-pathogen interaction
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11578118B2 (en) 2017-10-20 2023-02-14 Fred Hutchinson Cancer Center Systems and methods to produce B cells genetically modified to express selected antibodies
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2019087113A1 (en) 2017-11-01 2019-05-09 Novartis Ag Synthetic rnas and methods of use
US11332736B2 (en) 2017-12-07 2022-05-17 The Broad Institute, Inc. Methods and compositions for multiplexing single cell and single nuclei sequencing
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US12005127B2 (en) 2018-01-17 2024-06-11 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
WO2019143678A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
US11566236B2 (en) 2018-02-05 2023-01-31 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
WO2019204585A1 (en) 2018-04-19 2019-10-24 Massachusetts Institute Of Technology Single-stranded break detection in double-stranded dna
EP3560330A1 (en) 2018-04-24 2019-10-30 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
WO2019206927A1 (en) 2018-04-24 2019-10-31 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210268A2 (en) 2018-04-27 2019-10-31 The Broad Institute, Inc. Sequencing-based proteomics
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
US11802296B2 (en) 2018-05-16 2023-10-31 Synthego Corporation Methods and systems for guide RNA design and use
US11345932B2 (en) 2018-05-16 2022-05-31 Synthego Corporation Methods and systems for guide RNA design and use
US11697827B2 (en) 2018-05-16 2023-07-11 Synthego Corporation Systems and methods for gene modification
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020006049A1 (en) 2018-06-26 2020-01-02 The Broad Institute, Inc. Crispr/cas and transposase based amplification compositions, systems and methods
WO2020006036A1 (en) 2018-06-26 2020-01-02 Massachusetts Institute Of Technology Crispr effector system based amplification methods, systems, and diagnostics
WO2020028555A2 (en) 2018-07-31 2020-02-06 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2020033601A1 (en) 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
WO2020041387A1 (en) 2018-08-20 2020-02-27 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
EP4268831A2 (en) 2018-09-12 2023-11-01 Fred Hutchinson Cancer Center Reducing cd33 expression to selectively protect therapeutic cells
US11447527B2 (en) 2018-09-18 2022-09-20 Vnv Newco Inc. Endogenous Gag-based capsids and uses thereof
US11505578B2 (en) 2018-09-18 2022-11-22 Vnv Newco Inc. Endogenous Gag-based capsids and uses thereof
WO2020077236A1 (en) 2018-10-12 2020-04-16 The Broad Institute, Inc. Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
US11384344B2 (en) 2018-12-17 2022-07-12 The Broad Institute, Inc. CRISPR-associated transposase systems and methods of use thereof
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020131862A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US12121524B2 (en) 2019-01-16 2024-10-22 Vertex Pharmaceuticals Incorporated DNA-PK inhibitors
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
WO2020206036A1 (en) 2019-04-01 2020-10-08 The Broad Institute, Inc. Novel nucleic acid modifier
WO2020229533A1 (en) 2019-05-13 2020-11-19 KWS SAAT SE & Co. KGaA Drought tolerance in corn
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
WO2020239680A2 (en) 2019-05-25 2020-12-03 KWS SAAT SE & Co. KGaA Haploid induction enhancer
WO2020243661A1 (en) 2019-05-31 2020-12-03 The Broad Institute, Inc. Methods for treating metabolic disorders by targeting adcy5
WO2021003432A1 (en) 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
EP3772542A1 (en) 2019-08-07 2021-02-10 KWS SAAT SE & Co. KGaA Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021055874A1 (en) 2019-09-20 2021-03-25 The Broad Institute, Inc. Novel type vi crispr enzymes and systems
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
WO2021074367A1 (en) 2019-10-17 2021-04-22 KWS SAAT SE & Co. KGaA Enhanced disease resistance of crops by downregulation of repressor genes
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2021239986A1 (en) 2020-05-29 2021-12-02 KWS SAAT SE & Co. KGaA Plant haploid induction
WO2023006933A1 (en) 2021-07-30 2023-02-02 KWS SAAT SE & Co. KGaA Plants with improved digestibility and marker haplotypes
WO2023093862A1 (en) 2021-11-26 2023-06-01 Epigenic Therapeutics Inc. Method of modulating pcsk9 and uses thereof
CN114946765A (en) * 2022-05-11 2022-08-30 华南理工大学 Zebra fish model with congenital thrombocytopenic syndrome and application thereof
CN116083481A (en) * 2022-07-22 2023-05-09 湖北省农业科学院畜牧兽医研究所 Application of ACVR2B in regulation and control of pork production performance and method for improving pork production performance
WO2024042199A1 (en) 2022-08-26 2024-02-29 KWS SAAT SE & Co. KGaA Use of paired genes in hybrid breeding

Also Published As

Publication number Publication date
EP3011035A1 (en) 2016-04-27
WO2014204723A9 (en) 2016-02-25
US20160168594A1 (en) 2016-06-16
EP3011035B1 (en) 2020-05-13
US20190106710A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
US11597949B2 (en) Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
US20210292794A1 (en) Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
US20190106710A1 (en) Oncogenic Models Based on Delivery and Use of the CRISPR-Cas Systems, Vectors and Compositions
AU2019283878B2 (en) Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US20210108196A1 (en) Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
US20200165601A1 (en) Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
AU2014281030B2 (en) Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
AU2014281028A9 (en) Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14738672

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014738672

Country of ref document: EP